Leitlinie|Version|Jahr|Author|Inhaltstyp|Bester GoR|in QI|Position|Referenz|Link|Referenzen (gesamt)
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Standard|Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, et al. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. 2019;33 (11):2710-2719|https://pubmed.ncbi.nlm.nih.gov/31462732/|1078
Multiples Myelom|"1.0"|2022|Knop, Stefan|Hintergrund|||Erstautor|Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, et al. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. 2019;33 (11):2710-2719|https://pubmed.ncbi.nlm.nih.gov/31462732/|1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Hintergrund|||Standard|Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, et al. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clin Pharmacol. 2017;9 ():133-145|https://pubmed.ncbi.nlm.nih.gov/29184451/|1078
Multiples Myelom|"1.0"|2022|Raab, Marc-Steffen|Evidenzbasierte Empfehlung|0|False|Standard|Sellner L., Heiss C., Benner A., Raab M. S., Hillengass J., Hose D., et al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. None. 2013;119:2438-46|https://www.ncbi.nlm.nih.gov/pubmed/23576287|1078
Multiples Myelom|"1.0"|2022|Raab, Marc-Steffen|Hintergrund|||Standard|Sellner L., Heiss C., Benner A., Raab M. S., Hillengass J., Hose D., et al. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. None. 2013;119:2438-46|https://www.ncbi.nlm.nih.gov/pubmed/23576287|1078
Multiples Myelom|"1.0"|2022|Ramsenthaler, Christina|Hintergrund|||Erstautor|Ramsenthaler C., Kane P., Gao W., Siegert R. J., Edmonds P. M., Schey S. A., et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. None. 2016;97:416-429|https://www.ncbi.nlm.nih.gov/pubmed/27528496|1078
Multiples Myelom|"1.0"|2022|Ramsenthaler, Christina|Hintergrund|||Erstautor|Ramsenthaler C., Gao W., Siegert R. J., Schey S. A., Edmonds P. M., Higginson I. J. Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods. None. 2017;26:2931-2947|https://www.ncbi.nlm.nih.gov/pubmed/28752440|1078
Multiples Myelom|"1.0"|2022|Raab, Marc-Steffen|Hintergrund|||Standard|Rasche L., Kortum K. M., Raab M. S., Weinhold N. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. None. 2019;20:1248|https://www.ncbi.nlm.nih.gov/pubmed/30871078|1078
Multiples Myelom|"1.0"|2022|Weinhold, Niels|Hintergrund|||Letztautor|Rasche L., Kortum K. M., Raab M. S., Weinhold N. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. None. 2019;20:1248|https://www.ncbi.nlm.nih.gov/pubmed/30871078|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Palumbo A., Avet-Loiseau H., Oliva S., Lokhorst H. M., Goldschmidt H., Rosinol L., et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. None. 2015;33:2863-9|https://www.ncbi.nlm.nih.gov/pubmed/26240224|1078
Multiples Myelom|"1.0"|2022|Weinhold, Niels|Hintergrund|||Erstautor|Weinhold N., Ashby C., Rasche L., Chavan S. S., Stein C., Stephens O. W., et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. None. 2016;128:1735-44|https://www.ncbi.nlm.nih.gov/pubmed/27516441|1078
Multiples Myelom|"1.0"|2022|Derlin, Thorsten|Hintergrund|||Erstautor|Derlin T., Peldschus K., Munster S., Bannas P., Herrmann J., Stubig T., et al. Comparative diagnostic performance of (1)(8)F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. None. 2013;23:570-8|https://www.ncbi.nlm.nih.gov/pubmed/22843058|1078
Multiples Myelom|"1.0"|2022|Delorme, Stefan|Hintergrund|||Standard|Hillengass J., Moulopoulos L. A., Delorme S., Koutoulidis V., Mosebach J., Hielscher T., et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. None. 2017;7:e599|https://www.ncbi.nlm.nih.gov/pubmed/28841211|1078
Multiples Myelom|"1.0"|2022|Einsele, Hermann|Hintergrund|||Standard|Lapa C., Luckerath K., Malzahn U., Samnick S., Einsele H., Buck A. K., et al. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. None. 2014;5:7381-91|https://www.ncbi.nlm.nih.gov/pubmed/25277179|1078
Multiples Myelom|"1.0"|2022|Lapa, Constantin|Hintergrund|||Erstautor|Lapa C., Luckerath K., Malzahn U., Samnick S., Einsele H., Buck A. K., et al. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. None. 2014;5:7381-91|https://www.ncbi.nlm.nih.gov/pubmed/25277179|1078
Multiples Myelom|"1.0"|2022|Merz, Maximilian|Hintergrund|||Erstautor|Merz M., Hielscher T., Wagner B., Sauer S., Shah S., Raab M. S., et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. None. 2014;28:1902-8|https://www.ncbi.nlm.nih.gov/pubmed/24535407|1078
Multiples Myelom|"1.0"|2022|Raab, Marc-Steffen|Hintergrund|||Standard|Merz M., Hielscher T., Wagner B., Sauer S., Shah S., Raab M. S., et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. None. 2014;28:1902-8|https://www.ncbi.nlm.nih.gov/pubmed/24535407|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Sachpekidis C., Mai E. K., Goldschmidt H., Hillengass J., Hose D., Pan L., et al. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. None. 2015;40:e300-7|https://www.ncbi.nlm.nih.gov/pubmed/25783508|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Hintergrund|||Standard|Sachpekidis C., Mai E. K., Goldschmidt H., Hillengass J., Hose D., Pan L., et al. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. None. 2015;40:e300-7|https://www.ncbi.nlm.nih.gov/pubmed/25783508|1078
Multiples Myelom|"1.0"|2022|Dold, Sandra Maria|Hintergrund|||Standard|Engelhardt M., Domm A. S., Dold S. M., Ihorst G., Reinhardt H., Zober A., et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. None. 2017;102:910-921|https://www.ncbi.nlm.nih.gov/pubmed/28154088|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Erstautor|Engelhardt M., Domm A. S., Dold S. M., Ihorst G., Reinhardt H., Zober A., et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. None. 2017;102:910-921|https://www.ncbi.nlm.nih.gov/pubmed/28154088|1078
Multiples Myelom|"1.0"|2022|Reinhardt, Heike|Hintergrund|||Standard|Engelhardt M., Domm A. S., Dold S. M., Ihorst G., Reinhardt H., Zober A., et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. None. 2017;102:910-921|https://www.ncbi.nlm.nih.gov/pubmed/28154088|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Baertsch M. A., Hundemer M., Hillengass J., Goldschmidt H., Raab M. S. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach. None. 2018;36:258-261|https://www.ncbi.nlm.nih.gov/pubmed/28840598|1078
Multiples Myelom|"1.0"|2022|Hundemer, Michael|Hintergrund|||Standard|Baertsch M. A., Hundemer M., Hillengass J., Goldschmidt H., Raab M. S. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach. None. 2018;36:258-261|https://www.ncbi.nlm.nih.gov/pubmed/28840598|1078
Multiples Myelom|"1.0"|2022|Raab, Marc-Steffen|Hintergrund|||Letztautor|Baertsch M. A., Hundemer M., Hillengass J., Goldschmidt H., Raab M. S. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach. None. 2018;36:258-261|https://www.ncbi.nlm.nih.gov/pubmed/28840598|1078
Multiples Myelom|"1.0"|2022|Merz, Maximilian|Hintergrund|||Erstautor|Merz Maximilian, Hielscher Thomas, Seckinger Anja, Hose Dirk, Bertsch Uta, Neben Kai, et al. Longitudinal Fluorescence in Situ Hybridization at Primary Diagnosis and Relapse Reveals Clonal Evolution after Autologous Stem Cell Transplantation in Multiple Myeloma. None. 2016;128:4415-4415|https://doi.org/10.1182/blood.V128.22.4415.4415|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Kasperk C., Haas A., Hillengass J., Weiss C., Neben K., Goldschmidt H., et al. Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study. None. 2012;105:679-86|https://www.ncbi.nlm.nih.gov/pubmed/21960293|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|B|False|Standard|Auner H. W., Szydlo R., Hoek J., Goldschmidt H., Stoppa A. M., Morgan G. J., et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. None. 2015;50:209-15|https://www.ncbi.nlm.nih.gov/pubmed/25387088|1078
Multiples Myelom|"1.0"|2022|Dold, Sandra Maria|Hintergrund|||Standard|Engelhardt M., Dold S. M., Ihorst G., Zober A., Moller M., Reinhardt H., et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. None. 2016;101:1110-9|https://www.ncbi.nlm.nih.gov/pubmed/27479825|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Erstautor|Engelhardt M., Dold S. M., Ihorst G., Zober A., Moller M., Reinhardt H., et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. None. 2016;101:1110-9|https://www.ncbi.nlm.nih.gov/pubmed/27479825|1078
Multiples Myelom|"1.0"|2022|Reinhardt, Heike|Hintergrund|||Standard|Engelhardt M., Dold S. M., Ihorst G., Zober A., Moller M., Reinhardt H., et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. None. 2016;101:1110-9|https://www.ncbi.nlm.nih.gov/pubmed/27479825|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Hintergrund|||Erstautor|Mai E., Miah K., Merz M., Dürig J., Scheid C., Weisel K., et al. High Dose Melphalan (200mg/m2) And Autologous Transplantation In Newly-Diagnosed Multiple Myeloma Up To The Age Of 70 Years: A Subgroup Analysis From The Phase III GMMG-HD-5-Trial. None. 2019;3:251-252||1078
Multiples Myelom|"1.0"|2022|Merz, Maximilian|Hintergrund|||Standard|Mai E., Miah K., Merz M., Dürig J., Scheid C., Weisel K., et al. High Dose Melphalan (200mg/m2) And Autologous Transplantation In Newly-Diagnosed Multiple Myeloma Up To The Age Of 70 Years: A Subgroup Analysis From The Phase III GMMG-HD-5-Trial. None. 2019;3:251-252||1078
Multiples Myelom|"1.0"|2022|Scheid, Christof|Hintergrund|||Standard|Mai E., Miah K., Merz M., Dürig J., Scheid C., Weisel K., et al. High Dose Melphalan (200mg/m2) And Autologous Transplantation In Newly-Diagnosed Multiple Myeloma Up To The Age Of 70 Years: A Subgroup Analysis From The Phase III GMMG-HD-5-Trial. None. 2019;3:251-252||1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Hintergrund|||Standard|Mai E., Miah K., Merz M., Dürig J., Scheid C., Weisel K., et al. High Dose Melphalan (200mg/m2) And Autologous Transplantation In Newly-Diagnosed Multiple Myeloma Up To The Age Of 70 Years: A Subgroup Analysis From The Phase III GMMG-HD-5-Trial. None. 2019;3:251-252||1078
Multiples Myelom|"1.0"|2022|Merz, Maximilian|Hintergrund|||Erstautor|Merz M., Jansen L., Castro F. A., Hillengass J., Salwender H., Weisel K., et al. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. None. 2016;62:1-8|https://www.ncbi.nlm.nih.gov/pubmed/27185572|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Letztautor|Wörmann B, Driessen C Einsele H Goldschmidt H Gunsilius E Kortüm M Kröger N Ludwig H Mügge LO Naumann R Pritzkuleit R Röllig C Scheid C Taverna C Weisel K Weißinger F. Multiples Myelom. . 2018;:|www.onkopedia.com|1078
Multiples Myelom|"1.0"|2022|Einsele, Hermann|Hintergrund|||Erstautor|Einsele H., Engelhardt M., Tapprich C., Muller J., Liebisch P., Langer C., et al. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. None. 2017;179:586-597|https://www.ncbi.nlm.nih.gov/pubmed/28961309|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Standard|Einsele H., Engelhardt M., Tapprich C., Muller J., Liebisch P., Langer C., et al. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. None. 2017;179:586-597|https://www.ncbi.nlm.nih.gov/pubmed/28961309|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Erstautor|Goldschmidt H., Hegenbart U., Wallmeier M., Hohaus S., Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. None. 1997;98:736-44|https://www.ncbi.nlm.nih.gov/pubmed/9332333|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Erstautor|Goldschmidt Hartmut, Neben Kai, Bertsch Uta, Hielscher Thomas, van der Holt Bronno, Hose Dirk, et al. Bortezomib-Based Induction Therapy Followed by Autologous Stem Cell Transplantation and Maintenance Therapy with Bortezomib Improves Outcome In Myeloma Patients with Gain 1q21 and t(4;14) - a Subgroup Analysis of the HOVON-65/GMMG-HD4 Trial. None. 2010;116:305-305||1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Letztautor|Cook G., Larocca A., Facon T., Zweegman S., Engelhardt M. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. None. 2020;34:2285-2294|https://www.ncbi.nlm.nih.gov/pubmed/32555295|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Hintergrund|||Erstautor|Mai E. K., Bertsch U., Durig J., Kunz C., Haenel M., Blau I. W., et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. None. 2015;29:1721-9|https://www.ncbi.nlm.nih.gov/pubmed/25787915|1078
Multiples Myelom|"1.0"|2022|Dold, Sandra Maria|Hintergrund|||Standard|Gengenbach L., Reinhardt H., Ihorst G., Ajayi S., Dold S. M., Kohler M., et al. Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials<sup/>. None. 2018;59:2692-2699|https://www.ncbi.nlm.nih.gov/pubmed/29569975|1078
Multiples Myelom|"1.0"|2022|Reinhardt, Heike|Hintergrund|||Standard|Gengenbach L., Reinhardt H., Ihorst G., Ajayi S., Dold S. M., Kohler M., et al. Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials<sup/>. None. 2018;59:2692-2699|https://www.ncbi.nlm.nih.gov/pubmed/29569975|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|A|False|Standard|Sonneveld P., Goldschmidt H., Rosinol L., Blade J., Lahuerta J. J., Cavo M., et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. None. 2013;31:3279-87|https://www.ncbi.nlm.nih.gov/pubmed/23897961|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Sonneveld P., Goldschmidt H., Rosinol L., Blade J., Lahuerta J. J., Cavo M., et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. None. 2013;31:3279-87|https://www.ncbi.nlm.nih.gov/pubmed/23897961|1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Hintergrund|||Erstautor|Weisel K., Doyen C., Dimopoulos M., Yee A., Lahuerta J. J., Martin A., et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. None. 2017;58:153-161|https://www.ncbi.nlm.nih.gov/pubmed/27124703|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|0|False|Standard|Blocka J., Hielscher T., Goldschmidt H., Hillengass J. Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients. None. 2020;26:1280-1287|https://www.ncbi.nlm.nih.gov/pubmed/32194287|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Blocka J., Hielscher T., Goldschmidt H., Hillengass J. Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients. None. 2020;26:1280-1287|https://www.ncbi.nlm.nih.gov/pubmed/32194287|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|B|False|Standard|Blocka J., Hielscher T., Mueller-Tidow C., Goldschmidt H., Hillengass J. Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy. None. 2020;61:27-36|https://www.ncbi.nlm.nih.gov/pubmed/31423866|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Blocka J., Hielscher T., Mueller-Tidow C., Goldschmidt H., Hillengass J. Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy. None. 2020;61:27-36|https://www.ncbi.nlm.nih.gov/pubmed/31423866|1078
Multiples Myelom|"1.0"|2022|Raab, Marc-Steffen|Evidenzbasierte Empfehlung|B|False|Standard|Breitkreutz I., Lokhorst H. M., Raab M. S., Holt B. van der, Cremer F. W., Herrmann D., et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. None. 2007;21:1294-1299|https://doi.org/10.1038/sj.leu.2404661|1078
Multiples Myelom|"1.0"|2022|Raab, Marc-Steffen|Hintergrund|||Standard|Breitkreutz I., Lokhorst H. M., Raab M. S., Holt B. van der, Cremer F. W., Herrmann D., et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. None. 2007;21:1294-1299|https://doi.org/10.1038/sj.leu.2404661|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Cavo Michele, Goldschmidt Hartmut, Rosinol Laura, Pantani Lucia, Zweegman Sonja, Salwender Hans Jürgen, et al. Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. None. 2018;132:124-124|https://doi.org/10.1182/blood-2018-99-112899|1078
Multiples Myelom|"1.0"|2022|Scheubeck, Sophia|Hintergrund|||Standard|Kuchlin S., Duffner J., Scheubeck S., Schoeller K., Maruschke L., Seidl M., et al. Kidney embolization induces prompt organ response in a 86-year-old patient with MGRS-related AL-amyloidosis. None. 2019;23:E59-E64|https://www.ncbi.nlm.nih.gov/pubmed/30548910|1078
Multiples Myelom|"1.0"|2022|Schoeller, Katja|Hintergrund|||Standard|Kuchlin S., Duffner J., Scheubeck S., Schoeller K., Maruschke L., Seidl M., et al. Kidney embolization induces prompt organ response in a 86-year-old patient with MGRS-related AL-amyloidosis. None. 2019;23:E59-E64|https://www.ncbi.nlm.nih.gov/pubmed/30548910|1078
Multiples Myelom|"1.0"|2022|Einsele, Hermann|Hintergrund|||Erstautor|Einsele H. H. Goldschmidt C. Straka I. Blau N. Gramatzki B. Metzner N. Kröger H. Salwender M. Engelhardt. Leitlinien zur autologen Stammzelltransplantation von der Deutschen Arbeitsgemeinschaft für Knochenmark- und Blutstammzelltransplantation (DAG-KBT). None. 2018;None:None|https://www.dag-kbt.de/files/downloads/Leitlinien_auto_Kap-2.1_Multiples%20Myelom.pdf|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Evidenzbasierte Empfehlung|B|False|Standard|Lehners N., Becker N., Benner A., Pritsch M., Lopprich M., Mai E. K., et al. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. None. 2018;7:307-316|https://www.ncbi.nlm.nih.gov/pubmed/29282899|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Hintergrund|||Standard|Lehners N., Becker N., Benner A., Pritsch M., Lopprich M., Mai E. K., et al. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. None. 2018;7:307-316|https://www.ncbi.nlm.nih.gov/pubmed/29282899|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Hintergrund|||Erstautor|Mai E. K., Benner A., Bertsch U., Brossart P., Hanel A., Kunzmann V., et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. None. 2016;173:731-41|https://www.ncbi.nlm.nih.gov/pubmed/26990892|1078
Multiples Myelom|"1.0"|2022|Piechotta, Vanessa|Evidenzbasierte Empfehlung|A|False|Erstautor|Piechotta V., Jakob T., Langer P., Monsef I., Scheid C., Estcourt L. J., et al. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. None. 2019;2019:None|https://www.ncbi.nlm.nih.gov/pubmed/31765002|1078
Multiples Myelom|"1.0"|2022|Piechotta, Vanessa|Hintergrund|||Erstautor|Piechotta V., Jakob T., Langer P., Monsef I., Scheid C., Estcourt L. J., et al. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. None. 2019;2019:None|https://www.ncbi.nlm.nih.gov/pubmed/31765002|1078
Multiples Myelom|"1.0"|2022|Scheid, Christof|Evidenzbasierte Empfehlung|A|False|Standard|Piechotta V., Jakob T., Langer P., Monsef I., Scheid C., Estcourt L. J., et al. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. None. 2019;2019:None|https://www.ncbi.nlm.nih.gov/pubmed/31765002|1078
Multiples Myelom|"1.0"|2022|Scheid, Christof|Hintergrund|||Standard|Piechotta V., Jakob T., Langer P., Monsef I., Scheid C., Estcourt L. J., et al. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. None. 2019;2019:None|https://www.ncbi.nlm.nih.gov/pubmed/31765002|1078
Multiples Myelom|"1.0"|2022|Knop, Stefan|Hintergrund|||Standard|Straka Christian, Knop Stefan, Vogel Martin, Müller Jurgen, Kropff Martin, Metzner Bernd, et al. Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma. None. 2016;128:516-516|https://doi.org/10.1182/blood.V128.22.516.516|1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Hintergrund|||Standard|Dimopoulos M. A., Gay F., Schjesvold F., Beksac M., Hajek R., Weisel K. C., et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. None. 2019;393:253-264|https://www.ncbi.nlm.nih.gov/pubmed/30545780|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|0|False|Erstautor|Goldschmidt H., Lokhorst H. M., Mai E. K., van der Holt B., Blau I. W., Zweegman S., et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. None. 2018;32:383-390|https://www.ncbi.nlm.nih.gov/pubmed/28761118|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Erstautor|Goldschmidt H., Lokhorst H. M., Mai E. K., van der Holt B., Blau I. W., Zweegman S., et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. None. 2018;32:383-390|https://www.ncbi.nlm.nih.gov/pubmed/28761118|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Evidenzbasierte Empfehlung|0|False|Standard|Goldschmidt H., Lokhorst H. M., Mai E. K., van der Holt B., Blau I. W., Zweegman S., et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. None. 2018;32:383-390|https://www.ncbi.nlm.nih.gov/pubmed/28761118|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Hintergrund|||Standard|Goldschmidt H., Lokhorst H. M., Mai E. K., van der Holt B., Blau I. W., Zweegman S., et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. None. 2018;32:383-390|https://www.ncbi.nlm.nih.gov/pubmed/28761118|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|B|False|Erstautor|Goldschmidt H., Mai E. K., Durig J., Scheid C., Weisel K. C., Kunz C., et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. None. 2020;34:1853-1865|https://www.ncbi.nlm.nih.gov/pubmed/32034285|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Erstautor|Goldschmidt H., Mai E. K., Durig J., Scheid C., Weisel K. C., Kunz C., et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. None. 2020;34:1853-1865|https://www.ncbi.nlm.nih.gov/pubmed/32034285|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Evidenzbasierte Empfehlung|B|False|Standard|Goldschmidt H., Mai E. K., Durig J., Scheid C., Weisel K. C., Kunz C., et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. None. 2020;34:1853-1865|https://www.ncbi.nlm.nih.gov/pubmed/32034285|1078
Multiples Myelom|"1.0"|2022|Mai, Elias K.|Hintergrund|||Standard|Goldschmidt H., Mai E. K., Durig J., Scheid C., Weisel K. C., Kunz C., et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. None. 2020;34:1853-1865|https://www.ncbi.nlm.nih.gov/pubmed/32034285|1078
Multiples Myelom|"1.0"|2022|Scheid, Christof|Evidenzbasierte Empfehlung|B|False|Standard|Goldschmidt H., Mai E. K., Durig J., Scheid C., Weisel K. C., Kunz C., et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. None. 2020;34:1853-1865|https://www.ncbi.nlm.nih.gov/pubmed/32034285|1078
Multiples Myelom|"1.0"|2022|Scheid, Christof|Hintergrund|||Standard|Goldschmidt H., Mai E. K., Durig J., Scheid C., Weisel K. C., Kunz C., et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. None. 2020;34:1853-1865|https://www.ncbi.nlm.nih.gov/pubmed/32034285|1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Evidenzbasierte Empfehlung|B|False|Standard|Goldschmidt H., Mai E. K., Durig J., Scheid C., Weisel K. C., Kunz C., et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. None. 2020;34:1853-1865|https://www.ncbi.nlm.nih.gov/pubmed/32034285|1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Hintergrund|||Standard|Goldschmidt H., Mai E. K., Durig J., Scheid C., Weisel K. C., Kunz C., et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. None. 2020;34:1853-1865|https://www.ncbi.nlm.nih.gov/pubmed/32034285|1078
Multiples Myelom|"1.0"|2022|Jauch, Anna|Evidenzbasierte Empfehlung|0|False|Standard|Neben K., Lokhorst H. M., Jauch A., Bertsch U., Hielscher T., van der Holt B., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. None. 2012;119:940-8|https://www.ncbi.nlm.nih.gov/pubmed/22160383|1078
Multiples Myelom|"1.0"|2022|Jauch, Anna|Hintergrund|||Standard|Neben K., Lokhorst H. M., Jauch A., Bertsch U., Hielscher T., van der Holt B., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. None. 2012;119:940-8|https://www.ncbi.nlm.nih.gov/pubmed/22160383|1078
Multiples Myelom|"1.0"|2022|Scheid, Christof|Evidenzbasierte Empfehlung|0|False|Erstautor|Scheid C., Sonneveld P., Schmidt-Wolf I. G., van der Holt B., el Jarari L., Bertsch U., et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. None. 2014;99:148-54|https://www.ncbi.nlm.nih.gov/pubmed/23996482|1078
Multiples Myelom|"1.0"|2022|Scheid, Christof|Hintergrund|||Erstautor|Scheid C., Sonneveld P., Schmidt-Wolf I. G., van der Holt B., el Jarari L., Bertsch U., et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. None. 2014;99:148-54|https://www.ncbi.nlm.nih.gov/pubmed/23996482|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Erstautor|Engelhardt M. Therapie des rezidivierten und refraktären multiplen Myeloms. None. 2018;24:613-624||1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Evidenzbasierte Empfehlung|A|False|Standard|Palumbo A., Chanan-Khan A., Weisel K., Nooka A. K., Masszi T., Beksac M., et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. None. 2016;375:754-66|https://www.ncbi.nlm.nih.gov/pubmed/27557302|1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Hintergrund|||Standard|Palumbo A., Chanan-Khan A., Weisel K., Nooka A. K., Masszi T., Beksac M., et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. None. 2016;375:754-66|https://www.ncbi.nlm.nih.gov/pubmed/27557302|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|A|False|Standard|Chng W. J., Goldschmidt H., Dimopoulos M. A., Moreau P., Joshua D., Palumbo A., et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. None. 2017;31:1368-1374|https://www.ncbi.nlm.nih.gov/pubmed/28025582|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|A|False|Standard|Dimopoulos M. A., Goldschmidt H., Niesvizky R., Joshua D., Chng W. J., Oriol A., et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. None. 2017;18:1327-1337|https://www.ncbi.nlm.nih.gov/pubmed/28843768|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Garderet L., Iacobelli S., Koster L., Goldschmidt H., Johansson J. E., Bourhis J. H., et al. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. None. 2018;24:1372-1378|https://www.ncbi.nlm.nih.gov/pubmed/29408334|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Evidenzbasierte Empfehlung|0|False|Standard|Gay F., Engelhardt M., Terpos E., Wasch R., Giaccone L., Auner H. W., et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. None. 2018;103:197-211|https://www.ncbi.nlm.nih.gov/pubmed/29217780|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Standard|Gay F., Engelhardt M., Terpos E., Wasch R., Giaccone L., Auner H. W., et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. None. 2018;103:197-211|https://www.ncbi.nlm.nih.gov/pubmed/29217780|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Erstautor|Goldschmidt H., Baertsch M. A., Schlenzka J., Becker N., Habermehl C., Hielscher T., et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. None. 2021;35:1134-1144|https://www.ncbi.nlm.nih.gov/pubmed/32694619|1078
Multiples Myelom|"1.0"|2022|Knauf, Wolfgang|Evidenzbasierte Empfehlung|A|False|Standard|Kropff M., Vogel M., Bisping G., Schlag R., Weide R., Knauf W., et al. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. None. 2017;96:1857-1866|https://www.ncbi.nlm.nih.gov/pubmed/28905189|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Evidenzbasierte Empfehlung|A|False|Standard|Moreau P., Joshua D., Chng W. J., Palumbo A., Goldschmidt H., Hajek R., et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. None. 2017;31:115-122|https://www.ncbi.nlm.nih.gov/pubmed/27491641|1078
Multiples Myelom|"1.0"|2022|Einsele, Hermann|Hintergrund|||Standard|Patriarca F., Bruno B., Einsele H., Spina F., Giaccone L., Montefusco V., et al. Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. None. 2018;24:406-409|https://www.ncbi.nlm.nih.gov/pubmed/29032267|1078
Multiples Myelom|"1.0"|2022|Goede, Valentin|Hintergrund|||Erstautor|Goede V., Stauder R. Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology. None. 2019;10:497-503|https://www.ncbi.nlm.nih.gov/pubmed/30241779|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Auel B., Goldschmidt H., Geer T., Moehler T. M., Platzbecker U., Naumann R., et al. Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma. None. 2012;28:67-76|https://www.ncbi.nlm.nih.gov/pubmed/23730012|1078
Multiples Myelom|"1.0"|2022|Goede, Valentin|Hintergrund|||Erstautor|Goede V., Wedding U. Vom geriatrischen Assessment zur geriatrischen Intervention. None. 2019;25:776-783|https://doi.org/10.1007/s00761-019-0573-6|1078
Multiples Myelom|"1.0"|2022|Einsele, Hermann|Hintergrund|||Letztautor|Knop S., Straka C., Haen M., Schwedes R., Hebart H., Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. None. 2005;90:1287-8|https://www.ncbi.nlm.nih.gov/pubmed/16154860|1078
Multiples Myelom|"1.0"|2022|Knop, Stefan|Hintergrund|||Erstautor|Knop S., Straka C., Haen M., Schwedes R., Hebart H., Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. None. 2005;90:1287-8|https://www.ncbi.nlm.nih.gov/pubmed/16154860|1078
Multiples Myelom|"1.0"|2022|Goldschmidt, Hartmut|Hintergrund|||Standard|Kumar S. K., Dimopoulos M. A., Kastritis E., Terpos E., Nahi H., Goldschmidt H., et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. None. 2017;31:2443-2448|https://www.ncbi.nlm.nih.gov/pubmed/28620163|1078
Multiples Myelom|"1.0"|2022|Skoetz, Nicole|Evidenzbasierte Empfehlung|B|False|Letztautor|Knips L., Bergenthal N., Streckmann F., Monsef I., Elter T., Skoetz N. Aerobic physical exercise for adult patients with haematological malignancies. None. 2019;1:CD009075|https://www.ncbi.nlm.nih.gov/pubmed/30702150|1078
Multiples Myelom|"1.0"|2022|Skoetz, Nicole|Hintergrund|||Letztautor|Knips L., Bergenthal N., Streckmann F., Monsef I., Elter T., Skoetz N. Aerobic physical exercise for adult patients with haematological malignancies. None. 2019;1:CD009075|https://www.ncbi.nlm.nih.gov/pubmed/30702150|1078
Multiples Myelom|"1.0"|2022|Einsele, Hermann|Hintergrund|||Standard|Ljungman P., Engelhard D., de la Camara R., Einsele H., Locasciulli A., Martino R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. None. 2005;35:737-46|https://www.ncbi.nlm.nih.gov/pubmed/15750612|1078
Multiples Myelom|"1.0"|2022|Dold, Sandra Maria|Hintergrund|||Standard|Larocca A., Dold S. M., Zweegman S., Terpos E., Wasch R., D'Agostino M., et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). None. 2018;32:1697-1712|https://www.ncbi.nlm.nih.gov/pubmed/29880892|1078
Multiples Myelom|"1.0"|2022|Einsele, Hermann|Hintergrund|||Standard|Ludwig H., Delforge M., Facon T., Einsele H., Gay F., Moreau P., et al. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. None. 2017;None:None|https://www.ncbi.nlm.nih.gov/pubmed/29251284|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Erstautor|Engelhardt M., Terpos E., Kleber M., Gay F., Wasch R., Morgan G., et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. None. 2014;99:232-42|https://www.ncbi.nlm.nih.gov/pubmed/24497560|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Standard|Terpos E., Kleber M., Engelhardt M., Zweegman S., Gay F., Kastritis E., et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. None. 2015;100:1254-66|https://www.ncbi.nlm.nih.gov/pubmed/26432383|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Standard|Greil C., Engelhardt M., Ihorst G., Schoeller K., Bertz H., Marks R., et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. None. 2019;104:370-379|https://www.ncbi.nlm.nih.gov/pubmed/30237266|1078
Multiples Myelom|"1.0"|2022|Schoeller, Katja|Hintergrund|||Standard|Greil C., Engelhardt M., Ihorst G., Schoeller K., Bertz H., Marks R., et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. None. 2019;104:370-379|https://www.ncbi.nlm.nih.gov/pubmed/30237266|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Standard|Hieke S., Kleber M., Konig C., Engelhardt M., Schumacher M. Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time. None. 2015;21:1530-6|https://www.ncbi.nlm.nih.gov/pubmed/25833308|1078
Multiples Myelom|"1.0"|2022|Schinke, Maximilian|Hintergrund|||Erstautor|Schinke M., Ihorst G., Duyster J., Wasch R., Schumacher M., Engelhardt M. Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients. None. 2020;126:3504-3515|https://www.ncbi.nlm.nih.gov/pubmed/32459378|1078
Multiples Myelom|"1.0"|2022|Reinhardt, Heike|Hintergrund|||Standard|Kleber M., Ihorst G., Gross B., Koch B., Reinhardt H., Wasch R., et al. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. None. 2013;13:541-51|https://www.ncbi.nlm.nih.gov/pubmed/23810244|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Standard|Zweegman S., Engelhardt M., Larocca A., 'Aging Eha Swg on, Hematology. Elderly patients with multiple myeloma: towards a frailty approach?. None. 2017;29:315-321|https://www.ncbi.nlm.nih.gov/pubmed/28763310|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Erstautor|Engelhardt M., Ihorst G., Landgren O., Pantic M., Reinhardt H., Waldschmidt J., et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. None. 2015;100:1340-9|https://www.ncbi.nlm.nih.gov/pubmed/26160877|1078
Multiples Myelom|"1.0"|2022|Reinhardt, Heike|Hintergrund|||Standard|Engelhardt M., Ihorst G., Landgren O., Pantic M., Reinhardt H., Waldschmidt J., et al. Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. None. 2015;100:1340-9|https://www.ncbi.nlm.nih.gov/pubmed/26160877|1078
Multiples Myelom|"1.0"|2022|Engelhardt, Monika|Hintergrund|||Standard|van de Donk N. W., Palumbo A., Johnsen H. E., Engelhardt M., Gay F., Gregersen H., et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. None. 2014;99:984-96|https://www.ncbi.nlm.nih.gov/pubmed/24658815|1078
Multiples Myelom|"1.0"|2022|Gerlach, Christina|Hintergrund|||Erstautor|Gerlach C., Goebel S., Weber S., Weber M., Sleeman K. E. Space for intuition - the 'Surprise'-Question in haemato-oncology: Qualitative analysis of experiences and perceptions of haemato-oncologists. None. 2019;33:531-540|https://www.ncbi.nlm.nih.gov/pubmed/30688151|1078
Multiples Myelom|"1.0"|2022|Ramsenthaler, Christina|Hintergrund|||Standard|Osborne T. R., Ramsenthaler C., de Wolf-Linder S., Schey S. A., Siegert R. J., Edmonds P. M., et al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. None. 2014;14:496|https://www.ncbi.nlm.nih.gov/pubmed/25005145|1078
Multiples Myelom|"1.0"|2022|Ramsenthaler, Christina|Hintergrund|||Standard|Osborne T. R., Ramsenthaler C., Schey S. A., Siegert R. J., Edmonds P. M., Higginson I. J. Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS). None. 2015;15:280|https://www.ncbi.nlm.nih.gov/pubmed/25884627|1078
Multiples Myelom|"1.0"|2022|Ramsenthaler, Christina|Hintergrund|||Standard|Osborne T. R., Ramsenthaler C., Siegert R. J., Edmonds P. M., Schey S. A., Higginson I. J. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. None. 2012;89:437-57|https://www.ncbi.nlm.nih.gov/pubmed/22985406|1078
Multiples Myelom|"1.0"|2022|Raab, Marc-Steffen|Hintergrund|||Erstautor|Raab M. S., Breitkreutz I., Anderhub S., Ronnest M. H., Leber B., Larsen T. O., et al. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. None. 2012;72:5374-85|https://www.ncbi.nlm.nih.gov/pubmed/22942257|1078
Multiples Myelom|"1.0"|2022|Einsele, Hermann|Hintergrund|||Erstautor|Einsele H. , M. Vogel , J. Muller , S. Knop , M. Kropff , C. Langer , et al. Results from two phase 3 studies of post-transplant bortezomib (BTZ) consolidation vs observation (OBS) in patients with newly diagnosed multiple myeloma (NDMM). . 2015;:100, 151||1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Hintergrund|||Standard|Miguel J. S., Weisel K., Moreau P., Lacy M., Song K., Delforge M., et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. None. 2013;14:1055-1066|https://www.ncbi.nlm.nih.gov/pubmed/24007748|1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Evidenzbasierte Empfehlung|B|False|Letztautor|Zago M., Oehrlein K., Rendl C., Hahn-Ast C., Kanz L., Weisel K. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. None. 2014;93:1993-9|https://www.ncbi.nlm.nih.gov/pubmed/24974802|1078
Multiples Myelom|"1.0"|2022|Weisel, Katja|Hintergrund|||Letztautor|Zago M., Oehrlein K., Rendl C., Hahn-Ast C., Kanz L., Weisel K. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. None. 2014;93:1993-9|https://www.ncbi.nlm.nih.gov/pubmed/24974802|1078
Mundhöhlenkarzinom|"3.0"|2021|Al-Nawas, Bilal|Hintergrund|||Standard|Sagheb K., Sagheb K., Taylor K. J., Al-Nawas B., Walter C. Cervical metastases of squamous cell carcinoma of the maxilla: a retrospective study of 25 years. . 2014;18:1221-7|http://www.ncbi.nlm.nih.gov/pubmed/23934238|875
Mundhöhlenkarzinom|"3.0"|2021|Weitz, Jochen|Hintergrund|||Erstautor|Weitz J., Bauer F. J., Hapfelmeier A., Rohleder N. H., Wolff K. D., Kesting M. R. Accuracy of mandibular reconstruction by three-dimensional guided vascularised fibular free flap after segmental mandibulectomy. None. 2016;54:506-10|https://www.ncbi.nlm.nih.gov/pubmed/26898519|875
Mundhöhlenkarzinom|"3.0"|2021|Wolff, Klaus-Dietrich|Hintergrund|||Standard|Weitz J., Bauer F. J., Hapfelmeier A., Rohleder N. H., Wolff K. D., Kesting M. R. Accuracy of mandibular reconstruction by three-dimensional guided vascularised fibular free flap after segmental mandibulectomy. None. 2016;54:506-10|https://www.ncbi.nlm.nih.gov/pubmed/26898519|875
Mundhöhlenkarzinom|"3.0"|2021|Wolff, Klaus-Dietrich|Evidenzbasiertes Statement||False|Standard|Koerdt S., Rockl J., Rommel N., Mucke T., Wolff K. D., Kesting M. R. Lymph node management in the treatment of oral cancer: Analysis of a standardized approach. None. 2016;44:1737-1742|https://www.ncbi.nlm.nih.gov/pubmed/27580851|875
Mundhöhlenkarzinom|"3.0"|2021|Budach, Wilfried|Hintergrund|||Erstautor|Budach W., Hehr T., Budach V., Belka C., Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. . 2006;6:28||875
Mundhöhlenkarzinom|"3.0"|2021|Fietkau, Rainer|Hintergrund|||Erstautor|Fietkau R., Lautenschläger C., Sauer R., Dunst J., Becker A., MBaumann M., et al. Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96-3. None. None;None:None||875
Mundhöhlenkarzinom|"3.0"|2021|Al-Nawas, Bilal|Hintergrund|||Standard|Grotz K. A., Wustenberg P., Kohnen R., Al-Nawas B., Henneicke-von Zepelin H. H., Bockisch A., et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo-controlled, double-blind study. . 2001;39:34-9||875
Mundhöhlenkarzinom|"3.0"|2021|Hoffmann, Jürgen|Hintergrund|||Standard|Krimmel M., Hoffmann J., Krimmel C., Cornelius C. P., Schwenzer N. Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. . 1998;26:243-8||875
Mundhöhlenkarzinom|"3.0"|2021|Rau, Andrea|Hintergrund|||Standard|Bissinger O., Rau A., Koerdt S., Wolff K. D., Kesting M. R., Gotz C. Evaluating tumour after care in oral squamous cell carcinoma: Insights into patients' health related quality of life. None. 2017;45:262-266|http://www.ncbi.nlm.nih.gov/pubmed/28049604|875
Mundhöhlenkarzinom|"3.0"|2021|Wolff, Klaus-Dietrich|Hintergrund|||Standard|Bissinger O., Rau A., Koerdt S., Wolff K. D., Kesting M. R., Gotz C. Evaluating tumour after care in oral squamous cell carcinoma: Insights into patients' health related quality of life. None. 2017;45:262-266|http://www.ncbi.nlm.nih.gov/pubmed/28049604|875
Mundhöhlenkarzinom|"3.0"|2021|Wolff, Klaus-Dietrich|Hintergrund|||Standard|Gotz C., Drecoll E., Straub M., Bissinger O., Wolff K. D., Kolk A. Impact of HPV infection on oral squamous cell carcinoma. None. 2016;7:76704-76712|http://www.ncbi.nlm.nih.gov/pubmed/27732948|875
Mundhöhlenkarzinom|"3.0"|2021|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Brown A., Einenkel J., Hauss J., Hinz A., Klein A., et al. Identifying tumor patients' depression. . 2011;19:1697-703||875
Mundhöhlenkarzinom|"3.0"|2021|Al-Nawas, Bilal|Hintergrund|||Letztautor|Moergel M., Meurer P., Ingel K., Wendt T. G., Al-Nawas B. Effectiveness of postoperative radiotherapy in patients with small oral and oropharyngeal squamous cell carcinoma and concomitant ipsilateral singular cervical lymph node metastasis (pN1) : A meta-analysis. None. 2011;187:337-43|https://www.ncbi.nlm.nih.gov/pubmed/21603991|875
Mundhöhlenkarzinom|"3.0"|2021|Frerich, Bernhard|Hintergrund|||Letztautor|Schiefke F., Akdemir M., Weber A., Akdemir D., Singer S., Frerich B. Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection. None. 2009;31:503-12|https://www.ncbi.nlm.nih.gov/pubmed/19156833|875
Mundhöhlenkarzinom|"3.0"|2021|Singer, Susanne|Hintergrund|||Standard|Schiefke F., Akdemir M., Weber A., Akdemir D., Singer S., Frerich B. Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection. None. 2009;31:503-12|https://www.ncbi.nlm.nih.gov/pubmed/19156833|875
Mundhöhlenkarzinom|"3.0"|2021|Wolff, Klaus-Dietrich|Hintergrund|||Standard|Kesting Marco Rainer, Robitzky Luisa, Al-Benna Sammy, Steinstraesser Lars, Baurecht Hansjorg, Wolff Klaus-Dietrich, et al. Bronchoscopy screening in primary oral squamous cell carcinoma: a 10-year experience. . 2009;47:279-83||875
Mundhöhlenkarzinom|"3.0"|2021|Rau, Andrea|Hintergrund|||Standard|Unterhuber T., Duma M. N., Rau A., Nieberler M., Wolff K. D., Kesting M. R. Oral squamous cell carcinoma: the impact of stage-dependent therapy regimes on postoperative disease recurrence. None. 2016;121:133-8|https://www.ncbi.nlm.nih.gov/pubmed/26711710|875
Mundhöhlenkarzinom|"3.0"|2021|Wolff, Klaus-Dietrich|Hintergrund|||Standard|Unterhuber T., Duma M. N., Rau A., Nieberler M., Wolff K. D., Kesting M. R. Oral squamous cell carcinoma: the impact of stage-dependent therapy regimes on postoperative disease recurrence. None. 2016;121:133-8|https://www.ncbi.nlm.nih.gov/pubmed/26711710|875
Magenkarzinom|"2"|2019|Fischbach, Wolfgang|Evidenzbasierte Empfehlung|A|False|Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0–September 2015, AWMF-Registernummer: 021/023OL). None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Fischbach, Wolfgang|Hintergrund|||Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0–September 2015, AWMF-Registernummer: 021/023OL). None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Gockel, Ines|Evidenzbasierte Empfehlung|A|False|Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0–September 2015, AWMF-Registernummer: 021/023OL). None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Gockel, Ines|Hintergrund|||Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0–September 2015, AWMF-Registernummer: 021/023OL). None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Grenacher, Lars|Evidenzbasierte Empfehlung|A|False|Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0–September 2015, AWMF-Registernummer: 021/023OL). None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Grenacher, Lars|Hintergrund|||Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0–September 2015, AWMF-Registernummer: 021/023OL). None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Fischbach, Wolfgang|Hintergrund|||Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. [Not Available]. None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Gockel, Ines|Hintergrund|||Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. [Not Available]. None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Grenacher, Lars|Hintergrund|||Standard|Porschen R., Buck A., Fischbach W., Gockel I., Gorling U., Grenacher L., et al. [Not Available]. None. 2015;53:1288-347|https://www.ncbi.nlm.nih.gov/pubmed/26562403|952
Magenkarzinom|"2"|2019|Dietrich, C.|Hintergrund|||Erstautor|Dietrich C. F., Kratzer W., Strobe D., Danse E., Fessl R., Bunk A., et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. None. 2006;12:1699-705|https://www.ncbi.nlm.nih.gov/pubmed/16586537|952
Magenkarzinom|"2"|2019|Dietrich, C.|Hintergrund|||Standard|Claudon M., Dietrich C. F., Choi B. I., Cosgrove D. O., Kudo M., Nolsoe C. P., et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. None. 2013;34:11-29|https://www.ncbi.nlm.nih.gov/pubmed/23129518|952
Magenkarzinom|"2"|2019|Dietrich, C.|Hintergrund|||Standard|Strobel D., Seitz K., Blank W., Schuler A., Dietrich C., von Herbay A., et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions--diagnostic accuracy in clinical practice (DEGUM multicenter trial). None. 2008;29:499-505|https://www.ncbi.nlm.nih.gov/pubmed/19241506|952
Magenkarzinom|"2"|2019|Dietrich, C.|Hintergrund|||Standard|Strobel D., Seitz K., Blank W., Schuler A., Dietrich C. F., von Herbay A., et al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS). None. 2009;30:376-82|https://www.ncbi.nlm.nih.gov/pubmed/19688669|952
Magenkarzinom|"2"|2019|Schmiegel, Wolff|Evidenzbasierte Empfehlung|B|False|Letztautor|Hollerbach S., Willert J., Topalidis T., Reiser M., Schmiegel W. Endoscopic ultrasound-guided fine-needle aspiration biopsy of liver lesions: histological and cytological assessment. None. 2003;35:743-9|https://www.ncbi.nlm.nih.gov/pubmed/12929021|952
Magenkarzinom|"2"|2019|Schmiegel, Wolff|Hintergrund|||Letztautor|Hollerbach S., Willert J., Topalidis T., Reiser M., Schmiegel W. Endoscopic ultrasound-guided fine-needle aspiration biopsy of liver lesions: histological and cytological assessment. None. 2003;35:743-9|https://www.ncbi.nlm.nih.gov/pubmed/12929021|952
Magenkarzinom|"2"|2019|Dietrich, C.|Hintergrund|||Standard|Jenssen C., Dietrich C. F., Burmester E. [Malignant neoplasias of the gastrointestinal tract--endosonographic staging revisited]. None. 2011;49:357-68|https://www.ncbi.nlm.nih.gov/pubmed/21391168|952
Magenkarzinom|"2"|2019|Jenssen, Christian|Hintergrund|||Erstautor|Jenssen C., Dietrich C. F., Burmester E. [Malignant neoplasias of the gastrointestinal tract--endosonographic staging revisited]. None. 2011;49:357-68|https://www.ncbi.nlm.nih.gov/pubmed/21391168|952
Magenkarzinom|"2"|2019|Jenssen, Christian|Hintergrund|||Erstautor|Jenssen C., Hocke M., Fusaroli P., Gilja O. H., Buscarini E., Havre R. F., et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV - EUS-guided interventions: General Aspects and EUS-guided Sampling (Short Version). None. 2016;37:157-69|https://www.ncbi.nlm.nih.gov/pubmed/27058434|952
Magenkarzinom|"2"|2019|Jenssen, Christian|Hintergrund|||Erstautor|Jenssen C., Hocke M., Fusaroli P., Gilja O. H., Buscarini E., Havre R. F., et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV - EUS-guided Interventions: General aspects and EUS-guided sampling (Long Version). None. 2016;37:E33-76|https://www.ncbi.nlm.nih.gov/pubmed/26515966|952
Magenkarzinom|"2"|2019|Jenssen, Christian|Hintergrund|||Standard|Dumonceau J. M., Deprez P. H., Jenssen C., Iglesias-Garcia J., Larghi A., Vanbiervliet G., et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. None. 2017;49:695-714|https://www.ncbi.nlm.nih.gov/pubmed/28511234|952
Magenkarzinom|"2"|2019|Bornschein, Jan|Hintergrund|||Erstautor|Bornschein J., Selgrad M., Warnecke M., Kuester D., Wex T., Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. None. 2010;55:3124-31|https://www.ncbi.nlm.nih.gov/pubmed/20668939|952
Magenkarzinom|"2"|2019|Bornschein, Jan|Hintergrund|||Erstautor|Bornschein J., Dingwerth A., Selgrad M., Venerito M., Stuebs P., Frauenschlaeger K., et al. Adenocarcinomas at different positions at the gastro-oesophageal junction show distinct association with gastritis and gastric preneoplastic conditions. None. 2015;27:492-500|https://www.ncbi.nlm.nih.gov/pubmed/25822856|952
Magenkarzinom|"2"|2019|Messmann, Helmut|Hintergrund|||Letztautor|Probst A., Golger D., Arnholdt H., Messmann H. Endoscopic submucosal dissection of early cancers, flat adenomas, and submucosal tumors in the gastrointestinal tract. None. 2009;7:149-55|https://www.ncbi.nlm.nih.gov/pubmed/19032991|952
Magenkarzinom|"2"|2019|Meyer, Hans-Joachim|Hintergrund|||Erstautor|Meyer H. J. The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer. None. 2005;31:595-604|https://www.ncbi.nlm.nih.gov/pubmed/15919174|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Erstautor|Al-Batran S. E., Homann N., Pauligk C., Illerhaus G., Martens U. M., Stoehlmacher J., et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. None. 2017;3:1237-1244|https://www.ncbi.nlm.nih.gov/pubmed/28448662|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Erstautor|Al-Batran S. E., Goetze T. O., Mueller D. W., Vogel A., Winkler M., Lorenzen S., et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. None. 2017;17:893|https://www.ncbi.nlm.nih.gov/pubmed/29282088|952
Magenkarzinom|"2"|2019|Lorenzen, Sylvie|Hintergrund|||Standard|Al-Batran S. E., Goetze T. O., Mueller D. W., Vogel A., Winkler M., Lorenzen S., et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. None. 2017;17:893|https://www.ncbi.nlm.nih.gov/pubmed/29282088|952
Magenkarzinom|"2"|2019|Lordick, Florian|Konsensbasierte Empfehlung|A|False|Erstautor|Lordick F., Ott K., Novotny A., Schuhmacher C., Siewert J. R. [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]. None. 2007;78:792-801|https://www.ncbi.nlm.nih.gov/pubmed/17676284|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Erstautor|Lordick F., Ott K., Novotny A., Schuhmacher C., Siewert J. R. [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]. None. 2007;78:792-801|https://www.ncbi.nlm.nih.gov/pubmed/17676284|952
Magenkarzinom|"2"|2019|Ott, Katja|Konsensbasierte Empfehlung|A|False|Standard|Lordick F., Ott K., Novotny A., Schuhmacher C., Siewert J. R. [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]. None. 2007;78:792-801|https://www.ncbi.nlm.nih.gov/pubmed/17676284|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Standard|Lordick F., Ott K., Novotny A., Schuhmacher C., Siewert J. R. [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]. None. 2007;78:792-801|https://www.ncbi.nlm.nih.gov/pubmed/17676284|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Evidenzbasierte Empfehlung|0|False|Erstautor|Al-Batran S. E., Hofheinz R. D., Pauligk C., Kopp H. G., Haag G. M., Luley K. B., et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. None. 2016;17:1697-1708|https://www.ncbi.nlm.nih.gov/pubmed/27776843|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Erstautor|Al-Batran S. E., Hofheinz R. D., Pauligk C., Kopp H. G., Haag G. M., Luley K. B., et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. None. 2016;17:1697-1708|https://www.ncbi.nlm.nih.gov/pubmed/27776843|952
Magenkarzinom|"2"|2019|Lordick, Florian|Evidenzbasierte Empfehlung|A|False|Standard|Schuhmacher C., Gretschel S., Lordick F., Reichardt P., Hohenberger W., Eisenberger C. F., et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. None. 2010;28:5210-8|https://www.ncbi.nlm.nih.gov/pubmed/21060024|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Standard|Schuhmacher C., Gretschel S., Lordick F., Reichardt P., Hohenberger W., Eisenberger C. F., et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. None. 2010;28:5210-8|https://www.ncbi.nlm.nih.gov/pubmed/21060024|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Evidenzbasierte Empfehlung|A|False|Erstautor|Al-Batran S. E., Hartmann J. T., Probst S., Schmalenberg H., Hollerbach S., Hofheinz R., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. None. 2008;26:1435-42|https://www.ncbi.nlm.nih.gov/pubmed/18349393|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Erstautor|Al-Batran S. E., Hartmann J. T., Probst S., Schmalenberg H., Hollerbach S., Hofheinz R., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. None. 2008;26:1435-42|https://www.ncbi.nlm.nih.gov/pubmed/18349393|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Standard|Heger U., Bader F., Lordick F., Burian M., Langer R., Dobritz M., et al. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. None. 2014;17:478-88|https://www.ncbi.nlm.nih.gov/pubmed/23996162|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Standard|Beer A. J., Wieder H. A., Lordick F., Ott K., Fischer M., Becker K., et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. None. 2006;239:472-80|https://www.ncbi.nlm.nih.gov/pubmed/16543584|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Standard|Beer A. J., Wieder H. A., Lordick F., Ott K., Fischer M., Becker K., et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. None. 2006;239:472-80|https://www.ncbi.nlm.nih.gov/pubmed/16543584|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Standard|Weber W. A., Ott K., Becker K., Dittler H. J., Helmberger H., Avril N. E., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. None. 2001;19:3058-65|https://www.ncbi.nlm.nih.gov/pubmed/11408502|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Erstautor|Ott K., Fink U., Becker K., Stahl A., Dittler H. J., Busch R., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. None. 2003;21:4604-10|https://www.ncbi.nlm.nih.gov/pubmed/14673049|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Erstautor|Lordick F., Ott K., Krause B. J., Weber W. A., Becker K., Stein H. J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. None. 2007;8:797-805|https://www.ncbi.nlm.nih.gov/pubmed/17693134|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Standard|Lordick F., Ott K., Krause B. J., Weber W. A., Becker K., Stein H. J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. None. 2007;8:797-805|https://www.ncbi.nlm.nih.gov/pubmed/17693134|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Standard|Ott K., Herrmann K., Lordick F., Wieder H., Weber W. A., Becker K., et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. None. 2008;14:2012-8|https://www.ncbi.nlm.nih.gov/pubmed/18381939|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Erstautor|Ott K., Herrmann K., Lordick F., Wieder H., Weber W. A., Becker K., et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. None. 2008;14:2012-8|https://www.ncbi.nlm.nih.gov/pubmed/18381939|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Erstautor|Ott K., Herrmann K., Schuster T., Langer R., Becker K., Wieder H. A., et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. None. 2011;18:3316-23|https://www.ncbi.nlm.nih.gov/pubmed/21537865|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Erstautor|Ott K., Blank S., Becker K., Langer R., Weichert W., Roth W., et al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. None. 2013;398:239-49|https://www.ncbi.nlm.nih.gov/pubmed/23269519|952
Magenkarzinom|"2"|2019|Ott, Katja|Hintergrund|||Standard|Becker K., Mueller J. D., Schulmacher C., Ott K., Fink U., Busch R., et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. None. 2003;98:1521-30|https://www.ncbi.nlm.nih.gov/pubmed/14508841|952
Magenkarzinom|"2"|2019|Baretton, Gustavo|Hintergrund|||Standard|Ruschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. None. 2010;457:299-307|https://www.ncbi.nlm.nih.gov/pubmed/20665045|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Standard|Spoerl S., Novotny A., Al-Batran S. E., Lordick F., Thuss-Patience P., Pauligk C., et al. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. None. 2017;90:26-33|https://www.ncbi.nlm.nih.gov/pubmed/29272782|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Standard|Spoerl S., Novotny A., Al-Batran S. E., Lordick F., Thuss-Patience P., Pauligk C., et al. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. None. 2017;90:26-33|https://www.ncbi.nlm.nih.gov/pubmed/29272782|952
Magenkarzinom|"2"|2019|Thuss-Patience, Peter|Hintergrund|||Standard|Spoerl S., Novotny A., Al-Batran S. E., Lordick F., Thuss-Patience P., Pauligk C., et al. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. None. 2017;90:26-33|https://www.ncbi.nlm.nih.gov/pubmed/29272782|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Standard|Lorenzen S., Thuss-Patience P., Al-Batran S. E., Lordick F., Haller B., Schuster T., et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. None. 2013;24:2068-73|https://www.ncbi.nlm.nih.gov/pubmed/23592699|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Standard|Lorenzen S., Thuss-Patience P., Al-Batran S. E., Lordick F., Haller B., Schuster T., et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. None. 2013;24:2068-73|https://www.ncbi.nlm.nih.gov/pubmed/23592699|952
Magenkarzinom|"2"|2019|Lorenzen, Sylvie|Hintergrund|||Erstautor|Lorenzen S., Thuss-Patience P., Al-Batran S. E., Lordick F., Haller B., Schuster T., et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. None. 2013;24:2068-73|https://www.ncbi.nlm.nih.gov/pubmed/23592699|952
Magenkarzinom|"2"|2019|Thuss-Patience, Peter|Hintergrund|||Standard|Lorenzen S., Thuss-Patience P., Al-Batran S. E., Lordick F., Haller B., Schuster T., et al. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. None. 2013;24:2068-73|https://www.ncbi.nlm.nih.gov/pubmed/23592699|952
Magenkarzinom|"2"|2019|Meyer, Hans-Joachim|Hintergrund|||Standard|Stahl M., Walz M. K., Stuschke M., Lehmann N., Meyer H. J., Riera-Knorrenschild J., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. None. 2009;27:851-6|https://www.ncbi.nlm.nih.gov/pubmed/19139439|952
Magenkarzinom|"2"|2019|Budach, Wilfried|Hintergrund|||Standard|Kollmannsberger C., Budach W., Stahl M., Schleucher N., Hehr T., Wilke H., et al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. None. 2005;16:1326-33|https://www.ncbi.nlm.nih.gov/pubmed/15919686|952
Magenkarzinom|"2"|2019|Budach, Wilfried|Hintergrund|||Standard|Oechsle K., Bokemeyer C., Hartmann J. T., Budach W., Trarbach T., Stahl M., et al. Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. None. 2009;135:163-72|https://www.ncbi.nlm.nih.gov/pubmed/18825411|952
Magenkarzinom|"2"|2019|Budach, Wilfried|Hintergrund|||Letztautor|Welz S., Hehr T., Kollmannsberger C., Bokemeyer C., Belka C., Budach W. Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer. None. 2007;69:1429-35|https://www.ncbi.nlm.nih.gov/pubmed/17692474|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Erstautor|Al-Batran S. E., Ajani J. A. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. None. 2010;116:2511-8|https://www.ncbi.nlm.nih.gov/pubmed/20301114|952
Magenkarzinom|"2"|2019|Thuss-Patience, Peter|Evidenzbasierte Empfehlung|A|False|Erstautor|Thuss-Patience P. C., Kretzschmar A., Bichev D., Deist T., Hinke A., Breithaupt K., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). None. 2011;47:2306-14|https://www.ncbi.nlm.nih.gov/pubmed/21742485|952
Magenkarzinom|"2"|2019|Thuss-Patience, Peter|Hintergrund|||Erstautor|Thuss-Patience P. C., Kretzschmar A., Bichev D., Deist T., Hinke A., Breithaupt K., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). None. 2011;47:2306-14|https://www.ncbi.nlm.nih.gov/pubmed/21742485|952
Magenkarzinom|"2"|2019|Thuss-Patience, Peter|Evidenzbasierte Empfehlung|A|False|Standard|Janowitz T., Thuss-Patience P., Marshall A., Kang J. H., Connell C., Cook N., et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. None. 2016;114:381-7|https://www.ncbi.nlm.nih.gov/pubmed/26882063|952
Magenkarzinom|"2"|2019|Thuss-Patience, Peter|Hintergrund|||Standard|Janowitz T., Thuss-Patience P., Marshall A., Kang J. H., Connell C., Cook N., et al. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. None. 2016;114:381-7|https://www.ncbi.nlm.nih.gov/pubmed/26882063|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Standard|Kripp M., Al-Batran S. E., Rosowski J., Pauligk C., Homann N., Hartmann J. T., et al. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). None. 2014;17:181-7|https://www.ncbi.nlm.nih.gov/pubmed/23455717|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Evidenzbasierte Empfehlung|B|False|Erstautor|Al-Batran S. E., Hartmann J. T., Hofheinz R., Homann N., Rethwisch V., Probst S., et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. None. 2008;19:1882-7|https://www.ncbi.nlm.nih.gov/pubmed/18669868|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Erstautor|Al-Batran S. E., Hartmann J. T., Hofheinz R., Homann N., Rethwisch V., Probst S., et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. None. 2008;19:1882-7|https://www.ncbi.nlm.nih.gov/pubmed/18669868|952
Magenkarzinom|"2"|2019|Lutz, Manfred P.|Evidenzbasierte Empfehlung|B|False|Erstautor|Lutz M. P., Wilke H., Wagener D. J., Vanhoefer U., Jeziorski K., Hegewisch-Becker S., et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. None. 2007;25:2580-5|https://www.ncbi.nlm.nih.gov/pubmed/17577037|952
Magenkarzinom|"2"|2019|Lutz, Manfred P.|Hintergrund|||Erstautor|Lutz M. P., Wilke H., Wagener D. J., Vanhoefer U., Jeziorski K., Hegewisch-Becker S., et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. None. 2007;25:2580-5|https://www.ncbi.nlm.nih.gov/pubmed/17577037|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Standard|Lordick F., Al-Batran S. E., Dietel M., Gaiser T., Hofheinz R. D., Kirchner T., et al. HER2 testing in gastric cancer: results of a German expert meeting. None. 2017;143:835-841|https://www.ncbi.nlm.nih.gov/pubmed/28285403|952
Magenkarzinom|"2"|2019|Lordick, Florian|Hintergrund|||Erstautor|Lordick F., Al-Batran S. E., Dietel M., Gaiser T., Hofheinz R. D., Kirchner T., et al. HER2 testing in gastric cancer: results of a German expert meeting. None. 2017;143:835-841|https://www.ncbi.nlm.nih.gov/pubmed/28285403|952
Magenkarzinom|"2"|2019|Al-Batran, Salah|Hintergrund|||Erstautor|Al-Batran S. E., Pauligk C., Homann N., Hartmann J. T., Moehler M., Probst S., et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). None. 2013;49:835-42|https://www.ncbi.nlm.nih.gov/pubmed/23063354|952
Magenkarzinom|"2"|2019|Fischbach, Wolfgang|Evidenzbasiertes Statement||False|Erstautor|Fischbach W., Malfertheiner P., Lynen Jansen P., Bolten W., Bornschein J., Buderus S., et al. [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. None. 2016;54:327-63|https://www.ncbi.nlm.nih.gov/pubmed/27512738|952
Magenkarzinom|"2"|2019|Fischbach, Wolfgang|Hintergrund|||Erstautor|Fischbach W., Malfertheiner P., Lynen Jansen P., Bolten W., Bornschein J., Buderus S., et al. [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. None. 2016;54:327-63|https://www.ncbi.nlm.nih.gov/pubmed/27512738|952
Magenkarzinom|"2"|2019|Arends, Jann|Evidenzbasierte Empfehlung|B|False|Erstautor|Arends J. Bertz H. Bischoff S. C. Fietkau R. Hermann H. J. Holm E. … DGEM Steering Committee. S3-Leitline der Deutschen Gesellschaft für Ernährungsmedizin e. V. (DGEM) in Kooperation mit der Deutschen Gesellschaft für Hämatologie und Onkologie e. V. (DGHO) der Arbeitsgemeinschaft „Supportive Maßnahmen in der Onkologie Rehabilitation und Sozialmedizin“ der Deutschen Krebsgesellschaft (ASORS) und der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE). Klinische Ernährung in der Onkologie. None. 2015;40:e1–e74.||952
Magenkarzinom|"2"|2019|Arends, Jann|Hintergrund|||Erstautor|Arends J. Bertz H. Bischoff S. C. Fietkau R. Hermann H. J. Holm E. … DGEM Steering Committee. S3-Leitline der Deutschen Gesellschaft für Ernährungsmedizin e. V. (DGEM) in Kooperation mit der Deutschen Gesellschaft für Hämatologie und Onkologie e. V. (DGHO) der Arbeitsgemeinschaft „Supportive Maßnahmen in der Onkologie Rehabilitation und Sozialmedizin“ der Deutschen Krebsgesellschaft (ASORS) und der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE). Klinische Ernährung in der Onkologie. None. 2015;40:e1–e74.||952
Magenkarzinom|"2"|2019|Arends, Jann|Hintergrund|||Erstautor|Arends J., Bachmann P., Baracos V., Barthelemy N., Bertz H., Bozzetti F., et al. ESPEN guidelines on nutrition in cancer patients. None. 2017;36:11-48|https://www.ncbi.nlm.nih.gov/pubmed/27637832|952
Magenkarzinom|"2"|2019|Arends, Jann|Hintergrund|||Erstautor|Arends J. Vitamin D in oncology. None. 2011;18:176-84|https://www.ncbi.nlm.nih.gov/pubmed/21934317|952
Magenkarzinom|"2"|2019|Weimann, Arved|Evidenzbasierte Empfehlung|A|False|Erstautor|Weimann A., Braga M., Carli F., Higashiguchi T., Hubner M., Klek S., et al. ESPEN guideline: Clinical nutrition in surgery. None. 2017;36:623-650|https://www.ncbi.nlm.nih.gov/pubmed/28385477|952
Magenkarzinom|"2"|2019|Weimann, Arved|Hintergrund|||Erstautor|Weimann A., Braga M., Carli F., Higashiguchi T., Hubner M., Klek S., et al. ESPEN guideline: Clinical nutrition in surgery. None. 2017;36:623-650|https://www.ncbi.nlm.nih.gov/pubmed/28385477|952
Magenkarzinom|"2"|2019|Ebert, Matthias|Hintergrund|||Standard|Friess H., Bohm J., Ebert M., Buchler M. Enzyme treatment after gastrointestinal surgery. None. 1993;54 Suppl 2:48-53|https://www.ncbi.nlm.nih.gov/pubmed/8224572|952
Magenkarzinom|"2"|2019|Quante, Michael|Hintergrund|||Erstautor|Quante M., Bhagat G., Abrams J.A., Marrache F., Good P., Lee M.D., et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. . 2012;:||952
Magenkarzinom|"2"|2019|Schmiegel, Wolff|Konsensbasierte Empfehlung|B|False|Erstautor|Schmiegel W., Buchberger B., Follmann M., Graeven U., Heinemann V., Langer T., et al. S3-Leitlinie – Kolorektales Karzinom. None. 2017;55:1344-1498|https://www.ncbi.nlm.nih.gov/pubmed/29212104|952
Magenkarzinom|"2"|2019|Schmiegel, Wolff|Hintergrund|||Erstautor|Schmiegel W., Buchberger B., Follmann M., Graeven U., Heinemann V., Langer T., et al. S3-Leitlinie – Kolorektales Karzinom. None. 2017;55:1344-1498|https://www.ncbi.nlm.nih.gov/pubmed/29212104|952
DLBCL|"1.0"|2022|Horneber, Markus|Hintergrund|||Standard|Blödt S, Mittring N, Schützler L, Fischer F, Holmberg C, Horneber M, et al. A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study. BMC Cancer. 2016;16:843|https://pubmed.ncbi.nlm.nih.gov/27809814/|835
DLBCL|"1.0"|2022|Horneber, Markus|Hintergrund|||Erstautor|Horneber M, van Ackeren G, Fischer F, Kappauf H, Birkmann J. Addressing Unmet Information Needs: Results of a Clinician-Led Consultation Service About Complementary and Alternative Medicine for Cancer Patients and Their Relatives. Integr Cancer Ther. 2018;17:1172-82|https://pubmed.ncbi.nlm.nih.gov/30352519/|835
DLBCL|"1.0"|2022|Skoetz, Nicole|Hintergrund|||Letztautor|Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N. Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev. 2019;1:CD009075|https://pubmed.ncbi.nlm.nih.gov/30702150/|835
DLBCL|"1.0"|2022|Rieger, Christina|Hintergrund|||Erstautor|Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol. 2018;29:1354-65|https://pubmed.ncbi.nlm.nih.gov/29688266/|835
DLBCL|"1.0"|2022|Rieger, Christina|Hintergrund|||Letztautor|Christopeit M, Rieger C. Vakzinierung gegen die saisonale Influenza unter oder nach der Therapie mit Anti-CD20-Antikorpern - Stellungname vom 2.11.2020. . 2020;Online:|https://www.dgho.de/publikationen/stellungnahmen/gute-aerztliche-praxis/grippeschutzimpfung_anti-cd20-antikoerper/agiho_vakzinierung_saisonale_influenza_anti_b_zell_20201031.pdf|835
DLBCL|"1.0"|2022|Eich, Hans-Theodor|Evidenzbasierte Empfehlung|B|False|Standard|Kriz J, Spickermann M, Lehrich P, Schmidberger H, Reinartz G, Eich H, et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol. 2015;191:717-25|https://pubmed.ncbi.nlm.nih.gov/25876905/|835
DLBCL|"1.0"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Kriz J, Spickermann M, Lehrich P, Schmidberger H, Reinartz G, Eich H, et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol. 2015;191:717-25|https://pubmed.ncbi.nlm.nih.gov/25876905/|835
DLBCL|"1.0"|2022|Schmidberger, Heinz|Evidenzbasierte Empfehlung|B|False|Standard|Kriz J, Spickermann M, Lehrich P, Schmidberger H, Reinartz G, Eich H, et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol. 2015;191:717-25|https://pubmed.ncbi.nlm.nih.gov/25876905/|835
DLBCL|"1.0"|2022|Schmidberger, Heinz|Hintergrund|||Standard|Kriz J, Spickermann M, Lehrich P, Schmidberger H, Reinartz G, Eich H, et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol. 2015;191:717-25|https://pubmed.ncbi.nlm.nih.gov/25876905/|835
DLBCL|"1.0"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Mikhaeel NG, Milgrom SA, Terezakis S, Berthelsen AK, Hodgson D, Eich HT, et al. The optimal use of imaging in radiation therapy for lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2019;104:501-12|https://pubmed.ncbi.nlm.nih.gov/30763664/|835
DLBCL|"1.0"|2022|Borchmann, Peter|Evidenzbasierte Empfehlung|A|False|Standard|Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250-9|https://pubmed.ncbi.nlm.nih.gov/23168367/|835
DLBCL|"1.0"|2022|Borchmann, Peter|Hintergrund|||Standard|Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250-9|https://pubmed.ncbi.nlm.nih.gov/23168367/|835
DLBCL|"1.0"|2022|Frontzek, Fabian|Evidenzbasierte Empfehlung|B|False|Erstautor|Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/|835
DLBCL|"1.0"|2022|Frontzek, Fabian|Hintergrund|||Erstautor|Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021;8:e267-77|https://pubmed.ncbi.nlm.nih.gov/33667420/|835
DLBCL|"1.0"|2022|Friedrichs, Birte|Hintergrund|||Erstautor|Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol. 2019;184:760-8|https://pubmed.ncbi.nlm.nih.gov/30520013/|835
DLBCL|"1.0"|2022|Dietlein, Markus|Hintergrund|||Standard|Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-8|https://pubmed.ncbi.nlm.nih.gov/17242397/|835
DLBCL|"1.0"|2022|Oertel, Michael|Hintergrund|||Standard|Pepper NB, Oertel M, Kittel C, Kröger KJ, Elsayad K, Haverkamp U, et al. Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma. Strahlenther Onkol. 2021;197:56-62|https://pubmed.ncbi.nlm.nih.gov/32945894/|835
DLBCL|"1.0"|2022|Berdel, Christian|Hintergrund|||Standard|Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:||835
DLBCL|"1.0"|2022|Held, Gerhard|Hintergrund|||Erstautor|Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:||835
DLBCL|"1.0"|2022|Ott, German|Hintergrund|||Standard|Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:||835
DLBCL|"1.0"|2022|Thurner, Lorenz|Hintergrund|||Standard|Held G, Thurner L, Poeschel V, Berdel C, Ott G, Schmidt C, et al. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance. EHA Library. 2020;:||835
DLBCL|"1.0"|2022|Chapuy, Björn|Hintergrund|||Erstautor|Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019;134:2369-82|https://pubmed.ncbi.nlm.nih.gov/31697821/|835
DLBCL|"1.0"|2022|Chapuy, Björn|Hintergrund|||Erstautor|Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869-81|https://pubmed.ncbi.nlm.nih.gov/26702065/|835
DLBCL|"1.0"|2022|Chapuy, Björn|Hintergrund|||Erstautor|Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679-90|https://pubmed.ncbi.nlm.nih.gov/29713087/|835
DLBCL|"1.0"|2022|Held, Gerhard|Hintergrund|||Erstautor|Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31:4115-22|https://pubmed.ncbi.nlm.nih.gov/24062391/|835
DLBCL|"1.0"|2022|Klapper, Wolfram|Hintergrund|||Letztautor|Johl A, Lengfelder E, Hiddemann W, Klapper W. Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel. Ann Hematol. 2016;95:1281-6|https://pubmed.ncbi.nlm.nih.gov/27236576/|835
DLBCL|"1.0"|2022|Klapper, Wolfram|Hintergrund|||Erstautor|Klapper W, Hoster E, Rölver L, Schrader C, Janssen D, Tiemann M, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. J Clin Oncol. 2007;25:3330-6|https://pubmed.ncbi.nlm.nih.gov/17664481/|835
DLBCL|"1.0"|2022|Ott, German|Hintergrund|||Standard|Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27:1323-9|https://pubmed.ncbi.nlm.nih.gov/27117536/|835
DLBCL|"1.0"|2022|Liersch, Rüdiger|Hintergrund|||Standard|Pohlen M, Gerth HU, Liersch R, Koschmieder S, Mesters RM, Kessler T, et al. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. Am J Hematol. 2011;86:E61-4|https://pubmed.ncbi.nlm.nih.gov/21898532/|835
DLBCL|"1.0"|2022|Borchmann, Peter|Hintergrund|||Standard|Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45-56|https://pubmed.ncbi.nlm.nih.gov/30501490/|835
DLBCL|"1.0"|2022|Trümper, Lorenz|Hintergrund|||Standard|Pfreundschuh MG, Trümper L, Ma D, Österborg A, Pettengell R, Trneny M, et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. . 2004;22:6500||835
DLBCL|"1.0"|2022|Glaß, Bertram|Hintergrund|||Letztautor|Held G, Glaß B. Diffuses grosszelliges B-Zell Lymphom: Primar- und Rezidivtherapie. . 2019;:880-91||835
DLBCL|"1.0"|2022|Held, Gerhard|Hintergrund|||Erstautor|Held G, Glaß B. Diffuses grosszelliges B-Zell Lymphom: Primar- und Rezidivtherapie. . 2019;:880-91||835
DLBCL|"1.0"|2022|Frontzek, Fabian|Hintergrund|||Letztautor|Schmitz N, Frontzek F. CNS prophylaxis in DLBCL: Time to say goodbye?. Blood. 2022;139:315-7|https://pubmed.ncbi.nlm.nih.gov/35050332/|835
DLBCL|"1.0"|2022|Frontzek, Fabian|Hintergrund|||Erstautor|Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12:5183|https://pubmed.ncbi.nlm.nih.gov/34465776/|835
DLBCL|"1.0"|2022|Gerlach, Christina|Hintergrund|||Erstautor|Gerlach C, Alt-Epping B, Oechsle K. Specific challenges in end-of-life care for patients with hematological malignancies. Curr Opin Support Palliat Care. 2019;13:369-79|https://pubmed.ncbi.nlm.nih.gov/31644451/|835
DLBCL|"1.0"|2022|Klapper, Wolfram|Hintergrund|||Letztautor|Masqué-Soler N, Szczepanowski M, Kohler CW, Spang R, Klapper W. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood. 2013;122:1985-6|https://pubmed.ncbi.nlm.nih.gov/24030260/|835
DLBCL|"1.0"|2022|Ott, German|Hintergrund|||Standard|Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82|https://pubmed.ncbi.nlm.nih.gov/14504078/|835
DLBCL|"1.0"|2022|Held, Gerhard|Evidenzbasierte Empfehlung|A|False|Standard|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/|835
DLBCL|"1.0"|2022|Held, Gerhard|Hintergrund|||Standard|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/|835
DLBCL|"1.0"|2022|Kaddu-Mulindwa, Dominic|Evidenzbasierte Empfehlung|A|False|Erstautor|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/|835
DLBCL|"1.0"|2022|Kaddu-Mulindwa, Dominic|Hintergrund|||Erstautor|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/|835
DLBCL|"1.0"|2022|Thurner, Lorenz|Evidenzbasierte Empfehlung|A|False|Standard|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/|835
DLBCL|"1.0"|2022|Thurner, Lorenz|Hintergrund|||Standard|Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48:3550-9|https://pubmed.ncbi.nlm.nih.gov/33928400/|835
DLBCL|"1.0"|2022|Held, Gerhard|Hintergrund|||Erstautor|Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112-8|https://pubmed.ncbi.nlm.nih.gov/24493716/|835
DLBCL|"1.0"|2022|Kliesch, Sabine|Hintergrund|||Erstautor|Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, et al. Management of germ cell tumours of the testes in adult patients: German clinical practice guideline, part II - Recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy. Urol Int. 2021;105:181-91|https://pubmed.ncbi.nlm.nih.gov/33486494/|835
DLBCL|"1.0"|2022|Toth, Bettina|Hintergrund|||Erstautor|Toth B, Baston-Büst DM, Behre HM, Bielfeld A, Bohlmann M, Bühling K, et al. Diagnosis and treatment before assisted reproductive treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 2, hemostaseology, andrology, genetics and history of malignant disease. Geburtshilfe Frauenheilkd. 2019;79:1293-308|https://pubmed.ncbi.nlm.nih.gov/31875859/|835
DLBCL|"1.0"|2022|Held, Gerhard|Evidenzbasierte Empfehlung|A|True|Standard|Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/|835
DLBCL|"1.0"|2022|Held, Gerhard|Hintergrund|||Standard|Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/|835
DLBCL|"1.0"|2022|Thurner, Lorenz|Evidenzbasierte Empfehlung|A|True|Standard|Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/|835
DLBCL|"1.0"|2022|Thurner, Lorenz|Hintergrund|||Standard|Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271-81|https://pubmed.ncbi.nlm.nih.gov/31868632/|835
DLBCL|"1.0"|2022|Held, Gerhard|Hintergrund|||Standard|Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640-6|https://pubmed.ncbi.nlm.nih.gov/24297867/|835
DLBCL|"1.0"|2022|Held, Gerhard|Hintergrund|||Standard|Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276-84|https://pubmed.ncbi.nlm.nih.gov/22337718/|835
DLBCL|"1.0"|2022|Kliesch, Sabine|Hintergrund|||Standard|Dittrich R, Kliesch S, Schüring A, Balcerek M, Baston-Büst DM, Beck R, et al. Fertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM - Recommendations and statements for girls and women. Geburtshilfe Frauenheilkd. 2018;78:567-84|https://pubmed.ncbi.nlm.nih.gov/29962516/|835
Prävention Zervixkarzinom|"1.1"|2020|Schneider, Achim|Hintergrund|||Standard|Schwarz T. F., Spaczynski M., Schneider A., Wysocki J., Galaj A., Perona P., et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. None. 2009;27:581-7|https://www.ncbi.nlm.nih.gov/pubmed/19022320|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Erstautor|Petry K. U., Rinnau F., Bohmer G., Hollwitz B., Luyten A., Buttmann N., et al. Annual Papanicolaou screening for 5 years among human papillomavirus-negative women. None. 2013;13:379|https://www.ncbi.nlm.nih.gov/pubmed/23937771|658
Prävention Zervixkarzinom|"1.1"|2020|Schneider, Achim|Hintergrund|||Erstautor|Schneider A., Hoyer H., Lotz B., Leistritza S., Kuhne-Heid R., Nindl I., et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. None. 2000;89:529-34|https://www.ncbi.nlm.nih.gov/pubmed/11102899|658
Prävention Zervixkarzinom|"1.1"|2020|Klug, Stefanie|Evidenzbasiertes Statement||False|Erstautor|Klug S. J., Neis K. J., Harlfinger W., Malter A., Konig J., Spieth S., et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. None. 2013;132:2849-57|https://www.ncbi.nlm.nih.gov/pubmed/23175270|658
Prävention Zervixkarzinom|"1.1"|2020|Klug, Stefanie|Hintergrund|||Erstautor|Klug S. J., Neis K. J., Harlfinger W., Malter A., Konig J., Spieth S., et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. None. 2013;132:2849-57|https://www.ncbi.nlm.nih.gov/pubmed/23175270|658
Prävention Zervixkarzinom|"1.1"|2020|Neis, Klaus|Evidenzbasiertes Statement||False|Standard|Klug S. J., Neis K. J., Harlfinger W., Malter A., Konig J., Spieth S., et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. None. 2013;132:2849-57|https://www.ncbi.nlm.nih.gov/pubmed/23175270|658
Prävention Zervixkarzinom|"1.1"|2020|Neis, Klaus|Hintergrund|||Standard|Klug S. J., Neis K. J., Harlfinger W., Malter A., Konig J., Spieth S., et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. None. 2013;132:2849-57|https://www.ncbi.nlm.nih.gov/pubmed/23175270|658
Prävention Zervixkarzinom|"1.1"|2020|Iftner, Thomas|Hintergrund|||Letztautor|Stubenrauch F., Straub E., Fertey J., Iftner T. The E8 repression domain can replace the E2 transactivation domain for growth inhibition of HeLa cells by papillomavirus E2 proteins. None. 2007;121:2284-92|https://www.ncbi.nlm.nih.gov/pubmed/17583574|658
Prävention Zervixkarzinom|"1.1"|2020|Iftner, Thomas|Hintergrund|||Erstautor|Iftner T. HPV und Zervixkarzinom - Diagnostik und Prophylaxe. None. 2008;None:None||658
Prävention Zervixkarzinom|"1.1"|2020|Jordan, Bodo|Hintergrund|||Standard|Griesser H., Marquardt K., Jordan B., al. Et. Münchner Nomenklatur III. None. 2013;None:1042-1048||658
Prävention Zervixkarzinom|"1.1"|2020|Iftner, Thomas|Hintergrund|||Standard|Liebrich C., Brummer O., Von Wasielewski R., Wegener G., Meijer C., Iftner T., et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. None. 2009;30:45-8|https://www.ncbi.nlm.nih.gov/pubmed/19317256|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Standard|Dillner J., Rebolj M., Birembaut P., Petry K. U., Szarewski A., Munk C., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. None. 2008;337:a1754|https://www.ncbi.nlm.nih.gov/pubmed/18852164|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Erstautor|Petry K. U., Scheffel D., Bode U., Gabrysiak T., Kochel H., Kupsch E., et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. None. 1994;57:836-40|https://www.ncbi.nlm.nih.gov/pubmed/7911455|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Erstautor|Petry K. U., Kochel H., Bode U., Schedel I., Niesert S., Glaubitz M., et al. Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. None. 1996;60:30-4|https://www.ncbi.nlm.nih.gov/pubmed/8557224|658
Prävention Zervixkarzinom|"1.1"|2020|Ikenberg, Hans|Evidenzbasiertes Statement||False|Erstautor|Ikenberg H., Bergeron C., Schmidt D., Griesser H., Alameda F., Angeloni C., et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. None. 2013;105:1550-7|https://www.ncbi.nlm.nih.gov/pubmed/24096620|658
Prävention Zervixkarzinom|"1.1"|2020|Ikenberg, Hans|Hintergrund|||Erstautor|Ikenberg H., Bergeron C., Schmidt D., Griesser H., Alameda F., Angeloni C., et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. None. 2013;105:1550-7|https://www.ncbi.nlm.nih.gov/pubmed/24096620|658
Prävention Zervixkarzinom|"1.1"|2020|Schmidt, Dietmar|Evidenzbasiertes Statement||False|Standard|Ikenberg H., Bergeron C., Schmidt D., Griesser H., Alameda F., Angeloni C., et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. None. 2013;105:1550-7|https://www.ncbi.nlm.nih.gov/pubmed/24096620|658
Prävention Zervixkarzinom|"1.1"|2020|Schmidt, Dietmar|Hintergrund|||Standard|Ikenberg H., Bergeron C., Schmidt D., Griesser H., Alameda F., Angeloni C., et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. None. 2013;105:1550-7|https://www.ncbi.nlm.nih.gov/pubmed/24096620|658
Prävention Zervixkarzinom|"1.1"|2020|Schmidt, Dietmar|Evidenzbasierte Empfehlung|B|False|Erstautor|Schmidt D., Bergeron C., Denton K. J., Ridder R., European CINtec Cytology Study Group. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. . 2011;119:158-66|https://www.ncbi.nlm.nih.gov/pubmed/21442767|658
Prävention Zervixkarzinom|"1.1"|2020|Schmidt, Dietmar|Hintergrund|||Erstautor|Schmidt D., Bergeron C., Denton K. J., Ridder R., European CINtec Cytology Study Group. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. . 2011;119:158-66|https://www.ncbi.nlm.nih.gov/pubmed/21442767|658
Prävention Zervixkarzinom|"1.1"|2020|Ikenberg, Hans|Evidenzbasierte Empfehlung|B|False|Standard|Bergeron C., Ikenberg H., Sideri M., Denton K., Bogers J., Schmidt D., et al. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. . 2015;123:373-81|https://www.ncbi.nlm.nih.gov/pubmed/25891096|658
Prävention Zervixkarzinom|"1.1"|2020|Schmidt, Dietmar|Evidenzbasierte Empfehlung|B|False|Standard|Bergeron C., Ikenberg H., Sideri M., Denton K., Bogers J., Schmidt D., et al. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. . 2015;123:373-81|https://www.ncbi.nlm.nih.gov/pubmed/25891096|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Erstautor|Petry K. U., Schmidt D., Scherbring S., Luyten A., Reinecke-Luthge A., Bergeron C., et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. . 2011;121:505-9|https://www.ncbi.nlm.nih.gov/pubmed/21420158|658
Prävention Zervixkarzinom|"1.1"|2020|Schmidt, Dietmar|Hintergrund|||Standard|Petry K. U., Schmidt D., Scherbring S., Luyten A., Reinecke-Luthge A., Bergeron C., et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. . 2011;121:505-9|https://www.ncbi.nlm.nih.gov/pubmed/21420158|658
Prävention Zervixkarzinom|"1.1"|2020|Menton, Michael|Hintergrund|||Standard|Bornstein J., Bentley J., Bosze P., Girardi F., Haefner H., Menton M., et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. . 2012;120:166-72|https://www.ncbi.nlm.nih.gov/pubmed/22914406|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Standard|Moss E. L., Arbyn M., Dollery E., Leeson S., Petry K. U., Nieminen P., et al. European Federation of Colposcopy quality standards Delphi consultation. . 2013;170:255-8|https://www.ncbi.nlm.nih.gov/pubmed/23891389|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Erstautor|Petry K. U., Luyten A., Scherbring S. Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. . 2013;128:282-7|https://www.ncbi.nlm.nih.gov/pubmed/23088926|658
Prävention Zervixkarzinom|"1.1"|2020|Schneider, Volker|Hintergrund|||Letztautor|Marquardt K., Buettner H. H., Broschewitz U., Barten M., Schneider V. Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause. . 2011;:||658
Prävention Zervixkarzinom|"1.1"|2020|Klug, Stefanie|Hintergrund|||Erstautor|Klug S. J., Taylor K. J., Scheidemann-Wesp U., Lautz D., Guther B., Potthoff P., et al. Participation in cervical cancer screening in Germany. . 2010;51:431-2|https://www.ncbi.nlm.nih.gov/pubmed/20736032|658
Prävention Zervixkarzinom|"1.1"|2020|Dannecker, Christian|Hintergrund|||Erstautor|Dannecker C., Siebert U., Thaler C. J., Kiermeir D., Hepp H., Hillemanns P. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. . 2004;15:863-9|https://www.ncbi.nlm.nih.gov/pubmed/15151941|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Standard|Dannecker C., Siebert U., Thaler C. J., Kiermeir D., Hepp H., Hillemanns P. Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics. . 2004;15:863-9|https://www.ncbi.nlm.nih.gov/pubmed/15151941|658
Prävention Zervixkarzinom|"1.1"|2020|Dannecker, Christian|Evidenzbasierte Empfehlung|A|False|Standard|Hillemanns P., Kimmig R., Huttemann U., Dannecker C., Thaler C. J. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. . 1999;354:1970|https://www.ncbi.nlm.nih.gov/pubmed/10622304|658
Prävention Zervixkarzinom|"1.1"|2020|Kimmig, Rainer|Evidenzbasierte Empfehlung|A|False|Standard|Hillemanns P., Kimmig R., Huttemann U., Dannecker C., Thaler C. J. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. . 1999;354:1970|https://www.ncbi.nlm.nih.gov/pubmed/10622304|658
Prävention Zervixkarzinom|"1.1"|2020|Iftner, Thomas|Hintergrund|||Letztautor|Kjaer S. K., Frederiksen K., Munk C., Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. None. 2010;102:1478-88|https://www.ncbi.nlm.nih.gov/pubmed/20841605|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Standard|Arbyn M., Kyrgiou M., Gondry J., Petry K. U., Paraskevaidis E. Long term outcomes for women treated for cervical precancer. . 2014;348:f7700|https://www.ncbi.nlm.nih.gov/pubmed/24423750|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Letztautor|Sroczynski G., Siebert U. Evidence Report: Decision analysis to evaluate benefits, harms and cost-effectiveness of different cervical cancer screening strategies to inform the S3 clinical guideline "Prevention of Cervical Cancer" in the context of the German health care system. . 2015;:||658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Erstautor|Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? [Editorial]. . 2003;4:143-150|pdf, C:\!Fulltext\Siebert\Siebert_2003_Eur J Health Econom_When should DA modeling be used in econom eval.pdf|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Erstautor|Siebert U. Transparente Entscheidungen in Public Health mittels systematischer Entscheidungsanalyse. . 2012;:517-535|pdf|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Evidenzbasiertes Statement||False|Erstautor|Siebert U., Alagoz O., Bayoumi A.M., Jahn B., Owens D.K., Cohen D.J., et al. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -3. . 2012;32:690-700|pdf|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Erstautor|Siebert U., Alagoz O., Bayoumi A.M., Jahn B., Owens D.K., Cohen D.J., et al. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -3. . 2012;32:690-700|pdf|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Erstautor|Siebert U., Muth C., Sroczynski G., Velasco-Garrido M., Gerhardus A., Gibis B. Dünnschichtpräparationen und computergestützte Untersuchung von Zervixabstrichen im Rahmen der Krebsfrüherkennung – Medizinische Effektivität, gesundheitsökonomische Evaluation und systematische Entscheidungsanalyse. Schriftenreihe Health Technology Assessment Bd. 35. . 2004;35:444|pdf|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Erstautor|Siebert U., Sroczynski G., Hillemanns P., Engel J., Stabenow R., Stegmaier C., et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. . 2006;16:185-92|https://www.ncbi.nlm.nih.gov/pubmed/16469759|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Standard|Caro J. J., Briggs A.H., Siebert U., Kuntz K.M., on behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -1. . 2012;32:667-77|pdf|658
Prävention Zervixkarzinom|"1.1"|2020|Siebert, Uwe|Hintergrund|||Standard|Drummond M. F., Schwartz J. S., Jonsson B., Luce B. R., Neumann P. J., Siebert U., et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. . 2008;24:244-58; discussion 362-8|https://www.ncbi.nlm.nih.gov/pubmed/18601792|658
Prävention Zervixkarzinom|"1.1"|2020|Jordan, Bodo|Hintergrund|||Letztautor|Griesser H., Breinl H., Jordan B. Gynäkologische Dysplasien werden klar zugeordnet. . 2014;111:A-640 / B-550 / C-530||658
Prävention Zervixkarzinom|"1.1"|2020|Jordan, Bodo|Hintergrund|||Standard|Griesser H., Marquardt K., Jordan B., Kueppers V., Gieseking F., Kuehn W. Zervix-Zytologie. Das Prozedere bei auffälligen Befunden. Kommentar zur Münchner Nomenklatur III. . 2015;56:10-13||658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Standard|Cuzick J., Clavel C., Petry K. U., Meijer C. J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. . 2006;119:1095-101|https://www.ncbi.nlm.nih.gov/pubmed/16586444|658
Prävention Zervixkarzinom|"1.1"|2020|Reich, Olaf|Hintergrund|||Standard|Tjalma W. A., Fiander A., Reich O., Powell N., Nowakowski A. M., Kirschner B., et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. None. 2013;132:854-67|https://www.ncbi.nlm.nih.gov/pubmed/22752992|658
Prävention Zervixkarzinom|"1.1"|2020|Iftner, Thomas|Hintergrund|||Standard|Poljak M., Cuzick J., Kocjan B. J., Iftner T., Dillner J., Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. . 2012;30 Suppl 5:F100-6|https://www.ncbi.nlm.nih.gov/pubmed/23199952|658
Prävention Zervixkarzinom|"1.1"|2020|Schneider, Achim|Hintergrund|||Erstautor|Schneider A. Screening for high grade cervical intraepithelial neoplasia and cancer by testing for high risk HPV, routine cytology or colposcopy. . 2000;89:529-534|https://www.ncbi.nlm.nih.gov/pubmed/11102899|658
Prävention Zervixkarzinom|"1.1"|2020|Menton, Michael|Hintergrund|||Standard|Petry K. U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. None. 2003;88:1570-7|https://www.ncbi.nlm.nih.gov/pubmed/12771924|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Erstautor|Petry K. U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. None. 2003;88:1570-7|https://www.ncbi.nlm.nih.gov/pubmed/12771924|658
Prävention Zervixkarzinom|"1.1"|2020|Klug, Stefanie|Hintergrund|||Erstautor|Klug S. J., Hukelmann M., Hollwitz B., Duzenli N., Schopp B., Petry K. U., et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. None. 2007;79:616-25|https://www.ncbi.nlm.nih.gov/pubmed/17385693|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Standard|Klug S. J., Hukelmann M., Hollwitz B., Duzenli N., Schopp B., Petry K. U., et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. None. 2007;79:616-25|https://www.ncbi.nlm.nih.gov/pubmed/17385693|658
Prävention Zervixkarzinom|"1.1"|2020|Iftner, Thomas|Hintergrund|||Erstautor|Iftner T., Eberle S., Iftner A., Holz B., Banik N., Quint W., et al. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. . 2010;82:1928-1939|https://www.ncbi.nlm.nih.gov/pubmed/20872721|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Erstautor|Petry K. U., Luyten A., Justus A., Iftner A., Strehlke S., Schulze-Rath R., et al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. None. 2012;12:367|https://www.ncbi.nlm.nih.gov/pubmed/23259726|658
Prävention Zervixkarzinom|"1.1"|2020|Schneider, Achim|Hintergrund|||Standard|Delere Y., Remschmidt C., Leuschner J., Schuster M., Fesenfeld M., Schneider A., et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. None. 2014;14:87|https://www.ncbi.nlm.nih.gov/pubmed/24552260|658
Prävention Zervixkarzinom|"1.1"|2020|Petry, K. Ulrich|Hintergrund|||Erstautor|Petry K. U., Luyten A., Justus A., Iftner A., Strehlke S., Reinecke-Luthge A., et al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. None. 2013;13:135|https://www.ncbi.nlm.nih.gov/pubmed/23497108|658
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Erstautor|Garbe C., Eigentler T. K., Bauer J., Blodorn-Schlicht N., Fend F., Hantschke M., et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. None. 2011;9:690-9|http://www.ncbi.nlm.nih.gov/pubmed/21651721|930
Malignes Melanom|"3.3"|2020|Loquai, Carmen|Hintergrund|||Standard|Schlamann M., Loquai C., Goericke S., Forsting M., Wanke I. [Cerebral MRI in neurological asymptomatic patients with malignant melanoma]. None. 2008;180:143-7|http://www.ncbi.nlm.nih.gov/pubmed/18098094|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Evidenzbasierte Empfehlung|A|False|Erstautor|Garbe C., Paul A., Kohler-Spath H., Ellwanger U., Stroebel W., Schwarz M., et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. None. 2003;21:520-9|http://www.ncbi.nlm.nih.gov/pubmed/12560444|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Erstautor|Garbe C., Paul A., Kohler-Spath H., Ellwanger U., Stroebel W., Schwarz M., et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. None. 2003;21:520-9|http://www.ncbi.nlm.nih.gov/pubmed/12560444|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Erstautor|Garbe C., Leiter U., Ellwanger U., Blaheta H. J., Meier F., Rassner G., et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. None. 2003;97:1737-1745||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Letztautor|Schmitz C., Brenner W., Henze E., Christophers E., Hauschild A. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. None. 2000;20:5059-5063||930
Malignes Melanom|"3.3"|2020|Flaig, Michael|Hintergrund|||Standard|Kunte C., Geimer T., Baumert J., Konz B., Volkenandt M., Flaig M., et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. . 2010;20:330-7|http://www.ncbi.nlm.nih.gov/pubmed/20526218|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Satzger I., Meier A., Hoy L., Volker B., Kapp A., Hauschild A., et al. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. . 2011;18:514-20|http://www.ncbi.nlm.nih.gov/pubmed/20839060|930
Malignes Melanom|"3.3"|2020|Reske, Sven|Hintergrund|||Standard|Satzger I., Klein M., Loser C., Reske S., Kapp A., Gutzmer R. Sentinel node biopsy in malignant melanoma. . 2010;16:1140-1149||930
Malignes Melanom|"3.3"|2020|Werner, Andreas|Hintergrund|||Letztautor|Keller M., Werner A. Aufklärung und Begleitung von Tumorpatienten. . 2006;12:55-61||930
Malignes Melanom|"3.3"|2020|Kleeberg, Ulrich|Hintergrund|||Erstautor|Kleeberg U. R., Tews J. T., Ruprecht T., Hoing M., Kuhlmann A., Runge C. Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. . 2005;13:303-10|http://www.ncbi.nlm.nih.gov/pubmed/15729552|930
Malignes Melanom|"3.3"|2020|Sander, Christian|Hintergrund|||Letztautor|Buhles N., Sander C. [Dermato-oncological rehabilitation]. . 2005;56:659-64|http://www.ncbi.nlm.nih.gov/pubmed/15889229|930
Malignes Melanom|"3.3"|2020|Pfannenberg, Christina|Hintergrund|||Erstautor|Pfannenberg C., Aschoff P., Schanz S., Eschmann S. M., Plathow C., Eigentler T. K., et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. . 2007;43:557-64|http://www.ncbi.nlm.nih.gov/pubmed/17224266|930
Malignes Melanom|"3.3"|2020|Pfannenberg, Christina|Hintergrund|||Standard|Muller-Horvat C., Radny P., Eigentler T. K., Schafer J., Pfannenberg C., Horger M., et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. . 2006;42:342-50|http://www.ncbi.nlm.nih.gov/pubmed/16364631|930
Malignes Melanom|"3.3"|2020|Stadler, Rudolf|Hintergrund|||Standard|Leiter U., Stadler R., Mauch C., Hohenberger W., Brockmeyer N., Berking C., et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. . 2016;17:757-67||930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Evidenzbasiertes Statement||False|Standard|Fuhrmann D., Lippold A., Borrosch F., Ellwanger U., Garbe C., Suter L. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas?. None. 2001;144:66-70||930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Standard|Fuhrmann D., Lippold A., Borrosch F., Ellwanger U., Garbe C., Suter L. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas?. None. 2001;144:66-70||930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Standard|Suciu S., Eggermont A. M. M., Lorigan P., Kirkwood J. M., Markovic S. N., Garbe C., et al. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. None. 2018;110:None|https://www.ncbi.nlm.nih.gov/pubmed/28922786|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Evidenzbasierte Empfehlung|A|False|Erstautor|Garbe C., Eigentler T. K., Keilholz U., Hauschild A., Kirkwood J. M. Systematic review of medical treatment in melanoma: current status and future prospects. . 2011;16:5-24|http://www.ncbi.nlm.nih.gov/pubmed/21212434|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Erstautor|Garbe C., Eigentler T. K., Keilholz U., Hauschild A., Kirkwood J. M. Systematic review of medical treatment in melanoma: current status and future prospects. . 2011;16:5-24|http://www.ncbi.nlm.nih.gov/pubmed/21212434|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Evidenzbasierte Empfehlung|A|False|Standard|Garbe C., Eigentler T. K., Keilholz U., Hauschild A., Kirkwood J. M. Systematic review of medical treatment in melanoma: current status and future prospects. . 2011;16:5-24|http://www.ncbi.nlm.nih.gov/pubmed/21212434|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Garbe C., Eigentler T. K., Keilholz U., Hauschild A., Kirkwood J. M. Systematic review of medical treatment in melanoma: current status and future prospects. . 2011;16:5-24|http://www.ncbi.nlm.nih.gov/pubmed/21212434|930
Malignes Melanom|"3.3"|2020|Keilholz, Ulrich|Evidenzbasierte Empfehlung|A|False|Standard|Garbe C., Eigentler T. K., Keilholz U., Hauschild A., Kirkwood J. M. Systematic review of medical treatment in melanoma: current status and future prospects. . 2011;16:5-24|http://www.ncbi.nlm.nih.gov/pubmed/21212434|930
Malignes Melanom|"3.3"|2020|Keilholz, Ulrich|Hintergrund|||Standard|Garbe C., Eigentler T. K., Keilholz U., Hauschild A., Kirkwood J. M. Systematic review of medical treatment in melanoma: current status and future prospects. . 2011;16:5-24|http://www.ncbi.nlm.nih.gov/pubmed/21212434|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Erstautor|Garbe C., Radny P., Linse R., Dummer R., Gutzmer R., Ulrich J., et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. . 2008;19:1195-201||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Eigentler Thomas K., Radny Peter, Hauschild Axel, Gutzmer Ralf, Linse Ruthild, Pfoehler Claudia, et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. . 2008;18:353-358||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Evidenzbasierte Empfehlung|A|False|Standard|Long G. V., Hauschild A., Santinami M., Atkinson V., Mandala M., Chiarion-Sileni V., et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. None. 2017;377:1813-1823|https://www.ncbi.nlm.nih.gov/pubmed/28891408|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Long G. V., Hauschild A., Santinami M., Atkinson V., Mandala M., Chiarion-Sileni V., et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. None. 2017;377:1813-1823|https://www.ncbi.nlm.nih.gov/pubmed/28891408|930
Malignes Melanom|"3.3"|2020|Kleeberg, Ulrich|Hintergrund|||Erstautor|Kleeberg U. R., Suciu S., Brocker E. B., Ruiter D. J., Chartier C., Lienard D., et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha 2b versus rIFN-gamma versus ISCADOR M (R) versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. . 2004;40:390-402|https://www.ncbi.nlm.nih.gov/pubmed/14746858|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Evidenzbasierte Empfehlung|0|False|Standard|Avril M. F., Aamdal S., Grob J. J., Hauschild A., Mohr P., Bonerandi J. J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. . 2004;22:1118-25||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Avril M. F., Aamdal S., Grob J. J., Hauschild A., Mohr P., Bonerandi J. J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. . 2004;22:1118-25||930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Evidenzbasierte Empfehlung|0|False|Standard|Avril M. F., Aamdal S., Grob J. J., Hauschild A., Mohr P., Bonerandi J. J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. . 2004;22:1118-25||930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Hintergrund|||Standard|Avril M. F., Aamdal S., Grob J. J., Hauschild A., Mohr P., Bonerandi J. J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. . 2004;22:1118-25||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Evidenzbasierte Empfehlung|0|False|Standard|Chapman P. B., Hauschild A., Robert C., Haanen J. B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. . 2011;364:2507-16||930
Malignes Melanom|"3.3"|2020|Loquai, Carmen|Evidenzbasierte Empfehlung|0|False|Standard|O'Day S., Pavlick A., Loquai C., Lawson D., Gutzmer R., Richards J., et al. A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. . 2011;105:346-52||930
Malignes Melanom|"3.3"|2020|Loquai, Carmen|Hintergrund|||Standard|Hersh E. M., Del Vecchio M., Brown M. P., Kefford R., Loquai C., Testori A., et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. . 2015;26:2267-74||930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Letztautor|Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. . 2003;4:748-759||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Erstautor|Hauschild A., Agarwala S. S., Trefzer U., Hogg D., Robert C., Hersey P., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. . 2009;27:2823-30|http://www.ncbi.nlm.nih.gov/pubmed/19349552|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Malvehy J., Hauschild A., Curiel-Lewandrowski C., Mohr P., Hofmann-Wellenhof R., Motley R., et al. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. . 2014;171:1099-107||930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Hintergrund|||Standard|Malvehy J., Hauschild A., Curiel-Lewandrowski C., Mohr P., Hofmann-Wellenhof R., Motley R., et al. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. . 2014;171:1099-107||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Letztautor|Lacouture M. E., Wolchok J. D., Yosipovitch G., Kahler K. C., Busam K. J., Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. . 2014;71:161-9||930
Malignes Melanom|"3.3"|2020|Loquai, Carmen|Hintergrund|||Standard|Kahler K. C., Hassel J. C., Heinzerling L., Loquai C., Mossner R., Ugurel S., et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. . 2016;14:662-81|http://onlinelibrary.wiley.com/store/10.1111/ddg.13047/asset/ddg13047.pdf?v=1&t=iuf95tks&s=5398f4427ff9df12212e3f18e67bdbfe552464db|930
Malignes Melanom|"3.3"|2020|Forschner, Andrea|Hintergrund|||Standard|Hofmann L., Forschner A., Loquai C., Goldinger S. M., Zimmer L., Ugurel S., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. . 2016;60:190-209||930
Malignes Melanom|"3.3"|2020|Loquai, Carmen|Hintergrund|||Standard|Hofmann L., Forschner A., Loquai C., Goldinger S. M., Zimmer L., Ugurel S., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. . 2016;60:190-209||930
Malignes Melanom|"3.3"|2020|Loquai, Carmen|Hintergrund|||Standard|Zimmer L., Goldinger S. M., Hofmann L., Loquai C., Ugurel S., Thomas I., et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. . 2016;60:210-25||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Erstautor|Hauschild A., Chen S. C., Weichenthal M., Blum A., King H. C., Goldsmith J., et al. To excise or not: impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions. . 2014;12:606-14||930
Malignes Melanom|"3.3"|2020|Weichenthal, Michael|Hintergrund|||Standard|Hauschild A., Chen S. C., Weichenthal M., Blum A., King H. C., Goldsmith J., et al. To excise or not: impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions. . 2014;12:606-14||930
Malignes Melanom|"3.3"|2020|Schmid-Wendtner, Monika|Hintergrund|||Standard|Gambichler T., Schmid-Wendtner M. H., Plura I., Kampilafkos P., Stucker M., Berking C., et al. A multicentre pilot study investigating high-definition optical coherence tomography in the differentiation of cutaneous melanoma and melanocytic naevi. . 2015;29:537-41||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Evidenzbasierte Empfehlung||False|Standard|Siegel R., Hauschild A., Kettelhack C., Kahler K. C., Bembenek A., Schlag P. M. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. . 2007;33:627-32|http://www.ncbi.nlm.nih.gov/pubmed/17196362|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Siegel R., Hauschild A., Kettelhack C., Kahler K. C., Bembenek A., Schlag P. M. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. . 2007;33:627-32|http://www.ncbi.nlm.nih.gov/pubmed/17196362|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Standard|Tronnier M., Garbe C., Brocker E. B., Stadler R., Steinkraus V., Soyer H. P., et al. [Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society]. None. 1997;48:720-9|http://www.ncbi.nlm.nih.gov/pubmed/9441164|930
Malignes Melanom|"3.3"|2020|Stadler, Rudolf|Hintergrund|||Standard|Tronnier M., Garbe C., Brocker E. B., Stadler R., Steinkraus V., Soyer H. P., et al. [Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society]. None. 1997;48:720-9|http://www.ncbi.nlm.nih.gov/pubmed/9441164|930
Malignes Melanom|"3.3"|2020|Keilholz, Ulrich|Hintergrund|||Standard|Egerer G., Lehnert T., Max R., Naeher H., Keilholz U., Ho A. D. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. . 2001;6:25-8|http://www.ncbi.nlm.nih.gov/pubmed/11706523|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Evidenzbasierte Empfehlung|B|False|Standard|Mornex F., Thomas L., Mohr P., Hauschild A., Delaunay M. M., Lesimple T., et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. . 2003;13:97-103|http://www.ncbi.nlm.nih.gov/pubmed/12569292|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Mornex F., Thomas L., Mohr P., Hauschild A., Delaunay M. M., Lesimple T., et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. . 2003;13:97-103|http://www.ncbi.nlm.nih.gov/pubmed/12569292|930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Evidenzbasierte Empfehlung|B|False|Standard|Mornex F., Thomas L., Mohr P., Hauschild A., Delaunay M. M., Lesimple T., et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. . 2003;13:97-103|http://www.ncbi.nlm.nih.gov/pubmed/12569292|930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Hintergrund|||Standard|Mornex F., Thomas L., Mohr P., Hauschild A., Delaunay M. M., Lesimple T., et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. . 2003;13:97-103|http://www.ncbi.nlm.nih.gov/pubmed/12569292|930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Evidenzbasierte Empfehlung|B|False|Standard|Eigentler T. K., Figl A., Krex D., Mohr P., Mauch C., Rass K., et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. . 2011;:1697-1703||930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Hintergrund|||Standard|Eigentler T. K., Figl A., Krex D., Mohr P., Mauch C., Rass K., et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. . 2011;:1697-1703||930
Malignes Melanom|"3.3"|2020|Loquai, Carmen|Hintergrund|||Standard|Hecht M., Zimmer L., Loquai C., Weishaupt C., Gutzmer R., Schuster B., et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. . 2015;26:1238-44||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Schadendorf D., Hauschild A., Ugurel S., Thoelke A., Egberts F., Kreissig M., et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. . 2006;17:1592-7|http://www.ncbi.nlm.nih.gov/pubmed/17005632|930
Malignes Melanom|"3.3"|2020|Forschner, Andrea|Hintergrund|||Standard|Pflugfelder A., Weide B., Eigentler T. K., Forschner A., Leiter U., Held L., et al. Incisional biopsy and melanoma prognosis: Facts and controversies. None. 2010;28:316-8|http://www.ncbi.nlm.nih.gov/pubmed/20541685|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Dummer R., Hauschild A., Guggenheim M., Jost L., Pentheroudakis G. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. . 2010;21 Suppl 5:v194-7||930
Malignes Melanom|"3.3"|2020|Forschner, Andrea|Evidenzbasierte Empfehlung|A|False|Standard|Leiter U., Buettner P., Eigentler T., Forschner A., Meier F., Garbe C. Follow-up of cutaneous melanoma: Stage-dependent hazard rates of recurrence and coupled melanoma. . 2009;7:166-167||930
Malignes Melanom|"3.3"|2020|Forschner, Andrea|Hintergrund|||Standard|Leiter U., Buettner P., Eigentler T., Forschner A., Meier F., Garbe C. Follow-up of cutaneous melanoma: Stage-dependent hazard rates of recurrence and coupled melanoma. . 2009;7:166-167||930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Evidenzbasierte Empfehlung|A|False|Letztautor|Leiter U., Buettner P., Eigentler T., Forschner A., Meier F., Garbe C. Follow-up of cutaneous melanoma: Stage-dependent hazard rates of recurrence and coupled melanoma. . 2009;7:166-167||930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Letztautor|Leiter U., Buettner P., Eigentler T., Forschner A., Meier F., Garbe C. Follow-up of cutaneous melanoma: Stage-dependent hazard rates of recurrence and coupled melanoma. . 2009;7:166-167||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Letztautor|Egberts F., Hitschler W. N., Weichenthal M., Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. . 2009;19:31-5|http://www.ncbi.nlm.nih.gov/pubmed/19104452|930
Malignes Melanom|"3.3"|2020|Weichenthal, Michael|Hintergrund|||Standard|Egberts F., Hitschler W. N., Weichenthal M., Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. . 2009;19:31-5|http://www.ncbi.nlm.nih.gov/pubmed/19104452|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Standard|Mohrle M., Schippert W., Garbe C., Rassner G., Rocken M., Breuninger H. [Prognostic parameters and surgical strategies for facial melanomas]. None. 2003;1:457-63|http://www.ncbi.nlm.nih.gov/pubmed/16295139|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Standard|Moehrle M., Metzger S., Schippert W., Garbe C., Rassner G., Breuninger H. "Functional" surgery in subungual melanoma. None. 2003;29:366-74|http://www.ncbi.nlm.nih.gov/pubmed/12656815|930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Evidenzbasierte Empfehlung||False|Standard|Zimmer L., Eigentler T. K., Kiecker F., Simon J., Utikal J., Mohr P., et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. . 2015;13:351|http://www.ncbi.nlm.nih.gov/pubmed/26541511|930
Malignes Melanom|"3.3"|2020|Mohr, Peter|Hintergrund|||Standard|Zimmer L., Eigentler T. K., Kiecker F., Simon J., Utikal J., Mohr P., et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. . 2015;13:351|http://www.ncbi.nlm.nih.gov/pubmed/26541511|930
Malignes Melanom|"3.3"|2020|Augustin, Matthias|Hintergrund|||Erstautor|Augustin M.; Zschocke I.; Dieterle W.; Schöpf E.; Muthny F. Bedarf und Motivation zu psychosozialen Interventionen bei Patienten mit malignen Hauttumoren. . 1997;:333-338||930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Standard|Blum A., Blum D., Stroebel W., Rassner G., Garbe C., Hautzinger M. [Psychosocial burden and subjective experience of melanoma patients in the ambulant follow-up]. . 2003;53:258-66|http://www.ncbi.nlm.nih.gov/pubmed/12813660|930
Malignes Melanom|"3.3"|2020|Augustin, Matthias|Hintergrund|||Letztautor|Sollner W., Zschocke I., Augustin M. [Melanoma patients: psychosocial stress, coping with illness and social support. A systematic review]. . 1998;48:338-48|http://www.ncbi.nlm.nih.gov/pubmed/9785963|930
Malignes Melanom|"3.3"|2020|Augustin, Matthias|Hintergrund|||Standard|Rumpold G., Augustin M., Zschocke I., Strittmatter G., Sollner W. [The validity of the Hornheide questionnaire for psychosocial support in skin tumor patients: a survey in an Austrian and German outpatient population with melanoma]. . 2001;51:25-33|http://www.ncbi.nlm.nih.gov/pubmed/11227322|930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Erstautor|Hauschild A., Gogas H., Tarhini A., Middleton M. R., Testori A., Dreno B., et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. . 2008;112:982-94|http://www.ncbi.nlm.nih.gov/pubmed/18236459|930
Malignes Melanom|"3.3"|2020|Werner, Andreas|Hintergrund|||Standard|Beutel M. E., Blettner M., Fischbeck S., Loquay C., Werner A., Marian H. [Psycho-oncological aspects of malignant melanoma. A systematic review from 1990-2008]. . 2009;60:727-33|http://www.ncbi.nlm.nih.gov/pubmed/19701615|930
Malignes Melanom|"3.3"|2020|Garbe, Claus|Hintergrund|||Erstautor|Garbe C, Eigentler TK. Treatment of malignant melanoma at the stage of distant metastasis. . 2004;55:195-212||930
Malignes Melanom|"3.3"|2020|Hauschild, Axel|Hintergrund|||Standard|Testori A., Rutkowski P., Marsden J., Bastholt L., Chiarion-Sileni V., Hauschild A., et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. None. 2009;20 Suppl 6:vi22-9|http://www.ncbi.nlm.nih.gov/pubmed/19617294|930
Malignes Melanom|"3.3"|2020|Schmid-Wendtner, Monika|Hintergrund|||Erstautor|Schmid-Wendtner M. H., Brunner B., Konz B., Kaudewitz P., Wendtner C. M., Peter R. U., et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. None. 2000;43:477-82|http://www.ncbi.nlm.nih.gov/pubmed/10954659|930
Follikuläres Lymphom|"1"|2020|Pott, Christiane|Hintergrund|||Erstautor|Pott C., Bruggemann M., Ritgen M., van der Velden V. H., van Dongen J. J., Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. None. 2013;971:175-200|https://www.ncbi.nlm.nih.gov/pubmed/23296964|450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Evidenzbasierte Empfehlung|B|False|Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Herfarth, Klaus|Evidenzbasierte Empfehlung|B|False|Erstautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Herfarth, Klaus|Hintergrund|||Erstautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Hiddemann, Wolfgang|Evidenzbasierte Empfehlung|B|False|Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Hiddemann, Wolfgang|Hintergrund|||Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Hoster, Eva|Evidenzbasierte Empfehlung|B|False|Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Hoster, Eva|Hintergrund|||Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Pott, Christiane|Evidenzbasierte Empfehlung|B|False|Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Pott, Christiane|Hintergrund|||Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Viardot, Andreas|Evidenzbasierte Empfehlung|B|False|Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Viardot, Andreas|Hintergrund|||Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Witzens-Harig, Mathias|Evidenzbasierte Empfehlung|B|False|Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Witzens-Harig, Mathias|Hintergrund|||Letztautor|Herfarth K., Borchmann P., Schnaidt S., Hohloch K., Budach Volker; Engelhard Marianne; Viardot Andreas; Engenhart-Cabillic Rita; Keller Ulrich; Reinartz Gabriele; Eich Hans-Theodor; Witzens-Harig Mathias; Hess Clemens; Dörken Bernd; Dürig Jan; Wiegel Thomas; Hiddemann Wolfgang; Hoster Eva1; Pott Christiane; Dreyling Martin. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma. None. 2018;2:None||450
Follikuläres Lymphom|"1"|2020|Hoster, Eva|Hintergrund|||Standard|Pott Christiane, Hoster Eva, Kehden Britta, Unterhalt Michael, Herold Michael, van der Jagt Richard H, et al. Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. None. 2016;128:613-613||450
Follikuläres Lymphom|"1"|2020|Pott, Christiane|Hintergrund|||Erstautor|Pott Christiane, Hoster Eva, Kehden Britta, Unterhalt Michael, Herold Michael, van der Jagt Richard H, et al. Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. None. 2016;128:613-613||450
Follikuläres Lymphom|"1"|2020|Unterhalt, Michael|Hintergrund|||Standard|Pott Christiane, Hoster Eva, Kehden Britta, Unterhalt Michael, Herold Michael, van der Jagt Richard H, et al. Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. None. 2016;128:613-613||450
Follikuläres Lymphom|"1"|2020|Hoster, Eva|Hintergrund|||Standard|Pott Christiane, Hoster Eva, Kehden Britta, Unterhalt Michael, Herold Michael, van der Jagt Richard, et al. Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. None. 2018;132:396-396||450
Follikuläres Lymphom|"1"|2020|Pott, Christiane|Hintergrund|||Erstautor|Pott Christiane, Hoster Eva, Kehden Britta, Unterhalt Michael, Herold Michael, van der Jagt Richard, et al. Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. None. 2018;132:396-396||450
Follikuläres Lymphom|"1"|2020|Unterhalt, Michael|Hintergrund|||Standard|Pott Christiane, Hoster Eva, Kehden Britta, Unterhalt Michael, Herold Michael, van der Jagt Richard, et al. Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. None. 2018;132:396-396||450
Follikuläres Lymphom|"1"|2020|Pott, Christiane|Hintergrund|||Erstautor|Pott Christiane, Belada David, Danesi Nathalie, Fingerle-Rowson Günter, Gribben John, Harbron Chris, et al. Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. None. 2015;126:3978-3978||450
Follikuläres Lymphom|"1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Dittrich R., Kliesch S., Schuring A., Balcerek M., Baston-Bust D. M., Beck R., et al. Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k-Level, AWMF Registry No. 015/082, November 2017) - Recommendations and Statements for Girls and Women. None. 2018;78:567-584|https://www.ncbi.nlm.nih.gov/pubmed/29962516|450
Follikuläres Lymphom|"1"|2020|Kliesch, Sabine|Hintergrund|||Erstautor|Kliesch S., Behre H. M., Jurgens H., Nieschlag E. Cryopreservation of semen from adolescent patients with malignancies. . 1996;26:20-7||450
Follikuläres Lymphom|"1"|2020|Kliesch, Sabine|Hintergrund|||Erstautor|Kliesch Sabine, Kamischke Axel, Cooper Trevor G., Nieschlag Eberhard. Kryokonservierung menschlicher Spermien zur Zeugungsreserve. None. 2009;None:515-531|http://dx.doi.org/10.1007/978-3-540-92963-5_24|450
Follikuläres Lymphom|"1"|2020|Unterhalt, Michael|Hintergrund|||Erstautor|M. Engelhard M. Unterhalt M. Hansmann M. Stuschke. Follicular Lymphoma: Curability By Radiotherapy In Limited Stage Nodal Disease? Updated Results Of a Randomized Trial. None. 2011;22:iv90-iv91|http://dx.doi.org/10.1093/annonc/mdr189|450
Follikuläres Lymphom|"1"|2020|Unterhalt, Michael|Hintergrund|||Erstautor|Engelhard M. M. Unterhalt M. L. Hansmann and M. Stuschke. Follicular lymphoma: Final results of the randomized evaluation of curative radiotherapy in limited stage nodal disease. None. 2013;Volume 189, Supplement 1:None||450
Follikuläres Lymphom|"1"|2020|Herfarth, Klaus|Hintergrund|||Letztautor|Witzens-Harig M., Hensel M., Unterhalt M., Herfarth K. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. None. 2011;11:87|https://www.ncbi.nlm.nih.gov/pubmed/21352561|450
Follikuläres Lymphom|"1"|2020|Unterhalt, Michael|Hintergrund|||Standard|Witzens-Harig M., Hensel M., Unterhalt M., Herfarth K. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. None. 2011;11:87|https://www.ncbi.nlm.nih.gov/pubmed/21352561|450
Follikuläres Lymphom|"1"|2020|Witzens-Harig, Mathias|Hintergrund|||Erstautor|Witzens-Harig M., Hensel M., Unterhalt M., Herfarth K. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. None. 2011;11:87|https://www.ncbi.nlm.nih.gov/pubmed/21352561|450
Follikuläres Lymphom|"1"|2020|Herfarth, Klaus|Hintergrund|||Erstautor|Herfarth K., Konig L. [Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study]. None. 2014;190:1084-5|https://www.ncbi.nlm.nih.gov/pubmed/25538992|450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Erstautor|Dreyling M., Ghielmini M., Rule S., Salles G., Vitolo U., Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. None. 2016;27:v83-v90||450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Evidenzbasierte Empfehlung|A|False|Standard|Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. None. 2005;106:3725-32|https://www.ncbi.nlm.nih.gov/pubmed/16123223|450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Standard|Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. None. 2005;106:3725-32|https://www.ncbi.nlm.nih.gov/pubmed/16123223|450
Follikuläres Lymphom|"1"|2020|Hiddemann, Wolfgang|Evidenzbasierte Empfehlung|A|False|Erstautor|Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. None. 2005;106:3725-32|https://www.ncbi.nlm.nih.gov/pubmed/16123223|450
Follikuläres Lymphom|"1"|2020|Hiddemann, Wolfgang|Hintergrund|||Erstautor|Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. None. 2005;106:3725-32|https://www.ncbi.nlm.nih.gov/pubmed/16123223|450
Follikuläres Lymphom|"1"|2020|Herold, Michael|Evidenzbasierte Empfehlung|A|False|Erstautor|Herold M., Haas A., Srock S., Neser S., Al-Ali K. H., Neubauer A., et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. None. 2007;25:1986-92|https://www.ncbi.nlm.nih.gov/pubmed/17420513|450
Follikuläres Lymphom|"1"|2020|Herold, Michael|Hintergrund|||Erstautor|Herold M., Haas A., Srock S., Neser S., Al-Ali K. H., Neubauer A., et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. None. 2007;25:1986-92|https://www.ncbi.nlm.nih.gov/pubmed/17420513|450
Follikuläres Lymphom|"1"|2020|Klapper, Wolfram|Hintergrund|||Standard|Marcus R., Davies A., Ando K., Klapper W., Opat S., Owen C., et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. None. 2017;377:1331-1344|https://www.ncbi.nlm.nih.gov/pubmed/28976863|450
Follikuläres Lymphom|"1"|2020|Hiddemann, Wolfgang|Hintergrund|||Standard|Launonen Aino, Hiddemann Wolfgang, Duenzinger Ulrich, Fingerle-Rowson Günter, Nielsen Tina, Marcus Robert. Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study. None. 2017;130:1490-1490||450
Follikuläres Lymphom|"1"|2020|Buske, Christian|Hintergrund|||Standard|Kim W. S., Buske C., Ogura M., Jurczak W., Sancho J. M., Zhavrid E., et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. None. 2017;4:e362-e373|https://www.ncbi.nlm.nih.gov/pubmed/28712940|450
Follikuläres Lymphom|"1"|2020|Maschmeyer, Georg|Evidenzbasierte Empfehlung|B|False|Standard|Rummel M. J., Niederle N., Maschmeyer G., Banat G. A., von Grunhagen U., Losem C., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. None. 2013;381:1203-10|https://www.ncbi.nlm.nih.gov/pubmed/23433739|450
Follikuläres Lymphom|"1"|2020|Maschmeyer, Georg|Hintergrund|||Standard|Rummel M. J., Niederle N., Maschmeyer G., Banat G. A., von Grunhagen U., Losem C., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. None. 2013;381:1203-10|https://www.ncbi.nlm.nih.gov/pubmed/23433739|450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Evidenzbasierte Empfehlung|B|False|Standard|Grigg A., Dyer M. J., Diaz M. G., Dreyling M., Rule S., Lei G., et al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. None. 2017;102:765-772|https://www.ncbi.nlm.nih.gov/pubmed/28011903|450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Standard|Grigg A., Dyer M. J., Diaz M. G., Dreyling M., Rule S., Lei G., et al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. None. 2017;102:765-772|https://www.ncbi.nlm.nih.gov/pubmed/28011903|450
Follikuläres Lymphom|"1"|2020|Hiddemann, Wolfgang|Hintergrund|||Erstautor|Hiddemann W., Barbui A. M., Canales M. A., Cannell P. K., Collins G. P., Durig J., et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. None. 2018;36:2395-2404|https://www.ncbi.nlm.nih.gov/pubmed/29856692|450
Follikuläres Lymphom|"1"|2020|Hoster, Eva|Hintergrund|||Erstautor|Hoster E., Unterhalt M., Hänel M., Prange-Krex G., Forstpointner R., Florschütz A., et al. RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO. None. 2017;35:32-32|https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2437_12|450
Follikuläres Lymphom|"1"|2020|Unterhalt, Michael|Hintergrund|||Standard|Hoster E., Unterhalt M., Hänel M., Prange-Krex G., Forstpointner R., Florschütz A., et al. RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO. None. 2017;35:32-32|https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2437_12|450
Follikuläres Lymphom|"1"|2020|Buske, Christian|Hintergrund|||Standard|Rummel Mathias J, Buske Christian, Hertenstein Bernd, Lerchenmüller Christian, Koenigsmann Michael, Lange Elisabeth, et al. Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study). None. 2017;130:483-483||450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Standard|Lenz G., Dreyling M., Schiegnitz E., Forstpointner R., Wandt H., Freund M., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. None. 2004;104:2667-74|https://www.ncbi.nlm.nih.gov/pubmed/15238420|450
Follikuläres Lymphom|"1"|2020|Hoster, Eva|Hintergrund|||Standard|Koch K., Hoster E., Ziepert M., Unterhalt M., Ott G., Rosenwald A., et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. None. 2016;27:1323-9|https://www.ncbi.nlm.nih.gov/pubmed/27117536|450
Follikuläres Lymphom|"1"|2020|Unterhalt, Michael|Hintergrund|||Standard|Koch K., Hoster E., Ziepert M., Unterhalt M., Ott G., Rosenwald A., et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. None. 2016;27:1323-9|https://www.ncbi.nlm.nih.gov/pubmed/27117536|450
Follikuläres Lymphom|"1"|2020|Herfarth, Klaus|Hintergrund|||Letztautor|Konig L., Stade R., Rieber J., Debus J., Herfarth K. Radiotherapy of indolent orbital lymphomas : Two radiation concepts. None. 2016;192:414-21|https://www.ncbi.nlm.nih.gov/pubmed/27160291|450
Follikuläres Lymphom|"1"|2020|Viardot, Andreas|Hintergrund|||Standard|Lerch K., Meyer A. H., Stroux A., Hirt C., Keller U., Viardot A., et al. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis. None. 2015;94:981-8|https://www.ncbi.nlm.nih.gov/pubmed/25645656|450
Follikuläres Lymphom|"1"|2020|Goede, Valentin|Hintergrund|||Erstautor|Goede V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101|https://www.nejm.org/doi/full/10.1056/NEJMoa1313984|450
Follikuläres Lymphom|"1"|2020|Hiddemann, Wolfgang|Hintergrund|||Erstautor|Hiddemann W., Cheson B. D. How we manage follicular lymphoma. None. 2014;28:1388-95|https://www.ncbi.nlm.nih.gov/pubmed/24577532|450
Follikuläres Lymphom|"1"|2020|Herold, Michael|Hintergrund|||Standard|Casulo Carla, Le-Rademacher Jennifer, Dixon Jesse, Salles Gilles, Hoster Eva, Herold Michael, et al. Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials. None. 2017;130:412-412||450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Standard|Forstpointner R., Dreyling M., Repp R., Hermann S., Hanel A., Metzner B., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. None. 2004;104:3064-71|https://www.ncbi.nlm.nih.gov/pubmed/15284112|450
Follikuläres Lymphom|"1"|2020|Viardot, Andreas|Hintergrund|||Standard|Salles G., Schuster S. J., de Vos S., Wagner-Johnston N. D., Viardot A., Blum K. A., et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. None. 2017;102:e156-e159|https://www.ncbi.nlm.nih.gov/pubmed/27979923|450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Erstautor|Dreyling M., Morschhauser F., Bouabdallah K., Bron D., Cunningham D., Assouline S. E., et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. None. 2017;28:2169-2178|https://www.ncbi.nlm.nih.gov/pubmed/28633365|450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Standard|Vidal L., Gafter-Gvili A., Salles G., Dreyling M. H., Ghielmini M., Hsu Schmitz S. F., et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. None. 2011;103:1799-806|https://www.ncbi.nlm.nih.gov/pubmed/22021664|450
Follikuläres Lymphom|"1"|2020|Schmidberger, Heinz|Hintergrund|||Erstautor|Schmidberger H., Hey-Koch S. Strahlentherapie bei Non-Hodgin-Lymphomen. None. 2015;21:913-924|https://doi.org/10.1007/s00761-015-2964-7|450
Follikuläres Lymphom|"1"|2020|Dreyling, Martin|Hintergrund|||Standard|Montoto S., Corradini P., Dreyling M., Ghielmini M., Kimby E., Lopez-Guillermo A., et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. None. 2013;98:1014-21|https://www.ncbi.nlm.nih.gov/pubmed/23813647|450
Follikuläres Lymphom|"1"|2020|Pott, Christiane|Hintergrund|||Standard|Kornacker M., Stumm J., Pott C., Dietrich S., Sussmilch S., Hensel M., et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. None. 2009;20:722-8|https://www.ncbi.nlm.nih.gov/pubmed/19179546|450
Follikuläres Lymphom|"1"|2020|Pott, Christiane|Hintergrund|||Standard|Metzner B., Pott C., Muller T. H., Gebauer W., Casper J., Kraemer D., et al. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation. None. 2013;24:1609-15|https://www.ncbi.nlm.nih.gov/pubmed/23393125|450
Follikuläres Lymphom|"1"|2020|Dreger, Peter|Hintergrund|||Standard|Sureda A., Zhang M. J., Dreger P., Carreras J., Fenske T., Finel H., et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. None. 2018;124:1733-1742|https://www.ncbi.nlm.nih.gov/pubmed/29424927|450
Follikuläres Lymphom|"1"|2020|Dreger, Peter|Hintergrund|||Standard|Sureda A., Bader P., Cesaro S., Dreger P., Duarte R. F., Dufour C., et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. None. 2015;50:1037-56||450
Follikuläres Lymphom|"1"|2020|Sandherr, Michael|Hintergrund|||Erstautor|Sandherr M., Hentrich M., von Lilienfeld-Toal M., Massenkeil G., Neumann S., Penack O., et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). . 2015;94:1441-50||450
Follikuläres Lymphom|"1"|2020|Horneber, Markus|Hintergrund|||Erstautor|Horneber M., van Ackeren G., Fischer F., Kappauf H., Birkmann J. Addressing Unmet Information Needs: Results of a Clinician-Led Consultation Service About Complementary and Alternative Medicine for Cancer Patients and Their Relatives. None. 2018;17:1172-1182|https://www.ncbi.nlm.nih.gov/pubmed/30352519|450
Follikuläres Lymphom|"1"|2020|Schmidt, Christian|Hintergrund|||Erstautor|Schmidt C., Fingerle-Rowson G., Boehme A., Brendel K., Fischer R., Gonnermann M., et al. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009. None. 2015;56:694-702|https://www.ncbi.nlm.nih.gov/pubmed/24937122|450
Follikuläres Lymphom|"1"|2020|Hiddemann, Wolfgang|Hintergrund|||Standard|Johl A., Lengfelder E., Hiddemann W., Klapper W., German Low-grade Lymphoma Study Group. Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel. None. 2016;95:1281-6|https://www.ncbi.nlm.nih.gov/pubmed/27236576|450
Follikuläres Lymphom|"1"|2020|Klapper, Wolfram|Hintergrund|||Standard|Johl A., Lengfelder E., Hiddemann W., Klapper W., German Low-grade Lymphoma Study Group. Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel. None. 2016;95:1281-6|https://www.ncbi.nlm.nih.gov/pubmed/27236576|450
Follikuläres Lymphom|"1"|2020|Fend, Falko|Hintergrund|||Erstautor|Fend F., Quintanilla-Martinez L. Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma. None. 2014;99:599-602|https://www.ncbi.nlm.nih.gov/pubmed/24688106|450
Follikuläres Lymphom|"1"|2020|Fend, F.|Hintergrund|||Erstautor|Fend F., Quintanilla-Martinez L. Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma. None. 2014;99:599-602|https://www.ncbi.nlm.nih.gov/pubmed/24688106|450
Follikuläres Lymphom|"1"|2020|Weigert, Oliver|Hintergrund|||Erstautor|Weigert O., Weinstock D. M. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. None. 2017;130:1491-1498|https://www.ncbi.nlm.nih.gov/pubmed/28784599|450
Follikuläres Lymphom|"1"|2020|Hoster, Eva|Hintergrund|||Standard|Pastore A., Jurinovic V., Kridel R., Hoster E., Staiger A. M., Szczepanowski M., et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. None. 2015;16:1111-1122|https://www.ncbi.nlm.nih.gov/pubmed/26256760|450
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Standard|Lehmann C., Koch U., Mehnert A. Die Bedeutung der Arzt-Patient-Kommunikation für die psychische Belastung und die Inanspruchnahme von Unterstützungsangeboten bei Krebspatienten: Ein Literaturüberblick über den gegenwärtigen Forschungsstand unter besonderer Berücksichtigung patientenseitiger Präferenzen. None. 2009;59:3-27||1538
Psychoonkologie|"1.1"|2014|Hasenburg, Annette|Evidenzbasiertes Statement||False|Standard|Härter M., Reuter K., Schretzmann B., Hasenburg A., Aschenbrenner A., Weis J. Komorbide psychische Störungen bei Krebspatienten in der stationären Akutbehandlung und medizinischen Rehabilitation1. None. 2000;39:317-323||1538
Psychoonkologie|"1.1"|2014|Hasenburg, Annette|Hintergrund|||Standard|Härter M., Reuter K., Schretzmann B., Hasenburg A., Aschenbrenner A., Weis J. Komorbide psychische Störungen bei Krebspatienten in der stationären Akutbehandlung und medizinischen Rehabilitation1. None. 2000;39:317-323||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Evidenzbasiertes Statement||False|Letztautor|Härter M., Reuter K., Schretzmann B., Hasenburg A., Aschenbrenner A., Weis J. Komorbide psychische Störungen bei Krebspatienten in der stationären Akutbehandlung und medizinischen Rehabilitation1. None. 2000;39:317-323||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Letztautor|Härter M., Reuter K., Schretzmann B., Hasenburg A., Aschenbrenner A., Weis J. Komorbide psychische Störungen bei Krebspatienten in der stationären Akutbehandlung und medizinischen Rehabilitation1. None. 2000;39:317-323||1538
Psychoonkologie|"1.1"|2014|Faller, Hermann|Evidenzbasierte Empfehlung|A|False|Erstautor|Faller H., Schuler M., Richard M., Heckl U., Weis J., Küffner R. Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. None. 2013;31:782-793||1538
Psychoonkologie|"1.1"|2014|Faller, Hermann|Hintergrund|||Erstautor|Faller H., Schuler M., Richard M., Heckl U., Weis J., Küffner R. Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. None. 2013;31:782-793||1538
Psychoonkologie|"1.1"|2014|Heckl, Ulrike|Evidenzbasierte Empfehlung|A|False|Standard|Faller H., Schuler M., Richard M., Heckl U., Weis J., Küffner R. Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. None. 2013;31:782-793||1538
Psychoonkologie|"1.1"|2014|Heckl, Ulrike|Hintergrund|||Standard|Faller H., Schuler M., Richard M., Heckl U., Weis J., Küffner R. Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. None. 2013;31:782-793||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Evidenzbasierte Empfehlung|A|False|Standard|Faller H., Schuler M., Richard M., Heckl U., Weis J., Küffner R. Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. None. 2013;31:782-793||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Standard|Faller H., Schuler M., Richard M., Heckl U., Weis J., Küffner R. Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. None. 2013;31:782-793||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Götze H., Möbius C., Witzigmann H., Kortmann R. D., Lehmann A., et al. Quality of care and emotional support from the inpatient cancer patient's perspective. None. 2009;394:723-731||1538
Psychoonkologie|"1.1"|2014|Heußner, Pia|Hintergrund|||Letztautor|Herschbach Peter, Heußner Pia. Einführung in die psychoonkologische Behandlungspraxis. None. 2008;None:207||1538
Psychoonkologie|"1.1"|2014|Faller, Hermann|Hintergrund|||Erstautor|Faller H. Gesundheit und Krankheit. None. 2010;None:None||1538
Psychoonkologie|"1.1"|2014|Lang, Hauke|Hintergrund|||Standard|Faller H. Gesundheit und Krankheit. None. 2010;None:None||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Evidenzbasiertes Statement||False|Erstautor|Singer S., Bringmann H., Hauss J., Kortmann R. D., Köhler U., Krauss O., et al. Häufigkeit psychischer Begleiterkrankungen und der Wunsch nach psychosozialer Unterstützung bei Tumorpatienten im Akutkrankenhaus. None. 2007;132:2071-2076||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Bringmann H., Hauss J., Kortmann R. D., Köhler U., Krauss O., et al. Häufigkeit psychischer Begleiterkrankungen und der Wunsch nach psychosozialer Unterstützung bei Tumorpatienten im Akutkrankenhaus. None. 2007;132:2071-2076||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Letztautor|Mehnert A., Lehmann C., Cao P., Koch U. Die Erfassung psychosozialer Belastungen und Ressourcen in der Onkologie - Ein Literaturüberblick zu Screeningmethoden und Entwicklungstrends. None. 2006;56:462-479||1538
Psychoonkologie|"1.1"|2014|Beutel, Manfred|Hintergrund|||Erstautor|Beutel Manfred, Heinrich Gerhard, Sellschopp Almuth, Keller Monika, Adermayer Walburga. Bedarf und Inanspruchnahme ambulanter psychosozialer Versorgung Krebskranker - am Beispiel der onkologischen Tagesklinik. Need for and utilization of outpatient psychosocial care in cancer patients illustrated by the example of an oncological day-care hospital. None. 1996;46:304-311||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Standard|Beutel Manfred, Heinrich Gerhard, Sellschopp Almuth, Keller Monika, Adermayer Walburga. Bedarf und Inanspruchnahme ambulanter psychosozialer Versorgung Krebskranker - am Beispiel der onkologischen Tagesklinik. Need for and utilization of outpatient psychosocial care in cancer patients illustrated by the example of an oncological day-care hospital. None. 1996;46:304-311||1538
Psychoonkologie|"1.1"|2014|Sellschopp, Almuth|Hintergrund|||Standard|Beutel Manfred, Heinrich Gerhard, Sellschopp Almuth, Keller Monika, Adermayer Walburga. Bedarf und Inanspruchnahme ambulanter psychosozialer Versorgung Krebskranker - am Beispiel der onkologischen Tagesklinik. Need for and utilization of outpatient psychosocial care in cancer patients illustrated by the example of an oncological day-care hospital. None. 1996;46:304-311||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Evidenzbasiertes Statement||False|Erstautor|Singer S., Brown A., Einenkel J., Hauss J., Hinz A., Klein A., et al. Identifying tumor patients' depression. None. 2011;19:1697-1703||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Brown A., Einenkel J., Hauss J., Hinz A., Klein A., et al. Identifying tumor patients' depression. None. 2011;19:1697-1703||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Letztautor|Mehnert A., Koch U. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. None. 2008;64:383-391||1538
Psychoonkologie|"1.1"|2014|Faller, Hermann|Hintergrund|||Letztautor|Ströbl V., Friedl-Huber A., Küffner R., Reusch H., Vogel H., Faller H. Beschreibungs- und Bewertungskriterien für Patientenschulungen. None. 2007;20:11-14||1538
Psychoonkologie|"1.1"|2014|Heckl, Ulrike|Hintergrund|||Erstautor|Heckl U., Singer S., Wickert M., Weis J. Aktuelle Versorgungsstrukturen in der Psychoonkologie. None. 2011;3:124-130||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Standard|Heckl U., Singer S., Wickert M., Weis J. Aktuelle Versorgungsstrukturen in der Psychoonkologie. None. 2011;3:124-130||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Letztautor|Heckl U., Singer S., Wickert M., Weis J. Aktuelle Versorgungsstrukturen in der Psychoonkologie. None. 2011;3:124-130||1538
Psychoonkologie|"1.1"|2014|Wickert, Martin|Hintergrund|||Standard|Heckl U., Singer S., Wickert M., Weis J. Aktuelle Versorgungsstrukturen in der Psychoonkologie. None. 2011;3:124-130||1538
Psychoonkologie|"1.1"|2014|Heußner, Pia|Hintergrund|||Standard|Strittmatter G. Screening-Instrumente zur Ermittlung der Betreuungsbedürftigkeit von Tumorpatienten. None. 2006;None:122-142||1538
Psychoonkologie|"1.1"|2014|Sellschopp, Almuth|Hintergrund|||Standard|Strittmatter G. Screening-Instrumente zur Ermittlung der Betreuungsbedürftigkeit von Tumorpatienten. None. 2006;None:122-142||1538
Psychoonkologie|"1.1"|2014|Heckl, Ulrike|Evidenzbasiertes Statement||False|Standard|Vehling Sigrun, Koch Uwe, Ladehoff Natalie, Schön Gerhard, Wegscheider Karl, Heckl Ulrike, et al. Prävalenz affektiver und Angststörungen bei Krebs: Systematischer Literaturreview und Metaanalyse. None. 2012;62:249-258||1538
Psychoonkologie|"1.1"|2014|Heckl, Ulrike|Hintergrund|||Standard|Vehling Sigrun, Koch Uwe, Ladehoff Natalie, Schön Gerhard, Wegscheider Karl, Heckl Ulrike, et al. Prävalenz affektiver und Angststörungen bei Krebs: Systematischer Literaturreview und Metaanalyse. None. 2012;62:249-258||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Evidenzbasiertes Statement||False|Standard|Vehling Sigrun, Koch Uwe, Ladehoff Natalie, Schön Gerhard, Wegscheider Karl, Heckl Ulrike, et al. Prävalenz affektiver und Angststörungen bei Krebs: Systematischer Literaturreview und Metaanalyse. None. 2012;62:249-258||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Standard|Vehling Sigrun, Koch Uwe, Ladehoff Natalie, Schön Gerhard, Wegscheider Karl, Heckl Ulrike, et al. Prävalenz affektiver und Angststörungen bei Krebs: Systematischer Literaturreview und Metaanalyse. None. 2012;62:249-258||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Evidenzbasiertes Statement||False|Erstautor|Keller M., Sommerfeldt S., Fischer C., Knight L., Riesbeck M., Löwe B., et al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach. None. 2004;15:1243-1249||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Erstautor|Keller M., Sommerfeldt S., Fischer C., Knight L., Riesbeck M., Löwe B., et al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach. None. 2004;15:1243-1249||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Letztautor|Sommerfeldt S., Ihrig A., Brechtel A., Keller M. Psychoonkologisches Screening in der Routineversorgung. None. 2007;1:293-297||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Evidenzbasiertes Statement||False|Letztautor|Mehnert A., Koch U. Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. None. 2007;16:181-188||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Letztautor|Mehnert A., Koch U. Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. None. 2007;16:181-188||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Letztautor|Mehnert A., Müller D., Lehmann C., Koch U. Neue diagnostische Verfahren. Die deutsche Version des NCCN Distress-Thermometers - Empirische Prüfung eines Screening-Instruments zur Erfassung psychosozialer Belastung bei Krebspatienten. None. 2006;54:213-223||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Letztautor|Herschbach P., Weis J. Screeningverfahren in der Psychoonkologie. None. 2010;None:None||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Letztautor|Weis J., Koch U. Psychosoziale Rehabilitation nach Krebs. None. 2006;None:2455-2460||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Erstautor|Weis J., Koch U. Psychosoziale Rehabilitation nach Krebs. None. 2006;None:2455-2460||1538
Psychoonkologie|"1.1"|2014|Sellschopp, Almuth|Hintergrund|||Standard|Brandl T., Marten-Mittag B., Herschbach P. Psychoonkologische Basisdokumentation (PO-Bado). Eine Fremdeinschätzungsskala zur Klassifikation des subjektiven Befindens von Ca-Patienten. None. 2006;None:165-174||1538
Psychoonkologie|"1.1"|2014|Dietz, Andreas|Hintergrund|||Standard|Singer S., Danker H., Dietz A., Kienast U., Pabst F., Meister E. F., et al. Sexual Problems After Total or Partial Laryngectomy. None. 2008;118:2218-2224||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Danker H., Dietz A., Kienast U., Pabst F., Meister E. F., et al. Sexual Problems After Total or Partial Laryngectomy. None. 2008;118:2218-2224||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Erstautor|Koch U., Weis J. Krankheitsbewältigung bei Krebs und Möglichkeiten der Unterstützung. Der Förderschwerpunkt 'Rehabilitation von Krebskranken'. None. 1998;None:507||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Letztautor|Koch U., Weis J. Krankheitsbewältigung bei Krebs und Möglichkeiten der Unterstützung. Der Förderschwerpunkt 'Rehabilitation von Krebskranken'. None. 1998;None:507||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Erstautor|Keller M., Zwingmann J. Kommunikation in der Onkologie. None. 2010;None:641-655||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Standard|Herschbach P., Book K., Brandl T., Keller M., Marten-Mittag B. The Basic Documentation for Psycho-Oncology (PO-Bado): an expert rating scale for the psychosocial experience of cancer patients. None. 2008;31:591-596||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Erstautor|Weis Joachim. Krankheitsverarbeitung und Lebensqualität. None. 2008;None:332-340||1538
Psychoonkologie|"1.1"|2014|Kruse, Johannes|Hintergrund|||Erstautor|Kruse J., Schmitz N., Wöller W., Clar B., Meier E., Grinschgl A., et al. Effekte eines psychosozialen Fortbildungsprogramms zur Verbesserung der Arzt-Patient-Interaktion mit Krebspatienten. None. 2003;49:232-245||1538
Psychoonkologie|"1.1"|2014|Koch, Uwe|Hintergrund|||Standard|Scherwath A., Poppelreuter M., Weis J., Schulz-Kindermann F., Koch U., Mehnert A. Psychometrische Überprüfung einer neuropsychologischen Testbatterie zur Erfassung kognitiver Dysfunktionen bei Krebspatienten - Empfehlungen für ein Basisassessment. None. 2008;76:583-593||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Standard|Scherwath A., Poppelreuter M., Weis J., Schulz-Kindermann F., Koch U., Mehnert A. Psychometrische Überprüfung einer neuropsychologischen Testbatterie zur Erfassung kognitiver Dysfunktionen bei Krebspatienten - Empfehlungen für ein Basisassessment. None. 2008;76:583-593||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Erstautor|Keller M., Barthel Y. Patientenzentrierte Kommunikation in der Onkologie - Erfahrungen mit dem Kompass Training. None. 2012;None:None||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Standard|Keller M., Barthel Y. Patientenzentrierte Kommunikation in der Onkologie - Erfahrungen mit dem Kompass Training. None. 2012;None:None||1538
Psychoonkologie|"1.1"|2014|Blettner, Gabriele|Hintergrund|||Letztautor|Wickert M., Lehmann-Laue A., Blettner G. Ambulante psychosoziale Krebsberatung in Deutschland - Geschichte und Versorgungssituation. None. 2013;None:None||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Standard|Wickert M., Lehmann-Laue A., Blettner G. Ambulante psychosoziale Krebsberatung in Deutschland - Geschichte und Versorgungssituation. None. 2013;None:None||1538
Psychoonkologie|"1.1"|2014|Wickert, Martin|Hintergrund|||Erstautor|Wickert M., Lehmann-Laue A., Blettner G. Ambulante psychosoziale Krebsberatung in Deutschland - Geschichte und Versorgungssituation. None. 2013;None:None||1538
Psychoonkologie|"1.1"|2014|Englert, Gerhard|Hintergrund|||Erstautor|Englert G. Belastungen, Unterstützungs- und Informationsbedarf von Stomaträgern. None. 2004;31:41-46||1538
Psychoonkologie|"1.1"|2014|Hasenburg, Annette|Evidenzbasiertes Statement||False|Standard|Härter M., Reuter K., Aschenbrenner A., Schretzmann B., Marschner N., Hasenburg A., et al. Psychiatric disorders and associated factors in cancer: results of an interview study with patients in inpatient, rehabilitation and outpatient treatment. None. 2001;37:1385-1393||1538
Psychoonkologie|"1.1"|2014|Hasenburg, Annette|Hintergrund|||Standard|Härter M., Reuter K., Aschenbrenner A., Schretzmann B., Marschner N., Hasenburg A., et al. Psychiatric disorders and associated factors in cancer: results of an interview study with patients in inpatient, rehabilitation and outpatient treatment. None. 2001;37:1385-1393||1538
Psychoonkologie|"1.1"|2014|Schumacher, Andrea|Hintergrund|||Erstautor|Schumacher A. Stellenwert der Psychoonkologie im neuen deutschen Gesundheitssystem. None. 2004;10:98-102||1538
Psychoonkologie|"1.1"|2014|Heckl, Ulrike|Hintergrund|||Standard|Weis J., Giesler J., Heckl U., Völklin V., Kuhnt S., Eichhorn S. Qualitätssicherung in der Psychoonkologie. None. None;None:None||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Erstautor|Weis J., Giesler J., Heckl U., Völklin V., Kuhnt S., Eichhorn S. Qualitätssicherung in der Psychoonkologie. None. None;None:None||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Standard|Schmitz Torsten, Weis Joachim, Herschbach Peter. Qualitätssicherung in der Psychoonkologie. None. 2008;None:165-168||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Letztautor|Herschbach P., Brandl T., Knight L., Keller M. Das subjektive Befinden von Krebskranken einheitlich beschreiben - Vorstellung der Psycho-Onkologischen Basisdokumentation (PO-Bado). None. 2004;101:799-802||1538
Psychoonkologie|"1.1"|2014|Dietz, Andreas|Hintergrund|||Standard|Singer S., Kuhnt S., Zwerenz R., Eckert K., Hofmeister D., Dietz A., et al. Age- and sex-standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients. None. 2011;105:445-451||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Kuhnt S., Zwerenz R., Eckert K., Hofmeister D., Dietz A., et al. Age- and sex-standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients. None. 2011;105:445-451||1538
Psychoonkologie|"1.1"|2014|Berberich, Hermann|Hintergrund|||Standard|Richter D., Geue K., Matthes A., Berberich H. J., Alexander H., Strauß B., et al. Fertilität und Krebs – Skizzierung des Problemfeldes. None. 2010;61:246-253||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Erstautor|Keller M. Depression. None. 2011;None:1109-1127||1538
Psychoonkologie|"1.1"|2014|Faller, Hermann|Hintergrund|||Erstautor|Faller H., Olshausen B., Flentje M. Emotionale Belastung und Unterstützungsbedürfnis bei Mammakarzinompatientinnen zu Beginn der Strahlentherapie. None. 2003;53:229-235||1538
Psychoonkologie|"1.1"|2014|Dietz, Andreas|Evidenzbasiertes Statement||False|Standard|Singer S., Danker H., Dietz A., Hornemann B., Koscielny S., Oeken J., et al. Screening for mental disorders in laryngeal cancer patients: a comparison of 6 methods. None. 2008;17:280-286||1538
Psychoonkologie|"1.1"|2014|Dietz, Andreas|Hintergrund|||Standard|Singer S., Danker H., Dietz A., Hornemann B., Koscielny S., Oeken J., et al. Screening for mental disorders in laryngeal cancer patients: a comparison of 6 methods. None. 2008;17:280-286||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Evidenzbasiertes Statement||False|Erstautor|Singer S., Danker H., Dietz A., Hornemann B., Koscielny S., Oeken J., et al. Screening for mental disorders in laryngeal cancer patients: a comparison of 6 methods. None. 2008;17:280-286||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Danker H., Dietz A., Hornemann B., Koscielny S., Oeken J., et al. Screening for mental disorders in laryngeal cancer patients: a comparison of 6 methods. None. 2008;17:280-286||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Evidenzbasiertes Statement||False|Standard|Bringmann Holger, Singer Susanne, Höckel Michael, Stolzenburg Jens-Uwe, Krauß Oliver, Schwarz Reinhold. Long-term course of psychiatric disorders in cancer patients: a pilot study. None. 2008;5:None||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Standard|Bringmann Holger, Singer Susanne, Höckel Michael, Stolzenburg Jens-Uwe, Krauß Oliver, Schwarz Reinhold. Long-term course of psychiatric disorders in cancer patients: a pilot study. None. 2008;5:None||1538
Psychoonkologie|"1.1"|2014|Lehmann, Antje|Hintergrund|||Standard|Ernst J., Lehmann A., Krauß O., Köhler U., Schwarz † R. Psychosoziale Unterstützungswünsche und tatsächlich erhaltene Versorgung onkologischer Patienten. None. 2009;30:269-274||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Letztautor|Geue K., Goetze H., Buttstaedt M., Kleinert E., Richter D., Singer S. An overview of art therapy interventions for cancer patients and the results of research. None. 2010;18:160-170||1538
Psychoonkologie|"1.1"|2014|Heim, Manfred|Hintergrund|||Erstautor|Heim M. E., Malsburg M. L., Niklas A. Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue. None. 2007;30:429-434||1538
Psychoonkologie|"1.1"|2014|Siedentopf, Friederike|Hintergrund|||Erstautor|Siedentopf F., Marten-Mittag B., Utz-Billing I., Schoenegg W., Kentenich H., Dinkel A. Experiences with a specific screening instrument to identify psychosocial support needs in breast cancer patients. None. 2010;148:166-171||1538
Psychoonkologie|"1.1"|2014|Keller, Monika|Hintergrund|||Standard|Herschbach P., Keller M., Knight L., Brandl T., Huber B., Henrich G., et al. Psychological problems of cancer patients: a cancer distress screening with a cancer-specific questionnaire. None. 2004;91:504-511||1538
Psychoonkologie|"1.1"|2014|Blettner, Gabriele|Hintergrund|||Standard|Weis J., Schumacher A., Blettner G., Determann M., Reinert E., Rüffer J. U., et al. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin. None. 2007;13:185-194||1538
Psychoonkologie|"1.1"|2014|Rüffer, Jens Ulrich|Hintergrund|||Standard|Weis J., Schumacher A., Blettner G., Determann M., Reinert E., Rüffer J. U., et al. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin. None. 2007;13:185-194||1538
Psychoonkologie|"1.1"|2014|Schumacher, Andrea|Hintergrund|||Standard|Weis J., Schumacher A., Blettner G., Determann M., Reinert E., Rüffer J. U., et al. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin. None. 2007;13:185-194||1538
Psychoonkologie|"1.1"|2014|Weis, Joachim|Hintergrund|||Erstautor|Weis J., Schumacher A., Blettner G., Determann M., Reinert E., Rüffer J. U., et al. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin. None. 2007;13:185-194||1538
Psychoonkologie|"1.1"|2014|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Kuhnt S., Götze H., Hauss J., Hinz A., Liebmann A., et al. Hospital anxiety and depression scale cutoff scores for cancer patients in acute care. None. 2009;100:908-912||1538
Psychoonkologie|"1.1"|2014|Dietz, Andreas|Evidenzbasiertes Statement||False|Standard|Bussian Claudia, Wollbrück Dorit, Danker Helge, Herrmann Esther, Thiele Alexander, Dietz Andreas, et al. Mental health after laryngectomy and partial laryngectomy: a comparative study. None. 2010;267:261-266||1538
Psychoonkologie|"1.1"|2014|Dietz, Andreas|Hintergrund|||Standard|Bussian Claudia, Wollbrück Dorit, Danker Helge, Herrmann Esther, Thiele Alexander, Dietz Andreas, et al. Mental health after laryngectomy and partial laryngectomy: a comparative study. None. 2010;267:261-266||1538
Psychoonkologie|"1.1"|2014|Blettner, Gabriele|Hintergrund|||Letztautor|Wickert M., Blettner G. Ambulante psychosoziale Krebsberatung in Deutschland. None. 2009;24:53-56||1538
Psychoonkologie|"1.1"|2014|Wickert, Martin|Hintergrund|||Erstautor|Wickert M., Blettner G. Ambulante psychosoziale Krebsberatung in Deutschland. None. 2009;24:53-56||1538
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Erstautor|Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, et al. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous . Clin Cancer Res. 2021;27 (23):6333-6342|https://pubmed.ncbi.nlm.nih.gov/34503977/|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Evidenzbasierte Empfehlung|A|False|Standard|Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21 (7):923-934|https://pubmed.ncbi.nlm.nih.gov/32511981/|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Standard|Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21 (7):923-934|https://pubmed.ncbi.nlm.nih.gov/32511981/|799
Adulte Weichgewebesarkome|"1.1"|2022|Wardelmann, Eva|Hintergrund|||Erstautor|Wardelmann E., Haas R. L., Bovee J. V., Terrier P., Lazar A., Messiou C., et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. None. 2016;53:84-95|https://www.ncbi.nlm.nih.gov/pubmed/26700077|799
Adulte Weichgewebesarkome|"1.1"|2022|Harati, Kamran|Hintergrund|||Erstautor|Harati K., Goertz O., Pieper A., Daigeler A., Joneidi-Jafari H., Niggemann H., et al. Soft Tissue Sarcomas of the Extremities: Surgical Margins Can Be Close as Long as the Resected Tumor Has No Ink on It. None. 2017;22:1400-1410|https://www.ncbi.nlm.nih.gov/pubmed/28739867|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Le Cesne A., Ouali M., Leahy M. G., Santoro A., Hoekstra H. J., Hohenberger P., et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. None. 2014;25:2425-2432|https://www.ncbi.nlm.nih.gov/pubmed/25294887|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Ressing M., Wardelmann E., Hohenberger P., Jakob J., Kasper B., Emrich K., et al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. None. 2018;18:235|https://www.ncbi.nlm.nih.gov/pubmed/29433465|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Standard|Ressing M., Wardelmann E., Hohenberger P., Jakob J., Kasper B., Emrich K., et al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. None. 2018;18:235|https://www.ncbi.nlm.nih.gov/pubmed/29433465|799
Adulte Weichgewebesarkome|"1.1"|2022|Kasper, Bernd|Hintergrund|||Standard|Ressing M., Wardelmann E., Hohenberger P., Jakob J., Kasper B., Emrich K., et al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. None. 2018;18:235|https://www.ncbi.nlm.nih.gov/pubmed/29433465|799
Adulte Weichgewebesarkome|"1.1"|2022|Wardelmann, Eva|Hintergrund|||Standard|Ressing M., Wardelmann E., Hohenberger P., Jakob J., Kasper B., Emrich K., et al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. None. 2018;18:235|https://www.ncbi.nlm.nih.gov/pubmed/29433465|799
Adulte Weichgewebesarkome|"1.1"|2022|Lehnhardt, Marcus|Hintergrund|||Standard|Daigeler A., Lehnhardt M., Khadra A., Hauser J., Steinstraesser L., Langer S., et al. Proximal major limb amputations--a retrospective analysis of 45 oncological cases. None. 2009;7:15|https://www.ncbi.nlm.nih.gov/pubmed/19203359|799
Adulte Weichgewebesarkome|"1.1"|2022|Lindner, Lars|Hintergrund|||Standard|Rauh J., Klein A., Baur-Melnyk A., Knosel T., Lindner L., Roeder F., et al. The role of surgical margins in atypical Lipomatous Tumours of the extremities. None. 2018;19:152|https://www.ncbi.nlm.nih.gov/pubmed/29776450|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Letztautor|Schwarzbach M. H., Hohenberger P. Current concepts in the management of retroperitoneal soft tissue sarcoma. None. 2009;179:301-19|https://www.ncbi.nlm.nih.gov/pubmed/19230548|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Erstautor|Hohenberger P., Allenberg J. R., Schlag P. M., Reichardt P. Results of surgery and multimodal therapy for patients with soft tissue sarcoma invading to vascular structures. None. 1999;85:396-408|https://www.ncbi.nlm.nih.gov/pubmed/10023708|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Letztautor|Hohenberger P., Allenberg J. R., Schlag P. M., Reichardt P. Results of surgery and multimodal therapy for patients with soft tissue sarcoma invading to vascular structures. None. 1999;85:396-408|https://www.ncbi.nlm.nih.gov/pubmed/10023708|799
Adulte Weichgewebesarkome|"1.1"|2022|Andreou, Dimosthenis|Hintergrund|||Erstautor|Andreou D., Boldt H., Werner M., Hamann C., Pink D., Tunn P. U. Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread--results of a large prospective trial. None. 2013;24:1400-5|https://www.ncbi.nlm.nih.gov/pubmed/23372051|799
Adulte Weichgewebesarkome|"1.1"|2022|Ugurel, Selma|Hintergrund|||Erstautor|Ugurel S., Kortmann R. D., Mohr P., Mentzel T., Garbe C., Breuninger H., et al. S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018. None. 2019;17:663-668|https://www.ncbi.nlm.nih.gov/pubmed/31241846|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Raut C. P., Miceli R., Strauss D. C., Swallow C. J., Hohenberger P., van Coevorden F., et al. External validation of a multi-institutional retroperitoneal sarcoma nomogram. None. 2016;122:1417-24|https://www.ncbi.nlm.nih.gov/pubmed/26916507|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Haas R. L. M., Bonvalot S., Miceli R., Strauss D. C., Swallow C. J., Hohenberger P., et al. Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. None. 2019;125:1290-1300|https://www.ncbi.nlm.nih.gov/pubmed/30602058|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Erstautor|Jakob J., Gerres A., Ronellenfitsch U., Pilz L., Wartenberg M., Kasper B., et al. [Treatment of retroperitoneal sarcoma in Germany : Results of a survey of the German Society of General and Visceral Surgery, the German Interdisciplinary Sarcoma Study Group and the advocacy group Das Lebenshaus]. None. 2018;89:50-55|https://www.ncbi.nlm.nih.gov/pubmed/28905080|799
Adulte Weichgewebesarkome|"1.1"|2022|Wartenberg, Markus|Hintergrund|||Standard|Jakob J., Gerres A., Ronellenfitsch U., Pilz L., Wartenberg M., Kasper B., et al. [Treatment of retroperitoneal sarcoma in Germany : Results of a survey of the German Society of General and Visceral Surgery, the German Interdisciplinary Sarcoma Study Group and the advocacy group Das Lebenshaus]. None. 2018;89:50-55|https://www.ncbi.nlm.nih.gov/pubmed/28905080|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Gronchi A., Strauss D. C., Miceli R., Bonvalot S., Swallow C. J., Hohenberger P., et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. None. 2016;263:1002-9|https://www.ncbi.nlm.nih.gov/pubmed/26727100|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Erstautor|Hohenberger P., Dinter D., Stroebel P., Kasper B., Wenz F. [Principles of surgery for retroperitoneal sarcoma]. None. 2014;139 Suppl 2:e72-8|https://www.ncbi.nlm.nih.gov/pubmed/23115028|799
Adulte Weichgewebesarkome|"1.1"|2022|Kasper, Bernd|Hintergrund|||Standard|Hohenberger P., Dinter D., Stroebel P., Kasper B., Wenz F. [Principles of surgery for retroperitoneal sarcoma]. None. 2014;139 Suppl 2:e72-8|https://www.ncbi.nlm.nih.gov/pubmed/23115028|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|MacNeill A. J., Gronchi A., Miceli R., Bonvalot S., Swallow C. J., Hohenberger P., et al. Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group. None. 2018;267:959-964|https://www.ncbi.nlm.nih.gov/pubmed/28394870|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Letztautor|Jakob J., Simeonova A., Kasper B., Ronellenfitsch U., Wenz F., Hohenberger P. Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma. None. 2015;22:2839-45|https://www.ncbi.nlm.nih.gov/pubmed/26085221|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Erstautor|Jakob J., Simeonova A., Kasper B., Ronellenfitsch U., Wenz F., Hohenberger P. Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma. None. 2015;22:2839-45|https://www.ncbi.nlm.nih.gov/pubmed/26085221|799
Adulte Weichgewebesarkome|"1.1"|2022|Kasper, Bernd|Hintergrund|||Standard|Jakob J., Simeonova A., Kasper B., Ronellenfitsch U., Wenz F., Hohenberger P. Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma. None. 2015;22:2839-45|https://www.ncbi.nlm.nih.gov/pubmed/26085221|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Evidenzbasierte Empfehlung|B|False|Standard|Angele M. K., Albertsmeier M., Prix N. J., Hohenberger P., Abdel-Rahman S., Dieterle N., et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. None. 2014;260:749-54; discussion 754-6|https://www.ncbi.nlm.nih.gov/pubmed/25379845|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Angele M. K., Albertsmeier M., Prix N. J., Hohenberger P., Abdel-Rahman S., Dieterle N., et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. None. 2014;260:749-54; discussion 754-6|https://www.ncbi.nlm.nih.gov/pubmed/25379845|799
Adulte Weichgewebesarkome|"1.1"|2022|Lindner, Lars|Evidenzbasierte Empfehlung|B|False|Standard|Issels R. D., Lindner L. H., Verweij J., Wessalowski R., Reichardt P., Wust P., et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. None. 2018;4:483-492|https://www.ncbi.nlm.nih.gov/pubmed/29450452|799
Adulte Weichgewebesarkome|"1.1"|2022|Lindner, Lars|Hintergrund|||Standard|Issels R. D., Lindner L. H., Verweij J., Wessalowski R., Reichardt P., Wust P., et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. None. 2018;4:483-492|https://www.ncbi.nlm.nih.gov/pubmed/29450452|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Evidenzbasierte Empfehlung|B|False|Standard|Issels R. D., Lindner L. H., Verweij J., Wessalowski R., Reichardt P., Wust P., et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. None. 2018;4:483-492|https://www.ncbi.nlm.nih.gov/pubmed/29450452|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Issels R. D., Lindner L. H., Verweij J., Wessalowski R., Reichardt P., Wust P., et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. None. 2018;4:483-492|https://www.ncbi.nlm.nih.gov/pubmed/29450452|799
Adulte Weichgewebesarkome|"1.1"|2022|Lehnhardt, Marcus|Hintergrund|||Standard|Ring A., Kirchhoff P., Goertz O., Behr B., Daigeler A., Lehnhardt M., et al. Reconstruction of Soft-Tissue Defects at the Foot and Ankle after Oncological Resection. None. 2016;3:15|https://www.ncbi.nlm.nih.gov/pubmed/27014697|799
Adulte Weichgewebesarkome|"1.1"|2022|Harati, Kamran|Hintergrund|||Standard|Kapalschinski N., Goertz O., Harati K., Kueckelhaus M., Kolbenschlag J., Lehnhardt M., et al. Plastic Surgery in the Multimodal Treatment Concept of Soft Tissue Sarcoma: Influence of Radiation, Chemotherapy, and Isolated Limb Perfusion on Plastic Surgery Techniques. None. 2015;5:268|https://www.ncbi.nlm.nih.gov/pubmed/26649280|799
Adulte Weichgewebesarkome|"1.1"|2022|Lehnhardt, Marcus|Hintergrund|||Standard|Kapalschinski N., Goertz O., Harati K., Kueckelhaus M., Kolbenschlag J., Lehnhardt M., et al. Plastic Surgery in the Multimodal Treatment Concept of Soft Tissue Sarcoma: Influence of Radiation, Chemotherapy, and Isolated Limb Perfusion on Plastic Surgery Techniques. None. 2015;5:268|https://www.ncbi.nlm.nih.gov/pubmed/26649280|799
Adulte Weichgewebesarkome|"1.1"|2022|Budach, Wilfried|Hintergrund|||Erstautor|Budach W., Paulsen F., Welz S., Classen J., Scheithauer H., Marini P., et al. Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. None. 2002;86:470-6|https://www.ncbi.nlm.nih.gov/pubmed/11875717|799
Adulte Weichgewebesarkome|"1.1"|2022|Budach, Wilfried|Hintergrund|||Erstautor|Budach W., Budach V., Dinges S., Stuschke M., Sack H. Correlation between primary chemo- and radiation sensitivity in a panel of highly malignant human soft tissue sarcoma xenografts. None. 1997;42:181-7|https://www.ncbi.nlm.nih.gov/pubmed/9106928|799
Adulte Weichgewebesarkome|"1.1"|2022|Hartmann, Jörg Thomas|Hintergrund|||Standard|Eckert F., Matuschek C., Mueller A. C., Weinmann M., Hartmann J. T., Belka C., et al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. None. 2010;5:55|https://www.ncbi.nlm.nih.gov/pubmed/20553599|799
Adulte Weichgewebesarkome|"1.1"|2022|Kasper, Bernd|Hintergrund|||Standard|Schmitt T., Lehner B., Kasper B., Bischof M., Roeder F., Dietrich S., et al. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. None. 2011;11:510|https://www.ncbi.nlm.nih.gov/pubmed/22152120|799
Adulte Weichgewebesarkome|"1.1"|2022|Lehner, Burkhard|Hintergrund|||Standard|Schmitt T., Lehner B., Kasper B., Bischof M., Roeder F., Dietrich S., et al. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. None. 2011;11:510|https://www.ncbi.nlm.nih.gov/pubmed/22152120|799
Adulte Weichgewebesarkome|"1.1"|2022|Lindner, Lars|Hintergrund|||Letztautor|Issels R., Kampmann E., Kanaar R., Lindner L. H. Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application. None. 2016;32:89-95|https://www.ncbi.nlm.nih.gov/pubmed/26803991|799
Adulte Weichgewebesarkome|"1.1"|2022|Lindner, Lars|Evidenzbasierte Empfehlung|B|False|Standard|Issels R. D., Lindner L. H., Verweij J., Wust P., Reichardt P., Schem B. C., et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. None. 2010;11:561-70|https://www.ncbi.nlm.nih.gov/pubmed/20434400|799
Adulte Weichgewebesarkome|"1.1"|2022|Lindner, Lars|Hintergrund|||Standard|Issels R. D., Lindner L. H., Verweij J., Wust P., Reichardt P., Schem B. C., et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. None. 2010;11:561-70|https://www.ncbi.nlm.nih.gov/pubmed/20434400|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Evidenzbasierte Empfehlung|B|False|Standard|Issels R. D., Lindner L. H., Verweij J., Wust P., Reichardt P., Schem B. C., et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. None. 2010;11:561-70|https://www.ncbi.nlm.nih.gov/pubmed/20434400|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Issels R. D., Lindner L. H., Verweij J., Wust P., Reichardt P., Schem B. C., et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. None. 2010;11:561-70|https://www.ncbi.nlm.nih.gov/pubmed/20434400|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Letztautor|Jakob J., Hohenberger P. Role of isolated limb perfusion with recombinant human tumor necrosis factor alpha and melphalan in locally advanced extremity soft tissue sarcoma. None. 2016;122:2624-32|https://www.ncbi.nlm.nih.gov/pubmed/27197621|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Erstautor|Jakob J., Hohenberger P. Role of isolated limb perfusion with recombinant human tumor necrosis factor alpha and melphalan in locally advanced extremity soft tissue sarcoma. None. 2016;122:2624-32|https://www.ncbi.nlm.nih.gov/pubmed/27197621|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Erstautor|Hohenberger P., Haier J., Schlag P. M. Rhabdomyolysis and renal function impairment after isolated limb perfusion--comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug' regimen. None. 1997;33:596-601|https://www.ncbi.nlm.nih.gov/pubmed/9274441|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Erstautor|Hohenberger P., Latz E., Kettelhack C., Rezaei A. H., Schumann R., Schlag P. M. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. None. 2003;10:562-8|https://www.ncbi.nlm.nih.gov/pubmed/12794024|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Standard|Grabellus F., Kraft C., Sheu-Grabellus S. Y., Bauer S., Podleska L. E., Lauenstein T. C., et al. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. None. 2011;103:371-9|https://www.ncbi.nlm.nih.gov/pubmed/21400518|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Letztautor|Jakob J., Tunn P. U., Hayes A. J., Pilz L. R., Nowak K., Hohenberger P. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. None. 2014;109:786-90|https://www.ncbi.nlm.nih.gov/pubmed/24619722|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Erstautor|Jakob J., Tunn P. U., Hayes A. J., Pilz L. R., Nowak K., Hohenberger P. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. None. 2014;109:786-90|https://www.ncbi.nlm.nih.gov/pubmed/24619722|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Erstautor|Jakob J., Smith H. G., Wilkinson M. J., Pencavel T., Miah A. B., Thomas J. M., et al. Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. None. 2018;8:12|https://www.ncbi.nlm.nih.gov/pubmed/29988594|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Evidenzbasierte Empfehlung|B|False|Standard|Woll P. J., Reichardt P., Le Cesne A., Bonvalot S., Azzarelli A., Hoekstra H. J., et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. None. 2012;13:1045-54|https://www.ncbi.nlm.nih.gov/pubmed/22954508|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Woll P. J., Reichardt P., Le Cesne A., Bonvalot S., Azzarelli A., Hoekstra H. J., et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. None. 2012;13:1045-54|https://www.ncbi.nlm.nih.gov/pubmed/22954508|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Standard|Grabellus F., Podleska L. E., Sheu S. Y., Bauer S., Pottgen C., Kloeters C., et al. Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. None. 2013;39:61-7|https://www.ncbi.nlm.nih.gov/pubmed/23103117|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Standard|Grabellus F., Kraft C., Sheu S. Y., Ebeling P., Bauer S., Lendemans S., et al. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. None. 2009;16:676-86|https://www.ncbi.nlm.nih.gov/pubmed/19130134|799
Adulte Weichgewebesarkome|"1.1"|2022|Hartmann, Jörg Thomas|Evidenzbasierte Empfehlung|A|False|Standard|Judson I., Verweij J., Gelderblom H., Hartmann J. T., Schoffski P., Blay J. Y., et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. None. 2014;15:415-23|https://www.ncbi.nlm.nih.gov/pubmed/24618336|799
Adulte Weichgewebesarkome|"1.1"|2022|Hartmann, Jörg Thomas|Hintergrund|||Standard|Judson I., Verweij J., Gelderblom H., Hartmann J. T., Schoffski P., Blay J. Y., et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. None. 2014;15:415-23|https://www.ncbi.nlm.nih.gov/pubmed/24618336|799
Adulte Weichgewebesarkome|"1.1"|2022|Budach, Wilfried|Hintergrund|||Letztautor|Classen J., Hehr T., Lamprecht U., Zumbragel A., Bamberg M., Budach W. Hyperfractionated 192Ir brachytherapy for recurrent retroperitoneal sarcoma: a technique for delivery of local tumor boost dose. None. 2003;179:118-22|https://www.ncbi.nlm.nih.gov/pubmed/12590323|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Blay J. Y., Leahy M. G., Nguyen B. B., Patel S. R., Hohenberger P., Santoro A., et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. None. 2014;50:1137-47|https://www.ncbi.nlm.nih.gov/pubmed/24512981|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Letztautor|Bitz U., Pink D., Busemann C., Reichardt P. Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS). None. 2011;29:10094-10094|https://doi.org/10.1200/jco.2011.29.15_suppl.10094|799
Adulte Weichgewebesarkome|"1.1"|2022|Knoefel, Wolfram Trudo|Hintergrund|||Standard|Rehders A., Peiper M., Stoecklein N. H., Alexander A., Boelke E., Knoefel W. T., et al. Hepatic metastasectomy for soft-tissue sarcomas: is it justified?. None. 2009;33:111-7|https://www.ncbi.nlm.nih.gov/pubmed/18949511|799
Adulte Weichgewebesarkome|"1.1"|2022|Hettmer, Simone|Hintergrund|||Erstautor|Hettmer S., Archer N. M., Somers G. R., Novokmet A., Wagers A. J., Diller L., et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. None. 2014;120:1068-75|https://www.ncbi.nlm.nih.gov/pubmed/24382691|799
Adulte Weichgewebesarkome|"1.1"|2022|Sehouli, Jaild|Hintergrund|||Standard|de Wit M., Ortner P., Lipp H. P., Sehouli J., Untch M., Ruhnke M., et al. Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment. None. 2013;36:127-35|https://www.ncbi.nlm.nih.gov/pubmed/23486002|799
Adulte Weichgewebesarkome|"1.1"|2022|Sehouli, Jalid|Hintergrund|||Standard|de Wit M., Ortner P., Lipp H. P., Sehouli J., Untch M., Ruhnke M., et al. Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment. None. 2013;36:127-35|https://www.ncbi.nlm.nih.gov/pubmed/23486002|799
Adulte Weichgewebesarkome|"1.1"|2022|Kasper, Bernd|Hintergrund|||Erstautor|Kasper B., Harter C., Meissner J., Bellos F., Krasniqi F., Ho A. D., et al. Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?. None. 2004;12:205-7|https://www.ncbi.nlm.nih.gov/pubmed/14727169|799
Adulte Weichgewebesarkome|"1.1"|2022|Lindner, Lars|Hintergrund|||Standard|Durr H. R., Rauh J., Baur-Melnyk A., Knosel T., Lindner L., Roeder F., et al. Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients. None. 2018;18:304|https://www.ncbi.nlm.nih.gov/pubmed/29558901|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Standard|Casali P. G., Abecassis N., Aro H. T., Bauer S., Biagini R., Bielack S., et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. None. 2018;29:iv68-iv78|https://www.ncbi.nlm.nih.gov/pubmed/29846513|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Eriksson M., Reichardt P., Sundby Hall K., Schutte J., Cameron S., Hohenberger P., et al. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?. None. 2016;59:128-133|https://www.ncbi.nlm.nih.gov/pubmed/27033260|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Eriksson M., Reichardt P., Sundby Hall K., Schutte J., Cameron S., Hohenberger P., et al. Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?. None. 2016;59:128-133|https://www.ncbi.nlm.nih.gov/pubmed/27033260|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Erstautor|Hohenberger P., Eisenberg B. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST). None. 2010;17:2585-600|https://www.ncbi.nlm.nih.gov/pubmed/20407930|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Letztautor|Jakob J., Hohenberger P. Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors. None. 2018;34:359-365|https://www.ncbi.nlm.nih.gov/pubmed/30498703|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Erstautor|Jakob J., Hohenberger P. Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors. None. 2018;34:359-365|https://www.ncbi.nlm.nih.gov/pubmed/30498703|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Erstautor|Jakob J., Mussi C., Ronellenfitsch U., Wardelmann E., Negri T., Gronchi A., et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. None. 2013;20:586-92|https://www.ncbi.nlm.nih.gov/pubmed/22965573|799
Adulte Weichgewebesarkome|"1.1"|2022|Wardelmann, Eva|Hintergrund|||Standard|Jakob J., Mussi C., Ronellenfitsch U., Wardelmann E., Negri T., Gronchi A., et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. None. 2013;20:586-92|https://www.ncbi.nlm.nih.gov/pubmed/22965573|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Letztautor|Ronellenfitsch U., Hohenberger P. Surgery for Gastrointestinal Stromal Tumors: State of the Art of Laparoscopic Resection and Surgery for M1 Tumors. None. 2018;34:367-374|https://www.ncbi.nlm.nih.gov/pubmed/30498704|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Letztautor|Ronellenfitsch U., Staiger W., Kahler G., Strobel P., Schwarzbach M., Hohenberger P. Perioperative and oncological outcome of laparoscopic resection of gastrointestinal stromal tumour (GIST) of the stomach. None. 2009;2009:286138|https://www.ncbi.nlm.nih.gov/pubmed/19343179|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Erstautor|Hohenberger P., Ronellenfitsch U., Oladeji O., Pink D., Strobel P., Wardelmann E., et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. None. 2010;97:1854-9|https://www.ncbi.nlm.nih.gov/pubmed/20730857|799
Adulte Weichgewebesarkome|"1.1"|2022|Wardelmann, Eva|Hintergrund|||Standard|Hohenberger P., Ronellenfitsch U., Oladeji O., Pink D., Strobel P., Wardelmann E., et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. None. 2010;97:1854-9|https://www.ncbi.nlm.nih.gov/pubmed/20730857|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Erstautor|Hohenberger P., Bonvalot S., van Coevorden F., Rutkowski P., Stoeckle E., Olungu C., et al. Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study. None. 2019;120:47-53|https://www.ncbi.nlm.nih.gov/pubmed/31479947|799
Adulte Weichgewebesarkome|"1.1"|2022|Hartmann, Jörg Thomas|Evidenzbasierte Empfehlung|A|False|Standard|Joensuu H., Eriksson M., Sundby Hall K., Hartmann J. T., Pink D., Schutte J., et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. None. 2012;307:1265-72|https://www.ncbi.nlm.nih.gov/pubmed/22453568|799
Adulte Weichgewebesarkome|"1.1"|2022|Hartmann, Jörg Thomas|Hintergrund|||Standard|Joensuu H., Eriksson M., Sundby Hall K., Hartmann J. T., Pink D., Schutte J., et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. None. 2012;307:1265-72|https://www.ncbi.nlm.nih.gov/pubmed/22453568|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Debiec-Rychter M., Sciot R., Le Cesne A., Schlemmer M., Hohenberger P., van Oosterom A. T., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. None. 2006;42:1093-103|https://www.ncbi.nlm.nih.gov/pubmed/16624552|799
Adulte Weichgewebesarkome|"1.1"|2022|Wardelmann, Eva|Hintergrund|||Standard|Joensuu H., Wardelmann E., Sihto H., Eriksson M., Sundby Hall K., Reichardt A., et al. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. None. 2017;3:602-609|https://www.ncbi.nlm.nih.gov/pubmed/28334365|799
Adulte Weichgewebesarkome|"1.1"|2022|Hartmann, Jörg Thomas|Evidenzbasierte Empfehlung|A|False|Standard|Joensuu H., Eriksson M., Sundby Hall K., Reichardt A., Hartmann J. T., Pink D., et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. None. 2016;34:244-50|https://www.ncbi.nlm.nih.gov/pubmed/26527782|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Evidenzbasiertes Statement||False|Standard|Casali P. G., Le Cesne A., Poveda Velasco A., Kotasek D., Rutkowski P., Hohenberger P., et al. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. None. 2015;33:4276-83|https://www.ncbi.nlm.nih.gov/pubmed/26573069|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Casali P. G., Le Cesne A., Poveda Velasco A., Kotasek D., Rutkowski P., Hohenberger P., et al. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. None. 2015;33:4276-83|https://www.ncbi.nlm.nih.gov/pubmed/26573069|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Verweij J., Casali P. G., Zalcberg J., LeCesne A., Reichardt P., Blay J. Y., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. None. 2004;364:1127-34|https://www.ncbi.nlm.nih.gov/pubmed/15451219|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Standard|Antoch G., Kanja J., Bauer S., Kuehl H., Renzing-Koehler K., Schuette J., et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. None. 2004;45:357-65|https://www.ncbi.nlm.nih.gov/pubmed/15001674|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Erstautor|Bauer S., Rutkowski P., Hohenberger P., Miceli R., Fumagalli E., Siedlecki J. A., et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). None. 2014;40:412-9|https://www.ncbi.nlm.nih.gov/pubmed/24491288|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Bauer S., Rutkowski P., Hohenberger P., Miceli R., Fumagalli E., Siedlecki J. A., et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). None. 2014;40:412-9|https://www.ncbi.nlm.nih.gov/pubmed/24491288|799
Adulte Weichgewebesarkome|"1.1"|2022|Jakob, Jens|Hintergrund|||Standard|Mussi C., Ronellenfitsch U., Jakob J., Tamborini E., Reichardt P., Casali P. G., et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?. None. 2010;21:403-408|https://www.ncbi.nlm.nih.gov/pubmed/19628568|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Mussi C., Ronellenfitsch U., Jakob J., Tamborini E., Reichardt P., Casali P. G., et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?. None. 2010;21:403-408|https://www.ncbi.nlm.nih.gov/pubmed/19628568|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Van Glabbeke M., Verweij J., Casali P. G., Le Cesne A., Hohenberger P., Ray-Coquard I., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. None. 2005;23:5795-804|https://www.ncbi.nlm.nih.gov/pubmed/16110036|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Evidenzbasierte Empfehlung|A|False|Standard|Demetri G. D., Reichardt P., Kang Y. K., Blay J. Y., Rutkowski P., Gelderblom H., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. None. 2013;381:295-302|https://www.ncbi.nlm.nih.gov/pubmed/23177515|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Letztautor|Ronellenfitsch U., Henzler T., Menge F., Dimitrakopoulou-Strauss A., Hohenberger P. [Advanced gastrointestinal stromal tumors : What role does surgery currently play in multimodal concepts?]. None. 2016;87:389-97|https://www.ncbi.nlm.nih.gov/pubmed/27080051|799
Adulte Weichgewebesarkome|"1.1"|2022|Wardelmann, Eva|Hintergrund|||Erstautor|Wardelmann E., Thomas N., Merkelbach-Bruse S., Pauls K., Speidel N., Buttner R., et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. None. 2005;6:249-51|https://www.ncbi.nlm.nih.gov/pubmed/15811621|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Erstautor|Reichardt P., Blay J. Y., Gelderblom H., Schlemmer M., Demetri G. D., Bui-Nguyen B., et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. None. 2012;23:1680-7|https://www.ncbi.nlm.nih.gov/pubmed/22357255|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Joensuu H., Reichardt P., Eriksson M., Sundby Hall K., Vehtari A. Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients. None. 2014;271:96-103|https://www.ncbi.nlm.nih.gov/pubmed/24475826|799
Adulte Weichgewebesarkome|"1.1"|2022|Hettmer, Simone|Hintergrund|||Erstautor|Hettmer S., Teot L. A., Kozakewich H., Werger A. M., Davies K. J., Fletcher C. D., et al. Myogenic tumors in nevoid Basal cell carcinoma syndrome. None. 2015;37:147-9|https://www.ncbi.nlm.nih.gov/pubmed/24517962|799
Adulte Weichgewebesarkome|"1.1"|2022|Schneider, Ulrike|Hintergrund|||Standard|Kacker C., Marx A., Mossinger K., Svehla F., Schneider U., Hogendoorn P. C., et al. High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01. None. 2013;52:93-8|https://www.ncbi.nlm.nih.gov/pubmed/23012233|799
Adulte Weichgewebesarkome|"1.1"|2022|Hartmann, Jörg Thomas|Hintergrund|||Standard|Schlemmer M., Reichardt P., Verweij J., Hartmann J. T., Judson I., Thyss A., et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. None. 2008;44:2433-6|https://www.ncbi.nlm.nih.gov/pubmed/18771914|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Schlemmer M., Reichardt P., Verweij J., Hartmann J. T., Judson I., Thyss A., et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. None. 2008;44:2433-6|https://www.ncbi.nlm.nih.gov/pubmed/18771914|799
Adulte Weichgewebesarkome|"1.1"|2022|Wardelmann, Eva|Hintergrund|||Standard|Young R. J., Natukunda A., Litiere S., Woll P. J., Wardelmann E., van der Graaf W. T. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. None. 2014;50:3178-86|https://www.ncbi.nlm.nih.gov/pubmed/25459395|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Standard|Pink Daniel, Bauer Sebastian, Brodowicz Thomas, Reichardt Peter, Kasper Bernd, Richter Stephan, et al. Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study. None. 2018;36:11570-11570|https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.11570|799
Adulte Weichgewebesarkome|"1.1"|2022|Reichardt, Peter|Hintergrund|||Standard|Pink Daniel, Bauer Sebastian, Brodowicz Thomas, Reichardt Peter, Kasper Bernd, Richter Stephan, et al. Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study. None. 2018;36:11570-11570|https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.11570|799
Adulte Weichgewebesarkome|"1.1"|2022|Lindner, Lars|Hintergrund|||Standard|Schoffski P., Wozniak A., Stacchiotti S., Rutkowski P., Blay J. Y., Lindner L. H., et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. None. 2017;28:3000-3008|https://www.ncbi.nlm.nih.gov/pubmed/28950372|799
Adulte Weichgewebesarkome|"1.1"|2022|Bauer, Sebastian|Hintergrund|||Standard|Casali P. G., Abecassis N., Aro H. T., Bauer S., Biagini R., Bielack S., et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. None. 2018;29:iv51-iv67|https://www.ncbi.nlm.nih.gov/pubmed/29846498|799
Adulte Weichgewebesarkome|"1.1"|2022|Hohenberger, Peter|Hintergrund|||Standard|Birgin E., Yang C., Hetjens S., Reissfelder C., Hohenberger P., Rahbari N. N. Core needle biopsy versus incisional biopsy for differentiation of soft-tissue sarcomas: A systematic review and meta-analysis. None. 2020;126:1917-1928|https://www.ncbi.nlm.nih.gov/pubmed/32022262|799
Komplementärmedizin|"1.1"|2021|Beckmann, Matthias W.|Hintergrund|||Letztautor|Hack CC, Hüttner NB, Fasching PA, Beckmann MW. Development and Validation of a Standardized Questionnaire and Standardized Diary for Use in Integrative Medicine Consultations in Gynecologic Oncology. Geburtshilfe Frauenheilkd. 2015;75 (4):377-383|https://pubmed.ncbi.nlm.nih.gov/26028695/|975
Komplementärmedizin|"1.1"|2021|Hack, Carolin C.|Hintergrund|||Erstautor|Hack CC, Hüttner NB, Fasching PA, Beckmann MW. Development and Validation of a Standardized Questionnaire and Standardized Diary for Use in Integrative Medicine Consultations in Gynecologic Oncology. Geburtshilfe Frauenheilkd. 2015;75 (4):377-383|https://pubmed.ncbi.nlm.nih.gov/26028695/|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Evidenzbasierte Empfehlung|0|False|Letztautor|Haller H., Winkler M. M., Klose P., Dobos G., Kummel S., Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. None. 2017;56:1665-1676|https://www.ncbi.nlm.nih.gov/pubmed/28686520|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Letztautor|Haller H., Winkler M. M., Klose P., Dobos G., Kummel S., Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. None. 2017;56:1665-1676|https://www.ncbi.nlm.nih.gov/pubmed/28686520|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Evidenzbasierte Empfehlung|0|False|Standard|Haller H., Winkler M. M., Klose P., Dobos G., Kummel S., Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. None. 2017;56:1665-1676|https://www.ncbi.nlm.nih.gov/pubmed/28686520|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Hintergrund|||Standard|Haller H., Winkler M. M., Klose P., Dobos G., Kummel S., Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. None. 2017;56:1665-1676|https://www.ncbi.nlm.nih.gov/pubmed/28686520|975
Komplementärmedizin|"1.1"|2021|Haller, Heidemarie|Evidenzbasierte Empfehlung|0|False|Erstautor|Haller H., Winkler M. M., Klose P., Dobos G., Kummel S., Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. None. 2017;56:1665-1676|https://www.ncbi.nlm.nih.gov/pubmed/28686520|975
Komplementärmedizin|"1.1"|2021|Haller, Heidemarie|Hintergrund|||Erstautor|Haller H., Winkler M. M., Klose P., Dobos G., Kummel S., Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. None. 2017;56:1665-1676|https://www.ncbi.nlm.nih.gov/pubmed/28686520|975
Komplementärmedizin|"1.1"|2021|Klose, Petra|Evidenzbasierte Empfehlung|0|False|Standard|Haller H., Winkler M. M., Klose P., Dobos G., Kummel S., Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. None. 2017;56:1665-1676|https://www.ncbi.nlm.nih.gov/pubmed/28686520|975
Komplementärmedizin|"1.1"|2021|Klose, Petra|Hintergrund|||Standard|Haller H., Winkler M. M., Klose P., Dobos G., Kummel S., Cramer H. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. None. 2017;56:1665-1676|https://www.ncbi.nlm.nih.gov/pubmed/28686520|975
Komplementärmedizin|"1.1"|2021|Witt, Claudia|Evidenzbasierte Empfehlung|0|False|Erstautor|Witt C. M., Ausserer O., Baier S., Heidegger H., Icke K., Mayr O., et al. Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial. None. 2015;149:449-60|https://www.ncbi.nlm.nih.gov/pubmed/25555830|975
Komplementärmedizin|"1.1"|2021|Witt, Claudia|Hintergrund|||Erstautor|Witt C. M., Ausserer O., Baier S., Heidegger H., Icke K., Mayr O., et al. Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial. None. 2015;149:449-60|https://www.ncbi.nlm.nih.gov/pubmed/25555830|975
Komplementärmedizin|"1.1"|2021|Langhorst, Jost|Hintergrund|||Standard|Spahn G., Choi K. E., Kennemann C., Lüdtke R., Franken U., Langhorst J., et al. Can a multimodal mind-body program enhance the treatment effects of physical activity in breast cancer survivors with chronic tumor-associated fatigue? A randomized controlled trial. None. 2013;12:291-300||975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H., Ward L., Steel A., Lauche R., Dobos G., Zhang Y. Prevalence, Patterns, and Predictors of Yoga Use: Results of a U.S. Nationally Representative Survey. None. 2016;50:230-5|https://www.ncbi.nlm.nih.gov/pubmed/26497261|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Hintergrund|||Standard|Cramer H., Ward L., Steel A., Lauche R., Dobos G., Zhang Y. Prevalence, Patterns, and Predictors of Yoga Use: Results of a U.S. Nationally Representative Survey. None. 2016;50:230-5|https://www.ncbi.nlm.nih.gov/pubmed/26497261|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H. Yoga in Deutschland – Ergebnisse einer national repräsentativen Umfrage. None. 2015;22:298-303||975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H., Lauche R., Dobos G. Characteristics of randomized controlled trials of yoga: a bibliometric analysis. None. 2014;14:328|https://www.ncbi.nlm.nih.gov/pubmed/25183419|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Hintergrund|||Letztautor|Cramer H., Lauche R., Dobos G. Characteristics of randomized controlled trials of yoga: a bibliometric analysis. None. 2014;14:328|https://www.ncbi.nlm.nih.gov/pubmed/25183419|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H., Lauche R., Langhorst J., Dobos G. Is one yoga style better than another? A systematic review of associations of yoga style and conclusions in randomized yoga trials. None. 2016;25:178-87|https://www.ncbi.nlm.nih.gov/pubmed/27062966|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Hintergrund|||Letztautor|Cramer H., Lauche R., Langhorst J., Dobos G. Is one yoga style better than another? A systematic review of associations of yoga style and conclusions in randomized yoga trials. None. 2016;25:178-87|https://www.ncbi.nlm.nih.gov/pubmed/27062966|975
Komplementärmedizin|"1.1"|2021|Langhorst, Jost|Hintergrund|||Standard|Cramer H., Lauche R., Langhorst J., Dobos G. Is one yoga style better than another? A systematic review of associations of yoga style and conclusions in randomized yoga trials. None. 2016;25:178-87|https://www.ncbi.nlm.nih.gov/pubmed/27062966|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Evidenzbasierte Empfehlung|B|False|Erstautor|Cramer H., Lauche R., Klose P., Lange S., Langhorst J., Dobos G. J. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. None. 2017;1:CD010802|https://www.ncbi.nlm.nih.gov/pubmed/28045199|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H., Lauche R., Klose P., Lange S., Langhorst J., Dobos G. J. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. None. 2017;1:CD010802|https://www.ncbi.nlm.nih.gov/pubmed/28045199|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Evidenzbasierte Empfehlung|B|False|Letztautor|Cramer H., Lauche R., Klose P., Lange S., Langhorst J., Dobos G. J. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. None. 2017;1:CD010802|https://www.ncbi.nlm.nih.gov/pubmed/28045199|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Hintergrund|||Letztautor|Cramer H., Lauche R., Klose P., Lange S., Langhorst J., Dobos G. J. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. None. 2017;1:CD010802|https://www.ncbi.nlm.nih.gov/pubmed/28045199|975
Komplementärmedizin|"1.1"|2021|Klose, Petra|Evidenzbasierte Empfehlung|B|False|Standard|Cramer H., Lauche R., Klose P., Lange S., Langhorst J., Dobos G. J. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. None. 2017;1:CD010802|https://www.ncbi.nlm.nih.gov/pubmed/28045199|975
Komplementärmedizin|"1.1"|2021|Klose, Petra|Hintergrund|||Standard|Cramer H., Lauche R., Klose P., Lange S., Langhorst J., Dobos G. J. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. None. 2017;1:CD010802|https://www.ncbi.nlm.nih.gov/pubmed/28045199|975
Komplementärmedizin|"1.1"|2021|Langhorst, Jost|Evidenzbasierte Empfehlung|B|False|Standard|Cramer H., Lauche R., Klose P., Lange S., Langhorst J., Dobos G. J. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. None. 2017;1:CD010802|https://www.ncbi.nlm.nih.gov/pubmed/28045199|975
Komplementärmedizin|"1.1"|2021|Langhorst, Jost|Hintergrund|||Standard|Cramer H., Lauche R., Klose P., Lange S., Langhorst J., Dobos G. J. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. None. 2017;1:CD010802|https://www.ncbi.nlm.nih.gov/pubmed/28045199|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Evidenzbasierte Empfehlung|0|False|Erstautor|Cramer H., Rabsilber S., Lauche R., Kummel S., Dobos G. Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial. None. 2015;121:2175-84|https://www.ncbi.nlm.nih.gov/pubmed/25739642|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H., Rabsilber S., Lauche R., Kummel S., Dobos G. Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial. None. 2015;121:2175-84|https://www.ncbi.nlm.nih.gov/pubmed/25739642|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Evidenzbasierte Empfehlung|0|False|Letztautor|Cramer H., Rabsilber S., Lauche R., Kummel S., Dobos G. Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial. None. 2015;121:2175-84|https://www.ncbi.nlm.nih.gov/pubmed/25739642|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Hintergrund|||Letztautor|Cramer H., Rabsilber S., Lauche R., Kummel S., Dobos G. Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial. None. 2015;121:2175-84|https://www.ncbi.nlm.nih.gov/pubmed/25739642|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Evidenzbasierte Empfehlung|0|False|Erstautor|Cramer H., Pokhrel B., Fester C., Meier B., Gass F., Lauche R., et al. A randomized controlled bicenter trial of yoga for patients with colorectal cancer. None. 2016;25:412-20|https://www.ncbi.nlm.nih.gov/pubmed/26228466|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H., Pokhrel B., Fester C., Meier B., Gass F., Lauche R., et al. A randomized controlled bicenter trial of yoga for patients with colorectal cancer. None. 2016;25:412-20|https://www.ncbi.nlm.nih.gov/pubmed/26228466|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H., Ward L., Saper R., Fishbein D., Dobos G., Lauche R. The Safety of Yoga: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. None. 2015;182:281-93|https://www.ncbi.nlm.nih.gov/pubmed/26116216|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Hintergrund|||Standard|Cramer H., Ward L., Saper R., Fishbein D., Dobos G., Lauche R. The Safety of Yoga: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. None. 2015;182:281-93|https://www.ncbi.nlm.nih.gov/pubmed/26116216|975
Komplementärmedizin|"1.1"|2021|Cramer, Holger|Hintergrund|||Erstautor|Cramer H., Quinker D., Schumann D., Wardle J., Dobos G., Lauche R. Adverse effects of yoga: a national cross-sectional survey. None. 2019;19:190|https://www.ncbi.nlm.nih.gov/pubmed/31357980|975
Komplementärmedizin|"1.1"|2021|Dobos, Gustav|Hintergrund|||Standard|Cramer H., Quinker D., Schumann D., Wardle J., Dobos G., Lauche R. Adverse effects of yoga: a national cross-sectional survey. None. 2019;19:190|https://www.ncbi.nlm.nih.gov/pubmed/31357980|975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Hintergrund|||Erstautor|Micke Oliver, Bruns Frank, Glatzel Michael, Schönekaes Klaus, Micke Patrick, Mücke Ralph, et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. None. 2009;1:19-25||975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Evidenzbasierte Empfehlung|0|False|Letztautor|Buntzel J., Riesenbeck D., Glatzel M., Berndt-Skorka R., Riedel T., Micke O. Limited effects of selenium in the prevention of radiation-associated toxicities - results of a randomized study in head neck cancer patients. None. 2008;28:52|https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00725143/full|975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Hintergrund|||Letztautor|Buntzel J., Riesenbeck D., Glatzel M., Berndt-Skorka R., Riedel T., Micke O. Limited effects of selenium in the prevention of radiation-associated toxicities - results of a randomized study in head neck cancer patients. None. 2008;28:52|https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00725143/full|975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Hintergrund|||Standard|Muecke R., Micke O., Schomburg L., Buentzel J., Glatzel M., Baaske D., et al. Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial. None. 2013;8:72|https://www.ncbi.nlm.nih.gov/pubmed/23531280|975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Hintergrund|||Standard|Muecke R., Micke O., Schomburg L., Glatzel M., Reichl B., Kisters K., et al. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. None. 2014;13:463-7|https://www.ncbi.nlm.nih.gov/pubmed/25015649|975
Komplementärmedizin|"1.1"|2021|Bertz, Hartmut|Konsensbasiertes Statement||False|Standard|Arends J., Bertz H., Bischoff S., Fietkau R., Herrmann H., Holm E., et al. S3-Leitline der Deutschen Gesellschaft für Ernährungsmedizin e. V. (DGEM) in Kooperation mit der Deutschen Gesellschaft für Hämatologie und Onkologie e. V. (DGHO), der Arbeitsgemeinschaft „Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin“ der Deutschen Krebsgesellschaft (ASORS) und der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE). None. 2015;40:e1-e74||975
Komplementärmedizin|"1.1"|2021|Bertz, Hartmut|Hintergrund|||Standard|Arends J., Bertz H., Bischoff S., Fietkau R., Herrmann H., Holm E., et al. S3-Leitline der Deutschen Gesellschaft für Ernährungsmedizin e. V. (DGEM) in Kooperation mit der Deutschen Gesellschaft für Hämatologie und Onkologie e. V. (DGHO), der Arbeitsgemeinschaft „Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin“ der Deutschen Krebsgesellschaft (ASORS) und der Österreichischen Arbeitsgemeinschaft für klinische Ernährung (AKE). None. 2015;40:e1-e74||975
Komplementärmedizin|"1.1"|2021|Bertz, Hartmut|Hintergrund|||Standard|Arends J., Bachmann P., Baracos V., Barthelemy N., Bertz H., Bozzetti F., et al. ESPEN guidelines on nutrition in cancer patients. None. 2017;36:11-48|https://www.ncbi.nlm.nih.gov/pubmed/27637832|975
Komplementärmedizin|"1.1"|2021|Horneber, Markus|Evidenzbasierte Empfehlung|A|False|Letztautor|Milazzo S., Horneber M. Laetrile treatment for cancer. None. 2015;None:CD005476|https://www.ncbi.nlm.nih.gov/pubmed/25918920|975
Komplementärmedizin|"1.1"|2021|Horneber, Markus|Hintergrund|||Letztautor|Milazzo S., Horneber M. Laetrile treatment for cancer. None. 2015;None:CD005476|https://www.ncbi.nlm.nih.gov/pubmed/25918920|975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Hintergrund|||Standard|Huebner J., Micke O., Muecke R., Buentzel J., Prott F. J., Kleeberg U., et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. None. 2014;34:943-8|https://www.ncbi.nlm.nih.gov/pubmed/24511037|975
Komplementärmedizin|"1.1"|2021|Prott, Franz-Josef|Hintergrund|||Standard|Huebner J., Micke O., Muecke R., Buentzel J., Prott F. J., Kleeberg U., et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. None. 2014;34:943-8|https://www.ncbi.nlm.nih.gov/pubmed/24511037|975
Komplementärmedizin|"1.1"|2021|Rostock, Matthias|Evidenzbasiertes Statement|0|False|Erstautor|Rostock M., Jaroslawski K., Guethlin C., Ludtke R., Schroder S., Bartsch H. H. Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture. None. 2013;2013:349653|https://www.ncbi.nlm.nih.gov/pubmed/24066010|975
Komplementärmedizin|"1.1"|2021|Rostock, Matthias|Hintergrund|||Erstautor|Rostock M., Jaroslawski K., Guethlin C., Ludtke R., Schroder S., Bartsch H. H. Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture. None. 2013;2013:349653|https://www.ncbi.nlm.nih.gov/pubmed/24066010|975
Komplementärmedizin|"1.1"|2021|Witt, Claudia|Hintergrund|||Erstautor|Witt Claudia M, Balneaves Lynda G, Carlson Linda E, Cohen Misha, Deng Gary, Fouladbakhsh Judith M, et al. Education Competencies for Integrative Oncology—Results of a Systematic Review and an International and Interprofessional Consensus Procedure. None. 2020;None:1-9||975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Hintergrund|||Standard|Huebner J, Muenstedt K, Muecke R, Micke O, Stoll C, Kleeberg UR, et al. Counseling cancer patients on complementary and alternative medicine. . 2013;189:613-617|https://pubmed.ncbi.nlm.nih.gov/23824107/|975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Hintergrund|||Standard|Freuding M., Keinki C., Micke O., Buentzel J., Huebner J. Mistletoe in oncological treatment: a systematic review : Part 1: survival and safety. None. 2019;145:695-707|https://www.ncbi.nlm.nih.gov/pubmed/30673873|975
Komplementärmedizin|"1.1"|2021|Horneber, Markus|Evidenzbasierte Empfehlung|0|False|Erstautor|Horneber M. A., Bueschel G., Huber R., Linde K., Rostock M. Mistletoe therapy in oncology. None. 2008;None:CD003297|https://www.ncbi.nlm.nih.gov/pubmed/18425885|975
Komplementärmedizin|"1.1"|2021|Horneber, Markus|Hintergrund|||Erstautor|Horneber M. A., Bueschel G., Huber R., Linde K., Rostock M. Mistletoe therapy in oncology. None. 2008;None:CD003297|https://www.ncbi.nlm.nih.gov/pubmed/18425885|975
Komplementärmedizin|"1.1"|2021|Rostock, Matthias|Evidenzbasierte Empfehlung|0|False|Letztautor|Horneber M. A., Bueschel G., Huber R., Linde K., Rostock M. Mistletoe therapy in oncology. None. 2008;None:CD003297|https://www.ncbi.nlm.nih.gov/pubmed/18425885|975
Komplementärmedizin|"1.1"|2021|Rostock, Matthias|Hintergrund|||Letztautor|Horneber M. A., Bueschel G., Huber R., Linde K., Rostock M. Mistletoe therapy in oncology. None. 2008;None:CD003297|https://www.ncbi.nlm.nih.gov/pubmed/18425885|975
Komplementärmedizin|"1.1"|2021|Micke, Oliver|Evidenzbasierte Empfehlung|0|False|Standard|Freuding M., Keinki C., Kutschan S., Micke O., Buentzel J., Huebner J. Mistletoe in oncological treatment: a systematic review : Part 2: quality of life and toxicity of cancer treatment. None. 2019;145:927-939|https://www.ncbi.nlm.nih.gov/pubmed/30673872|975
Komplementärmedizin|"1.1"|2021|Matthes, Harald|Hintergrund|||Standard|Piao B. K., Wang Y. X., Xie G. R., Mansmann U., Matthes H., Beuth J., et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. None. 2004;24:303-9|https://www.ncbi.nlm.nih.gov/pubmed/15015612|975
Komplementärmedizin|"1.1"|2021|Witt, Claudia|Hintergrund|||Erstautor|Witt Claudia M, Helmer Stefanie M, Schofield Penelope, Wastell Marisa, Canella Claudia, Thomae Anita V, et al. Training oncology physicians to advise their patients on complementary and integrative medicine: An implementation study for a manual‐guided consultation. None. 2020;None:None||975
Komplementärmedizin|"1.1"|2021|Witt, Claudia|Hintergrund|||Standard|Hamre HJ, Becker-Witt C, Glockmann A, Ziegler R, Willich SN, Kiene H. Anthroposophische Therapien bei chronischen Erkrankungen: Die Anthroposophische Medizin Outcomes-Studie (AMOS). None. 2004;None:None||975
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Ritgen M., Stilgenbauer S., von Neuhoff N., Humpe A., Bruggemann M., Pott C., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. . 2004;104:2600-2||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Dreger, Peter|Hintergrund|||Erstautor|Dreger P., Corradini P., Kimby E., Michallet M., Milligan D., Schetelig J., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. . 2007;21:12-7||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Schetelig, Johannes|Hintergrund|||Erstautor|Schetelig J., van Biezen A., Brand R., Caballero D., Martino R., Itala M., et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. . 2008;26:5094-100||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Dreger, Peter|Hintergrund|||Erstautor|Dreger P., Dohner H., Ritgen M., Bottcher S., Busch R., Dietrich S., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia:long-term clinical and MRD results of the GCLLSG CLL3X trial. . 2010;116:2438-2447||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Fischer K., Cramer P., Busch R., Bottcher S., Bahlo J., Schubert J., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. . 2012;30:3209-16||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Hintergrund|||Standard|Fischer K., Cramer P., Busch R., Bottcher S., Bahlo J., Schubert J., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. . 2012;30:3209-16||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Evidenzbasierte Empfehlung|A|False|Standard|Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Evidenzbasierte Empfehlung|A|False|Erstautor|Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Erstautor|Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Maurer, Christian|Evidenzbasierte Empfehlung|A|False|Standard|Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Maurer, Christian|Hintergrund|||Standard|Eichhorst B., Fink A. M., Bahlo J., Busch R., Kovacs G., Maurer C., et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Haferlach, Claudia|Hintergrund|||Erstautor|Haferlach C., Dicker F., Weiss T., Schnittger S., Beck C., Grote-Metke A., et al. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. . 2010;49:851-9||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Kovacs G, Böttcher S., Bahlo J, Kluth S, Ritgen M., Fink A-M, et al. Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). None. 2014;124:Abstract 23||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Böttcher, Sebastian|Hintergrund|||Standard|Kovacs G, Böttcher S., Bahlo J, Kluth S, Ritgen M., Fink A-M, et al. Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). None. 2014;124:Abstract 23||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Wendtner, Clemens|Hintergrund|||Erstautor|Wendtner C. M., Ritgen M., Schweighofer C. D., Fingerle-Rowson G., Campe H., Jager G., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). . 2004;18:1093-101||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Standard|Schweighofer C. D., Ritgen M., Eichhorst B. F., Busch R., Abenhardt W., Kneba M., et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). . 2009;144:95-8||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Standard|Fink A. M., Bottcher S., Ritgen M., Fischer K., Pflug N., Eichhorst B., et al. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. . 2013;27:1949-52||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Pflug, Natali|Hintergrund|||Standard|Fink A. M., Bottcher S., Ritgen M., Fischer K., Pflug N., Eichhorst B., et al. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. . 2013;27:1949-52||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Haferlach, Claudia|Hintergrund|||Erstautor|Haferlach C., Bacher U. Cytogenetic methods in chronic lymphocytic leukemia. . 2011;730:119-30||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Maurer C., Pflug N., Bahlo J., Kluth S., Rhein C., Cramer P., et al. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. . 2016;97:253-60||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Hintergrund|||Standard|Maurer C., Pflug N., Bahlo J., Kluth S., Rhein C., Cramer P., et al. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. . 2016;97:253-60||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Maurer, Christian|Hintergrund|||Erstautor|Maurer C., Pflug N., Bahlo J., Kluth S., Rhein C., Cramer P., et al. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. . 2016;97:253-60||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Pflug, Natali|Hintergrund|||Standard|Maurer C., Pflug N., Bahlo J., Kluth S., Rhein C., Cramer P., et al. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. . 2016;97:253-60||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Wendtner, Clemens|Hintergrund|||Standard|Buhler A., Wendtner C. M., Kipps T. J., Rassenti L., Fraser G. A., Michallet A. S., et al. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. . 2016;6:e404||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Evidenzbasierte Empfehlung|A|False|Standard|Bauer K., Rancea M., Roloff V., Elter T., Hallek M., Engert A., et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. . 2012;11:CD008079||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Standard|Bauer K., Rancea M., Roloff V., Elter T., Hallek M., Engert A., et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. . 2012;11:CD008079||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Fischer K., Cramer P., Busch R., Stilgenbauer S., Bahlo J., Schweighofer C. D., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. . 2011;29:3559-66||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Hintergrund|||Standard|Fischer K., Cramer P., Busch R., Stilgenbauer S., Bahlo J., Schweighofer C. D., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. . 2011;29:3559-66||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Fischer K., Cramer P., Busch R., Stilgenbauer S., Bahlo J., Schweighofer C. D., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. . 2011;29:3559-66||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Langerbeins, Petra|Evidenzbasierte Empfehlung|B|False|Erstautor|Langerbeins P., Busch R., Anheier N., Durig J., Bergmann M., Goebeler M. E., et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. . 2014;89:E239-43||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Langerbeins, Petra|Hintergrund|||Erstautor|Langerbeins P., Busch R., Anheier N., Durig J., Bergmann M., Goebeler M. E., et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. . 2014;89:E239-43||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Hintergrund|||Standard|Chanan-Khan A., Cramer P., Demirkan F., Fraser G., Silva R. S., Grosicki S., et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. . 2016;17:200-11||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Wierda W. G., Kipps T. J., Mayer J., Stilgenbauer S., Williams C. D., Hellmann A., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. . 2010;28:1749-55||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Erstautor|Stilgenbauer S., Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. . 2002;347:452-3||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Evidenzbasierte Empfehlung|A|False|Standard|Skoetz N., Bauer K., Elter T., Monsef I., Roloff V., Hallek M., et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. . 2012;2:CD008078||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Standard|Skoetz N., Bauer K., Elter T., Monsef I., Roloff V., Hallek M., et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. . 2012;2:CD008078||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Evidenzbasierte Empfehlung|A|False|Standard|Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J. F., Munir T., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Standard|Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J. F., Munir T., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Schetelig, Johannes|Evidenzbasierte Empfehlung|A|False|Standard|Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J. F., Munir T., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Schetelig, Johannes|Hintergrund|||Standard|Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J. F., Munir T., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Evidenzbasierte Empfehlung|A|False|Erstautor|Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J. F., Munir T., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Erstautor|Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J. F., Munir T., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Erstautor|Hallek M., Cheson B. D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. . 2008;111:5446-56||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Hintergrund|||Standard|Goede V., Cramer P., Busch R., Bergmann M., Stauch M., Hopfinger G., et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. . 2014;99:1095-100||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Hintergrund|||Erstautor|Goede V., Cramer P., Busch R., Bergmann M., Stauch M., Hopfinger G., et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. . 2014;99:1095-100||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Hintergrund|||Erstautor|Goede Valentin, Raymonde Busch, Stilgenbauer Stephan, Winter Elina, Fink Anna-Maria, Fischer Kirsten, et al. Cumulative Illness Rating Scale (CIRS) is a valuable tool to assess and weigh comorbidity in patients with chronic lymphocytic leukemia: Results from the CLL8 trial of the German CLL Study Group. None. 2012;97:0154||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Goede Valentin, Raymonde Busch, Stilgenbauer Stephan, Winter Elina, Fink Anna-Maria, Fischer Kirsten, et al. Cumulative Illness Rating Scale (CIRS) is a valuable tool to assess and weigh comorbidity in patients with chronic lymphocytic leukemia: Results from the CLL8 trial of the German CLL Study Group. None. 2012;97:0154||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Goede V., Bahlo J., Chataline V., Eichhorst B., Durig J., Stilgenbauer S., et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. . 2016;57:789-96||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Standard|Goede V., Bahlo J., Chataline V., Eichhorst B., Durig J., Stilgenbauer S., et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. . 2016;57:789-96||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Hintergrund|||Erstautor|Goede V., Bahlo J., Chataline V., Eichhorst B., Durig J., Stilgenbauer S., et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. . 2016;57:789-96||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Evidenzbasierte Empfehlung|A|True|Erstautor|Hallek M., Fischer K., Fingerle-Rowson G., Fink A. M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. . 2010;376:1164-74||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Erstautor|Hallek M., Fischer K., Fingerle-Rowson G., Fink A. M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. . 2010;376:1164-74||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Erstautor|Eichhorst Barbara, Fink Anna Maria, Busch Raymonde, Kovacs Gabor, Maurer Christian, Lange Elisabeth, et al. Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic …. None. 2014;124:19-19||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Standard|Stauder R., Eichhorst B., Hamaker M., Kaplanov K., Morrison V., Osterborg A., et al. Management of Chronic Lymphocytic Leukemia (CLL) in the Elderly: A Position Paper from an International Society of Geriatric Oncology (SIOG) Task Force. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Erstautor|Eichhorst B., Dreyling M., Robak T., Montserrat E., Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. . 2011;22 Suppl 6:vi50-4||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Letztautor|Eichhorst B., Dreyling M., Robak T., Montserrat E., Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. . 2011;22 Suppl 6:vi50-4||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Dreger, Peter|Hintergrund|||Erstautor|Dreger P., Dohner H., McClanahan F., Busch R., Ritgen M., Greinix H., et al. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. . 2012;119:4851-9||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Dreger, Peter|Hintergrund|||Erstautor|Dreger P., Brand R., Milligan D., Corradini P., Finke J., Lambertenghi Deliliers G., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. . 2005;19:1029-33||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Schetelig, Johannes|Hintergrund|||Erstautor|Schetelig J., Thiede C., Bornhauser M., Schwerdtfeger R., Kiehl M., Beyer J., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. . 2003;21:2747-53||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Dreger, Peter|Hintergrund|||Letztautor|Bottcher S., Ritgen M., Dreger P. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. . 2011;25:91-6||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Ritgen M., Bottcher S., Stilgenbauer S., Bunjes D., Schubert J., Cohen S., et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. . 2008;22:1377-86||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Dreger, Peter|Hintergrund|||Erstautor|Dreger P., Schnaiter A., Zenz T., Bottcher S., Rossi M., Paschka P., et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. . 2013;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Dreger, Peter|Hintergrund|||Erstautor|Dreger P., Schetelig J., Andersen N., Corradini P., van Gelder M., Gribben J., et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. . 2014;124:3841-9||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Schetelig, Johannes|Hintergrund|||Standard|Dreger P., Schetelig J., Andersen N., Corradini P., van Gelder M., Gribben J., et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. . 2014;124:3841-9||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Evidenzbasierte Empfehlung|A|False|Standard|Cwynarski K., van Biezen A., de Wreede L., Stilgenbauer S., Bunjes D., Metzner B., et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. . 2012;30:2211-7||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Cwynarski K., van Biezen A., de Wreede L., Stilgenbauer S., Bunjes D., Metzner B., et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. . 2012;30:2211-7||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Dreger, Peter|Hintergrund|||Erstautor|Dreger P., Brand R., Hansz J., Milligan D., Corradini P., Finke J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. . 2003;17:841-8||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Schneider, Sven|Hintergrund|||Standard|Metzgeroth G., Schneider S., Walz C., Reiter S., Hofmann W. K., Marx A., et al. Fine needle aspiration and core needle biopsy in the diagnosis of lymphadenopathy of unknown aetiology. . 2012;91:1477-84||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Fend, Falko|Hintergrund|||Standard|Gotze K. S., Hoffmann D., Schatzl H. M., Peschel C., Fend F., Decker T. Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. . 2007;92:1282-3||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Letztautor|Zenz T., Mertens D., Kuppers R., Dohner H., Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. . 2010;10:37-50||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Herling C. D., Klaumunzer M., Rocha C. K., Altmuller J., Thiele H., Bahlo J., et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. . 2016;128:395-404||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Herling, Carmen|Hintergrund|||Erstautor|Herling C. D., Klaumunzer M., Rocha C. K., Altmuller J., Thiele H., Bahlo J., et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. . 2016;128:395-404||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Standard|Zenz T., Eichhorst B., Busch R., Denzel T., Habe S., Winkler D., et al. TP53 mutation and survival in chronic lymphocytic leukemia. . 2010;28:4473-9||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Erstautor|Stilgenbauer S., Schnaiter A., Paschka P., Zenz T., Rossi M., Dohner K., et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. . 2014;123:3247-54||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Erstautor|Eichhorst B. F., Busch R., Obwandner T., Kuhn-Hallek I., Herschbach P., Hallek M. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. . 2007;25:1722-31||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Letztautor|Eichhorst B. F., Busch R., Obwandner T., Kuhn-Hallek I., Herschbach P., Hallek M. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. . 2007;25:1722-31||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Erstautor|Eichhorst B. F., Fischer K., Fink A. M., Elter T., Wendtner C. M., Goede V., et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. . 2011;117:1817-21||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Wendtner, Clemens|Hintergrund|||Standard|Eichhorst B. F., Fischer K., Fink A. M., Elter T., Wendtner C. M., Goede V., et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. . 2011;117:1817-21||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Ghia P., Stamatopoulos K., Belessi C., Moreno C., Stilgenbauer S., Stevenson F., et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. . 2007;21:1-3||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Maurer C., Langerbeins P., Bahlo J., Cramer P., Fink A. M., Pflug N., et al. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Hintergrund|||Standard|Maurer C., Langerbeins P., Bahlo J., Cramer P., Fink A. M., Pflug N., et al. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Langerbeins, Petra|Hintergrund|||Standard|Maurer C., Langerbeins P., Bahlo J., Cramer P., Fink A. M., Pflug N., et al. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Maurer, Christian|Hintergrund|||Erstautor|Maurer C., Langerbeins P., Bahlo J., Cramer P., Fink A. M., Pflug N., et al. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Pflug, Natali|Hintergrund|||Standard|Maurer C., Langerbeins P., Bahlo J., Cramer P., Fink A. M., Pflug N., et al. Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Pflug N., Bahlo J., Shanafelt T. D., Eichhorst B. F., Bergmann M. A., Elter T., et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. . 2014;124:49-62||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Standard|Pflug N., Bahlo J., Shanafelt T. D., Eichhorst B. F., Bergmann M. A., Elter T., et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. . 2014;124:49-62||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Pflug, Natali|Hintergrund|||Erstautor|Pflug N., Bahlo J., Shanafelt T. D., Eichhorst B. F., Bergmann M. A., Elter T., et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. . 2014;124:49-62||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Erstautor|Eichhorst B., Goede V., Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. . 2009;50:171-8||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Hintergrund|||Standard|Eichhorst B., Goede V., Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. . 2009;50:171-8||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Letztautor|Eichhorst B., Goede V., Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. . 2009;50:171-8||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Hintergrund|||Erstautor|Goede V., Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. . 2011;28:163-76||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Letztautor|Goede V., Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. . 2011;28:163-76||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Bottcher S., Ritgen M., Fischer K., Stilgenbauer S., Busch R. M., Fingerle-Rowson G., et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. . 2012;30:980-8||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Kovacs G., Robrecht S., Fink A. M., Bahlo J., Cramer P., von Tresckow J., et al. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Hintergrund|||Standard|Kovacs G., Robrecht S., Fink A. M., Bahlo J., Cramer P., von Tresckow J., et al. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. . 2016;:||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Bottcher S., Stilgenbauer S., Busch R., Bruggemann M., Raff T., Pott C., et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. . 2009;23:2007-17||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Erstautor|Kusch M. Labouvie H. Hein-Nau B. Schwarzkamp U. Wolf J. Hallek M. Integrierte Psychoonkologie am Centrum für Integrierte Onkologie Köln Bonn. None. 2014 Nov;139(46):2357-60||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hein-Nau, Birgitt|Hintergrund|||Erstautor|Kusch M. Labouvie H. Hein-Nau B. Schwarzkamp U. Wolf J. Hallek M. Integrierte Psychoonkologie am Centrum für Integrierte Onkologie Köln Bonn. None. 2014 Nov;139(46):2357-60||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Kusch, Michael|Hintergrund|||Erstautor|Kusch M. Labouvie H. Hein-Nau B. Schwarzkamp U. Wolf J. Hallek M. Integrierte Psychoonkologie am Centrum für Integrierte Onkologie Köln Bonn. None. 2014 Nov;139(46):2357-60||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hein-Nau, Birgitt|Hintergrund|||Erstautor|Kusch M. Labouvie H. Hein-Nau B. Klinische Psychoonkologie. None. 2013;None:None||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Kusch, Michael|Hintergrund|||Erstautor|Kusch M. Labouvie H. Hein-Nau B. Klinische Psychoonkologie. None. 2013;None:None||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Erstautor|Eichhorst B. F., Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. . 2006;107:885-91||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Erstautor|Hallek M., Fischer K., Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia: a Randomised, Open-label, Phase III Trial. . 2010;376:1164-1174||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Hallek, Michael|Hintergrund|||Erstautor|Hallek M., Fischer K., Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia: a Randomised, Open-label, Phase III Trial. None. 2010;376:1164-1174||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Evidenzbasierte Empfehlung|A|True|Standard|Fischer K., Bahlo J., Fink A. M., Goede V., Herling C. D., Cramer P., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. . 2016;127:208-15||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Fischer K., Bahlo J., Fink A. M., Goede V., Herling C. D., Cramer P., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. . 2016;127:208-15||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Evidenzbasierte Empfehlung|A|True|Standard|Fischer K., Bahlo J., Fink A. M., Goede V., Herling C. D., Cramer P., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. . 2016;127:208-15||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Cramer, Paula|Hintergrund|||Standard|Fischer K., Bahlo J., Fink A. M., Goede V., Herling C. D., Cramer P., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. . 2016;127:208-15||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Evidenzbasierte Empfehlung|A|True|Standard|Fischer K., Bahlo J., Fink A. M., Goede V., Herling C. D., Cramer P., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. . 2016;127:208-15||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Hintergrund|||Standard|Fischer K., Bahlo J., Fink A. M., Goede V., Herling C. D., Cramer P., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. . 2016;127:208-15||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Herling, Carmen|Evidenzbasierte Empfehlung|A|True|Standard|Fischer K., Bahlo J., Fink A. M., Goede V., Herling C. D., Cramer P., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. . 2016;127:208-15||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Herling, Carmen|Hintergrund|||Standard|Fischer K., Bahlo J., Fink A. M., Goede V., Herling C. D., Cramer P., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. . 2016;127:208-15||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Evidenzbasierte Empfehlung|A|True|Standard|Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C. M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. . 2014;370:1101-10||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Eichhorst, Barbara|Hintergrund|||Standard|Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C. M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. . 2014;370:1101-10||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Evidenzbasierte Empfehlung|A|True|Erstautor|Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C. M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. . 2014;370:1101-10||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Hintergrund|||Erstautor|Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C. M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. . 2014;370:1101-10||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Wendtner, Clemens|Evidenzbasierte Empfehlung|A|True|Standard|Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C. M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. . 2014;370:1101-10||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Wendtner, Clemens|Hintergrund|||Standard|Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C. M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. . 2014;370:1101-10||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Evidenzbasierte Empfehlung|A|True|Erstautor|Goede V., Fischer K., Engelke A., Schlag R., Lepretre S., Montero L. F., et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. . 2015;29:1602-4||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Goede, Valentin|Hintergrund|||Erstautor|Goede V., Fischer K., Engelke A., Schlag R., Lepretre S., Montero L. F., et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. . 2015;29:1602-4||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|D&#246;hner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. . 2000;343:1910-6||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Standard|Döhner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. None. 2000;343:1910-6||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Bahlo, Jasmin|Hintergrund|||Standard|Landau D. A., Tausch E., Taylor-Weiner A. N., Stewart C., Reiter J. G., Bahlo J., et al. Mutations driving CLL and their evolution in progression and relapse. . 2015;526:525-30||425
Chronisch lymphatische Leukämie (CLL)|"1"|2018|Stilgenbauer, Stephan|Hintergrund|||Erstautor|Stilgenbauer S., Zenz T., Winkler D., Buhler A., Schlenk R. F., Groner S., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. . 2009;27:3994-4001||425
Kolorektales Karzinom|"2.1"|2019|Hofheinz, R.-D.|Hintergrund|||Standard|Rodel C., Hofheinz R., Liersch T. Rectal cancer: state of the art in 2012. . 2012;24:441-7|https://www.ncbi.nlm.nih.gov/pubmed/22450150|2398
Kolorektales Karzinom|"2.1"|2019|Sauer, R.|Hintergrund|||Letztautor|Rodel C., Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer. None. 2004;13:93-101||2398
Kolorektales Karzinom|"2.1"|2019|Stintzing, S.|Hintergrund|||Standard|Modest D. P., Stintzing S., von Weikersthal L. F., Decker T., Kiani A., Vehling-Kaiser U., et al. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. None. 2015;33:3718-26||2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Evidenzbasierte Empfehlung|A|False|Standard|Van Cutsem E., Lenz H. J., Kohne C. H., Heinemann V., Tejpar S., Melezinek I., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. None. 2015;33:692-700||2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Hintergrund|||Standard|Van Cutsem E., Lenz H. J., Kohne C. H., Heinemann V., Tejpar S., Melezinek I., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. None. 2015;33:692-700||2398
Kolorektales Karzinom|"2.1"|2019|Stintzing, S.|Hintergrund|||Erstautor|Stintzing S., Modest D. P., Rossius L., Lerch M. M., von Weikersthal L. F., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. None. 2016;17:1426-1434||2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Evidenzbasierte Empfehlung|A|False|Standard|Bokemeyer C., Kohne C. H., Ciardiello F., Lenz H. J., Heinemann V., Klinkhardt U., et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. None. 2015;51:1243-52||2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Hintergrund|||Standard|Bokemeyer C., Kohne C. H., Ciardiello F., Lenz H. J., Heinemann V., Klinkhardt U., et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. None. 2015;51:1243-52||2398
Kolorektales Karzinom|"2.1"|2019|Altenhofen, L.|Hintergrund|||Standard|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Stillfried D. V., Schmiegel W. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. None. 2012;None:1460-7.e2.|http://www.ncbi.nlm.nih.gov/pubmed/22446606|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Standard|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Stillfried D. V., Schmiegel W. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. None. 2012;None:1460-7.e2.|http://www.ncbi.nlm.nih.gov/pubmed/22446606|2398
Kolorektales Karzinom|"2.1"|2019|Pox, C.|Hintergrund|||Erstautor|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Stillfried D. V., Schmiegel W. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. None. 2012;None:1460-7.e2.|http://www.ncbi.nlm.nih.gov/pubmed/22446606|2398
Kolorektales Karzinom|"2.1"|2019|Schmiegel, W.|Hintergrund|||Letztautor|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Stillfried D. V., Schmiegel W. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. None. 2012;None:1460-7.e2.|http://www.ncbi.nlm.nih.gov/pubmed/22446606|2398
Kolorektales Karzinom|"2.1"|2019|Theilmeier, A.|Hintergrund|||Standard|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Stillfried D. V., Schmiegel W. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. None. 2012;None:1460-7.e2.|http://www.ncbi.nlm.nih.gov/pubmed/22446606|2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Hintergrund|||Letztautor|Holch J. W., Ricard I., Stintzing S., Modest D. P., Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. None. 2017;70:87-98||2398
Kolorektales Karzinom|"2.1"|2019|Stintzing, S.|Hintergrund|||Standard|Holch J. W., Ricard I., Stintzing S., Modest D. P., Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. None. 2017;70:87-98||2398
Kolorektales Karzinom|"2.1"|2019|Arnold, Dirk|Hintergrund|||Erstautor|Arnold D., Lueza B., Douillard J. Y., Peeters M., Lenz H. J., Venook A., et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. None. 2017;28:1713-1729|https://www.ncbi.nlm.nih.gov/pubmed/28407110|2398
Kolorektales Karzinom|"2.1"|2019|Stintzing, S.|Hintergrund|||Standard|Tejpar S., Stintzing S., Ciardiello F., Tabernero J., Van Cutsem E., Beier F., et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. None. 2016;None:None||2398
Kolorektales Karzinom|"2.1"|2019|Tannapfel, A.|Hintergrund|||Standard|Huppe D., Hartmann H., Felten G., Kemen M., Tannapfel A., Gillessen A., et al. [Effectiveness of screening colonoscopy in a community-based study]. None. 2008;46:193-200|http://www.ncbi.nlm.nih.gov/pubmed/18253898|2398
Kolorektales Karzinom|"2.1"|2019|Tannapfel, A.|Evidenzbasierte Empfehlung|B|False|Standard|Huppe D., Hartmann H., Felten G., Kemen M., Tannapfel A., Gillessen A., et al. [Effectiveness of screening colonoscopy in a community-based study]. None. 2008;46:193-200||2398
Kolorektales Karzinom|"2.1"|2019|Schmiegel, W.|Hintergrund|||Erstautor|Schmiegel W., Scott R. J., Dooley S., Lewis W., Meldrum C. J., Pockney P., et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. . 2017;11:208-219|https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12023|2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Hintergrund|||Erstautor|Heinemann V., Rivera F., O'Neil B. H., Stintzing S., Koukakis R., Terwey J. H., et al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. None. 2016;67:11-20||2398
Kolorektales Karzinom|"2.1"|2019|Stintzing, S.|Hintergrund|||Standard|Heinemann V., Rivera F., O'Neil B. H., Stintzing S., Koukakis R., Terwey J. H., et al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. None. 2016;67:11-20||2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Hintergrund|||Standard|von Einem J. C., Heinemann V., von Weikersthal L. F., Vehling-Kaiser U., Stauch M., Hass H. G., et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. None. 2014;140:1607-14|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131148/pdf/432_2014_Article_1678.pdf|2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Evidenzbasierte Empfehlung|B|False|Standard|von Einem J. C., Heinemann V., von Weikersthal L. F., Vehling-Kaiser U., Stauch M., Hass H. G., et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. None. 2014;140:1607-14|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131148/pdf/432_2014_Article_1678.pdf|2398
Kolorektales Karzinom|"2.1"|2019|Stintzing, S.|Hintergrund|||Erstautor|Stintzing S., Fischer von Weikersthal L., Decker T., Vehling-Kaiser U., Jager E., Heintges T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. . 2012;23:1693-9|https://academic.oup.com/annonc/article/23/7/1693/202344|2398
Kolorektales Karzinom|"2.1"|2019|Stintzing, S.|Hintergrund|||Erstautor|Stintzing S., Jung L., Rossius D.P. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. None. 2014;32:suppl 3; abstract 445||2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Evidenzbasierte Empfehlung|A|False|Erstautor|Heinemann V., von Weikersthal L. F., Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S. E., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. None. 2014;15:1065-75||2398
Kolorektales Karzinom|"2.1"|2019|Graeven, U.|Hintergrund|||Standard|Hegewisch-Becker S., Graeven U., Lerchenmuller C. A., Killing B., Depenbusch R., Steffens C. C., et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. None. 2015;16:1355-69||2398
Kolorektales Karzinom|"2.1"|2019|Hegewisch-Becker, S.|Hintergrund|||Erstautor|Hegewisch-Becker S., Graeven U., Lerchenmuller C. A., Killing B., Depenbusch R., Steffens C. C., et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. None. 2015;16:1355-69||2398
Kolorektales Karzinom|"2.1"|2019|Altenhofen, L.|Hintergrund|||Standard|Brenner H., Hoffmeister M., Arndt V., Stegmaier C., Altenhofen L., Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. None. 2010;102:89-95|http://www.ncbi.nlm.nih.gov/pubmed/20042716|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Erstautor|Brenner H., Hoffmeister M., Arndt V., Stegmaier C., Altenhofen L., Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. None. 2010;102:89-95|http://www.ncbi.nlm.nih.gov/pubmed/20042716|2398
Kolorektales Karzinom|"2.1"|2019|Altenhofen, L.|Evidenzbasierte Empfehlung|B|False|Standard|Brenner H., Hoffmeister M., Arndt V., Stegmaier C., Altenhofen L., Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. None. 2010;102:89-95||2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung|B|False|Erstautor|Brenner H., Hoffmeister M., Arndt V., Stegmaier C., Altenhofen L., Haug U. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. None. 2010;102:89-95||2398
Kolorektales Karzinom|"2.1"|2019|Graeven, U.|Hintergrund|||Standard|Quidde J., Hegewisch-Becker S., Graeven U., Lerchenmuller C. A., Killing B., Depenbusch R., et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. None. 2016;27:2203-2210|https://academic.oup.com/annonc/article-abstract/27/12/2203/2282795/Quality-of-life-assessment-in-patients-with?redirectedFrom=fulltext|2398
Kolorektales Karzinom|"2.1"|2019|Hegewisch-Becker, S.|Hintergrund|||Standard|Quidde J., Hegewisch-Becker S., Graeven U., Lerchenmuller C. A., Killing B., Depenbusch R., et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. None. 2016;27:2203-2210|https://academic.oup.com/annonc/article-abstract/27/12/2203/2282795/Quality-of-life-assessment-in-patients-with?redirectedFrom=fulltext|2398
Kolorektales Karzinom|"2.1"|2019|Graeven, U.|Evidenzbasierte Empfehlung|0|False|Standard|Quidde J., Hegewisch-Becker S., Graeven U., Lerchenmuller C. A., Killing B., Depenbusch R., et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. None. 2016;27:2203-2210|https://academic.oup.com/annonc/article-abstract/27/12/2203/2282795/Quality-of-life-assessment-in-patients-with?redirectedFrom=fulltext|2398
Kolorektales Karzinom|"2.1"|2019|Hegewisch-Becker, S.|Evidenzbasierte Empfehlung|0|False|Standard|Quidde J., Hegewisch-Becker S., Graeven U., Lerchenmuller C. A., Killing B., Depenbusch R., et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. None. 2016;27:2203-2210|https://academic.oup.com/annonc/article-abstract/27/12/2203/2282795/Quality-of-life-assessment-in-patients-with?redirectedFrom=fulltext|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Erstautor|Brenner H., Chang-Claude J., Seiler C. M., Rickert A., Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. None. 2011;154:22-30|http://annals.org/aim/article/746683/protection-from-colorectal-cancer-after-colonoscopy-population-based-case-control|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung|B|False|Erstautor|Brenner H., Chang-Claude J., Seiler C. M., Rickert A., Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. None. 2011;154:22-30||2398
Kolorektales Karzinom|"2.1"|2019|Arnold, Dirk|Hintergrund|||Standard|Bennouna J., Sastre J., Arnold D., Osterlund P., Greil R., Van Cutsem E., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. None. 2013;14:29-37||2398
Kolorektales Karzinom|"2.1"|2019|Sieg, A.|Evidenzbasierte Empfehlung|B|False|Erstautor|Sieg A., Hachmoeller-Eisenbach U., Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. None. 2001;53:620-7||2398
Kolorektales Karzinom|"2.1"|2019|Sieg, A.|Hintergrund|||Erstautor|Sieg A., Hachmoeller-Eisenbach U., Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. None. 2001;53:620-7||2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Erstautor|Brenner H., Chang-Claude J., Seiler C. M., Hoffmeister M. Long-term risk of colorectal cancer after negative colonoscopy. None. 2011;29:3761-7|http://www.ncbi.nlm.nih.gov/pubmed/21876077|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung|B|False|Erstautor|Brenner H., Chang-Claude J., Seiler C. M., Hoffmeister M. Long-term risk of colorectal cancer after negative colonoscopy. None. 2011;29:3761-7||2398
Kolorektales Karzinom|"2.1"|2019|Vogl, Thomas J.|Hintergrund|||Erstautor|Vogl T. J., Eckert R., Naguib N. N., Beeres M., Gruber-Rouh T., Nour-Eldin N. A. Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation. None. 2016;207:1340-1349||2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Hintergrund|||Standard|van Hazel G. A., Heinemann V., Sharma N. K., Findlay M. P., Ricke J., Peeters M., et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. None. 2016;34:1723-31||2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Letztautor|Merkel S., Meyer T., Gohl J., Hohenberger W. Late locoregional recurrence in rectal carcinoma. None. 2002;28:716-22|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12431468, http://www.ejso.com/article/S0748-7983(02)91305-3/abstract|2398
Kolorektales Karzinom|"2.1"|2019|Seufferlein, Thomas|Hintergrund|||Letztautor|Adler G., Seufferlein T. [Hope and disappointment in cancer medicine]. None. 2007;101:287-92|http://www.ncbi.nlm.nih.gov/pubmed/17711253|2398
Kolorektales Karzinom|"2.1"|2019|Neuhaus, Horst|Evidenzbasierte Empfehlung|B|False|Standard|Spada C., Hassan C., Munoz-Navas M., Neuhaus H., Deviere J., Fockens P., et al. Second-generation colon capsule endoscopy compared with colonoscopy. None. 2011;74:581-589 e1||2398
Kolorektales Karzinom|"2.1"|2019|Neuhaus, Horst|Hintergrund|||Standard|Spada C., Hassan C., Munoz-Navas M., Neuhaus H., Deviere J., Fockens P., et al. Second-generation colon capsule endoscopy compared with colonoscopy. None. 2011;74:581-589 e1|http://www.ncbi.nlm.nih.gov/pubmed/21601200|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung||False|Letztautor|Hundt S., Haug U., Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. None. 2009;150:162-9||2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung||False|Erstautor|Brenner H., Haug U., Hundt S. Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. None. 2010;127:1643-9||2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Letztautor|Hundt S., Haug U., Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. None. 2009;150:162-9|http://www.ncbi.nlm.nih.gov/pubmed/19189905|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Erstautor|Brenner H., Haug U., Hundt S. Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. None. 2010;127:1643-9|http://www.ncbi.nlm.nih.gov/pubmed/20049840|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung||False|Letztautor|Haug U., Kuntz K. M., Knudsen A. B., Hundt S., Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. None. 2011;104:1779-85||2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung||False|Letztautor|Haug U., Hundt S., Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. None. 2010;105:682-90||2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung|B|False|Letztautor|Haug U., Hundt S., Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. None. 2008;99:133-5||2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Letztautor|Haug U., Hundt S., Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. None. 2008;99:133-5|http://www.ncbi.nlm.nih.gov/pubmed/18542075|2398
Kolorektales Karzinom|"2.1"|2019|Theilmeier, A.|Evidenzbasierte Empfehlung|B|False|Standard|Moslein G., Schneider C., Theilmeier A., Erckenbrecht H., Normann S., Hoffmann B., et al. [Analysis of the statistical value of various commercially available stool tests - a comparison of one stool sample in correlation to colonoscopy]. None. 2010;135:557-62||2398
Kolorektales Karzinom|"2.1"|2019|Theilmeier, A.|Hintergrund|||Standard|Moslein G., Schneider C., Theilmeier A., Erckenbrecht H., Normann S., Hoffmann B., et al. [Analysis of the statistical value of various commercially available stool tests - a comparison of one stool sample in correlation to colonoscopy]. None. 2010;135:557-62|http://www.ncbi.nlm.nih.gov/pubmed/20209426|2398
Kolorektales Karzinom|"2.1"|2019|Pox, C.|Evidenzbasierte Empfehlung|B|False|Erstautor|Pox C. P., Schmiegel W. Role of CT colonography in colorectal cancer screening: risks and benefits. None. 2010;59:692-700||2398
Kolorektales Karzinom|"2.1"|2019|Schmiegel, W.|Evidenzbasierte Empfehlung|B|False|Letztautor|Pox C. P., Schmiegel W. Role of CT colonography in colorectal cancer screening: risks and benefits. None. 2010;59:692-700||2398
Kolorektales Karzinom|"2.1"|2019|Pox, C.|Hintergrund|||Erstautor|Pox C. P., Schmiegel W. Role of CT colonography in colorectal cancer screening: risks and benefits. None. 2010;59:692-700|http://www.ncbi.nlm.nih.gov/pubmed/20427403|2398
Kolorektales Karzinom|"2.1"|2019|Schmiegel, W.|Hintergrund|||Letztautor|Pox C. P., Schmiegel W. Role of CT colonography in colorectal cancer screening: risks and benefits. None. 2010;59:692-700|http://www.ncbi.nlm.nih.gov/pubmed/20427403|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Letztautor|Lansdorp-Vogelaar I., Knudsen A. B., Brenner H. Cost-effectiveness of colorectal cancer screening. None. 2011;33:88-100|http://www.ncbi.nlm.nih.gov/pubmed/21633092|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Erstautor|Brenner H., Hoffmeister M., Haug U. Family history and age at initiation of colorectal cancer screening. None. 2008;103:2326-31|http://www.ncbi.nlm.nih.gov/pubmed/18702651|2398
Kolorektales Karzinom|"2.1"|2019|Rahner, Nils|Hintergrund|||Standard|Engel C., Rahner N., Schulmann K., Holinski-Feder E., Goecke T. O., Schackert H. K., et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. None. 2010;8:174-82|http://www.ncbi.nlm.nih.gov/pubmed/19835992|2398
Kolorektales Karzinom|"2.1"|2019|Schulmann, K.|Hintergrund|||Standard|Engel C., Rahner N., Schulmann K., Holinski-Feder E., Goecke T. O., Schackert H. K., et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. None. 2010;8:174-82|http://www.ncbi.nlm.nih.gov/pubmed/19835992|2398
Kolorektales Karzinom|"2.1"|2019|Schmiegel, W.|Hintergrund|||Letztautor|Schulmann K., Engel C., Propping P., Schmiegel W. Small bowel cancer risk in Lynch syndrome. None. 2008;57:1629-30|http://www.ncbi.nlm.nih.gov/pubmed/18941010|2398
Kolorektales Karzinom|"2.1"|2019|Schulmann, K.|Hintergrund|||Erstautor|Schulmann K., Engel C., Propping P., Schmiegel W. Small bowel cancer risk in Lynch syndrome. None. 2008;57:1629-30|http://www.ncbi.nlm.nih.gov/pubmed/18941010|2398
Kolorektales Karzinom|"2.1"|2019|Schulmann, K.|Hintergrund|||Erstautor|Schulmann K., Brasch F. E., Kunstmann E., Engel C., Pagenstecher C., Vogelsang H., et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. None. 2005;128:590-9|http://www.ncbi.nlm.nih.gov/pubmed/15765394|2398
Kolorektales Karzinom|"2.1"|2019|Rahner, Nils|Hintergrund|||Standard|Huneburg R., Lammert F., Rabe C., Rahner N., Kahl P., Buttner R., et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. None. 2009;41:316-22|http://www.ncbi.nlm.nih.gov/pubmed/19340735|2398
Kolorektales Karzinom|"2.1"|2019|Schulmann, K.|Hintergrund|||Standard|Goecke T., Schulmann K., Engel C., Holinski-Feder E., Pagenstecher C., Schackert H. K., et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. None. 2006;24:4285-92|http://www.ncbi.nlm.nih.gov/pubmed/16908935|2398
Kolorektales Karzinom|"2.1"|2019|Caspari, Reiner|Hintergrund|||Standard|Friedl W., Caspari R., Sengteller M., Uhlhaas S., Lamberti C., Jungck M., et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. None. 2001;48:515-21|http://www.ncbi.nlm.nih.gov/pubmed/11247896|2398
Kolorektales Karzinom|"2.1"|2019|Riemann, J.F.|Hintergrund|||Standard|Rembacken B., Hassan C., Riemann J. F., Chilton A., Rutter M., Dumonceau J. M., et al. Quality in screening colonoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE). None. 2012;44:957-68|https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0032-1325686.pdf|2398
Kolorektales Karzinom|"2.1"|2019|Kiesslich, R.|Hintergrund|||Erstautor|Kiesslich R., Fritsch J., Holtmann M., Koehler H. H., Stolte M., Kanzler S., et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. None. 2003;124:880-8|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12671882, http://www.gastrojournal.org/article/S0016-5085(03)00060-X/pdf|2398
Kolorektales Karzinom|"2.1"|2019|Kiesslich, R.|Hintergrund|||Erstautor|Kiesslich R., von Bergh M., Hahn M., Hermann G., Jung M. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. None. 2001;33:1001-6|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11740641, https://www.thieme-connect.com/DOI/DOI?10.1055/s-2001-18932|2398
Kolorektales Karzinom|"2.1"|2019|Kiesslich, R.|Hintergrund|||Erstautor|Kiesslich R., Burg J., Vieth M., Gnaendiger J., Enders M., Delaney P., et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. None. 2004;127:706-13|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15362025, http://www.gastrojournal.org/article/S0016-5085(04)01182-5/pdf|2398
Kolorektales Karzinom|"2.1"|2019|Neuhaus, Horst|Hintergrund|||Standard|Knabe M., Pohl J., Gerges C., Ell C., Neuhaus H., Schumacher B. Standardized long-term follow-up after endoscopic resection of large, nonpedunculated colorectal lesions: a prospective two-center study. None. 2014;109:183-9||2398
Kolorektales Karzinom|"2.1"|2019|Anthuber, M.|Hintergrund|||Standard|Probst A., Golger D., Anthuber M., Markl B., Messmann H. Endoscopic submucosal dissection in large sessile lesions of the rectosigmoid: learning curve in a European center. None. 2012;44:660-7|https://www.thieme-connect.com/DOI/DOI?10.1055/s-0032-1309403|2398
Kolorektales Karzinom|"2.1"|2019|Anthuber, M.|Hintergrund|||Standard|Probst A., Ebigbo A., Markl B., Schaller T., Anthuber M., Fleischmann C., et al. Endoscopic submucosal dissection for early rectal neoplasia: experience from a European center. None. 2017;49:222-232|https://www.thieme-connect.com/DOI/DOI?10.1055/s-0042-118449|2398
Kolorektales Karzinom|"2.1"|2019|Bokemeyer, B.|Hintergrund|||Erstautor|Bokemeyer B., Bock H., Huppe D., Duffelmeyer M., Rambow A., Tacke W., et al. Screening colonoscopy for colorectal cancer prevention: results from a German online registry on 269000 cases. None. 2009;21:650-5||2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Letztautor|Stock C., Ihle P., Sieg A., Schubert I., Hoffmeister M., Brenner H. Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies. None. 2013;77:419-29|http://www.giejournal.org/article/S0016-5107(12)02864-7/fulltext|2398
Kolorektales Karzinom|"2.1"|2019|Sieg, A.|Hintergrund|||Standard|Stock C., Ihle P., Sieg A., Schubert I., Hoffmeister M., Brenner H. Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies. None. 2013;77:419-29|http://www.giejournal.org/article/S0016-5107(12)02864-7/fulltext|2398
Kolorektales Karzinom|"2.1"|2019|Baretton, G.|Hintergrund|||Erstautor|Baretton G. B., Tannapfel A., Schmitt W. [Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification]. None. 2011;32:289-96|http://link.springer.com/article/10.1007%2Fs00292-011-1436-0|2398
Kolorektales Karzinom|"2.1"|2019|Schmitt, W.|Hintergrund|||Letztautor|Baretton G. B., Tannapfel A., Schmitt W. [Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification]. None. 2011;32:289-96|http://link.springer.com/article/10.1007%2Fs00292-011-1436-0|2398
Kolorektales Karzinom|"2.1"|2019|Tannapfel, A.|Hintergrund|||Standard|Baretton G. B., Tannapfel A., Schmitt W. [Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification]. None. 2011;32:289-96|http://link.springer.com/article/10.1007%2Fs00292-011-1436-0|2398
Kolorektales Karzinom|"2.1"|2019|Schmitt, W.|Hintergrund|||Letztautor|Meining A., von Delius S., Eames T. M., Popp B., Seib H. J., Schmitt W. Risk factors for unfavorable outcomes after endoscopic removal of submucosal invasive colorectal tumors. None. 2011;9:590-4||2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Evidenzbasierte Empfehlung|B|False|Standard|Gohl J., Hohenberger W., Merkel S. Lymph node dissection in rectal carcinoma: TME and what else?. None. 2009;32:57-61||2398
Kolorektales Karzinom|"2.1"|2019|Weitz, J.|Evidenzbasierte Empfehlung|A|False|Letztautor|Koch M., Kienle P., Antolovic D., Buchler M. W., Weitz J. Is the lateral lymph node compartment relevant?. None. 2005;165:40-5||2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Evidenzbasiertes Statement||False|Letztautor|Hermanek P., Hohenberger W. The importance of volume in colorectal cancer surgery. None. 1996;22:213-5||2398
Kolorektales Karzinom|"2.1"|2019|Anthuber, M.|Hintergrund|||Standard|Spatz J., Holl G., Sciuk J., Anthuber M., Arnholdt H. M., Markl B. Neoadjuvant chemotherapy affects staging of colorectal liver metastasis--a comparison of PET, CT and intraoperative ultrasound. None. 2011;26:165-71|http://www.ncbi.nlm.nih.gov/pubmed/20960208|2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Standard|Merkel S., Mansmann U., Siassi M., Papadopoulos T., Hohenberger W., Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. None. 2001;16:298-304|http://www.ncbi.nlm.nih.gov/pubmed/11686527|2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Erstautor|Hohenberger W., Weber K., Matzel K., Papadopoulos T., Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. None. 2009;11:354-64; discussion 364-5|http://www.ncbi.nlm.nih.gov/pubmed/19016817|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Evidenzbasierte Empfehlung|B|False|Standard|Jansen L., Herrmann A., Stegmaier C., Singer S., Brenner H., Arndt V. Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. None. 2011;29:3263-9||2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Erstautor|Hohenberger W., Lahmer G., Fietkau R., Croner R. S., Merkel S., Gohl J., et al. [Neoadjuvant radiochemotherapy for rectal cancer]. None. 2009;80:294-302|http://www.ncbi.nlm.nih.gov/pubmed/19350306|2398
Kolorektales Karzinom|"2.1"|2019|Porschen, R.|Evidenzbasierte Empfehlung||True|Letztautor|Arkenau H. T., Rettig K., Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. None. 2005;20:258-61||2398
Kolorektales Karzinom|"2.1"|2019|Sauer, R.|Evidenzbasierte Empfehlung||True|Letztautor|Rodel C., Sauer R. Neoadjuvant radiotherapy and radiochemotherapy for rectal cancer. None. 2005;165:221-30||2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Standard|West N. P., Hohenberger W., Weber K., Perrakis A., Finan P. J., Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. None. 2010;28:272-8|http://www.ncbi.nlm.nih.gov/pubmed/19949013|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Standard|Jansen L., Herrmann A., Stegmaier C., Singer S., Brenner H., Arndt V. Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. None. 2011;29:3263-9|http://www.ncbi.nlm.nih.gov/pubmed/21768465|2398
Kolorektales Karzinom|"2.1"|2019|Arnold, Dirk|Evidenzbasierte Empfehlung|B|False|Standard|Schmiegel W., Reinacher-Schick A., Arnold D., Graeven U., Heinemann V., Porschen R., et al. [Update S3-guideline "colorectal cancer" 2008]. None. 2008;46:799-840||2398
Kolorektales Karzinom|"2.1"|2019|Graeven, U.|Evidenzbasierte Empfehlung|B|False|Standard|Schmiegel W., Reinacher-Schick A., Arnold D., Graeven U., Heinemann V., Porschen R., et al. [Update S3-guideline "colorectal cancer" 2008]. None. 2008;46:799-840||2398
Kolorektales Karzinom|"2.1"|2019|Heinemann, Volker|Evidenzbasierte Empfehlung|B|False|Standard|Schmiegel W., Reinacher-Schick A., Arnold D., Graeven U., Heinemann V., Porschen R., et al. [Update S3-guideline "colorectal cancer" 2008]. None. 2008;46:799-840||2398
Kolorektales Karzinom|"2.1"|2019|Porschen, R.|Evidenzbasierte Empfehlung|B|False|Standard|Schmiegel W., Reinacher-Schick A., Arnold D., Graeven U., Heinemann V., Porschen R., et al. [Update S3-guideline "colorectal cancer" 2008]. None. 2008;46:799-840||2398
Kolorektales Karzinom|"2.1"|2019|Reinacher-Schick, Anke|Evidenzbasierte Empfehlung|B|False|Standard|Schmiegel W., Reinacher-Schick A., Arnold D., Graeven U., Heinemann V., Porschen R., et al. [Update S3-guideline "colorectal cancer" 2008]. None. 2008;46:799-840||2398
Kolorektales Karzinom|"2.1"|2019|Schmiegel, W.|Evidenzbasierte Empfehlung|B|False|Erstautor|Schmiegel W., Reinacher-Schick A., Arnold D., Graeven U., Heinemann V., Porschen R., et al. [Update S3-guideline "colorectal cancer" 2008]. None. 2008;46:799-840||2398
Kolorektales Karzinom|"2.1"|2019|Jauch, K-W.|Evidenzbasierte Empfehlung|B|False|Standard|Lorenz M., Staib-Sebler E., Gog C., Proschek D., Jauch K. W., Ridwelski K., et al. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. None. 2003;128:87-94||2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Evidenzbasierte Empfehlung|B|False|Letztautor|Merkel S., Weber K., Matzel K. E., Agaimy A., Gohl J., Hohenberger W. Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision. None. 2016;103:1220-9|http://onlinelibrary.wiley.com/doi/10.1002/bjs.10183/abstract?systemMessage=Wiley+Online+Library+Journal+subscribe+and+renew+pages+for+some+journals+will+be+unavailable+on+Wednesday+11th+January+2017+from+06%3A00-12%3A00+GMT+%2F+01%3A00-07%3A00+EST+%2F+14%3A00-20%3A00+SGT+for+essential+maintenance.+Apologies+for+the+inconvenience|2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Letztautor|Merkel S., Weber K., Matzel K. E., Agaimy A., Gohl J., Hohenberger W. Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision. None. 2016;103:1220-9|http://onlinelibrary.wiley.com/doi/10.1002/bjs.10183/abstract?systemMessage=Wiley+Online+Library+Journal+subscribe+and+renew+pages+for+some+journals+will+be+unavailable+on+Wednesday+11th+January+2017+from+06%3A00-12%3A00+GMT+%2F+01%3A00-07%3A00+EST+%2F+14%3A00-20%3A00+SGT+for+essential+maintenance.+Apologies+for+the+inconvenience|2398
Kolorektales Karzinom|"2.1"|2019|Folprecht, Gunnar|Evidenzbasierte Empfehlung|A|False|Erstautor|Folprecht G., Grothey A., Alberts S., Raab H. R., Kohne C. H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. None. 2005;16:1311-9||2398
Kolorektales Karzinom|"2.1"|2019|Raab, Hans-Rudolf|Evidenzbasierte Empfehlung|A|False|Standard|Folprecht G., Grothey A., Alberts S., Raab H. R., Kohne C. H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. None. 2005;16:1311-9||2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Standard|Merkel S., Wein A., Gunther K., Papadopoulos T., Hohenberger W., Hermanek P. High-risk groups of patients with Stage II colon carcinoma. None. 2001;92:1435-43|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11745220|2398
Kolorektales Karzinom|"2.1"|2019|Porschen, R.|Evidenzbasierte Empfehlung|A|False|Erstautor|Porschen R., Arkenau H. T., Kubicka S., Greil R., Seufferlein T., Freier W., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. None. 2007;25:4217-23||2398
Kolorektales Karzinom|"2.1"|2019|Seufferlein, Thomas|Evidenzbasierte Empfehlung|A|False|Standard|Porschen R., Arkenau H. T., Kubicka S., Greil R., Seufferlein T., Freier W., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. None. 2007;25:4217-23||2398
Kolorektales Karzinom|"2.1"|2019|Köhne, C.-H.|Hintergrund|||Standard|Carrato A., Köhne C., Bedenne L., Popov I., Bouche O., Gaspar E., et al. Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. None. 2006;None:None||2398
Kolorektales Karzinom|"2.1"|2019|Porschen, R.|Hintergrund|||Letztautor|Arkenau H. T., Rettig K., Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. None. 2005;20:258-61|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15549327, http://link.springer.com/article/10.1007%2Fs00384-004-0657-6|2398
Kolorektales Karzinom|"2.1"|2019|Folprecht, Gunnar|Hintergrund|||Standard|Taieb J., Tabernero J., Mini E., Subtil F., Folprecht G., Van Laethem J. L., et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. None. 2014;15:862-73|http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70227-X/abstract|2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Standard|Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. None. 2004;351:1731-40|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15496622, http://www.nejm.org/doi/pdf/10.1056/NEJMoa040694|2398
Kolorektales Karzinom|"2.1"|2019|Sauer, R.|Hintergrund|||Erstautor|Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. None. 2004;351:1731-40|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15496622, http://www.nejm.org/doi/pdf/10.1056/NEJMoa040694|2398
Kolorektales Karzinom|"2.1"|2019|Wittekind, C.|Hintergrund|||Standard|Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. None. 2004;351:1731-40|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15496622, http://www.nejm.org/doi/pdf/10.1056/NEJMoa040694|2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Standard|Sauer R., Liersch T., Merkel S., Fietkau R., Hohenberger W., Hess C., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. None. 2012;30:1926-33||2398
Kolorektales Karzinom|"2.1"|2019|Sauer, R.|Hintergrund|||Erstautor|Sauer R., Liersch T., Merkel S., Fietkau R., Hohenberger W., Hess C., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. None. 2012;30:1926-33||2398
Kolorektales Karzinom|"2.1"|2019|Arnold, Dirk|Hintergrund|||Standard|Rodel C., Graeven U., Fietkau R., Hohenberger W., Hothorn T., Arnold D., et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. None. 2015;16:979-89||2398
Kolorektales Karzinom|"2.1"|2019|Graeven, U.|Hintergrund|||Standard|Rodel C., Graeven U., Fietkau R., Hohenberger W., Hothorn T., Arnold D., et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. None. 2015;16:979-89||2398
Kolorektales Karzinom|"2.1"|2019|Hohenberger, W.|Hintergrund|||Standard|Rodel C., Graeven U., Fietkau R., Hohenberger W., Hothorn T., Arnold D., et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. None. 2015;16:979-89||2398
Kolorektales Karzinom|"2.1"|2019|Altenhofen, L.|Hintergrund|||Standard|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Von Stillfried D., Schmiegel W. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. None. 2012;142:1460-7.e2.|http://www.gastrojournal.org/article/S0016-5085(12)00398-8/pdf|2398
Kolorektales Karzinom|"2.1"|2019|Brenner, H.|Hintergrund|||Standard|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Von Stillfried D., Schmiegel W. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. None. 2012;142:1460-7.e2.|http://www.gastrojournal.org/article/S0016-5085(12)00398-8/pdf|2398
Kolorektales Karzinom|"2.1"|2019|Pox, C.|Hintergrund|||Erstautor|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Von Stillfried D., Schmiegel W. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. None. 2012;142:1460-7.e2.|http://www.gastrojournal.org/article/S0016-5085(12)00398-8/pdf|2398
Kolorektales Karzinom|"2.1"|2019|Schmiegel, W.|Hintergrund|||Letztautor|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Von Stillfried D., Schmiegel W. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. None. 2012;142:1460-7.e2.|http://www.gastrojournal.org/article/S0016-5085(12)00398-8/pdf|2398
Kolorektales Karzinom|"2.1"|2019|Theilmeier, A.|Hintergrund|||Standard|Pox C. P., Altenhofen L., Brenner H., Theilmeier A., Von Stillfried D., Schmiegel W. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. None. 2012;142:1460-7.e2.|http://www.gastrojournal.org/article/S0016-5085(12)00398-8/pdf|2398
Kolorektales Karzinom|"2.1"|2019|Hofheinz, R.-D.|Hintergrund|||Erstautor|Hofheinz R. D., Wenz F., Post S., Matzdorff A., Laechelt S., Hartmann J. T., et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. None. 2012;13:579-88||2398
Kolorektales Karzinom|"2.1"|2019|Post, S.|Hintergrund|||Standard|Hofheinz R. D., Wenz F., Post S., Matzdorff A., Laechelt S., Hartmann J. T., et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. None. 2012;13:579-88||2398
Pankreaskarzinom|"2.0"|2021|Esposito, Irene|Hintergrund|||Standard|Shrikhande S. V., Kleeff J., Reiser C., Weitz J., Hinz U., Esposito I., et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. . 2007;14:118-27|https://pubmed.ncbi.nlm.nih.gov/17066229/|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Hintergrund|||Standard|Hartwig W., Hackert T., Hinz U., Hassenpflug M., Strobel O., Buchler M. W., et al. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. . 2009;250:81-7|https://pubmed.ncbi.nlm.nih.gov/19561478/|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Evidenzbasierte Empfehlung|A|True|Standard|Hartwig W., Hackert T., Hinz U., Gluth A., Bergmann F., Strobel O., et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. None. 2011;254:311-9|https://www.ncbi.nlm.nih.gov/pubmed/21606835|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Hintergrund|||Standard|Hartwig W., Hackert T., Hinz U., Gluth A., Bergmann F., Strobel O., et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. None. 2011;254:311-9|https://www.ncbi.nlm.nih.gov/pubmed/21606835|1103
Pankreaskarzinom|"2.0"|2021|Esposito, Irene|Evidenzbasierte Empfehlung|A|True|Erstautor|Esposito I., Kleeff J., Bergmann F., Reiser C., Herpel E., Friess H., et al. Most pancreatic cancer resections are R1 resections. None. 2008;15:1651-60|https://www.ncbi.nlm.nih.gov/pubmed/18351300|1103
Pankreaskarzinom|"2.0"|2021|Esposito, Irene|Hintergrund|||Erstautor|Esposito I., Kleeff J., Bergmann F., Reiser C., Herpel E., Friess H., et al. Most pancreatic cancer resections are R1 resections. None. 2008;15:1651-60|https://www.ncbi.nlm.nih.gov/pubmed/18351300|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Hintergrund|||Standard|Isaji S., Mizuno S., Windsor J. A., Bassi C., Fernandez-Del Castillo C., Hackert T., et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. None. 2018;18:2-11|https://www.ncbi.nlm.nih.gov/pubmed/29191513|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Evidenzbasierte Empfehlung|B|False|Standard|Hartwig W., Strobel O., Hinz U., Fritz S., Hackert T., Roth C., et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. None. 2013;20:2188-96|https://www.ncbi.nlm.nih.gov/pubmed/23247983|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Hintergrund|||Standard|Hartwig W., Strobel O., Hinz U., Fritz S., Hackert T., Roth C., et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. None. 2013;20:2188-96|https://www.ncbi.nlm.nih.gov/pubmed/23247983|1103
Pankreaskarzinom|"2.0"|2021|Brunner, Thomas|Hintergrund|||Standard|Takaori K., Bassi C., Biankin A., Brunner T. B., Cataldo I., Campbell F., et al. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. . 2016;16:14-27|https://pubmed.ncbi.nlm.nih.gov/26699808/|1103
Pankreaskarzinom|"2.0"|2021|Keck, Tobias|Hintergrund|||Standard|Riediger H., Keck T., Wellner U., zur Hausen A., Adam U., Hopt U. T., et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. . 2009;13:1337-44|https://pubmed.ncbi.nlm.nih.gov/19418101/|1103
Pankreaskarzinom|"2.0"|2021|Uhl, Wolfgang|Hintergrund|||Standard|Wittel U. A., Lubgan D., Ghadimi M., Belyaev O., Uhl W., Bechstein W. O., et al. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial. . 2019;19:979|https://pubmed.ncbi.nlm.nih.gov/31640628/|1103
Pankreaskarzinom|"2.0"|2021|Uhl, Waldemar|Hintergrund|||Standard|Wittel U. A., Lubgan D., Ghadimi M., Belyaev O., Uhl W., Bechstein W. O., et al. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial. . 2019;19:979|https://pubmed.ncbi.nlm.nih.gov/31640628/|1103
Pankreaskarzinom|"2.0"|2021|Bruns, Christiane|Evidenzbasierte Empfehlung|A|True|Letztautor|Gebauer F., Damanakis A. I., Bruns C. [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy]. None. 2018;89:510-515|https://www.ncbi.nlm.nih.gov/pubmed/29557488|1103
Pankreaskarzinom|"2.0"|2021|Bruns, Christiane|Hintergrund|||Letztautor|Gebauer F., Damanakis A. I., Bruns C. [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy]. None. 2018;89:510-515|https://www.ncbi.nlm.nih.gov/pubmed/29557488|1103
Pankreaskarzinom|"2.0"|2021|Uhl, Wolfgang|Evidenzbasierte Empfehlung|A|True|Standard|Tachezy Michael, Gebauer Florian, Janot Monika, Uhl Waldemar, Zerbi Alessandro, Montorsi Marco, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. . 2016;160:136-144|https://pubmed.ncbi.nlm.nih.gov/27048934/|1103
Pankreaskarzinom|"2.0"|2021|Uhl, Waldemar|Evidenzbasierte Empfehlung|A|True|Standard|Tachezy Michael, Gebauer Florian, Janot Monika, Uhl Waldemar, Zerbi Alessandro, Montorsi Marco, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. . 2016;160:136-144|https://pubmed.ncbi.nlm.nih.gov/27048934/|1103
Pankreaskarzinom|"2.0"|2021|Tannapfel, Andrea|Hintergrund|||Letztautor|Munding J., Uhl W., Tannapfel A. [R classification and pancreatic ductal adenocarcinoma--R 0 is R 0]. . 2011;49:1423-7|https://pubmed.ncbi.nlm.nih.gov/21964897/|1103
Pankreaskarzinom|"2.0"|2021|Uhl, Wolfgang|Hintergrund|||Standard|Munding J., Uhl W., Tannapfel A. [R classification and pancreatic ductal adenocarcinoma--R 0 is R 0]. . 2011;49:1423-7|https://pubmed.ncbi.nlm.nih.gov/21964897/|1103
Pankreaskarzinom|"2.0"|2021|Uhl, Waldemar|Hintergrund|||Standard|Munding J., Uhl W., Tannapfel A. [R classification and pancreatic ductal adenocarcinoma--R 0 is R 0]. . 2011;49:1423-7|https://pubmed.ncbi.nlm.nih.gov/21964897/|1103
Pankreaskarzinom|"2.0"|2021|Esposito, Irene|Evidenzbasierte Empfehlung|A|True|Standard|Shrikhande S. V., Kleeff J., Reiser C., Weitz J., Hinz U., Esposito I., et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. None. 2007;14:118-27|http://www.ncbi.nlm.nih.gov/pubmed/17066229|1103
Pankreaskarzinom|"2.0"|2021|Esposito, Irene|Hintergrund|||Standard|Shrikhande S. V., Kleeff J., Reiser C., Weitz J., Hinz U., Esposito I., et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. None. 2007;14:118-27|http://www.ncbi.nlm.nih.gov/pubmed/17066229|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Hintergrund|||Erstautor|Hackert T., Niesen W., Hinz U., Tjaden C., Strobel O., Ulrich A., et al. Radical surgery of oligometastatic pancreatic cancer. None. 2017;43:358-363|https://www.ncbi.nlm.nih.gov/pubmed/27856064|1103
Pankreaskarzinom|"2.0"|2021|Oettle, Helmut|Hintergrund|||Erstautor|Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. . 2007;297:267-77|https://pubmed.ncbi.nlm.nih.gov/17227978/|1103
Pankreaskarzinom|"2.0"|2021|Keck, Tobias|Evidenzbasierte Empfehlung|A|True|Standard|Riediger H., Keck T., Wellner U., zur Hausen A., Adam U., Hopt U. T., et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. None. 2009;13:1337-44|http://www.ncbi.nlm.nih.gov/pubmed/19418101|1103
Pankreaskarzinom|"2.0"|2021|Heinemann, Volker|Hintergrund|||Erstautor|Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. . 2006;24:3946-52|https://pubmed.ncbi.nlm.nih.gov/16921047/|1103
Pankreaskarzinom|"2.0"|2021|Oettle, Helmut|Hintergrund|||Standard|Van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne W. L., Szawlowski A., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. . 2004;22:1430-8|https://pubmed.ncbi.nlm.nih.gov/15084616/|1103
Pankreaskarzinom|"2.0"|2021|Oettle, Helmut|Evidenzbasierte Empfehlung|A|True|Erstautor|Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. None. 2007;297:267-77|http://www.ncbi.nlm.nih.gov/pubmed/17227978|1103
Pankreaskarzinom|"2.0"|2021|Oettle, Helmut|Hintergrund|||Erstautor|Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. None. 2007;297:267-77|http://www.ncbi.nlm.nih.gov/pubmed/17227978|1103
Pankreaskarzinom|"2.0"|2021|Oettle, Helmut|Evidenzbasierte Empfehlung|A|True|Erstautor|Oettle Helmut, Neuhaus Peter, Hochhaus Andreas, Hartmann JÇôrg Thomas, Gellert Klaus, Ridwelski Karsten, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. . 2013;310:1473-1481|https://pubmed.ncbi.nlm.nih.gov/24104372/|1103
Pankreaskarzinom|"2.0"|2021|Oettle, Helmut|Hintergrund|||Erstautor|Oettle Helmut, Neuhaus Peter, Hochhaus Andreas, Hartmann JÇôrg Thomas, Gellert Klaus, Ridwelski Karsten, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. . 2013;310:1473-1481|https://pubmed.ncbi.nlm.nih.gov/24104372/|1103
Pankreaskarzinom|"2.0"|2021|Sinn, Marianne|Hintergrund|||Erstautor|Sinn M., Liersch T., Riess H., Gellert K., Stübs P., Waldschmidt D., et al. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. . 2020;138:172-181|https://pubmed.ncbi.nlm.nih.gov/32890813/|1103
Pankreaskarzinom|"2.0"|2021|Sinn, Marianne|Hintergrund|||Erstautor|Sinn M., Liersch T., Gellert K., Riess H., Stübs P., Waldschmidt D. T., et al. LBA18 - Conko-006: a Randomized Double-Blinded Phase Iib-Study of Adjuvant Therapy with Gemcitabine + Sorafenib/Placebo for Patients with R1-Resection of Pancreatic Cancer. . 2014;25:v1|https://pubmed.ncbi.nlm.nih.gov/32890813/|1103
Pankreaskarzinom|"2.0"|2021|Sinn, Marianne|Evidenzbasierte Empfehlung|B|False|Erstautor|Sinn Marianne, Bahra Marcus, Liersch Torsten, Gellert Klaus, Messmann Helmut, Bechstein Wolf, et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. . 2017;35:3330-3337|https://pubmed.ncbi.nlm.nih.gov/28817370/|1103
Pankreaskarzinom|"2.0"|2021|Sinn, Marianne|Hintergrund|||Erstautor|Sinn Marianne, Bahra Marcus, Liersch Torsten, Gellert Klaus, Messmann Helmut, Bechstein Wolf, et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. . 2017;35:3330-3337|https://pubmed.ncbi.nlm.nih.gov/28817370/|1103
Pankreaskarzinom|"2.0"|2021|Brunner, Thomas|Evidenzbasierte Empfehlung|B|False|Erstautor|Brunner T. B., Merkel S., Grabenbauer G. G., Meyer T., Baum U., Papadopoulos T., et al. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. None. 2005;62:1021-9|https://www.ncbi.nlm.nih.gov/pubmed/15990004|1103
Pankreaskarzinom|"2.0"|2021|Brunner, Thomas|Hintergrund|||Erstautor|Brunner T. B., Merkel S., Grabenbauer G. G., Meyer T., Baum U., Papadopoulos T., et al. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. None. 2005;62:1021-9|https://www.ncbi.nlm.nih.gov/pubmed/15990004|1103
Pankreaskarzinom|"2.0"|2021|Brunner, Thomas|Hintergrund|||Standard|Golcher H., Brunner T. B., Witzigmann H., Marti L., Bechstein W. O., Bruns C., et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. None. 2015;191:7-16|https://www.ncbi.nlm.nih.gov/pubmed/25252602|1103
Pankreaskarzinom|"2.0"|2021|Bruns, Christiane|Hintergrund|||Standard|Golcher H., Brunner T. B., Witzigmann H., Marti L., Bechstein W. O., Bruns C., et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. None. 2015;191:7-16|https://www.ncbi.nlm.nih.gov/pubmed/25252602|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Evidenzbasierte Empfehlung|B|False|Erstautor|Hackert T., Sachsenmaier M., Hinz U., Schneider L., Michalski C. W., Springfeld C., et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. None. 2016;264:457-63|https://www.ncbi.nlm.nih.gov/pubmed/27355262|1103
Pankreaskarzinom|"2.0"|2021|Hackert, Thilo|Hintergrund|||Erstautor|Hackert T., Sachsenmaier M., Hinz U., Schneider L., Michalski C. W., Springfeld C., et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. None. 2016;264:457-63|https://www.ncbi.nlm.nih.gov/pubmed/27355262|1103
Pankreaskarzinom|"2.0"|2021|Kunzmann, Volker|Hintergrund|||Erstautor|Kunzmann V., Siveke J. T., Algül H., Goekkurt E., Siegler G., Martens U., et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. . 2021;6:128-138|https://pubmed.ncbi.nlm.nih.gov/33338442/|1103
Pankreaskarzinom|"2.0"|2021|Heinemann, Volker|Hintergrund|||Erstautor|Heinemann V., Boeck S., Hinke A., Labianca R., Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. None. 2008;8:82|http://www.ncbi.nlm.nih.gov/pubmed/18373843|1103
Pankreaskarzinom|"2.0"|2021|Heinemann, Volker|Hintergrund|||Standard|Goldstein D., El-Maraghi R. H., Hammel P., Heinemann V., Kunzmann V., Sastre J., et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. None. 2015;107:None|https://www.ncbi.nlm.nih.gov/pubmed/25638248|1103
Pankreaskarzinom|"2.0"|2021|Kunzmann, Volker|Hintergrund|||Standard|Goldstein D., El-Maraghi R. H., Hammel P., Heinemann V., Kunzmann V., Sastre J., et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. None. 2015;107:None|https://www.ncbi.nlm.nih.gov/pubmed/25638248|1103
Pankreaskarzinom|"2.0"|2021|Oettle, Helmut|Hintergrund|||Erstautor|Oettle H., Richards D., Ramanathan R. K., van Laethem J. L., Peeters M., Fuchs M., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. . 2005;16:1639-45|https://pubmed.ncbi.nlm.nih.gov/16087696/|1103
Pankreaskarzinom|"2.0"|2021|Heinemann, Volker|Evidenzbasierte Empfehlung|B|False|Erstautor|Heinemann V., Vehling-Kaiser U., Waldschmidt D., Kettner E., Marten A., Winkelmann C., et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). . 2013;62:751-759|https://pubmed.ncbi.nlm.nih.gov/22773551/|1103
Pankreaskarzinom|"2.0"|2021|Heinemann, Volker|Hintergrund|||Erstautor|Heinemann V., Vehling-Kaiser U., Waldschmidt D., Kettner E., Marten A., Winkelmann C., et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). . 2013;62:751-759|https://pubmed.ncbi.nlm.nih.gov/22773551/|1103
Pankreaskarzinom|"2.0"|2021|Caca, Karel|Hintergrund|||Standard|Haas M., Siveke J. T., Schenk M., Lerch M. M., Caca K., Freiberg-Richter J., et al. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the Arbeitsgemeinschaft Internistische Onkologie-T. . 2018;94:95-103|https://pubmed.ncbi.nlm.nih.gov/29549862/|1103
Pankreaskarzinom|"2.0"|2021|Oettle, Helmut|Hintergrund|||Erstautor|Oettle H., Riess H., Stieler J. M., Heil G., Schwaner I., Seraphin J., et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. . 2014;32:2423-2429|https://pubmed.ncbi.nlm.nih.gov/24982456/|1103
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Evidenzbasierte Empfehlung|B|False|Erstautor|Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy–results from Paloma-3. None. 2016;34:abstr 524||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Hintergrund|||Erstautor|Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy–results from Paloma-3. None. 2016;34:abstr 524||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Hintergrund|||Erstautor|Harbeck N., Iyer S., Turner N., Cristofanilli M., Ro J., Andre F., et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. . 2016;27:1047-54||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Standard|Finn R. S., Crown J. P., Ettl J., Schmidt M., Bondarenko I. M., Lang I., et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. . 2016;18:67||3215
Mammakarzinom|"4.4"|2021|Welt, Anja|Evidenzbasierte Empfehlung|0|False|Erstautor|Welt A., Marschner N., Lerchenmueller C., Decker T., Steffens C. C., Koehler A., et al. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. None. 2016;156:97-107||3215
Mammakarzinom|"4.4"|2021|Welt, Anja|Hintergrund|||Erstautor|Welt A., Marschner N., Lerchenmueller C., Decker T., Steffens C. C., Koehler A., et al. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. None. 2016;156:97-107||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Erstautor|Schmidt M., Thomssen C., Untch M. Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis. None. 2016;39:102-10||3215
Mammakarzinom|"4.4"|2021|Thomssen, Christoph|Hintergrund|||Standard|Schmidt M., Thomssen C., Untch M. Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis. None. 2016;39:102-10||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Hintergrund|||Letztautor|Schmidt M., Thomssen C., Untch M. Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis. None. 2016;39:102-10||3215
Mammakarzinom|"4.4"|2021|Huober, Jens|Hintergrund|||Standard|Luck H. J., Du Bois A., Loibl S., Schrader I., Huober J., Heilmann V., et al. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. None. 2013;139:779-87||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Hintergrund|||Standard|Luck H. J., Du Bois A., Loibl S., Schrader I., Huober J., Heilmann V., et al. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. None. 2013;139:779-87||3215
Mammakarzinom|"4.4"|2021|Fasching, Peter|Hintergrund|||Standard|Huober J., Fasching P. A., Barsoum M., Petruzelka L., Wallwiener D., Thomssen C., et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. None. 2012;21:27-33||3215
Mammakarzinom|"4.4"|2021|Huober, Jens|Hintergrund|||Erstautor|Huober J., Fasching P. A., Barsoum M., Petruzelka L., Wallwiener D., Thomssen C., et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. None. 2012;21:27-33||3215
Mammakarzinom|"4.4"|2021|Thomssen, Christoph|Hintergrund|||Standard|Huober J., Fasching P. A., Barsoum M., Petruzelka L., Wallwiener D., Thomssen C., et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. None. 2012;21:27-33||3215
Mammakarzinom|"4.4"|2021|Dunst, Jürgen|Hintergrund|||Standard|Rades D., Kieckebusch S., Haatanen T., Lohynska R., Dunst J., Schild S. E. Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis. None. 2008;70:1319-24||3215
Mammakarzinom|"4.4"|2021|Steckelberg, Anke|Evidenzbasierte Empfehlung|A|False|Letztautor|Mühlhauser I., Steckelberg A. Evidenzbasierte Patienteninformation: Wünsche der Betroffenen. None. 2009;106:A-2554–A-2556||3215
Mammakarzinom|"4.4"|2021|Steckelberg, Anke|Hintergrund|||Letztautor|Mühlhauser I., Steckelberg A. Evidenzbasierte Patienteninformation: Wünsche der Betroffenen. None. 2009;106:A-2554–A-2556||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Erstautor|Weis Joachim, Schwarz Reinhold, Blettner Gabriele. Psychoonkologische Versorgung in Deutschland: Qualität und Quantität/Psychooncological care in Germany: Quality and quantity. None. 2000;46:4-17||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Erstautor|Weis J, Schumacher A, Blettner G, Determann M, Reinert E, Rüffer JU, et al. Psychoonkologie. None. 2007;13:185-194||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Letztautor|Koch Uwe, Weis Joachim. Krankheitsbewältigung bei Krebs und Möglichkeiten der Unterstützung. None. 1998;None:None||3215
Mammakarzinom|"4.4"|2021|Albert, Ute-Susann|Hintergrund|||Erstautor|Albert U. S., Koller M., Lorenz W., Kopp I., Heitmann C., Stinner B., et al. Quality of life profile: from measurement to clinical application. . 2002;11:324-34||3215
Mammakarzinom|"4.4"|2021|Heitmann, Christoph|Hintergrund|||Standard|Albert U. S., Koller M., Lorenz W., Kopp I., Heitmann C., Stinner B., et al. Quality of life profile: from measurement to clinical application. . 2002;11:324-34||3215
Mammakarzinom|"4.4"|2021|Albert, Ute-Susann|Hintergrund|||Erstautor|Albert U. S., Koller M., Lorenz W., Kopp I., Heitmann C., Stinner B., et al. Quality of life profile: from measurement to clinical application. None. 2002;11:324-34||3215
Mammakarzinom|"4.4"|2021|Heitmann, Christoph|Hintergrund|||Standard|Albert U. S., Koller M., Lorenz W., Kopp I., Heitmann C., Stinner B., et al. Quality of life profile: from measurement to clinical application. None. 2002;11:324-34||3215
Mammakarzinom|"4.4"|2021|Bartsch, Hans Helge|Hintergrund|||Letztautor|Poppelreuter M, Weis J, Schmid J, Bartsch HH. Neuropsychologische Folgestörungen nach adjuvanter Therapie des Mammakarzinoms. None. 2006;12:27-35||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Standard|Poppelreuter M, Weis J, Schmid J, Bartsch HH. Neuropsychologische Folgestörungen nach adjuvanter Therapie des Mammakarzinoms. None. 2006;12:27-35||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Evidenzbasierte Empfehlung|A|False|Standard|Faller H., Schuler M., Richard M., Heckl U., Weis J., Kuffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. None. 2013;31:782-93||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Standard|Faller H., Schuler M., Richard M., Heckl U., Weis J., Kuffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. None. 2013;31:782-93||3215
Mammakarzinom|"4.4"|2021|Feyer, Petra|Hintergrund|||Standard|Basch E., Prestrud A. A., Hesketh P. J., Kris M. G., Feyer P. C., Somerfield M. R., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. None. 2011;29:4189-98||3215
Mammakarzinom|"4.4"|2021|Link, Hartmut|Hintergrund|||Erstautor|Link H., Maschmeyer G., Meyer P., Hiddemann W., Stille W., Helmerking M., et al. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy. None. 1994;69:231-43||3215
Mammakarzinom|"4.4"|2021|Link, Hartmut|Hintergrund|||Erstautor|Link H., Bohme A., Cornely O. A., Hoffken K., Kellner O., Kern W. V., et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). None. 2003;82 Suppl 2:S105-17||3215
Mammakarzinom|"4.4"|2021|Link, Hartmut|Hintergrund|||Standard|Schiel X., Link H., Maschmeyer G., Glass B., Cornely O. A., Buchheidt D., et al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. None. 2006;34:118-26||3215
Mammakarzinom|"4.4"|2021|Link, Hartmut|Hintergrund|||Erstautor|Link H, Buchheidt D, Maschmeyer G, Böhme A, Mahlberg R, Mousset S, et al. Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) dDGfHuOeVD, Sektion Infektionen in der Hämatologie und Onkologie dP-E-GfCeVP, Arbeitsgemeinschaft Supportivmaßnahmen in der Onkologie dDKeVA, Deutschsprachige Mykologische Gesellschaft eV (DMykG)(2006) Infektionen bei Neutropenie–Diagnostik und Therapie 2006–Empfehlungen für die Praxis. None. 2006;None:None||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Erstautor|Weis J., Giesler J. M. Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence. None. 2008;73:511-8||3215
Mammakarzinom|"4.4"|2021|Huober, Jens|Hintergrund|||Standard|Moebus V., Jackisch C., Schneeweiss A., Huober J., Lueck H. J., du Bois A., et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. None. 2013;105:1018-26||3215
Mammakarzinom|"4.4"|2021|Jackisch, Christian|Hintergrund|||Standard|Moebus V., Jackisch C., Schneeweiss A., Huober J., Lueck H. J., du Bois A., et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. None. 2013;105:1018-26||3215
Mammakarzinom|"4.4"|2021|Schneeweiss, Andreas|Hintergrund|||Standard|Moebus V., Jackisch C., Schneeweiss A., Huober J., Lueck H. J., du Bois A., et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. None. 2013;105:1018-26||3215
Mammakarzinom|"4.4"|2021|Gerber, Bernd|Hintergrund|||Standard|Berger M. D., Gerber B., Arn K., Senn O., Schanz U., Stussi G. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. None. 2012;97:116-22||3215
Mammakarzinom|"4.4"|2021|Fasching, Peter|Evidenzbasierte Empfehlung|A|False|Standard|Bani H. A., Fasching P. A., Lux M. M., Rauh C., Willner M., Eder I., et al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. None. 2007;66:311-8||3215
Mammakarzinom|"4.4"|2021|Lux, Michael|Evidenzbasierte Empfehlung|A|False|Standard|Bani H. A., Fasching P. A., Lux M. M., Rauh C., Willner M., Eder I., et al. Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit. None. 2007;66:311-8||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Hintergrund|||Standard|Hahnen E., Lederer B., Hauke J., Loibl S., Kröber S., Schneeweiss A, et al. Germline mutation status, pathological complete response and disease-free survival rates in triple-negative breast cancer (GeparSixto trial), A Randomized Clinical Trial. None. 2017;None:None||3215
Mammakarzinom|"4.4"|2021|Schneeweiss, Andreas|Hintergrund|||Standard|Hahnen E., Lederer B., Hauke J., Loibl S., Kröber S., Schneeweiss A, et al. Germline mutation status, pathological complete response and disease-free survival rates in triple-negative breast cancer (GeparSixto trial), A Randomized Clinical Trial. None. 2017;None:None||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Erstautor|Weis J. Cancer-related fatigue: prevalence, assessment and treatment strategies. None. 2011;11:441-6||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Letztautor|Heim Manfred E, Weis Joachim. Fatigue bei Krebserkrankungen: Erkennen–Behandeln–Vorbeugen. None. 2014;None:None||3215
Mammakarzinom|"4.4"|2021|Rick, Oliver|Hintergrund|||Letztautor|Geiger G., Mikus E., Dertinger H., Rick O. Low frequency magnetic field therapy in patients with cytostatic-induced polyneuropathy: a phase II pilot study. None. 2015;36:251-4||3215
Mammakarzinom|"4.4"|2021|Rick, Oliver|Hintergrund|||Erstautor|Rick O, Mikus E, Dertinger H, Geiger G. Treatment of chemotherapy-induced polyneuropathy with magnetic field therapy: A randomized, double-blind placebo-controlled comparative phase Iii study. None. 2014;37:189||3215
Mammakarzinom|"4.4"|2021|Weis, Joachim|Hintergrund|||Standard|Scherwath A., Poppelreuter M., Weis J., Schulz-Kindermann F., Koch U., Mehnert A. [Psychometric evaluation of a neuropsychological test battery measuring cognitive dysfunction in cancer patients--recommendations for a screening tool]. None. 2008;76:583-93||3215
Mammakarzinom|"4.4"|2021|Beckmann, Matthias W.|Hintergrund|||Standard|Kalder M., Muller T., Fischer D., Muller A., Bader W., Beckmann M. W., et al. A Review of Integrative Medicine in Gynaecological Oncology. None. 2016;76:150-155||3215
Mammakarzinom|"4.4"|2021|Albert, Ute-Susann|Hintergrund|||Erstautor|Albert U-S, Koller M, Wagner U, Schulz K-D. Survival chances and psychological aspects of quality of life in patients with localized early stage breast cancer. None. 2004;53:S136-S141||3215
Mammakarzinom|"4.4"|2021|Fasching, Peter|Hintergrund|||Standard|Slamon Dennis J., Neven Patrick, Chia Stephen, Fasching Peter A., De Laurentiis Michelino, Im Seock-Ah, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. None. 2019;None:None|https://doi.org/10.1056/NEJMoa1911149|3215
Mammakarzinom|"4.4"|2021|Hanf, Volker|Hintergrund|||Erstautor|Hanf V., Schutz F., Liedtke C., Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2015. None. 2015;10:189-97||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Evidenzbasierte Empfehlung|A|False|Erstautor|Loibl S., Han S. N., von Minckwitz G., Bontenbal M., Ring A., Giermek J., et al. Treatment of breast cancer during pregnancy: an observational study. None. 2012;13:887-96||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Evidenzbasierte Empfehlung|A|False|Standard|Loibl S., Han S. N., von Minckwitz G., Bontenbal M., Ring A., Giermek J., et al. Treatment of breast cancer during pregnancy: an observational study. None. 2012;13:887-96||3215
Mammakarzinom|"4.4"|2021|Denkert, Carsten|Evidenzbasierte Empfehlung|A|False|Standard|Loibl S., Schmidt A., Gentilini O., Kaufman B., Kuhl C., Denkert C., et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. None. 2015;1:1145-53||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Evidenzbasierte Empfehlung|A|False|Erstautor|Loibl S., Schmidt A., Gentilini O., Kaufman B., Kuhl C., Denkert C., et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. None. 2015;1:1145-53||3215
Mammakarzinom|"4.4"|2021|Gerber, Bernd|Evidenzbasierte Empfehlung|0|False|Erstautor|Gerber B., von Minckwitz G., Stehle H., Reimer T., Felberbaum R., Maass N., et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. None. 2011;29:2334-41||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Evidenzbasierte Empfehlung|0|False|Standard|Gerber B., von Minckwitz G., Stehle H., Reimer T., Felberbaum R., Maass N., et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. None. 2011;29:2334-41||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Evidenzbasierte Empfehlung|B|False|Standard|Biganzoli L., Wildiers H., Oakman C., Marotti L., Loibl S., Kunkler I., et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). None. 2012;13:e148-60||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Evidenzbasierte Empfehlung|B|False|Standard|Biganzoli L., Aapro M., Loibl S., Wildiers H., Brain E. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. None. 2016;43:19-26||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Evidenzbasierte Empfehlung|B|False|Standard|Loibl S., von Minckwitz G., Harbeck N., Janni W., Elling D., Kaufmann M., et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. None. 2008;10:R77||3215
Mammakarzinom|"4.4"|2021|Janni, Wolfgang|Evidenzbasierte Empfehlung|B|False|Standard|Loibl S., von Minckwitz G., Harbeck N., Janni W., Elling D., Kaufmann M., et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. None. 2008;10:R77||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Evidenzbasierte Empfehlung|B|False|Erstautor|Loibl S., von Minckwitz G., Harbeck N., Janni W., Elling D., Kaufmann M., et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. None. 2008;10:R77||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Evidenzbasierte Empfehlung|B|False|Standard|Loibl S., von Minckwitz G., Harbeck N., Janni W., Elling D., Kaufmann M., et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. None. 2008;10:R77||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Hintergrund|||Standard|Eggemann H., Ignatov A., Stabenow R., von Minckwitz G., Rohl F. W., Hass P., et al. Male breast cancer: 20-year survival data for post-mastectomy radiotherapy. None. 2013;8:270-5||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Hintergrund|||Standard|Eggemann H., Ignatov A., Smith B. J., Altmann U., von Minckwitz G., Rohl F. W., et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. None. 2013;137:465-70||3215
Mammakarzinom|"4.4"|2021|Lebeau, Annette|Hintergrund|||Erstautor|Lebeau A., Kriegsmann M., Burandt E., Sinn H. P. [Invasive breast cancer: the current WHO classification]. None. 2014;35:7-17||3215
Mammakarzinom|"4.4"|2021|Sinn, Hans-Peter|Hintergrund|||Letztautor|Lebeau A., Kriegsmann M., Burandt E., Sinn H. P. [Invasive breast cancer: the current WHO classification]. None. 2014;35:7-17||3215
Mammakarzinom|"4.4"|2021|Fasching, Peter|Hintergrund|||Standard|Slamon D. J., Neven P., Chia S., Fasching P. A., De Laurentiis M., Im S. A., et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. None. 2018;36:2465-2472||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Standard|van Sprundel T. C., Schmidt M. K., Rookus M. A., Brohet R., van Asperen C. J., Rutgers E. J., et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. None. 2005;93:287-92||3215
Mammakarzinom|"4.4"|2021|Fallenberg, Eva|Hintergrund|||Erstautor|Fallenberg E. M., Dromain C., Diekmann F., Renz D. M., Amer H., Ingold-Heppner B., et al. Contrast-enhanced spectral mammography: Does mammography provide additional clinical benefits or can some radiation exposure be avoided?. None. 2014;146:371-81||3215
Mammakarzinom|"4.4"|2021|Fallenberg, Eva|Hintergrund|||Erstautor|Fallenberg E. M., Schmitzberger F. F., Amer H., Ingold-Heppner B., Balleyguier C., Diekmann F., et al. Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation. None. 2017;27:2752-2764||3215
Mammakarzinom|"4.4"|2021|Degenhardt, Friedrich|Hintergrund|||Standard|Mueller-Schimpfle M. P., Brandenbusch V. C., Degenhardt F., Duda V., Madjar H., Mundinger A., et al. The Problem of Mammographic Breast Density - The Position of the DEGUM Working Group on Breast Ultrasound. None. 2016;37:170-5||3215
Mammakarzinom|"4.4"|2021|Müller-Schimpfle, Markus|Evidenzbasierte Empfehlung|A|False|Erstautor|Müller-Schimpfle M, Graf O, Madjar H, al. et. Diskussionspapier - BI-RADS die 5. - eine Kurzmitteilung aus deutsch- /österreichischer Sicht. None. 2016;None:346-352||3215
Mammakarzinom|"4.4"|2021|Degenhardt, Friedrich|Hintergrund|||Standard|Wurstlein R., Degenhardt F., Duda V., Madjar H., Merz E., Mundinger A., et al. [Evaluation of the nationwide DEGUM breast ultrasound training program]. None. 2014;35:345-9||3215
Mammakarzinom|"4.4"|2021|Albert, Ute-Susann|Hintergrund|||Erstautor|Albert U-S, Schulz K-D, Alt D, Beck V, Doherty J, Holsteg K, et al. Eine Leitlinie für Leitlinien: die methodische Entwicklung und Anwendung der Leitlinie Fraueninformation. None. 2003;125:484-493||3215
Mammakarzinom|"4.4"|2021|Schulz-Wendtland, Rüdiger|Evidenzbasierte Empfehlung|B|False|Erstautor|Schulz-Wendtland R., Aichinger U., Kramer S., Tartsch M., Kuchar I., Magener A., et al. [Sonographical breast biopsy: how many core biopsy specimens are needed?]. None. 2003;175:94-8||3215
Mammakarzinom|"4.4"|2021|Lebeau, Annette|Hintergrund|||Erstautor|Lebeau A., Kuhn T. Updates in the treatment of ductal carcinoma in situ of the breast. None. 2016;28:49-58||3215
Mammakarzinom|"4.4"|2021|Sinn, Hans-Peter|Hintergrund|||Erstautor|Sinn H. P., Helmchen B., Heil J., Aulmann S. [Lobular neoplasms and invasive lobular breast cancer]. None. 2014;35:45-53||3215
Mammakarzinom|"4.4"|2021|Sinn, Hans-Peter|Hintergrund|||Erstautor|Sinn H. P. Breast cancer precursors: lessons learned from molecular genetics. None. 2009;87:113-5||3215
Mammakarzinom|"4.4"|2021|Janni, Wolfgang|Evidenzbasierte Empfehlung|0|False|Standard|Wolters R., Wockel A., Janni W., Novopashenny I., Ebner F., Kreienberg R., et al. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. None. 2013;142:579-90||3215
Mammakarzinom|"4.4"|2021|Janni, Wolfgang|Hintergrund|||Standard|Wolters R., Wockel A., Janni W., Novopashenny I., Ebner F., Kreienberg R., et al. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. None. 2013;142:579-90||3215
Mammakarzinom|"4.4"|2021|Albert, Ute-Susann|Evidenzbasierte Empfehlung|0|False|Erstautor|Albert Ute Susann, Altland H, Duda V. Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland. None. 2008;None:None||3215
Mammakarzinom|"4.4"|2021|Albert, Ute-Susann|Hintergrund|||Erstautor|Albert Ute Susann, Altland H, Duda V. Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland. None. 2008;None:None||3215
Mammakarzinom|"4.4"|2021|Fehm, Tanja|Evidenzbasierte Empfehlung|B|False|Standard|Kuehn Thorsten, Bauerfeind Ingo, Fehm Tanja, Fleige Barbara, Hausschild Maik, Helms Gisela, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. None. 2013;14:609-618||3215
Mammakarzinom|"4.4"|2021|Fehm, Tanja|Hintergrund|||Standard|Kuehn Thorsten, Bauerfeind Ingo, Fehm Tanja, Fleige Barbara, Hausschild Maik, Helms Gisela, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. None. 2013;14:609-618||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Standard|Vogt H., Schmidt M., Bares R., Brenner W., Grunwald F., Kopp J., et al. [Procedure guideline for sentinel lymph node diagnosis]. None. 2010;49:167-72; quiz N19||3215
Mammakarzinom|"4.4"|2021|Sinn, Hans-Peter|Hintergrund|||Erstautor|Sinn H. P., Anton H. W., Magener A., von Fournier D., Bastert G., Otto H. F. Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. None. 1998;34:646-53||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Hintergrund|||Letztautor|Christgen M., Langer F., Kreipe H. [Histological grading of breast cancer]. None. 2016;37:328-36||3215
Mammakarzinom|"4.4"|2021|Lebeau, Annette|Hintergrund|||Erstautor|Lebeau A., Turzynski A., Braun S., Behrhof W., Fleige B., Schmitt W. D., et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. None. 2010;28:3264-70||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Hintergrund|||Standard|Rüschoff J., Lebeau A., Kreipe H., Sinn P., Gerharz C. D., Koch W., et al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. None. 2017;30:217-226||3215
Mammakarzinom|"4.4"|2021|Lebeau, Annette|Hintergrund|||Standard|Rüschoff J., Lebeau A., Kreipe H., Sinn P., Gerharz C. D., Koch W., et al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. None. 2017;30:217-226||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Hintergrund|||Letztautor|Mengel M., von Wasielewski R., Wiese B., Rudiger T., Muller-Hermelink H. K., Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. None. 2002;198:292-9||3215
Mammakarzinom|"4.4"|2021|Huober, Jens|Evidenzbasiertes Statement|A|False|Standard|Nitz U., Gluz O., Huober J., Kreipe H. H., Kates R. E., Hartmann A., et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. None. 2014;25:1551-7||3215
Mammakarzinom|"4.4"|2021|Huober, Jens|Hintergrund|||Standard|Nitz U., Gluz O., Huober J., Kreipe H. H., Kates R. E., Hartmann A., et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. None. 2014;25:1551-7||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Evidenzbasiertes Statement|A|False|Standard|Nitz U., Gluz O., Huober J., Kreipe H. H., Kates R. E., Hartmann A., et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. None. 2014;25:1551-7||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Hintergrund|||Standard|Nitz U., Gluz O., Huober J., Kreipe H. H., Kates R. E., Hartmann A., et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. None. 2014;25:1551-7||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Hintergrund|||Letztautor|Christgen M., Winkens W., Kreipe H. H. [Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67]. None. 2014;35:54-60||3215
Mammakarzinom|"4.4"|2021|Denkert, Carsten|Hintergrund|||Erstautor|Denkert C., Budczies J., von Minckwitz G., Wienert S., Loibl S., Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. None. 2015;24 Suppl 2:S67-72||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Hintergrund|||Standard|Denkert C., Budczies J., von Minckwitz G., Wienert S., Loibl S., Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. None. 2015;24 Suppl 2:S67-72||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Hintergrund|||Standard|Denkert C., Budczies J., von Minckwitz G., Wienert S., Loibl S., Klauschen F. Strategies for developing Ki67 as a useful biomarker in breast cancer. None. 2015;24 Suppl 2:S67-72||3215
Mammakarzinom|"4.4"|2021|Blohmer, Jens|Hintergrund|||Standard|Klauschen F., Wienert S., Schmitt W. D., Loibl S., Gerber B., Blohmer J. U., et al. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. None. 2015;21:3651-7||3215
Mammakarzinom|"4.4"|2021|Gerber, Bernd|Hintergrund|||Standard|Klauschen F., Wienert S., Schmitt W. D., Loibl S., Gerber B., Blohmer J. U., et al. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. None. 2015;21:3651-7||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Hintergrund|||Standard|Klauschen F., Wienert S., Schmitt W. D., Loibl S., Gerber B., Blohmer J. U., et al. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. None. 2015;21:3651-7||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Hintergrund|||Letztautor|Christgen M., von Ahsen S., Christgen H., Langer F., Kreipe H. The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. None. 2015;46:1341-9||3215
Mammakarzinom|"4.4"|2021|Denkert, Carsten|Evidenzbasierte Empfehlung|0|False|Standard|Buus R., Sestak I., Kronenwett R., Denkert C., Dubsky P., Krappmann K., et al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. None. 2016;108:None||3215
Mammakarzinom|"4.4"|2021|Denkert, Carsten|Hintergrund|||Standard|Buus R., Sestak I., Kronenwett R., Denkert C., Dubsky P., Krappmann K., et al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. None. 2016;108:None||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Hintergrund|||Erstautor|Harbeck N., Schmitt M., Meisner C., Friedel C., Untch M., Schmidt M., et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. None. 2013;49:1825-35||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Standard|Harbeck N., Schmitt M., Meisner C., Friedel C., Untch M., Schmidt M., et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. None. 2013;49:1825-35||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Hintergrund|||Standard|Harbeck N., Schmitt M., Meisner C., Friedel C., Untch M., Schmidt M., et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. None. 2013;49:1825-35||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Erstautor|Schmidt M., Dogan G., Battista M., Lenhard H. G., Lebrecht A., Hönig A., et al. Zusammenhang zwischen urokinase-typ Plasminogen Aktivator (uPA)/Plasminogen Aktivator Inhibitor-1 (PAI-1) und intrinsischen Subtypen beim frühen Mammakarzinom. None. 2014;74:PO_Onko07_18||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Standard|Witzel I., Milde-Langosch K., Schmidt M., Karn T., Becker S., Wirtz R., et al. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. None. 2014;7:2205-13||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Evidenzbasierte Empfehlung|A|False|Standard|Houssami N., Macaskill P., von Minckwitz G., Marinovich M. L., Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. None. 2012;48:3342-54||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Hintergrund|||Standard|Houssami N., Macaskill P., von Minckwitz G., Marinovich M. L., Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. None. 2012;48:3342-54||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Evidenzbasierte Empfehlung|A|False|Standard|von Minckwitz G., Untch M., Nuesch E., Loibl S., Kaufmann M., Kummel S., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. None. 2011;125:145-56||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Hintergrund|||Standard|von Minckwitz G., Untch M., Nuesch E., Loibl S., Kaufmann M., Kummel S., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. None. 2011;125:145-56||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Evidenzbasierte Empfehlung|A|False|Standard|von Minckwitz G., Untch M., Nuesch E., Loibl S., Kaufmann M., Kummel S., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. None. 2011;125:145-56||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Hintergrund|||Standard|von Minckwitz G., Untch M., Nuesch E., Loibl S., Kaufmann M., Kummel S., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. None. 2011;125:145-56||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Evidenzbasierte Empfehlung|A|False|Erstautor|von Minckwitz G., Untch M., Nuesch E., Loibl S., Kaufmann M., Kummel S., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. None. 2011;125:145-56||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Hintergrund|||Erstautor|von Minckwitz G., Untch M., Nuesch E., Loibl S., Kaufmann M., Kummel S., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. None. 2011;125:145-56||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Evidenzbasiertes Statement|0|False|Standard|Cortazar P., Zhang L., Untch M., Mehta K., Costantino J. P., Wolmark N., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. None. 2014;384:164-72||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Hintergrund|||Standard|Cortazar P., Zhang L., Untch M., Mehta K., Costantino J. P., Wolmark N., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. None. 2014;384:164-72||3215
Mammakarzinom|"4.4"|2021|Denkert, Carsten|Hintergrund|||Erstautor|Denkert C., Loibl S., Muller B. M., Eidtmann H., Schmitt W. D., Eiermann W., et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. None. 2013;24:2786-93||3215
Mammakarzinom|"4.4"|2021|Loibl, Sibylle|Hintergrund|||Standard|Denkert C., Loibl S., Muller B. M., Eidtmann H., Schmitt W. D., Eiermann W., et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. None. 2013;24:2786-93||3215
Mammakarzinom|"4.4"|2021|Denkert, Carsten|Hintergrund|||Erstautor|Denkert C., von Minckwitz G. Reply to Ki67 in breast cancer: a useful prognostic marker!. None. 2014;25:542-3||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Hintergrund|||Letztautor|Denkert C., von Minckwitz G. Reply to Ki67 in breast cancer: a useful prognostic marker!. None. 2014;25:542-3||3215
Mammakarzinom|"4.4"|2021|Denkert, Carsten|Hintergrund|||Standard|Ingold Heppner B., Untch M., Denkert C., Pfitzner B. M., Lederer B., Schmitt W., et al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. None. 2016;22:5747-5754||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Hintergrund|||Standard|Ingold Heppner B., Untch M., Denkert C., Pfitzner B. M., Lederer B., Schmitt W., et al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. None. 2016;22:5747-5754||3215
Mammakarzinom|"4.4"|2021|Denkert, Carsten|Hintergrund|||Standard|Salgado R., Denkert C., Demaria S., Sirtaine N., Klauschen F., Pruneri G., et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. None. 2015;26:259-71||3215
Mammakarzinom|"4.4"|2021|Lebeau, Annette|Hintergrund|||Erstautor|Lebeau A. [Prognostic factors in ductal carcinoma in situ]. None. 2006;27:326-36||3215
Mammakarzinom|"4.4"|2021|Budach, Wilfried|Hintergrund|||Standard|Sedlmayer F., Sautter-Bihl M. L., Budach W., Dunst J., Fastner G., Feyer P., et al. DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. None. 2013;189:825-33||3215
Mammakarzinom|"4.4"|2021|Dunst, Jürgen|Hintergrund|||Standard|Sedlmayer F., Sautter-Bihl M. L., Budach W., Dunst J., Fastner G., Feyer P., et al. DEGRO practical guidelines: radiotherapy of breast cancer I: radiotherapy following breast conserving therapy for invasive breast cancer. None. 2013;189:825-33||3215
Mammakarzinom|"4.4"|2021|Denkinger, Michael|Hintergrund|||Standard|Hancke K., Denkinger M. D., Konig J., Kurzeder C., Wockel A., Herr D., et al. Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. None. 2010;21:748-53||3215
Mammakarzinom|"4.4"|2021|Budach, Volker|Evidenzbasierte Empfehlung|A|False|Standard|Poortmans Philip M, Collette Sandra, Kirkove Carine, Van Limbergen Erik, Budach Volker, Struikmans Henk, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. None. 2015;373:317-327||3215
Mammakarzinom|"4.4"|2021|Budach, Volker|Hintergrund|||Standard|Poortmans Philip M, Collette Sandra, Kirkove Carine, Van Limbergen Erik, Budach Volker, Struikmans Henk, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. None. 2015;373:317-327||3215
Mammakarzinom|"4.4"|2021|Katalinic, Alexander|Hintergrund|||Letztautor|Obi N., Waldmann A., Schafer F., Schreer I., Katalinic A. Impact of the Quality assured Mamma Diagnostic (QuaMaDi) programme on survival of breast cancer patients. None. 2011;35:286-92||3215
Mammakarzinom|"4.4"|2021|Schreer, Ingrid|Hintergrund|||Standard|Obi N., Waldmann A., Schafer F., Schreer I., Katalinic A. Impact of the Quality assured Mamma Diagnostic (QuaMaDi) programme on survival of breast cancer patients. None. 2011;35:286-92||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Hintergrund|||Standard|Aly M. M., Abo-Madyan Y., Jahnke L., Wenz F., Glatting G. Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH). None. 2016;11:16||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Evidenzbasierte Empfehlung|0|False|Standard|Vaidya J. S., Wenz F., Bulsara M., Tobias J. S., Joseph D. J., Keshtgar M., et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. None. 2014;383:603-13||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Hintergrund|||Standard|Vaidya J. S., Wenz F., Bulsara M., Tobias J. S., Joseph D. J., Keshtgar M., et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. None. 2014;383:603-13||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Hintergrund|||Letztautor|Herskind C., Griebel J., Kraus-Tiefenbacher U., Wenz F. Sphere of equivalence--a novel target volume concept for intraoperative radiotherapy using low-energy X rays. None. 2008;72:1575-81||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Hintergrund|||Erstautor|Wenz Frederik, Welzel Grit, Blank Elena, Hermann Brigitte, Steil Volker, Sütterlin Marc, et al. Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays: the first 5 years of experience with a novel approach. None. 2010;77:1309-1314||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Hintergrund|||Standard|Vaidya J. S., Baum M., Tobias J. S., Wenz F., Massarut S., Keshtgar M., et al. Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery. None. 2011;81:1091-7||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Hintergrund|||Standard|Vaidya J. S., Joseph D. J., Tobias J. S., Bulsara M., Wenz F., Saunders C., et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. None. 2010;376:91-102||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Hintergrund|||Standard|Vaidya J. S., Bulsara M., Wenz F., Coombs N., Singer J., Ebbs S., et al. Reduced Mortality With Partial-Breast Irradiation for Early Breast Cancer: A Meta-Analysis of Randomized Trials. None. 2016;96:259-65||3215
Mammakarzinom|"4.4"|2021|Wenz, Frederik|Hintergrund|||Standard|Keshtgar M. R., Vaidya J. S., Tobias J. S., Wenz F., Joseph D., Stacey C., et al. Targeted intraoperative radiotherapy for breast cancer in patients in whom external beam radiation is not possible. None. 2011;80:31-8||3215
Mammakarzinom|"4.4"|2021|Budach, Wilfried|Evidenzbasierte Empfehlung|A|False|Erstautor|Budach W., Bolke E., Kammers K., Gerber P. A., Nestle-Kramling C., Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. None. 2015;10:258||3215
Mammakarzinom|"4.4"|2021|Budach, Wilfried|Hintergrund|||Erstautor|Budach W., Bolke E., Kammers K., Gerber P. A., Nestle-Kramling C., Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. None. 2015;10:258||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Evidenzbasierte Empfehlung|B|False|Standard|Im S. A., Lu Y. S., Bardia A., Harbeck N., Colleoni M., Franke F., et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. None. 2019;381:307-316||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Hintergrund|||Standard|Im S. A., Lu Y. S., Bardia A., Harbeck N., Colleoni M., Franke F., et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. None. 2019;381:307-316||3215
Mammakarzinom|"4.4"|2021|Heywang-Köbrunner, Sylvia|Evidenzbasierte Empfehlung|0|False|Standard|Hodgson Robert, Heywang-Köbrunner Sylvia H, Harvey Susan C, Edwards Mary, Shaikh Javed, Arber Mick, et al. Systematic review of 3D mammography for breast cancer screening. None. 2016;27:52-61||3215
Mammakarzinom|"4.4"|2021|Heywang-Köbrunner, Sylvia|Hintergrund|||Standard|Hodgson Robert, Heywang-Köbrunner Sylvia H, Harvey Susan C, Edwards Mary, Shaikh Javed, Arber Mick, et al. Systematic review of 3D mammography for breast cancer screening. None. 2016;27:52-61||3215
Mammakarzinom|"4.4"|2021|Katalinic, Alexander|Hintergrund|||Standard|Schaefer F. K., Waldmann A., Katalinic A., Wefelnberg C., Heller M., Jonat W., et al. Influence of additional breast ultrasound on cancer detection in a cohort study for quality assurance in breast diagnosis--analysis of 102,577 diagnostic procedures. . 2010;20:1085-92||3215
Mammakarzinom|"4.4"|2021|Jackisch, Christian|Evidenzbasierte Empfehlung|B|False|Standard|Moebus V., Jackisch C., Lueck H. J., du Bois A., Thomssen C., Kurbacher C., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. . 2010;28:2874-80||3215
Mammakarzinom|"4.4"|2021|Thomssen, Christoph|Evidenzbasierte Empfehlung|B|False|Standard|Moebus V., Jackisch C., Lueck H. J., du Bois A., Thomssen C., Kurbacher C., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. . 2010;28:2874-80||3215
Mammakarzinom|"4.4"|2021|Jackisch, Christian|Evidenzbasierte Empfehlung|B|False|Standard|Moebus V., Jackisch C., Lueck H. J., du Bois A., Thomssen C., Kurbacher C., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. None. 2010;28:2874-80||3215
Mammakarzinom|"4.4"|2021|Jackisch, Christian|Hintergrund|||Standard|Moebus V., Jackisch C., Lueck H. J., du Bois A., Thomssen C., Kurbacher C., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. None. 2010;28:2874-80||3215
Mammakarzinom|"4.4"|2021|Thomssen, Christoph|Evidenzbasierte Empfehlung|B|False|Standard|Moebus V., Jackisch C., Lueck H. J., du Bois A., Thomssen C., Kurbacher C., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. None. 2010;28:2874-80||3215
Mammakarzinom|"4.4"|2021|Thomssen, Christoph|Hintergrund|||Standard|Moebus V., Jackisch C., Lueck H. J., du Bois A., Thomssen C., Kurbacher C., et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. None. 2010;28:2874-80||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Evidenzbasierte Empfehlung|A|False|Erstautor|Harbeck Nadia, Gluz Oleg, Clemens Michael R, Malter Wolfram, Reimer Toralf, Nuding Benno, et al. Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→ 4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. None. 2017;None:None||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Hintergrund|||Erstautor|Harbeck Nadia, Gluz Oleg, Clemens Michael R, Malter Wolfram, Reimer Toralf, Nuding Benno, et al. Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→ 4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. None. 2017;None:None||3215
Mammakarzinom|"4.4"|2021|Degenhardt, Friedrich|Evidenzbasierte Empfehlung|A|False|Standard|Nothacker M., Duda V., Hahn M., Warm M., Degenhardt F., Madjar H., et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. None. 2009;9:335||3215
Mammakarzinom|"4.4"|2021|Hahn, Markus|Evidenzbasierte Empfehlung|A|False|Standard|Nothacker M., Duda V., Hahn M., Warm M., Degenhardt F., Madjar H., et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. None. 2009;9:335||3215
Mammakarzinom|"4.4"|2021|Degenhardt, Friedrich|Hintergrund|||Standard|Nothacker M., Duda V., Hahn M., Warm M., Degenhardt F., Madjar H., et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. . 2009;9:335||3215
Mammakarzinom|"4.4"|2021|Hahn, Markus|Hintergrund|||Standard|Nothacker M., Duda V., Hahn M., Warm M., Degenhardt F., Madjar H., et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. . 2009;9:335||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Hintergrund|||Standard|Foukakis T., von Minckwitz G., Bengtsson N. O., Brandberg Y., Wallberg B., Fornander T., et al. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. None. 2016;316:1888-1896||3215
Mammakarzinom|"4.4"|2021|Blohmer, Jens|Evidenzbasiertes Statement||False|Standard|von Minckwitz G., Blohmer J. U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. None. 2005;16:56-63||3215
Mammakarzinom|"4.4"|2021|Blohmer, Jens|Hintergrund|||Standard|von Minckwitz G., Blohmer J. U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. None. 2005;16:56-63||3215
Mammakarzinom|"4.4"|2021|Gerber, Bernd|Evidenzbasiertes Statement||False|Standard|von Minckwitz G., Blohmer J. U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. None. 2005;16:56-63||3215
Mammakarzinom|"4.4"|2021|Gerber, Bernd|Hintergrund|||Standard|von Minckwitz G., Blohmer J. U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. None. 2005;16:56-63||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Evidenzbasiertes Statement||False|Erstautor|von Minckwitz G., Blohmer J. U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. None. 2005;16:56-63||3215
Mammakarzinom|"4.4"|2021|von Minckwitz, Gunter|Hintergrund|||Erstautor|von Minckwitz G., Blohmer J. U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. None. 2005;16:56-63||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Evidenzbasierte Empfehlung|B|False|Standard|Tripathy D., Im S. A., Colleoni M., Franke F., Bardia A., Harbeck N., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. None. 2018;19:904-915||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Hintergrund|||Standard|Tripathy D., Im S. A., Colleoni M., Franke F., Bardia A., Harbeck N., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. None. 2018;19:904-915||3215
Mammakarzinom|"4.4"|2021|Fasching, Peter|Hintergrund|||Standard|Untch M., Fasching P. A., Konecny G. E., Hasmuller S., Lebeau A., Kreienberg R., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. None. 2011;29:3351-7||3215
Mammakarzinom|"4.4"|2021|Lebeau, Annette|Hintergrund|||Standard|Untch M., Fasching P. A., Konecny G. E., Hasmuller S., Lebeau A., Kreienberg R., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. None. 2011;29:3351-7||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Hintergrund|||Erstautor|Untch M., Fasching P. A., Konecny G. E., Hasmuller S., Lebeau A., Kreienberg R., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. None. 2011;29:3351-7||3215
Mammakarzinom|"4.4"|2021|Schneeweiss, Andreas|Hintergrund|||Erstautor|Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). None. 2013;24:2278-2284||3215
Mammakarzinom|"4.4"|2021|Blohmer, Jens|Hintergrund|||Standard|Smith I. E., Dowsett M., Ebbs S. R., Dixon J. M., Skene A., Blohmer J. U., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. None. 2005;23:5108-16||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Hintergrund|||Standard|Ruschoff J., Lebeau A., Kreipe H., Sinn P., Gerharz C. D., Koch W., et al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. None. 2016;None:None||3215
Mammakarzinom|"4.4"|2021|Lebeau, Annette|Hintergrund|||Standard|Ruschoff J., Lebeau A., Kreipe H., Sinn P., Gerharz C. D., Koch W., et al. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. None. 2016;None:None||3215
Mammakarzinom|"4.4"|2021|Kreipe, Hans H.|Hintergrund|||Letztautor|Choritz H., Busche G., Kreipe H. Quality assessment of HER2 testing by monitoring of positivity rates. None. 2011;459:283-9||3215
Mammakarzinom|"4.4"|2021|Degenhardt, Friedrich|Hintergrund|||Letztautor|Wojcinski S., Gyapong S., Farrokh A., Soergel P., Hillemanns P., Degenhardt F. Diagnostic performance and inter-observer concordance in lesion detection with the automated breast volume scanner (ABVS). . 2013;13:36||3215
Mammakarzinom|"4.4"|2021|Jackisch, Christian|Hintergrund|||Standard|Untch M., Gelber R. D., Jackisch C., Procter M., Baselga J., Bell R., et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. None. 2008;19:1090-6||3215
Mammakarzinom|"4.4"|2021|Untch, Michael|Hintergrund|||Erstautor|Untch M., Gelber R. D., Jackisch C., Procter M., Baselga J., Bell R., et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. None. 2008;19:1090-6||3215
Mammakarzinom|"4.4"|2021|Hadji, Peyman|Hintergrund|||Erstautor|Hadji P., Kauka A., Ziller M., Birkholz K., Baier M., Muth M., et al. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. None. 2014;25:1369-78||3215
Mammakarzinom|"4.4"|2021|Hadji, Peyman|Hintergrund|||Letztautor|Kalder M., Hans D., Kyvernitakis I., Lamy O., Bauer M., Hadji P. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer. None. 2014;17:66-71||3215
Mammakarzinom|"4.4"|2021|Hadji, Peyman|Evidenzbasierte Empfehlung|B|False|Erstautor|Hadji P., Asmar L., van Nes J. G., Menschik T., Hasenburg A., Kuck J., et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. None. 2011;137:1015-25||3215
Mammakarzinom|"4.4"|2021|Hadji, Peyman|Hintergrund|||Erstautor|Hadji P., Asmar L., van Nes J. G., Menschik T., Hasenburg A., Kuck J., et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. None. 2011;137:1015-25||3215
Mammakarzinom|"4.4"|2021|Albert, Ute-Susann|Hintergrund|||Standard|Hadji P., Ziller M., Maskow C., Albert U., Kalder M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. None. 2009;45:3205-12||3215
Mammakarzinom|"4.4"|2021|Hadji, Peyman|Hintergrund|||Erstautor|Hadji P., Ziller M., Maskow C., Albert U., Kalder M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. None. 2009;45:3205-12||3215
Mammakarzinom|"4.4"|2021|Janni, Wolfgang|Hintergrund|||Standard|Banys M., Solomayer E. F., Gebauer G., Janni W., Krawczyk N., Lueck H. J., et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. None. 2013;13:480||3215
Mammakarzinom|"4.4"|2021|Hadji, Peyman|Hintergrund|||Standard|Coleman R., Body J. J., Aapro M., Hadji P., Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. None. 2014;25 Suppl 3:iii124-37||3215
Mammakarzinom|"4.4"|2021|Hauner, Hans|Evidenzbasierte Empfehlung|B|False|Letztautor|Hauner D., Janni W., Rack B., Hauner H. The effect of overweight and nutrition on prognosis in breast cancer. None. 2011;108:795-801||3215
Mammakarzinom|"4.4"|2021|Janni, Wolfgang|Evidenzbasierte Empfehlung|B|False|Standard|Hauner D., Janni W., Rack B., Hauner H. The effect of overweight and nutrition on prognosis in breast cancer. None. 2011;108:795-801||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Evidenzbasierte Empfehlung|B|False|Standard|Steindorf K., Schmidt M. E., Klassen O., Ulrich C. M., Oelmann J., Habermann N., et al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. None. 2014;25:2237-43||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Standard|Steindorf K., Schmidt M. E., Klassen O., Ulrich C. M., Oelmann J., Habermann N., et al. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. None. 2014;25:2237-43||3215
Mammakarzinom|"4.4"|2021|Baumann, Freerk|Evidenzbasierte Empfehlung|B|False|Standard|Streckmann F., Kneis S., Leifert J. A., Baumann F. T., Kleber M., Ihorst G., et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. None. 2014;25:493-9||3215
Mammakarzinom|"4.4"|2021|Baumann, Freerk|Hintergrund|||Standard|Streckmann F., Kneis S., Leifert J. A., Baumann F. T., Kleber M., Ihorst G., et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. None. 2014;25:493-9||3215
Mammakarzinom|"4.4"|2021|Dunst, Jürgen|Hintergrund|||Erstautor|Dunst J., Steil B., Furch S., Fach A., Lautenschlager C., Diestelhorst A., et al. Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy. None. 2001;177:504-10||3215
Mammakarzinom|"4.4"|2021|Engel, Jutta|Hintergrund|||Standard|Hölzel Dieter, Engel Jutta, Schmidt Michael, Sauer Hansjörg. Modell zur primären und sekundären Metastasierung beim Mammakarzinom und dessen klinische Bedeutung. None. 2001;177:10-24||3215
Mammakarzinom|"4.4"|2021|Hölzel, Dieter|Hintergrund|||Erstautor|Hölzel Dieter, Engel Jutta, Schmidt Michael, Sauer Hansjörg. Modell zur primären und sekundären Metastasierung beim Mammakarzinom und dessen klinische Bedeutung. None. 2001;177:10-24||3215
Mammakarzinom|"4.4"|2021|Schmidt, Marcus|Hintergrund|||Standard|Hölzel Dieter, Engel Jutta, Schmidt Michael, Sauer Hansjörg. Modell zur primären und sekundären Metastasierung beim Mammakarzinom und dessen klinische Bedeutung. None. 2001;177:10-24||3215
Mammakarzinom|"4.4"|2021|Engel, Jutta|Hintergrund|||Erstautor|Engel J., Eckel R., Aydemir U., Aydemir S., Kerr J., Schlesinger-Raab A., et al. Determinants and prognoses of locoregional and distant progression in breast cancer. . 2003;55:1186-95||3215
Mammakarzinom|"4.4"|2021|Engel, Jutta|Hintergrund|||Erstautor|Engel J., Eckel R., Aydemir U., Aydemir S., Kerr J., Schlesinger-Raab A., et al. Determinants and prognoses of locoregional and distant progression in breast cancer. None. 2003;55:1186-95||3215
Mammakarzinom|"4.4"|2021|Harbeck, Nadia|Hintergrund|||Standard|Cardoso F., Harbeck N., Fallowfield L., Kyriakides S., Senkus E. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. None. 2012;23 Suppl 7:vii11-9||3215
Peniskarzinom|"1.0"|2020|Naumann, Carsten Maik|Evidenzbasierte Empfehlung|A|True|Erstautor|Naumann C. M., Alkatout I., Al-Najar A., Korda J. B., Hegele A., Bolenz C., et al. Lymph-node metastases in intermediate-risk squamous cell carcinoma of the penis. None. 2008;102:1102-6|https://www.ncbi.nlm.nih.gov/pubmed/18489528|312
Peniskarzinom|"1.0"|2020|Naumann, Carsten Maik|Hintergrund|||Erstautor|Naumann C. M., Alkatout I., Al-Najar A., Korda J. B., Hegele A., Bolenz C., et al. Lymph-node metastases in intermediate-risk squamous cell carcinoma of the penis. None. 2008;102:1102-6|https://www.ncbi.nlm.nih.gov/pubmed/18489528|312
Peniskarzinom|"1.0"|2020|Naumann, Carsten Maik|Evidenzbasierte Empfehlung|A|True|Erstautor|Naumann C. M., Filippow N., Seif C., van der Horst C., Roelver L., Braun P. M., et al. Penile carcinoma (pT1 G2): surveillance or inguinal lymph node dissection?. None. 2005;28:135-8|https://www.ncbi.nlm.nih.gov/pubmed/15772463|312
Peniskarzinom|"1.0"|2020|Naumann, Carsten Maik|Hintergrund|||Erstautor|Naumann C. M., Filippow N., Seif C., van der Horst C., Roelver L., Braun P. M., et al. Penile carcinoma (pT1 G2): surveillance or inguinal lymph node dissection?. None. 2005;28:135-8|https://www.ncbi.nlm.nih.gov/pubmed/15772463|312
Peniskarzinom|"1.0"|2020|Naumann, Carsten Maik|Evidenzbasierte Empfehlung|A|True|Erstautor|Naumann C. M., van der Horst C., Volkmer B., Kurtz F., Martinez Portillo F. J., Seif C., et al. [The influence of the T stage on the risk of metastasis of penis cancer: T1 vs. T2]. None. 2006;45:1424, 1426-30|https://www.ncbi.nlm.nih.gov/pubmed/16906416|312
Peniskarzinom|"1.0"|2020|Naumann, Carsten Maik|Hintergrund|||Erstautor|Naumann C. M., van der Horst C., Volkmer B., Kurtz F., Martinez Portillo F. J., Seif C., et al. [The influence of the T stage on the risk of metastasis of penis cancer: T1 vs. T2]. None. 2006;45:1424, 1426-30|https://www.ncbi.nlm.nih.gov/pubmed/16906416|312
Peniskarzinom|"1.0"|2020|Protzel, Chris|Evidenzbasiertes Statement||False|Erstautor|Protzel C., Alcaraz A., Horenblas S., Pizzocaro G., Zlotta A., Hakenberg O. W. Lymphadenectomy in the surgical management of penile cancer. None. 2009;55:1075-88|https://www.ncbi.nlm.nih.gov/pubmed/19264390|312
Peniskarzinom|"1.0"|2020|Protzel, Chris|Hintergrund|||Erstautor|Protzel C., Alcaraz A., Horenblas S., Pizzocaro G., Zlotta A., Hakenberg O. W. Lymphadenectomy in the surgical management of penile cancer. None. 2009;55:1075-88|https://www.ncbi.nlm.nih.gov/pubmed/19264390|312
Peniskarzinom|"1.0"|2020|Schneede, Peter|Evidenzbasierte Empfehlung|0|False|Standard|Schlenker B., Gratzke C., Seitz M., Bader M. J., Reich O., Schneede P., et al. Fluorescence-guided laser therapy for penile carcinoma and precancerous lesions: long-term follow-up. None. 2011;29:788-93|https://www.ncbi.nlm.nih.gov/pubmed/19945305|312
Peniskarzinom|"1.0"|2020|Schneede, Peter|Hintergrund|||Standard|Schlenker B., Gratzke C., Seitz M., Bader M. J., Reich O., Schneede P., et al. Fluorescence-guided laser therapy for penile carcinoma and precancerous lesions: long-term follow-up. None. 2011;29:788-93|https://www.ncbi.nlm.nih.gov/pubmed/19945305|312
Peniskarzinom|"1.0"|2020|Schneede, Peter|Evidenzbasierte Empfehlung|0|False|Standard|Schlenker B., Tilki D., Seitz M., Bader M. J., Reich O., Schneede P., et al. Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. None. 2010;106:786-90|https://www.ncbi.nlm.nih.gov/pubmed/20089106|312
Peniskarzinom|"1.0"|2020|Schneede, Peter|Hintergrund|||Standard|Schlenker B., Tilki D., Seitz M., Bader M. J., Reich O., Schneede P., et al. Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. None. 2010;106:786-90|https://www.ncbi.nlm.nih.gov/pubmed/20089106|312
Peniskarzinom|"1.0"|2020|Schneede, Peter|Hintergrund|||Letztautor|Frimberger D., Hungerhuber E., Zaak D., Waidelich R., Hofstetter A., Schneede P. Penile carcinoma. Is Nd:YAG laser therapy radical enough?. None. 2002;168:2418-21; discussion 2421|https://www.ncbi.nlm.nih.gov/pubmed/12441930|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Evidenzbasiertes Statement||False|Standard|Robinson R., Marconi L., MacPepple E., Hakenberg O. W., Watkin N., Yuan Y., et al. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. None. 2018;74:76-83|https://www.ncbi.nlm.nih.gov/pubmed/29703686|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Hintergrund|||Standard|Robinson R., Marconi L., MacPepple E., Hakenberg O. W., Watkin N., Yuan Y., et al. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. None. 2018;74:76-83|https://www.ncbi.nlm.nih.gov/pubmed/29703686|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Evidenzbasierte Empfehlung|A|True|Letztautor|Protzel C., Hakenberg O. W. Chemotherapy in patients with penile carcinoma. None. 2009;82:1-7|https://www.ncbi.nlm.nih.gov/pubmed/19172088|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Hintergrund|||Letztautor|Protzel C., Hakenberg O. W. Chemotherapy in patients with penile carcinoma. None. 2009;82:1-7|https://www.ncbi.nlm.nih.gov/pubmed/19172088|312
Peniskarzinom|"1.0"|2020|Protzel, Chris|Evidenzbasierte Empfehlung|A|True|Erstautor|Protzel C., Hakenberg O. W. Chemotherapy in patients with penile carcinoma. None. 2009;82:1-7|https://www.ncbi.nlm.nih.gov/pubmed/19172088|312
Peniskarzinom|"1.0"|2020|Protzel, Chris|Hintergrund|||Erstautor|Protzel C., Hakenberg O. W. Chemotherapy in patients with penile carcinoma. None. 2009;82:1-7|https://www.ncbi.nlm.nih.gov/pubmed/19172088|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Evidenzbasierte Empfehlung|B|False|Letztautor|Drager D. L., Milerski S., Sievert K. D., Hakenberg O. W. [Psychosocial effects in patients with penile cancer : A systematic review]. None. 2018;57:444-452|https://www.ncbi.nlm.nih.gov/pubmed/29476193|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Hintergrund|||Letztautor|Drager D. L., Milerski S., Sievert K. D., Hakenberg O. W. [Psychosocial effects in patients with penile cancer : A systematic review]. None. 2018;57:444-452|https://www.ncbi.nlm.nih.gov/pubmed/29476193|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Hintergrund|||Letztautor|Drager D. L., Protzel C., Hakenberg O. W. Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer. None. 2017;15:605-609|https://www.ncbi.nlm.nih.gov/pubmed/28499559|312
Peniskarzinom|"1.0"|2020|Protzel, Chris|Hintergrund|||Standard|Drager D. L., Protzel C., Hakenberg O. W. Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer. None. 2017;15:605-609|https://www.ncbi.nlm.nih.gov/pubmed/28499559|312
Peniskarzinom|"1.0"|2020|Erbersdobler, Andreas|Hintergrund|||Standard|Kakies Ch, Lopez-Beltran A., Comperat E., Erbersdobler A., Grobholz R., Hakenberg O. W., et al. Reproducibility of histopathologic tumor grading in penile cancer--results of a European project. None. 2014;464:453-61|https://www.ncbi.nlm.nih.gov/pubmed/24535700|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Hintergrund|||Standard|Kakies Ch, Lopez-Beltran A., Comperat E., Erbersdobler A., Grobholz R., Hakenberg O. W., et al. Reproducibility of histopathologic tumor grading in penile cancer--results of a European project. None. 2014;464:453-61|https://www.ncbi.nlm.nih.gov/pubmed/24535700|312
Peniskarzinom|"1.0"|2020|Erbersdobler, Andreas|Hintergrund|||Standard|Gunia S., Kakies C., Erbersdobler A., Hakenberg O. W., Koch S., May M. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. None. 2012;65:232-6|https://www.ncbi.nlm.nih.gov/pubmed/22135025|312
Peniskarzinom|"1.0"|2020|Hakenberg, Oliver|Hintergrund|||Standard|Gunia S., Kakies C., Erbersdobler A., Hakenberg O. W., Koch S., May M. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. None. 2012;65:232-6|https://www.ncbi.nlm.nih.gov/pubmed/22135025|312
Peniskarzinom|"1.0"|2020|Protzel, Chris|Hintergrund|||Erstautor|Protzel C., Knoedel J., Zimmermann U., Woenckhaus C., Poetsch M., Giebel J. Expression of proliferation marker Ki67 correlates to occurrence of metastasis and prognosis, histological subtypes and HPV DNA detection in penile carcinomas. None. 2007;22:1197-204|https://www.ncbi.nlm.nih.gov/pubmed/17647192|312
Harnblasenkarzinom|"2"|2020|Albers, Peter|Hintergrund|||Standard|Fechner G., Siener R., Reimann M., Kobalz L., Albers P., German Association Of Urologic Oncology Bladder Cancer Study Group. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). . 2006;60:27-31||1460
Harnblasenkarzinom|"2"|2020|Albers, Peter|Evidenzbasierte Empfehlung|0|False|Standard|Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J. E., Fechner G., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). . 2009;55:1293-9||1460
Harnblasenkarzinom|"2"|2020|Albers, Peter|Hintergrund|||Standard|Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J. E., Fechner G., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). . 2009;55:1293-9||1460
Harnblasenkarzinom|"2"|2020|Gschwend, Jürgen|Evidenzbasierte Empfehlung|0|False|Standard|Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J. E., Fechner G., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). . 2009;55:1293-9||1460
Harnblasenkarzinom|"2"|2020|Gschwend, Jürgen|Hintergrund|||Standard|Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J. E., Fechner G., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). . 2009;55:1293-9||1460
Harnblasenkarzinom|"2"|2020|Volkmer, Björn|Evidenzbasierte Empfehlung|0|False|Standard|Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J. E., Fechner G., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). . 2009;55:1293-9||1460
Harnblasenkarzinom|"2"|2020|Volkmer, Björn|Hintergrund|||Standard|Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J. E., Fechner G., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). . 2009;55:1293-9||1460
Harnblasenkarzinom|"2"|2020|Krege, Susanne|Evidenzbasierte Empfehlung|0|False|Standard|Otto T., Krege S., Suhr J., Rubben H. Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. . 2001;57:55-9||1460
Harnblasenkarzinom|"2"|2020|Krege, Susanne|Hintergrund|||Standard|Otto T., Krege S., Suhr J., Rubben H. Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. . 2001;57:55-9||1460
Harnblasenkarzinom|"2"|2020|Otto, Ullrich|Hintergrund|||Standard|Vahlensieck W., Gack M., Gleissner J., Hoffmann W., Liedke S., Otto U., et al. [Structure and process quality of inpatient urologic rehabilitation]. . 2005;44:51-6||1460
Harnblasenkarzinom|"2"|2020|Otto, Ullrich|Hintergrund|||Erstautor|Müller G.; Borrusch H.; Otto U. Rehabilitation. Allgemeine Grundlagen. . 2014;6. Auflage:64-83||1460
Harnblasenkarzinom|"2"|2020|Otto, Ullrich|Hintergrund|||Erstautor|Dombo O.; Otto U. Stress-Inkontinenz beim Mann: Anamtomische und funktionelle Besonderheiten. . 2004;1:7-12||1460
Harnblasenkarzinom|"2"|2020|Otto, Ullrich|Hintergrund|||Erstautor|Müller G.;Brock O.; Otto U. Wie effektiv ist die fachspezifische stationäre Anschlussheilbehandlung (AHB) nach Zystektomie mit Anlage einer Ileum Neoblase?. . 2014;53 (Suppl.):||1460
Harnblasenkarzinom|"2"|2020|Rick, Oliver|Hintergrund|||Letztautor|Geiger G., Mikus E., Dertinger H., Rick O. Low frequency magnetic field therapy in patients with cytostatic-induced polyneuropathy: a phase II pilot study. . 2015;36:251-4||1460
Harnblasenkarzinom|"2"|2020|Rick, Oliver|Hintergrund|||Erstautor|Rick O.; Mikus E.; Deringer H.; Geiger G. Treatment of chemotherapy-induced polyneuropathy with magnetic foled Therapy: A randomized, double-blind placebo-controlled comparative phase III study. . 2014;37:(suppl. 5): 189||1460
Harnblasenkarzinom|"2"|2020|Rick, Oliver|Hintergrund|||Erstautor|Rick O. Kognitive Dysfunktion oder Chemobrain. . 2014;3:||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Standard|Babjuk M., Burger M., Zigeuner R., Shariat S. F., van Rhijn B. W., Comperat E., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. . 2013;64:639-53||1460
Harnblasenkarzinom|"2"|2020|de Wit, Maike|Hintergrund|||Erstautor|de Wit M., Ortner P., Lipp H. P., Sehouli J., Untch M., Ruhnke M., et al. Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment. . 2013;36:127-35||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Erstautor|Burger M., Catto J. W., Dalbagni G., Grossman H. B., Herr H., Karakiewicz P., et al. Epidemiology and risk factors of urothelial bladder cancer. . 2013;63:234-41||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Hintergrund|||Erstautor|Bolenz C., Auer M., Strobel P., Heinzelbecker J., Schubert C., Trojan L. The lymphatic system in clinically localized urothelial carcinoma of the bladder: morphologic characteristics and predictive value. . 2013;31:1606-14||1460
Harnblasenkarzinom|"2"|2020|Volkmer, Björn|Hintergrund|||Erstautor|Volkmer B. G., Kuefer R., Bartsch G. C. Jr., Gust K., Hautmann R. E. Oncological followup after radical cystectomy for bladder cancer-is there any benefit?. . 2009;181:1587-93; discussion 1593||1460
Harnblasenkarzinom|"2"|2020|Weiss, Christian|Hintergrund|||Erstautor|Weiss C., Engehausen D. G., Krause F. S., Papadopoulos T., Dunst J., Sauer R., et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. . 2007;68:1072-80||1460
Harnblasenkarzinom|"2"|2020|Hartmann, Arndt|Hintergrund|||Standard|Masson-Lecomte A., Rava M., Real F. X., Hartmann A., Allory Y., Malats N. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. . 2014;66:1078-91||1460
Harnblasenkarzinom|"2"|2020|Schwentner, C.|Hintergrund|||Standard|Pesch B., Taeger D., Johnen G., Gawrych K., Bonberg N., Schwentner C., et al. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. . 2014;87:715-24||1460
Harnblasenkarzinom|"2"|2020|Schwentner, C.|Hintergrund|||Standard|Bonberg N., Taeger D., Gawrych K., Johnen G., Banek S., Schwentner C., et al. Chromosomal instability and bladder cancer: the UroVysion(TM) test in the UroScreen study. . 2013;112:E372-82||1460
Harnblasenkarzinom|"2"|2020|Hartmann, Arndt|Hintergrund|||Letztautor|Bertz S., Schmitz-Drager B. J., Protzel C., Hartmann A. Intraoperative frozen section diagnosis of the genitourinary tract. . 2012;33:441-9||1460
Harnblasenkarzinom|"2"|2020|Gakis, G.|Hintergrund|||Erstautor|Gakis G., Schilling D., Perner S., Schwentner C., Sievert K. D., Stenzl A. Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis. . 2011;29:451-6||1460
Harnblasenkarzinom|"2"|2020|Schwentner, C.|Hintergrund|||Standard|Gakis G., Schilling D., Perner S., Schwentner C., Sievert K. D., Stenzl A. Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis. . 2011;29:451-6||1460
Harnblasenkarzinom|"2"|2020|Gakis, G.|Hintergrund|||Erstautor|Gakis G., Efstathiou J., Lerner S. P., Cookson M. S., Keegan K. A., Guru K. A., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. . 2013;63:45-57||1460
Harnblasenkarzinom|"2"|2020|Hartmann, Arndt|Hintergrund|||Standard|Catto J. W., Hartmann A., Stoehr R., Bolderson E., Rehman I., Rosario D. J., et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. . 2006;175:2323-30||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Standard|Otto W., Denzinger S., Fritsche H. M., Burger M., Wieland W. F., Hofstadter F., et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. . 2011;107:404-8||1460
Harnblasenkarzinom|"2"|2020|Volkmer, Björn|Hintergrund|||Erstautor|Volkmer B. G., Schnoeller T., Kuefer R., Gust K., Finter F., Hautmann R. E. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?. . 2009;182:2632-7||1460
Harnblasenkarzinom|"2"|2020|Schwentner, C.|Hintergrund|||Standard|Cha E. K., Tirsar L. A., Schwentner C., Christos P. J., Mian C., Hennenlotter J., et al. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. . 2012;61:185-92||1460
Harnblasenkarzinom|"2"|2020|Goebell, Peter Jürgen|Hintergrund|||Erstautor|Goebell P. J., Kamat A. M., Sylvester R. J., Black P., Droller M., Godoy G., et al. Assessing the quality of studies on the diagnostic accuracy of tumor markers. . 2014;32:1051-60||1460
Harnblasenkarzinom|"2"|2020|Golka, Klaus|Hintergrund|||Erstautor|Golka K., Kopps S., Myslak Z. W. Carcinogenicity of azo colorants: influence of solubility and bioavailability. . 2004;151:203-10||1460
Harnblasenkarzinom|"2"|2020|Hakenberg, Oliver|Hintergrund|||Standard|May M., Hakenberg O. W., Gunia S., Pohling P., Helke C., Lubbe L., et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. . 2007;70:449-53||1460
Harnblasenkarzinom|"2"|2020|Goebell, Peter Jürgen|Evidenzbasierte Empfehlung|B|False|Standard|Richterstetter M., Wullich B., Amann K., Haeberle L., Engehausen D. G., Goebell P. J., et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. . 2012;110:E76-9||1460
Harnblasenkarzinom|"2"|2020|Goebell, Peter Jürgen|Hintergrund|||Standard|Richterstetter M., Wullich B., Amann K., Haeberle L., Engehausen D. G., Goebell P. J., et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. . 2012;110:E76-9||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Evidenzbasiertes Statement||False|Standard|Kausch I., Sommerauer M., Montorsi F., Stenzl A., Jacqmin D., Jichlinski P., et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. . 2010;57:595-606||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Standard|Kausch I., Sommerauer M., Montorsi F., Stenzl A., Jacqmin D., Jichlinski P., et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. . 2010;57:595-606||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Evidenzbasiertes Statement||False|Erstautor|Stenzl A., Penkoff H., Dajc-Sommerer E., Zumbraegel A., Hoeltl L., Scholz M., et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial. . 2011;117:938-47||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Erstautor|Stenzl A., Penkoff H., Dajc-Sommerer E., Zumbraegel A., Hoeltl L., Scholz M., et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial. . 2011;117:938-47||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Evidenzbasiertes Statement||False|Standard|Stenzl A., Burger M., Fradet Y., Mynderse L. A., Soloway M. S., Witjes J. A., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. . 2010;184:1907-13||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Standard|Stenzl A., Burger M., Fradet Y., Mynderse L. A., Soloway M. S., Witjes J. A., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. . 2010;184:1907-13||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Evidenzbasiertes Statement||False|Erstautor|Stenzl A., Burger M., Fradet Y., Mynderse L. A., Soloway M. S., Witjes J. A., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. . 2010;184:1907-13||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Erstautor|Stenzl A., Burger M., Fradet Y., Mynderse L. A., Soloway M. S., Witjes J. A., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. . 2010;184:1907-13||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Erstautor|Burger Maximilian, Stief Christian G, Zaak Dirk, Stenzl Arnulf, Wieland Wolf F, Jocham Dieter, et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. None. 2009;74:1282-1286||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Standard|Burger Maximilian, Stief Christian G, Zaak Dirk, Stenzl Arnulf, Wieland Wolf F, Jocham Dieter, et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. None. 2009;74:1282-1286||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Erstautor|Burger M., Grossman H. B., Droller M., Schmidbauer J., Hermann G., Dragoescu O., et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. . 2013;64:846-54||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Standard|Grossman H. B., Stenzl A., Fradet Y., Mynderse L. A., Kriegmair M., Witjes J. A., et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. . 2012;188:58-62||1460
Harnblasenkarzinom|"2"|2020|Schwaibold, H.|Evidenzbasiertes Statement||False|Letztautor|Sivalingam S., Probert J. L., Schwaibold H. The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer. . 2005;96:759-62||1460
Harnblasenkarzinom|"2"|2020|Schwaibold, H.|Hintergrund|||Letztautor|Sivalingam S., Probert J. L., Schwaibold H. The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer. . 2005;96:759-62||1460
Harnblasenkarzinom|"2"|2020|Grimm, Marc-Oliver|Evidenzbasiertes Statement||False|Standard|Vogeli T. A., Grimm M. O., Simon X., Ackermann R. [Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma]. . 2002;41:470-4||1460
Harnblasenkarzinom|"2"|2020|Grimm, Marc-Oliver|Hintergrund|||Standard|Vogeli T. A., Grimm M. O., Simon X., Ackermann R. [Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma]. . 2002;41:470-4||1460
Harnblasenkarzinom|"2"|2020|Schwaibold, H.|Hintergrund|||Erstautor|Schwaibold H. E., Sivalingam S., May F., Hartung R. The value of a second transurethral resection for T1 bladder cancer. . 2006;97:1199-201||1460
Harnblasenkarzinom|"2"|2020|Krege, Susanne|Evidenzbasierte Empfehlung|0|False|Erstautor|Krege S., Giani G., Meyer R., Otto T., Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. . 1996;156:962-6||1460
Harnblasenkarzinom|"2"|2020|Krege, Susanne|Hintergrund|||Erstautor|Krege S., Giani G., Meyer R., Otto T., Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. . 1996;156:962-6||1460
Harnblasenkarzinom|"2"|2020|Krege, Susanne|Evidenzbasierte Empfehlung|A|False|Standard|Malmstrom P. U., Sylvester R. J., Crawford D. E., Friedrich M., Krege S., Rintala E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. . 2009;56:247-56||1460
Harnblasenkarzinom|"2"|2020|Krege, Susanne|Hintergrund|||Standard|Malmstrom P. U., Sylvester R. J., Crawford D. E., Friedrich M., Krege S., Rintala E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. . 2009;56:247-56||1460
Harnblasenkarzinom|"2"|2020|Schwaibold, H.|Evidenzbasierte Empfehlung|A|False|Standard|Friedrich M. G., Pichlmeier U., Schwaibold H., Conrad S., Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. . 2007;52:1123-29||1460
Harnblasenkarzinom|"2"|2020|Schwaibold, H.|Hintergrund|||Standard|Friedrich M. G., Pichlmeier U., Schwaibold H., Conrad S., Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. . 2007;52:1123-29||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Standard|Fritsche H. M., Burger M., Dietmaier W., Denzinger S., Bach E., Otto W., et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. . 2010;134:597-603||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Erstautor|Burger M., Oosterlinck W., Konety B., Chang S., Gudjonsson S., Pruthi R., et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. . 2013;63:36-44||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Hintergrund|||Erstautor|Bolenz C., West A. M., Ortiz N., Kabbani W., Lotan Y. Urinary cytology for the detection of urothelial carcinoma of the bladder-a flawed adjunct to cystoscopy?. . 2013;31:366-71||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Evidenzbasierte Empfehlung|A|False|Standard|Fritsche H. M., Burger M., Svatek R. S., Jeldres C., Karakiewicz P. I., Novara G., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. . 2010;57:300-9||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Standard|Fritsche H. M., Burger M., Svatek R. S., Jeldres C., Karakiewicz P. I., Novara G., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. . 2010;57:300-9||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Hintergrund|||Standard|May M., Bastian P. J., Brookman-May S., Burger M., Bolenz C., Trojan L., et al. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. . 2011;45:251-7||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Standard|May M., Bastian P. J., Brookman-May S., Burger M., Bolenz C., Trojan L., et al. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. . 2011;45:251-7||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Standard|Bertz S., Otto W., Denzinger S., Wieland W. F., Burger M., Stohr R., et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. . 2014;65:218-26||1460
Harnblasenkarzinom|"2"|2020|Ott, O.|Hintergrund|||Standard|Krause F. S., Walter B., Ott O. J., Haberle L., Weiss C., Rodel C., et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. . 2011;31:985-90||1460
Harnblasenkarzinom|"2"|2020|Weiss, Christian|Hintergrund|||Standard|Krause F. S., Walter B., Ott O. J., Haberle L., Weiss C., Rodel C., et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. . 2011;31:985-90||1460
Harnblasenkarzinom|"2"|2020|Weiss, Christian|Hintergrund|||Standard|Rodel C., Weiss C., Sauer R. Combined systemic therapy and radiotherapy for bladder cancer. . 2007;183 Spec No 2:29-31||1460
Harnblasenkarzinom|"2"|2020|Ott, O.|Hintergrund|||Standard|Weiss C., Wolze C., Engehausen D. G., Ott O. J., Krause F. S., Schrott K. M., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?. . 2006;24:2318-24||1460
Harnblasenkarzinom|"2"|2020|Weiss, Christian|Hintergrund|||Erstautor|Weiss C., Wolze C., Engehausen D. G., Ott O. J., Krause F. S., Schrott K. M., et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?. . 2006;24:2318-24||1460
Harnblasenkarzinom|"2"|2020|Burger, Maximilian|Hintergrund|||Standard|Denzinger S., Burger M., Fritsche H. M., Ganzer R., Blana A., Wieland W. F., et al. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?]. . 2008;39:58-61; discussion 62-3||1460
Harnblasenkarzinom|"2"|2020|Hakenberg, Oliver|Hintergrund|||Standard|Lawrentschuk N., Colombo R., Hakenberg O. W., Lerner S. P., Mansson W., Sagalowsky A., et al. Prevention and management of complications following radical cystectomy for bladder cancer. . 2010;57:983-1001||1460
Harnblasenkarzinom|"2"|2020|Volkmer, Björn|Hintergrund|||Letztautor|Hautmann R. E., de Petriconi R. C., Pfeiffer C., Volkmer B. G. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. None. 2012;61:1039-47|https://www.ncbi.nlm.nih.gov/pubmed/22381169|1460
Harnblasenkarzinom|"2"|2020|Gakis, G.|Evidenzbasierte Empfehlung|A|False|Erstautor|Gakis G., Todenhofer T., Renninger M., Schilling D., Sievert K. D., Schwentner C., et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. . 2011;108:1800-5||1460
Harnblasenkarzinom|"2"|2020|Gakis, G.|Hintergrund|||Erstautor|Gakis G., Todenhofer T., Renninger M., Schilling D., Sievert K. D., Schwentner C., et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. . 2011;108:1800-5||1460
Harnblasenkarzinom|"2"|2020|Schwentner, C.|Evidenzbasierte Empfehlung|A|False|Standard|Gakis G., Todenhofer T., Renninger M., Schilling D., Sievert K. D., Schwentner C., et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. . 2011;108:1800-5||1460
Harnblasenkarzinom|"2"|2020|Schwentner, C.|Hintergrund|||Standard|Gakis G., Todenhofer T., Renninger M., Schilling D., Sievert K. D., Schwentner C., et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. . 2011;108:1800-5||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Evidenzbasierte Empfehlung|A|False|Erstautor|Bolenz C., Herrmann E., Bastian P. J., Michel M. S., Wulfing C., Tiemann A., et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. . 2010;106:493-9||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Hintergrund|||Erstautor|Bolenz C., Herrmann E., Bastian P. J., Michel M. S., Wulfing C., Tiemann A., et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. . 2010;106:493-9||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Evidenzbasiertes Statement||False|Standard|May M., Herrmann E., Bolenz C., Tiemann A., Brookman-May S., Fritsche H. M., et al. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. . 2011;59:712-8||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Hintergrund|||Standard|May M., Herrmann E., Bolenz C., Tiemann A., Brookman-May S., Fritsche H. M., et al. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. . 2011;59:712-8||1460
Harnblasenkarzinom|"2"|2020|Gakis, G.|Hintergrund|||Erstautor|Gakis G., Schwentner C., Todenhofer T., Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. . 2012;110:233-7||1460
Harnblasenkarzinom|"2"|2020|Schwentner, C.|Hintergrund|||Standard|Gakis G., Schwentner C., Todenhofer T., Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. . 2012;110:233-7||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Letztautor|Gakis G., Schwentner C., Todenhofer T., Stenzl A. Current status of molecular markers for prognostication and outcome in invasive bladder cancer. . 2012;110:233-7||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Erstautor|Stenzl A., Colleselli K., Bartsch G. Update of urethra-sparing approaches in cystectomy in women. . 1997;15:134-8||1460
Harnblasenkarzinom|"2"|2020|Albers, Peter|Hintergrund|||Standard|Niegisch G., Albers P., Rabenalt R. Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). . 2014;32:966-74||1460
Harnblasenkarzinom|"2"|2020|Niegisch, G.|Hintergrund|||Erstautor|Niegisch G., Albers P., Rabenalt R. Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC). . 2014;32:966-74||1460
Harnblasenkarzinom|"2"|2020|Golka, Klaus|Hintergrund|||Erstautor|Golka K., Heitmann P., Gieseler F., Hodzic J., Masche N., Bolt H. M., et al. Elevated bladder cancer risk due to colorants--a statewide case-control study in North Rhine-Westphalia, Germany. . 2008;71:851-5||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Erstautor|Stenzl A., Jarolim L., Coloby P., Golia S., Bartsch G., Babjuk M., et al. Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. . 2001;92:1864-71||1460
Harnblasenkarzinom|"2"|2020|Ohlmann, Carsten-Henning|Hintergrund|||Standard|Saar M., Ohlmann C. H., Siemer S., Lehmann J., Becker F., Stockle M., et al. Fast-track rehabilitation after robot-assisted laparoscopic cystectomy accelerates postoperative recovery. . 2013;112:E99-106||1460
Harnblasenkarzinom|"2"|2020|Retz, Margitta|Evidenzbasierte Empfehlung||False|Standard|Sharma P., Retz M., Siefker-Radtke A., Baron A., Necchi A., Bedke J., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. None. 2017;18:312-322|http://www.ncbi.nlm.nih.gov/pubmed/28131785|1460
Harnblasenkarzinom|"2"|2020|Retz, Margitta|Hintergrund|||Standard|Sharma P., Retz M., Siefker-Radtke A., Baron A., Necchi A., Bedke J., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. None. 2017;18:312-322|http://www.ncbi.nlm.nih.gov/pubmed/28131785|1460
Harnblasenkarzinom|"2"|2020|Gschwend, Jürgen|Evidenzbasiertes Statement||False|Standard|Karl A., Carroll P. R., Gschwend J. E., Knuchel R., Montorsi F., Stief C. G., et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. . 2009;55:826-35||1460
Harnblasenkarzinom|"2"|2020|Gschwend, Jürgen|Hintergrund|||Standard|Karl A., Carroll P. R., Gschwend J. E., Knuchel R., Montorsi F., Stief C. G., et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. . 2009;55:826-35||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Evidenzbasiertes Statement|0|False|Standard|May M., Herrmann E., Bolenz C., Brookman-May S., Tiemann A., Moritz R., et al. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. . 2011;18:2018-25||1460
Harnblasenkarzinom|"2"|2020|Bolenz, Christian|Hintergrund|||Standard|May M., Herrmann E., Bolenz C., Brookman-May S., Tiemann A., Moritz R., et al. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. . 2011;18:2018-25||1460
Harnblasenkarzinom|"2"|2020|Golka, Klaus|Hintergrund|||Erstautor|Golka K., Bandel T., Schlaefke S., Reich S. E., Reckwitz T., Urfer W., et al. Urothelial cancer of the bladder in an area of former coal, iron, and steel industries in Germany: a case-control study. . 1998;4:79-84||1460
Harnblasenkarzinom|"2"|2020|Horn, Thomas|Hintergrund|||Standard|Poulsen A. L., Horn T., Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. . 1998;160:2015-9; discussion 2020||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Evidenzbasiertes Statement||False|Erstautor|Stenzl A., Draxl H., Posch B., Colleselli K., Falk M., Bartsch G. The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract?. . 1995;153:950-5||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Erstautor|Stenzl A., Draxl H., Posch B., Colleselli K., Falk M., Bartsch G. The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract?. . 1995;153:950-5||1460
Harnblasenkarzinom|"2"|2020|Gakis, G.|Evidenzbasiertes Statement||False|Erstautor|Gakis G., Ali-El-Dein B., Babjuk M., Hrbacek J., Macek P., Burkhard F. C., et al. Urethral recurrence in women with orthotopic bladder substitutes: A multi-institutional study. . 2015;33:204.e17-23||1460
Harnblasenkarzinom|"2"|2020|Gakis, G.|Hintergrund|||Erstautor|Gakis G., Ali-El-Dein B., Babjuk M., Hrbacek J., Macek P., Burkhard F. C., et al. Urethral recurrence in women with orthotopic bladder substitutes: A multi-institutional study. . 2015;33:204.e17-23||1460
Harnblasenkarzinom|"2"|2020|Golka, Klaus|Hintergrund|||Erstautor|Golka K., Kopps S., Prager H. M., Mende Sv, Thiel R., Jungmann O., et al. Bladder cancer in crack testers applying azo dye-based sprays to metal bodies. . 2012;75:566-71||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Erstautor|Stenzl A., Bartsch G., Rogatsch H. The remnant urothelium after reconstructive bladder surgery. . 2002;41:124-31||1460
Harnblasenkarzinom|"2"|2020|Weiss, Christian|Hintergrund|||Standard|Rodel C., Weiss C., Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. . 2006;24:5536-44||1460
Harnblasenkarzinom|"2"|2020|Ott, O.|Hintergrund|||Standard|Weiss C., Wittlinger M., Engehausen D. G., Krause F. S., Ott O. J., Dunst J., et al. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. . 2008;70:1502-6||1460
Harnblasenkarzinom|"2"|2020|Weiss, Christian|Hintergrund|||Erstautor|Weiss C., Wittlinger M., Engehausen D. G., Krause F. S., Ott O. J., Dunst J., et al. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. . 2008;70:1502-6||1460
Harnblasenkarzinom|"2"|2020|Weiss, Christian|Hintergrund|||Standard|Wittlinger M., Rodel C. M., Weiss C., Krause S. F., Kuhn R., Fietkau R., et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. . 2009;93:358-63||1460
Harnblasenkarzinom|"2"|2020|Niegisch, G.|Hintergrund|||Standard|Sonpavde G., Pond G. R., Choueiri T. K., Mullane S., Niegisch G., Albers P., et al. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. None. 2016;69:634-641|http://www.ncbi.nlm.nih.gov/pubmed/26264159|1460
Harnblasenkarzinom|"2"|2020|Gschwend, Jürgen|Hintergrund|||Standard|Hautmann R. E., Volkmer B. G., Schumacher M. C., Gschwend J. E., Studer U. E. Long-term results of standard procedures in urology: the ileal neobladder. None. 2006;24:305-14|https://www.ncbi.nlm.nih.gov/pubmed/16830152|1460
Harnblasenkarzinom|"2"|2020|Volkmer, Björn|Hintergrund|||Standard|Hautmann R. E., Volkmer B. G., Schumacher M. C., Gschwend J. E., Studer U. E. Long-term results of standard procedures in urology: the ileal neobladder. None. 2006;24:305-14|https://www.ncbi.nlm.nih.gov/pubmed/16830152|1460
Harnblasenkarzinom|"2"|2020|Kuczyk, Markus|Hintergrund|||Standard|Stenzl A., Cowan N. C., De Santis M., Kuczyk M. A., Merseburger A. S., Ribal M. J., et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. . 2011;59:1009-18||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Erstautor|Stenzl A., Cowan N. C., De Santis M., Kuczyk M. A., Merseburger A. S., Ribal M. J., et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. . 2011;59:1009-18||1460
Harnblasenkarzinom|"2"|2020|Gakis, G.|Hintergrund|||Erstautor|Gakis G., Abdelhafez M. F., Stenzl A. The "I-Pouch": Results of a new ileal neobladder technique. . 2015;49:400-6||1460
Harnblasenkarzinom|"2"|2020|Stenzl, Arnulf|Hintergrund|||Letztautor|Gakis G., Abdelhafez M. F., Stenzl A. The "I-Pouch": Results of a new ileal neobladder technique. . 2015;49:400-6||1460
Harnblasenkarzinom|"2"|2020|Gruber, Gabriele|Hintergrund|||Erstautor|Droste W. & Gruber G. Sektorenübergreifender Leitfaden Stomatherapie für Krankenhäuser, die ambulante Homecare-Versorgung und Rehabilitationskliniken. . 2010;:||1460
Harnblasenkarzinom|"2"|2020|Albers, Peter|Hintergrund|||Standard|Sternberg C. N., Skoneczna I., Kerst J. M., Albers P., Fossa S. D., Agerbaek M., et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. . 2015;16:76-86||1460
Harnblasenkarzinom|"2"|2020|Krege, Susanne|Hintergrund|||Erstautor|Otto T.; Bürgermann C.; Krege S.; Rübben H. Adjuvant chemotherapy in locally advanced bladder cancer - a phase III study. . 2001;:||1460
Harnblasenkarzinom|"2"|2020|Rübben, Herbert|Hintergrund|||Erstautor|Otto T.; Bürgermann C.; Krege S.; Rübben H. Adjuvant chemotherapy in locally advanced bladder cancer - a phase III study. . 2001;:||1460
Harnblasenkarzinom|"2"|2020|Hartmann, Arndt|Hintergrund|||Standard|Nordentoft I., Dyrskjot L., Bodker J. S., Wild P. J., Hartmann A., Bertz S., et al. Increased expression of transcription factor TFAP2alpha correlates with chemosensitivity in advanced bladder cancer. . 2011;11:135||1460
Harnblasenkarzinom|"2"|2020|Goebell, Peter Jürgen|Hintergrund|||Standard|Chatterjee S. J., Datar R., Youssefzadeh D., George B., Goebell P. J., Stein J. P., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. . 2004;22:1007-13||1460
Harnblasenkarzinom|"2"|2020|Hartmann, Arndt|Hintergrund|||Erstautor|Hartmann A., Zanardo L., Bocker-Edmonston T., Blaszyk H., Dietmaier W., Stoehr R., et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. None. 2002;62:6796-802|https://www.ncbi.nlm.nih.gov/pubmed/12460887|1460
Harnblasenkarzinom|"2"|2020|Albers, Peter|Hintergrund|||Letztautor|Niegisch G., Fimmers R., Siener R., Park S. I., Albers P. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). . 2011;60:1087-96||1460
Harnblasenkarzinom|"2"|2020|Niegisch, G.|Hintergrund|||Erstautor|Niegisch G., Fimmers R., Siener R., Park S. I., Albers P. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). . 2011;60:1087-96||1460
Harnblasenkarzinom|"2"|2020|Albers, Peter|Evidenzbasierte Empfehlung||False|Erstautor|Albers P., Park S. I., Niegisch G., Fechner G., Steiner U., Lehmann J., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. . 2011;22:288-94||1460
Harnblasenkarzinom|"2"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P., Park S. I., Niegisch G., Fechner G., Steiner U., Lehmann J., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. . 2011;22:288-94||1460
Harnblasenkarzinom|"2"|2020|Niegisch, G.|Evidenzbasierte Empfehlung||False|Standard|Albers P., Park S. I., Niegisch G., Fechner G., Steiner U., Lehmann J., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. . 2011;22:288-94||1460
Harnblasenkarzinom|"2"|2020|Niegisch, G.|Hintergrund|||Standard|Albers P., Park S. I., Niegisch G., Fechner G., Steiner U., Lehmann J., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. . 2011;22:288-94||1460
Hautkrebsprävention|"2.1"|2021|Baumann, Eva|Hintergrund|||Erstautor|Klimmt C. Maurer M. & Baumann E. Prozessevaluation der Kampagnenfortsetzung 2011-2012 „Runter vom Gas!“ (ID  - 503. None. 2014;None:None||1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Standard|Mitchell D. L., Volkmer B., Breitbart E. W., Byrom M., Lowery M. G., Greinert R. Identification of a non-dividing subpopulation of mouse and human epidermal cells exhibiting high levels of persistent ultraviolet photodamage. None. 2001;117:590-5|https://www.ncbi.nlm.nih.gov/pubmed/11564164|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Letztautor|Mitchell D. L., Volkmer B., Breitbart E. W., Byrom M., Lowery M. G., Greinert R. Identification of a non-dividing subpopulation of mouse and human epidermal cells exhibiting high levels of persistent ultraviolet photodamage. None. 2001;117:590-5|https://www.ncbi.nlm.nih.gov/pubmed/11564164|1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Hintergrund|||Standard|Mitchell D. L., Volkmer B., Breitbart E. W., Byrom M., Lowery M. G., Greinert R. Identification of a non-dividing subpopulation of mouse and human epidermal cells exhibiting high levels of persistent ultraviolet photodamage. None. 2001;117:590-5|https://www.ncbi.nlm.nih.gov/pubmed/11564164|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Standard|Greinert R., Volkmer B., Henning S., Breitbart E. W., Greulich K. O., Cardoso M. C., et al. UVA-induced DNA double-strand breaks result from the repair of clustered oxidative DNA damages. None. 2012;40:10263-73|https://www.ncbi.nlm.nih.gov/pubmed/22941639|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Erstautor|Greinert R., Volkmer B., Henning S., Breitbart E. W., Greulich K. O., Cardoso M. C., et al. UVA-induced DNA double-strand breaks result from the repair of clustered oxidative DNA damages. None. 2012;40:10263-73|https://www.ncbi.nlm.nih.gov/pubmed/22941639|1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Hintergrund|||Standard|Greinert R., Volkmer B., Henning S., Breitbart E. W., Greulich K. O., Cardoso M. C., et al. UVA-induced DNA double-strand breaks result from the repair of clustered oxidative DNA damages. None. 2012;40:10263-73|https://www.ncbi.nlm.nih.gov/pubmed/22941639|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Erstautor|Greinert R. Breitbart E.W. Volkmer B. UV-radiation biology as part of cancer research. None. 2004;None:None||1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Erstautor|Greinert R. Breitbart E.W. Volkmer B. UV-radiation biology as part of cancer research. None. 2004;None:None||1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Hintergrund|||Erstautor|Greinert R. Breitbart E.W. Volkmer B. UV-radiation biology as part of cancer research. None. 2004;None:None||1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Hintergrund|||Erstautor|Katalinic Alexander, Kunze Uta, Sch&#228;fer Torsten. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). . 2003;149:1200-1206||1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Eisemann N., Jansen L., Holleczek B., Waldmann A., Luttmann S., Emrich K., et al. Up-to-date results on survival of patients with melanoma in Germany. None. 2012;167:606-12|https://www.ncbi.nlm.nih.gov/pubmed/22564081|1629
Hautkrebsprävention|"2.1"|2021|Kraywinkel, Klaus|Hintergrund|||Standard|Brunssen A., Jansen L., Eisemann N., Waldmann A., Weberpals J., Kraywinkel K., et al. Long-term relative survival from melanoma in Germany 1997-2013. None. 2020;30:386-395|https://www.ncbi.nlm.nih.gov/pubmed/30020195|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Brunssen A., Jansen L., Eisemann N., Waldmann A., Weberpals J., Kraywinkel K., et al. Long-term relative survival from melanoma in Germany 1997-2013. None. 2020;30:386-395|https://www.ncbi.nlm.nih.gov/pubmed/30020195|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Standard|Erdmann F., Lortet-Tieulent J., Schuz J., Zeeb H., Greinert R., Breitbart E. W., et al. International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk?. None. 2013;132:385-400|https://www.ncbi.nlm.nih.gov/pubmed/22532371|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Standard|Erdmann F., Lortet-Tieulent J., Schuz J., Zeeb H., Greinert R., Breitbart E. W., et al. International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk?. None. 2013;132:385-400|https://www.ncbi.nlm.nih.gov/pubmed/22532371|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Evidenzbasiertes Statement||False|Standard|Katalinic A., Waldmann A., Weinstock M. A., Geller A. C., Eisemann N., Greinert R., et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. None. 2012;118:5395-402|https://www.ncbi.nlm.nih.gov/pubmed/22517033|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Standard|Katalinic A., Waldmann A., Weinstock M. A., Geller A. C., Eisemann N., Greinert R., et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. None. 2012;118:5395-402|https://www.ncbi.nlm.nih.gov/pubmed/22517033|1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Evidenzbasiertes Statement||False|Erstautor|Katalinic A., Waldmann A., Weinstock M. A., Geller A. C., Eisemann N., Greinert R., et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. None. 2012;118:5395-402|https://www.ncbi.nlm.nih.gov/pubmed/22517033|1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Hintergrund|||Erstautor|Katalinic A., Waldmann A., Weinstock M. A., Geller A. C., Eisemann N., Greinert R., et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. None. 2012;118:5395-402|https://www.ncbi.nlm.nih.gov/pubmed/22517033|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Evidenzbasiertes Statement||False|Standard|Katalinic A., Waldmann A., Weinstock M. A., Geller A. C., Eisemann N., Greinert R., et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. None. 2012;118:5395-402|https://www.ncbi.nlm.nih.gov/pubmed/22517033|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Katalinic A., Waldmann A., Weinstock M. A., Geller A. C., Eisemann N., Greinert R., et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. None. 2012;118:5395-402|https://www.ncbi.nlm.nih.gov/pubmed/22517033|1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Evidenzbasiertes Statement||False|Erstautor|Katalinic A., Eisemann N., Waldmann A. Hautkrebsscreening in Deutschland. Erfassung der Melanominzidenz und -sterblichkeit von 2008 bis 2013. Skin Cancer Screening in Germany - Documenting Melanoma Incidence and Mortality From 2008 to 2013. None. 2015;112:None|http://www.zbmed.de/ccmedimages/2015/ZBMED-20159195155-3.pdf|1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Hintergrund|||Erstautor|Katalinic A., Eisemann N., Waldmann A. Hautkrebsscreening in Deutschland. Erfassung der Melanominzidenz und -sterblichkeit von 2008 bis 2013. Skin Cancer Screening in Germany - Documenting Melanoma Incidence and Mortality From 2008 to 2013. None. 2015;112:None|http://www.zbmed.de/ccmedimages/2015/ZBMED-20159195155-3.pdf|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Evidenzbasiertes Statement||False|Letztautor|Katalinic A., Eisemann N., Waldmann A. Hautkrebsscreening in Deutschland. Erfassung der Melanominzidenz und -sterblichkeit von 2008 bis 2013. Skin Cancer Screening in Germany - Documenting Melanoma Incidence and Mortality From 2008 to 2013. None. 2015;112:None|http://www.zbmed.de/ccmedimages/2015/ZBMED-20159195155-3.pdf|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Letztautor|Katalinic A., Eisemann N., Waldmann A. Hautkrebsscreening in Deutschland. Erfassung der Melanominzidenz und -sterblichkeit von 2008 bis 2013. Skin Cancer Screening in Germany - Documenting Melanoma Incidence and Mortality From 2008 to 2013. None. 2015;112:None|http://www.zbmed.de/ccmedimages/2015/ZBMED-20159195155-3.pdf|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Evidenzbasiertes Statement||False|Erstautor|Breitbart E. W., Waldmann A., Nolte S., Capellaro M., Greinert R., Volkmer B., et al. Systematic skin cancer screening in Northern Germany. None. 2012;66:201-11|https://www.ncbi.nlm.nih.gov/pubmed/22074699|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Erstautor|Breitbart E. W., Waldmann A., Nolte S., Capellaro M., Greinert R., Volkmer B., et al. Systematic skin cancer screening in Northern Germany. None. 2012;66:201-11|https://www.ncbi.nlm.nih.gov/pubmed/22074699|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Evidenzbasiertes Statement||False|Standard|Breitbart E. W., Waldmann A., Nolte S., Capellaro M., Greinert R., Volkmer B., et al. Systematic skin cancer screening in Northern Germany. None. 2012;66:201-11|https://www.ncbi.nlm.nih.gov/pubmed/22074699|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Standard|Breitbart E. W., Waldmann A., Nolte S., Capellaro M., Greinert R., Volkmer B., et al. Systematic skin cancer screening in Northern Germany. None. 2012;66:201-11|https://www.ncbi.nlm.nih.gov/pubmed/22074699|1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Evidenzbasiertes Statement||False|Standard|Breitbart E. W., Waldmann A., Nolte S., Capellaro M., Greinert R., Volkmer B., et al. Systematic skin cancer screening in Northern Germany. None. 2012;66:201-11|https://www.ncbi.nlm.nih.gov/pubmed/22074699|1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Hintergrund|||Standard|Breitbart E. W., Waldmann A., Nolte S., Capellaro M., Greinert R., Volkmer B., et al. Systematic skin cancer screening in Northern Germany. None. 2012;66:201-11|https://www.ncbi.nlm.nih.gov/pubmed/22074699|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Evidenzbasiertes Statement||False|Standard|Breitbart E. W., Waldmann A., Nolte S., Capellaro M., Greinert R., Volkmer B., et al. Systematic skin cancer screening in Northern Germany. None. 2012;66:201-11|https://www.ncbi.nlm.nih.gov/pubmed/22074699|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Breitbart E. W., Waldmann A., Nolte S., Capellaro M., Greinert R., Volkmer B., et al. Systematic skin cancer screening in Northern Germany. None. 2012;66:201-11|https://www.ncbi.nlm.nih.gov/pubmed/22074699|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Evidenzbasiertes Statement||False|Standard|Waldmann A., Nolte S., Weinstock M. A., Breitbart E. W., Eisemann N., Geller A. C., et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. None. 2012;106:970-4|https://www.ncbi.nlm.nih.gov/pubmed/22294187|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Standard|Waldmann A., Nolte S., Weinstock M. A., Breitbart E. W., Eisemann N., Geller A. C., et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. None. 2012;106:970-4|https://www.ncbi.nlm.nih.gov/pubmed/22294187|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Evidenzbasiertes Statement||False|Erstautor|Waldmann A., Nolte S., Weinstock M. A., Breitbart E. W., Eisemann N., Geller A. C., et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. None. 2012;106:970-4|https://www.ncbi.nlm.nih.gov/pubmed/22294187|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Erstautor|Waldmann A., Nolte S., Weinstock M. A., Breitbart E. W., Eisemann N., Geller A. C., et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. None. 2012;106:970-4|https://www.ncbi.nlm.nih.gov/pubmed/22294187|1629
Hautkrebsprävention|"2.1"|2021|Hübner, Joachim|Hintergrund|||Erstautor|Hübner J., Hübner Franziska, Terheyden Peter, Katalinic A. Trendwende bei der Hautkrebsmortalität. Eine Analyse der Entwicklung in Deutschland 1998 bis 2017. None. 2019;70:989–992||1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Hintergrund|||Letztautor|Hübner J., Hübner Franziska, Terheyden Peter, Katalinic A. Trendwende bei der Hautkrebsmortalität. Eine Analyse der Entwicklung in Deutschland 1998 bis 2017. None. 2019;70:989–992||1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Hubner J., Waldmann A., Eisemann N., Noftz M., Geller A. C., Weinstock M. A., et al. Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening. None. 2018;27:563-569|https://www.ncbi.nlm.nih.gov/pubmed/28692584|1629
Hautkrebsprävention|"2.1"|2021|Elsner, Peter|Hintergrund|||Standard|Schmitt J., Haufe E., Trautmann F., Schulze H. J., Elsner P., Drexler H., et al. Is ultraviolet exposure acquired at work the most important risk factor for cutaneous squamous cell carcinoma? Results of the population-based case-control study FB-181. None. 2018;178:462-472|https://www.ncbi.nlm.nih.gov/pubmed/28845516|1629
Hautkrebsprävention|"2.1"|2021|Elsner, Peter|Hintergrund|||Standard|Schmitt J., Haufe E., Trautmann F., Schulze H. J., Elsner P., Drexler H., et al. Occupational UV-Exposure is a Major Risk Factor for Basal Cell Carcinoma: Results of the Population-Based Case-Control Study FB-181. None. 2018;60:36-43|https://www.ncbi.nlm.nih.gov/pubmed/29111985|1629
Hautkrebsprävention|"2.1"|2021|Stang, Andreas|Hintergrund|||Erstautor|Stang A., Pukkala E., Sankila R., Soderman B., Hakulinen T. Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases. None. 2006;119:380-4|https://www.ncbi.nlm.nih.gov/pubmed/16477634|1629
Hautkrebsprävention|"2.1"|2021|Stang, Andreas|Hintergrund|||Erstautor|Stang A., Valiukeviciene S., Aleknaviciene B., Kurtinaitis J. Time trends of incidence, mortality, and relative survival of invasive skin melanoma in Lithuania. None. 2006;42:660-7|https://www.ncbi.nlm.nih.gov/pubmed/16510281|1629
Hautkrebsprävention|"2.1"|2021|Bauer, Andrea|Hintergrund|||Standard|Lang B., Balermpas P., Bauer A., Blum A. Brölsch G., Dirschka T., Follmann M., et al. S2k-Leitlinie Basalzellkarzinom der Hau. None. 2018;None:None|https://www.awmf.org/uploads/tx_szleitlinien/032-021l_S2k_Basalzellkarzinom-der-Haut_2018-09_01.pdf|1629
Hautkrebsprävention|"2.1"|2021|Elsner, Peter|Hintergrund|||Letztautor|Antonov D., Hollunder M., Schliemann S., Elsner P. Ultraviolet Exposure and Protection Behavior in the General Population: A Structured Interview Survey. None. 2016;232:11-6|https://www.ncbi.nlm.nih.gov/pubmed/26619287|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Standard|Diehl K., Göring T., Greinert R., Breitbart E.W., Schneider S. Trends in Tanning Bed Use, Motivation, and Risk Awareness: Findings from four waves of the National Cancer Aid Monitoring (NCAM). None. 2019;16:3913||1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Standard|Diehl K., Göring T., Greinert R., Breitbart E.W., Schneider S. Trends in Tanning Bed Use, Motivation, and Risk Awareness: Findings from four waves of the National Cancer Aid Monitoring (NCAM). None. 2019;16:3913||1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Standard|Schneider S., Gorig T., Schilling L., Breitbart E. W., Greinert R., Diehl K. German "National Cancer Aid Monitoring" 2015-2019 - study protocol and initial results. None. 2017;15:895-903|https://www.ncbi.nlm.nih.gov/pubmed/28771939|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Standard|Schneider S., Gorig T., Schilling L., Breitbart E. W., Greinert R., Diehl K. German "National Cancer Aid Monitoring" 2015-2019 - study protocol and initial results. None. 2017;15:895-903|https://www.ncbi.nlm.nih.gov/pubmed/28771939|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Standard|Borner F., Greinert R., Schutz H., Wiedemann P. [UV risk perception by the general public: results of a representative questionnaire in Germany]. None. 2010;72:e89-97|https://www.ncbi.nlm.nih.gov/pubmed/20049688|1629
Hautkrebsprävention|"2.1"|2021|Reifegerste, Doreen|Hintergrund|||Erstautor|Reifegerste Doreen, Rössler Patrick. Soziale Appelle in der Gesundheitskommunikation. Motivkategorien als Grundlage für die theoretische Integration und die Systematisierung empirischer Befunde. None. 2014;62:606-634|https://doi.org/10.5771/1615-634x-2014-4-606|1629
Hautkrebsprävention|"2.1"|2021|Baldermann, Cornelia|Hintergrund|||Standard|Allinson Sarah, Asmuss Monika, Baldermann Cornelia, Bentzen Joan, Buller David, Gerber Nathalie, et al. Validity and Use of the UV Index: Report from the UVI Working Group, Schloss Hohenkammer, Germany, 5–7 December 2011. None. 2012;103:301-306 10.1097/HP0b013e31825b581e|http://journals.lww.com/health-physics/Fulltext/2012/09000/Validity_and_Use_of_the_UV_Index___Report_from_the.9.aspx|1629
Hautkrebsprävention|"2.1"|2021|Baumann, Eva|Hintergrund|||Letztautor|Reifegerste D., Baumann E. Vielfalt und Herausforderungen der Evidenzbasierung in der strategischen Gesundheitskommunikation. None. 2018;None:73-83||1629
Hautkrebsprävention|"2.1"|2021|Reifegerste, Doreen|Hintergrund|||Erstautor|Reifegerste D., Baumann E. Vielfalt und Herausforderungen der Evidenzbasierung in der strategischen Gesundheitskommunikation. None. 2018;None:73-83||1629
Hautkrebsprävention|"2.1"|2021|Baldermann, Cornelia|Hintergrund|||Erstautor|Baldermann C., Lorenz Sebastian. UV-Strahlung in Deutschland: Einflüsse des Ozonabbaus und des Klimawandels sowie Maßnahmen zum Schutz der Bevölkerung. None. 2019;62:639-645||1629
Hautkrebsprävention|"2.1"|2021|Augustin, Jobst|Hintergrund|||Erstautor|Augustin J., Kis A., Sorbe C., Schafer I., Augustin M. Epidemiology of skin cancer in the German population: impact of socioeconomic and geographic factors. None. 2018;32:1906-1913|https://www.ncbi.nlm.nih.gov/pubmed/29633375|1629
Hautkrebsprävention|"2.1"|2021|Augustin, Jobst|Hintergrund|||Erstautor|Augustin J., Sauerborn R., Burkart K., Endlicher W., Jochner S., Koppe C., et al. Klimawandel in Deutschland. None. 2017;None:None||1629
Hautkrebsprävention|"2.1"|2021|Matzarakis, Andreas|Hintergrund|||Letztautor|Muthers S, aschewski G, Matzarakis A. The Summers 2003 and 2015 in South-West Germany: HeatWaves and Heat-Related Mortality in the Context of Climate Change. None. 2017;8:224||1629
Hautkrebsprävention|"2.1"|2021|Laschewski, Gudrun|Hintergrund|||Standard|Staiger H., Laschewski G., Gratz A. The perceived temperature - a versatile index for the assessment of the human thermal environment. Part A: scientific basics. None. 2012;56:165-76|https://www.ncbi.nlm.nih.gov/pubmed/21336880|1629
Hautkrebsprävention|"2.1"|2021|Matzarakis, Andreas|Hintergrund|||Letztautor|Streiling S., Matzarakis A. Streiling, S., A. Matzarakis, (2003). Influence of singular trees and small clusters of trees on the bioclimate of a city – a case study. Journal of Arboriculture 29, 309-316. None. 2003;20:309-316||1629
Hautkrebsprävention|"2.1"|2021|Wittlich, Marc|Hintergrund|||Erstautor|Wittlich M., Westerhausen S., Kleinespel P., Rifer G., Stoppelmann W. An approximation of occupational lifetime UVR exposure: algorithm for retrospective assessment and current measurements. None. 2016;30 Suppl 3:27-33|https://www.ncbi.nlm.nih.gov/pubmed/26995020|1629
Hautkrebsprävention|"2.1"|2021|John, Swen Malte|Hintergrund|||Standard|Wittlich M., John S. M., Tiplica G. S., Salavastru C. M., Butacu A. I., Modenese A., et al. Personal solar ultraviolet radiation dosimetry in an occupational setting across Europe. None. 2020;n/a:None|https://www.ncbi.nlm.nih.gov/pubmed/32080895|1629
Hautkrebsprävention|"2.1"|2021|Wittlich, Marc|Hintergrund|||Erstautor|Wittlich M., John S. M., Tiplica G. S., Salavastru C. M., Butacu A. I., Modenese A., et al. Personal solar ultraviolet radiation dosimetry in an occupational setting across Europe. None. 2020;n/a:None|https://www.ncbi.nlm.nih.gov/pubmed/32080895|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Evidenzbasiertes Statement||False|Standard|Eisemann N., Waldmann A., Geller A. C., Weinstock M. A., Volkmer B., Greinert R., et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. None. 2014;134:43-50|https://www.ncbi.nlm.nih.gov/pubmed/23877569|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Standard|Eisemann N., Waldmann A., Geller A. C., Weinstock M. A., Volkmer B., Greinert R., et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. None. 2014;134:43-50|https://www.ncbi.nlm.nih.gov/pubmed/23877569|1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Evidenzbasiertes Statement||False|Standard|Eisemann N., Waldmann A., Geller A. C., Weinstock M. A., Volkmer B., Greinert R., et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. None. 2014;134:43-50|https://www.ncbi.nlm.nih.gov/pubmed/23877569|1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Hintergrund|||Standard|Eisemann N., Waldmann A., Geller A. C., Weinstock M. A., Volkmer B., Greinert R., et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. None. 2014;134:43-50|https://www.ncbi.nlm.nih.gov/pubmed/23877569|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Evidenzbasiertes Statement||False|Standard|Eisemann N., Waldmann A., Geller A. C., Weinstock M. A., Volkmer B., Greinert R., et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. None. 2014;134:43-50|https://www.ncbi.nlm.nih.gov/pubmed/23877569|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Eisemann N., Waldmann A., Geller A. C., Weinstock M. A., Volkmer B., Greinert R., et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. None. 2014;134:43-50|https://www.ncbi.nlm.nih.gov/pubmed/23877569|1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Evidenzbasiertes Statement||False|Letztautor|Eisemann N., Waldmann A., Katalinic A. [Incidence of melanoma and changes in stage-specific incidence after implementation of skin cancer screening in Schleswig-Holstein]. None. 2014;57:77-83|https://www.ncbi.nlm.nih.gov/pubmed/24357176|1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Hintergrund|||Letztautor|Eisemann N., Waldmann A., Katalinic A. [Incidence of melanoma and changes in stage-specific incidence after implementation of skin cancer screening in Schleswig-Holstein]. None. 2014;57:77-83|https://www.ncbi.nlm.nih.gov/pubmed/24357176|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Evidenzbasiertes Statement||False|Standard|Eisemann N., Waldmann A., Katalinic A. [Incidence of melanoma and changes in stage-specific incidence after implementation of skin cancer screening in Schleswig-Holstein]. None. 2014;57:77-83|https://www.ncbi.nlm.nih.gov/pubmed/24357176|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Eisemann N., Waldmann A., Katalinic A. [Incidence of melanoma and changes in stage-specific incidence after implementation of skin cancer screening in Schleswig-Holstein]. None. 2014;57:77-83|https://www.ncbi.nlm.nih.gov/pubmed/24357176|1629
Hautkrebsprävention|"2.1"|2021|Stang, Andreas|Evidenzbasiertes Statement||False|Erstautor|Stang A., Jöckel K. H., Heidinger O. Skin cancer rates in North Rhine-Westphalia, Germany before and after the introduction of the nationwide skin cancer screening program (2000–2015). None. 2018;33:303-312||1629
Hautkrebsprävention|"2.1"|2021|Stang, Andreas|Hintergrund|||Erstautor|Stang A., Jöckel K. H., Heidinger O. Skin cancer rates in North Rhine-Westphalia, Germany before and after the introduction of the nationwide skin cancer screening program (2000–2015). None. 2018;33:303-312||1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Evidenzbasiertes Statement||False|Standard|Hubner J., Waldmann A., Geller A. C., Weinstock M. A., Eisemann N., Noftz M., et al. Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma. None. 2017;116:253-259|https://www.ncbi.nlm.nih.gov/pubmed/27898656|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Hubner J., Waldmann A., Geller A. C., Weinstock M. A., Eisemann N., Noftz M., et al. Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma. None. 2017;116:253-259|https://www.ncbi.nlm.nih.gov/pubmed/27898656|1629
Hautkrebsprävention|"2.1"|2021|Stang, Andreas|Evidenzbasiertes Statement||False|Erstautor|Stang A., Jockel K. H. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. None. 2016;122:432-7|https://www.ncbi.nlm.nih.gov/pubmed/26480048|1629
Hautkrebsprävention|"2.1"|2021|Stang, Andreas|Hintergrund|||Erstautor|Stang A., Jockel K. H. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. None. 2016;122:432-7|https://www.ncbi.nlm.nih.gov/pubmed/26480048|1629
Hautkrebsprävention|"2.1"|2021|Hübner, Joachim|Hintergrund|||Erstautor|Hübner J., Eisemann N., Brunßen A., Katalinic A. Hautkrebsscreening in Deutschland: Bilanz nach zehn Jahren. None. 2018;None:None||1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Hintergrund|||Letztautor|Hübner J., Eisemann N., Brunßen A., Katalinic A. Hautkrebsscreening in Deutschland: Bilanz nach zehn Jahren. None. 2018;None:None||1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Letztautor|Anders M. P., Fengler S., Volkmer B., Greinert R., Breitbart E. W. Nationwide skin cancer screening in Germany: Evaluation of the training program. None. 2017;56:1046-1051|https://www.ncbi.nlm.nih.gov/pubmed/28832980|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Standard|Anders M. P., Fengler S., Volkmer B., Greinert R., Breitbart E. W. Nationwide skin cancer screening in Germany: Evaluation of the training program. None. 2017;56:1046-1051|https://www.ncbi.nlm.nih.gov/pubmed/28832980|1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Hintergrund|||Standard|Anders M. P., Fengler S., Volkmer B., Greinert R., Breitbart E. W. Nationwide skin cancer screening in Germany: Evaluation of the training program. None. 2017;56:1046-1051|https://www.ncbi.nlm.nih.gov/pubmed/28832980|1629
Hautkrebsprävention|"2.1"|2021|Wolff, Michaela|Evidenzbasierte Empfehlung|B|False|Standard|Gerbert B., Bronstone A., Wolff M., Maurer T., Berger T., Pantilat S., et al. Improving primary care residents' proficiency in the diagnosis of skin cancer. None. 1998;13:91-7|https://www.ncbi.nlm.nih.gov/pubmed/9502368|1629
Hautkrebsprävention|"2.1"|2021|Wolff, Michaela|Hintergrund|||Standard|Gerbert B., Bronstone A., Wolff M., Maurer T., Berger T., Pantilat S., et al. Improving primary care residents' proficiency in the diagnosis of skin cancer. None. 1998;13:91-7|https://www.ncbi.nlm.nih.gov/pubmed/9502368|1629
Hautkrebsprävention|"2.1"|2021|Katalinic, Alexander|Hintergrund|||Letztautor|Hentschel Stefan, Katalinic Alexander. Das Manual der epidemiologischen Krebsregistrierung. None. 2011;1. Auflage:None||1629
Hautkrebsprävention|"2.1"|2021|Reifegerste, Doreen|Hintergrund|||Erstautor|Reifegerste D. Gesundheitskommunikation in der Prävention und Gesundheitsförderung für schwer erreichbare Zielgruppen. None. 2019;None:None||1629
Hautkrebsprävention|"2.1"|2021|Baumann, Eva|Hintergrund|||Standard|Geber S., Baumann E., Klimmt C. Tailoring in risk communication by linking risk profiles and communication preferences: The case of speeding of young car drivers. None. 2016;97:315-325|https://www.ncbi.nlm.nih.gov/pubmed/26432690|1629
Hautkrebsprävention|"2.1"|2021|Baumann, Eva|Hintergrund|||Erstautor|Baumann E. Auf der Suche nach der Zielgruppe - Das Informationsverhalten hinsichtlich Gesundheit und Krankheit als Grundlage erfolgreicher Gesundheitskommunikation. None. 2006;None:117-153||1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Hintergrund|||Standard|Anders M. P., Nolte S., Waldmann A., Capellaro M., Volkmer B., Greinert R., et al. The German SCREEN project--design and evaluation of the communication strategy. None. 2015;25:150-5|https://www.ncbi.nlm.nih.gov/pubmed/24760725|1629
Hautkrebsprävention|"2.1"|2021|Waldmann, Annika|Hintergrund|||Standard|Anders M. P., Nolte S., Waldmann A., Capellaro M., Volkmer B., Greinert R., et al. The German SCREEN project--design and evaluation of the communication strategy. None. 2015;25:150-5|https://www.ncbi.nlm.nih.gov/pubmed/24760725|1629
Hautkrebsprävention|"2.1"|2021|Berking, Carola|Hintergrund|||Standard|Gambichler T., Schmid-Wendtner M. H., Plura I., Kampilafkos P., Stucker M., Berking C., et al. A multicentre pilot study investigating high-definition optical coherence tomography in the differentiation of cutaneous melanoma and melanocytic naevi. None. 2015;29:537-41|https://www.ncbi.nlm.nih.gov/pubmed/25073788|1629
Hautkrebsprävention|"2.1"|2021|Mohr, Peter|Hintergrund|||Standard|Malvehy J., Hauschild A., Curiel-Lewandrowski C., Mohr P., Hofmann-Wellenhof R., Motley R., et al. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. None. 2014;171:1099-107|https://www.ncbi.nlm.nih.gov/pubmed/24841846|1629
Hautkrebsprävention|"2.1"|2021|Siebert, Uwe|Hintergrund|||Erstautor|Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? [Editorial]. None. 2003;4:143-150|pdf, C:\!Fulltext\Siebert\Siebert_2003_Eur J Health Econom_When should DA modeling be used in econom eval.pdf|1629
Hautkrebsprävention|"2.1"|2021|Siebert, Uwe|Hintergrund|||Erstautor|Siebert U. Transparente Entscheidungen in Public Health mittels systematischer Entscheidungsanalyse. None. 2012;None:517-535|pdf|1629
Hautkrebsprävention|"2.1"|2021|Siebert, Uwe|Hintergrund|||Erstautor|Siebert U., Alagoz O., Bayoumi A.M., Jahn B., Owens D.K., Cohen D.J., et al. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -3. None. 2012;32:690-700|pdf|1629
Hautkrebsprävention|"2.1"|2021|Breitbart, Eckhard W.|Hintergrund|||Standard|Greinert R., Boguhn O., Harder D., Breitbart E. W., Mitchell D. L., Volkmer B. The dose dependence of cyclobutane dimer induction and repair in UVB-irradiated human keratinocytes. None. 2000;72:701-8|https://www.ncbi.nlm.nih.gov/pubmed/11107858|1629
Hautkrebsprävention|"2.1"|2021|Greinert, Rüdiger|Hintergrund|||Erstautor|Greinert R., Boguhn O., Harder D., Breitbart E. W., Mitchell D. L., Volkmer B. The dose dependence of cyclobutane dimer induction and repair in UVB-irradiated human keratinocytes. None. 2000;72:701-8|https://www.ncbi.nlm.nih.gov/pubmed/11107858|1629
Hautkrebsprävention|"2.1"|2021|Volkmer, Beate|Hintergrund|||Letztautor|Greinert R., Boguhn O., Harder D., Breitbart E. W., Mitchell D. L., Volkmer B. The dose dependence of cyclobutane dimer induction and repair in UVB-irradiated human keratinocytes. None. 2000;72:701-8|https://www.ncbi.nlm.nih.gov/pubmed/11107858|1629
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Erstautor|Jordan K., Behlendorf T., Surov A., Kegel T., Maher G., Wolf H. H. Venous access ports: frequency and management of complications in oncology patients. None. 2008;31:404-10||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Standard|Surov A., Jordan K., Buerke M., Arnold D., John E., Spielmann R. P., et al. Port catheter insufficiency: incidence and clinical-radiological correlations. None. 2008;31:455-61||1446
Supportive Therapie|"1.3"|2020|Al-Nawas, Bilal|Hintergrund|||Letztautor|Grötz K.A., Piesold J.-U., Al-Nawas B. Bisphosphonat-assoziierte Kiefernekkrose (BP-ONJ) und andere Medikamenten-assoziierteKiefernekrose. None. 2012;None:None||1446
Supportive Therapie|"1.3"|2020|Grötz, Knut|Hintergrund|||Erstautor|Grötz K.A., Piesold J.-U., Al-Nawas B. Bisphosphonat-assoziierte Kiefernekkrose (BP-ONJ) und andere Medikamenten-assoziierteKiefernekrose. None. 2012;None:None||1446
Supportive Therapie|"1.3"|2020|Micke, Oliver|Evidenzbasierte Empfehlung|0|False|Standard|Buentzel J., Micke O., Adamietz I. A., Monnier A., Glatzel M., de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. None. 2006;64:684-91||1446
Supportive Therapie|"1.3"|2020|Micke, Oliver|Hintergrund|||Standard|Buentzel J., Micke O., Adamietz I. A., Monnier A., Glatzel M., de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. None. 2006;64:684-91||1446
Supportive Therapie|"1.3"|2020|Riesenbeck, Dorothea|Evidenzbasiertes Statement||False|Standard|Buentzel J., Riesenbeck D., Glatzel M., Berndt-Skorka R., Riedel T., Mucke R., et al. Limited effects of selenium substitution in the prevention of radiation-associated toxicities. results of a randomized study in head and neck cancer patients. None. 2010;30:1829-32||1446
Supportive Therapie|"1.3"|2020|Riesenbeck, Dorothea|Hintergrund|||Standard|Buentzel J., Riesenbeck D., Glatzel M., Berndt-Skorka R., Riedel T., Mucke R., et al. Limited effects of selenium substitution in the prevention of radiation-associated toxicities. results of a randomized study in head and neck cancer patients. None. 2010;30:1829-32||1446
Supportive Therapie|"1.3"|2020|Feyer, Petra|Hintergrund|||Erstautor|Feyer P., Jahn F., Jordan K. Prophylactic Management of Radiation-Induced Nausea and Vomiting. None. 2015;2015:893013||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Letztautor|Feyer P., Jahn F., Jordan K. Prophylactic Management of Radiation-Induced Nausea and Vomiting. None. 2015;2015:893013||1446
Supportive Therapie|"1.3"|2020|Feyer, Petra|Evidenzbasierte Empfehlung|0|False|Erstautor|Feyer PCh, Maranzano E., Molassiotis A., Clark-Snow R. A., Roila F., Warr D., et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. None. 2005;13:122-8||1446
Supportive Therapie|"1.3"|2020|Feyer, Petra|Hintergrund|||Erstautor|Feyer PCh, Maranzano E., Molassiotis A., Clark-Snow R. A., Roila F., Warr D., et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. None. 2005;13:122-8||1446
Supportive Therapie|"1.3"|2020|Feyer, Petra|Evidenzbasierte Empfehlung|A|False|Erstautor|Feyer P. C., Maranzano E., Molassiotis A., Roila F., Clark-Snow R. A., Jordan K. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. None. 2011;19 Suppl 1:S5-14||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Evidenzbasierte Empfehlung|A|False|Letztautor|Feyer P. C., Maranzano E., Molassiotis A., Roila F., Clark-Snow R. A., Jordan K. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. None. 2011;19 Suppl 1:S5-14||1446
Supportive Therapie|"1.3"|2020|Feyer, Petra|Hintergrund|||Standard|Kris M. G., Hesketh P. J., Somerfield M. R., Feyer P., Clark-Snow R., Koeller J. M., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. None. 2006;24:2932-47||1446
Supportive Therapie|"1.3"|2020|Jahn, Patrick|Hintergrund|||Standard|Jahn F., Riesner A., Jahn P., Sieker F., Vordermark D., Jordan K. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. None. 2015;92:1101-7||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Letztautor|Jahn F., Riesner A., Jahn P., Sieker F., Vordermark D., Jordan K. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. None. 2015;92:1101-7||1446
Supportive Therapie|"1.3"|2020|Cornely, Oliver|Evidenzbasiertes Statement||False|Standard|Vehreschild J. J., Bohme A., Cornely O. A., Kahl C., Karthaus M., Kreuzer K. A., et al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy--evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). None. 2014;None:None||1446
Supportive Therapie|"1.3"|2020|Cornely, Oliver|Hintergrund|||Standard|Vehreschild J. J., Bohme A., Cornely O. A., Kahl C., Karthaus M., Kreuzer K. A., et al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy--evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). None. 2014;None:None||1446
Supportive Therapie|"1.3"|2020|Vehreschild, Jörg Janne|Evidenzbasiertes Statement||False|Erstautor|Vehreschild J. J., Bohme A., Cornely O. A., Kahl C., Karthaus M., Kreuzer K. A., et al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy--evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). None. 2014;None:None||1446
Supportive Therapie|"1.3"|2020|Vehreschild, Jörg Janne|Hintergrund|||Erstautor|Vehreschild J. J., Bohme A., Cornely O. A., Kahl C., Karthaus M., Kreuzer K. A., et al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy--evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). None. 2014;None:None||1446
Supportive Therapie|"1.3"|2020|Huober, Jens|Evidenzbasierte Empfehlung|A|False|Standard|Moebus V., Jackisch C., Schneeweiss A., Huober J., Lueck H. J., du Bois A., et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. None. 2013;105:1018-26||1446
Supportive Therapie|"1.3"|2020|Huober, Jens|Hintergrund|||Standard|Moebus V., Jackisch C., Schneeweiss A., Huober J., Lueck H. J., du Bois A., et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. None. 2013;105:1018-26||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Erstautor|Jordan K., Jahn F., Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. None. 2015;26:1081-1090||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Standard|Grunberg S. M., Warr D., Gralla R. J., Rapoport B. L., Hesketh P. J., Jordan K., et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. None. 2011;19 Suppl 1:S43-7||1446
Supportive Therapie|"1.3"|2020|Feyer, Petra|Evidenzbasierte Empfehlung|A|False|Standard|Basch E., Prestrud A. A., Hesketh P. J., Kris M. G., Feyer P. C., Somerfield M. R., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. None. 2011;29:4189-98||1446
Supportive Therapie|"1.3"|2020|Feyer, Petra|Hintergrund|||Standard|Basch E., Prestrud A. A., Hesketh P. J., Kris M. G., Feyer P. C., Somerfield M. R., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. None. 2011;29:4189-98||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Evidenzbasierte Empfehlung|A|False|Standard|Rapoport B. L., Jordan K., Boice J. A., Taylor A., Brown C., Hardwick J. S., et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. None. 2010;18:423-31||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Standard|Rapoport B. L., Jordan K., Boice J. A., Taylor A., Brown C., Hardwick J. S., et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. None. 2010;18:423-31||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Erstautor|Jordan K., Hinke A., Grothey A., Voigt W., Arnold D., Wolf H. H., et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. None. 2007;15:1023-33||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Evidenzbasierte Empfehlung|B|False|Standard|Gralla R., Jordan K., Rapoport B., Street J. C., Carides A. Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs). None. 2010;28:9057||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Standard|Gralla R., Jordan K., Rapoport B., Street J. C., Carides A. Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs). None. 2010;28:9057||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Standard|Weinstein C., Jordan K., Green S. A., Camacho E., Khanani S., Beckford-Brathwaite E., et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. None. 2016;27:172-8||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Erstautor|Jordan K., Gralla R., Jahn F., Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. None. 2014;722:197-202||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Evidenzbasierte Empfehlung|B|False|Erstautor|Jordan K., Kinitz I., Voigt W., Behlendorf T., Wolf H. H., Schmoll H. J. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. None. 2009;45:1184-7||1446
Supportive Therapie|"1.3"|2020|Vehreschild, Jörg Janne|Hintergrund|||Standard|Vehreschild M. J., Vehreschild J. J., Hubel K., Hentrich M., Schmidt-Hieber M., Christopeit M., et al. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). None. 2013;24:1189-202||1446
Supportive Therapie|"1.3"|2020|Potthoff, Katrin|Hintergrund|||Erstautor|Potthoff Karin M., Hassel Jessica C., Wollenberg Andreas, Hofheinz Ralf-Dieter. Therapie und Prophylaxe EGFR-Inhibitorinduzierter Hautreaktionen. None. 2010;28:191-198||1446
Supportive Therapie|"1.3"|2020|Schulz, Holger|Evidenzbasierte Empfehlung|A|False|Standard|Hofheinz R. D., Gencer D., Schulz H., Stahl M., Hegewisch-Becker S., Loeffler L. M., et al. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. None. 2015;33:2444-9||1446
Supportive Therapie|"1.3"|2020|Schulz, Holger|Hintergrund|||Standard|Hofheinz R. D., Gencer D., Schulz H., Stahl M., Hegewisch-Becker S., Loeffler L. M., et al. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. None. 2015;33:2444-9||1446
Supportive Therapie|"1.3"|2020|Potthoff, Katrin|Hintergrund|||Erstautor|Potthoff K., Hofheinz R., Hassel J. C., Volkenandt M., Lordick F., Hartmann J. T., et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. None. 2011;22:524-35||1446
Supportive Therapie|"1.3"|2020|Koeppen, Susanne|Evidenzbasiertes Statement||False|Erstautor|Koeppen S., Verstappen C. C., Korte R., Scheulen M. E., Strumberg D., Postma T. J., et al. Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. None. 2004;130:153-60||1446
Supportive Therapie|"1.3"|2020|Koeppen, Susanne|Hintergrund|||Erstautor|Koeppen S., Verstappen C. C., Korte R., Scheulen M. E., Strumberg D., Postma T. J., et al. Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. None. 2004;130:153-60||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Evidenzbasiertes Statement||False|Letztautor|Jordan Berit, Jahn Franziska, Beckmann Juliane, Unverzagt Susanne, Müller-Tidow Carsten, Jordan Karin. Calcium and Magnesium infusions for the prevention of oxaliplatin- induced peripheral neurotoxicity, a systematic review. None. 2016;None:None||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Letztautor|Jordan Berit, Jahn Franziska, Beckmann Juliane, Unverzagt Susanne, Müller-Tidow Carsten, Jordan Karin. Calcium and Magnesium infusions for the prevention of oxaliplatin- induced peripheral neurotoxicity, a systematic review. None. 2016;None:None||1446
Supportive Therapie|"1.3"|2020|Kerschgens, Christa|Hintergrund|||Standard|Steimann M., Kerschgens C., Barth J. Rehabilitation bei Chemotherapieinduzierter. None. 2011;None:940–947||1446
Supportive Therapie|"1.3"|2020|Palmedo, Holger|Hintergrund|||Erstautor|Palmedo H., Marx C., Ebert A., Kreft B., Ko Y., Türler A., et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. None. 2014;None:None||1446
Supportive Therapie|"1.3"|2020|Weber, Marc-André|Hintergrund|||Letztautor|Kloth J.K., Wolf M., Rehnitz C., Lehner B., Wiedenhöfer B., Weber M.-A. Radiologische Diagnostik spinaler Tumoren. None. 2012;41:595-607||1446
Supportive Therapie|"1.3"|2020|Diel, Ingo J.|Evidenzbasierte Empfehlung|B|False|Standard|Body J. J., Diel I. J., Lichinitser M. R., Kreuser E. D., Dornoff W., Gorbunova V. A., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. None. 2003;14:1399-405||1446
Supportive Therapie|"1.3"|2020|Al-Nawas, Bilal|Evidenzbasierte Empfehlung|A|True|Letztautor|Grötz K. A., Piesold J. U., Al-Nawas B. Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. None. 2012;None:None||1446
Supportive Therapie|"1.3"|2020|Al-Nawas, Bilal|Hintergrund|||Letztautor|Grötz K. A., Piesold J. U., Al-Nawas B. Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. None. 2012;None:None||1446
Supportive Therapie|"1.3"|2020|Grötz, Knut|Evidenzbasierte Empfehlung|A|True|Erstautor|Grötz K. A., Piesold J. U., Al-Nawas B. Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. None. 2012;None:None||1446
Supportive Therapie|"1.3"|2020|Grötz, Knut|Hintergrund|||Erstautor|Grötz K. A., Piesold J. U., Al-Nawas B. Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. None. 2012;None:None||1446
Supportive Therapie|"1.3"|2020|Diel, Ingo J.|Hintergrund|||Standard|Stopeck A. T., Fizazi K., Body J. J., Brown J. E., Carducci M., Diel I., et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. None. 2015;None:None||1446
Supportive Therapie|"1.3"|2020|de Wit, Maike|Evidenzbasierte Empfehlung|B|False|Erstautor|de Wit M., Ortner P., Lipp H. P., Sehouli J., Untch M., Ruhnke M., et al. Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment. None. 2013;36:127-35||1446
Supportive Therapie|"1.3"|2020|de Wit, Maike|Hintergrund|||Erstautor|de Wit M., Ortner P., Lipp H. P., Sehouli J., Untch M., Ruhnke M., et al. Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment. None. 2013;36:127-35||1446
Supportive Therapie|"1.3"|2020|Jordan, Karin|Hintergrund|||Erstautor|Jordan K., Grothe W., Schmoll H. J. [Extravasation of chemotherapeutic agents: prevention and therapy]. None. 2005;130:33-7||1446
Nierenzellkarzinom|"3.0"|2021|Junker, Kerstin|Hintergrund|||Erstautor|Junker K., Ficarra V., Kwon E. D., Leibovich B. C., Thompson R. H., Oosterwijk E. Potential role of genetic markers in the management of kidney cancer. . 2013;63:333-40|http://www.ncbi.nlm.nih.gov/pubmed/23040205|882
Nierenzellkarzinom|"3.0"|2021|Bex, Axel|Evidenzbasierte Empfehlung|A|False|Standard|Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, et al. Guidelines on renal cell carcinoma. None. 2013;None:None||882
Nierenzellkarzinom|"3.0"|2021|Bex, Axel|Hintergrund|||Standard|Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, et al. Guidelines on renal cell carcinoma. None. 2013;None:None||882
Nierenzellkarzinom|"3.0"|2021|Weikert, Steffen|Evidenzbasiertes Statement|0|False|Erstautor|Weikert S., Boeing H., Pischon T., Weikert C., Olsen A., Tjonneland A., et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. . 2008;167:438-46|http://www.ncbi.nlm.nih.gov/pubmed/18048375|882
Nierenzellkarzinom|"3.0"|2021|Weikert, Steffen|Hintergrund|||Erstautor|Weikert S., Boeing H., Pischon T., Weikert C., Olsen A., Tjonneland A., et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. . 2008;167:438-46|http://www.ncbi.nlm.nih.gov/pubmed/18048375|882
Nierenzellkarzinom|"3.0"|2021|Siemer, Stefan|Hintergrund|||Letztautor|Steffens J., Humke U., Ziegler M., Siemer S. Partial nephrectomy with perfusion cooling for imperative indications: a 24-year experience. . 2005;96:608-11|http://www.ncbi.nlm.nih.gov/pubmed/16104919|882
Nierenzellkarzinom|"3.0"|2021|Golka, Klaus|Hintergrund|||Standard|Jungmann O. P., Schöps W., Golka K., Rohde D. Beruflich bedingte urologische Tumoren. None. 2019;5:None|https://www.springermedizin.de/gesundheitsschaeden-und-berufskrankheiten/recht-fuer-aerzte/beruflich-bedingte-urologische-tumoren/17098732|882
Nierenzellkarzinom|"3.0"|2021|Weikert, Steffen|Hintergrund|||Erstautor|Weikert S., Boeing H., Pischon T., Olsen A., Tjonneland A., Overvad K., et al. Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC). . 2006;118:3133-9|http://www.ncbi.nlm.nih.gov/pubmed/16425278|882
Nierenzellkarzinom|"3.0"|2021|Siemer, Stefan|Hintergrund|||Standard|Becker F., Roos F. C., Janssen M., Brenner W., Hampel C., Siemer S., et al. Short-term functional and oncologic outcomes of nephron-sparing surgery for renal tumours >/= 7 cm. . 2011;59:931-7|http://www.ncbi.nlm.nih.gov/pubmed/21371812|882
Nierenzellkarzinom|"3.0"|2021|Varga, Zoltan|Hintergrund|||Standard|Schrader A. J., Olbert P. J., Hegele A., Varga Z., Hofmann R. Metastatic non-clear cell renal cell carcinoma: current therapeutic options. . 2008;101:1343-5|http://www.ncbi.nlm.nih.gov/pubmed/18241246|882
Nierenzellkarzinom|"3.0"|2021|Bergmann, Lothar|Hintergrund|||Standard|Atzpodien J., Kirchner H., Jonas U., Bergmann L., Schott H., Heynemann H., et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). . 2004;22:1188-94|http://www.ncbi.nlm.nih.gov/pubmed/14981107|882
Nierenzellkarzinom|"3.0"|2021|Varga, Zoltan|Hintergrund|||Letztautor|Heidenreich A., Schrader A. J., Varga Z. Basic science and research in renal cell carcinoma: from workbench to bedside. . 2003;13:457-62|http://www.ncbi.nlm.nih.gov/pubmed/14560138|882
Nierenzellkarzinom|"3.0"|2021|Eichelberg, Christian|Evidenzbasierte Empfehlung|B|False|Erstautor|Eichelberg C., Vervenne W. L., De Santis M., Fischer von Weikersthal L., Goebell P. J., Lerchenmuller C., et al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. . 2015;68:837-47|http://www.ncbi.nlm.nih.gov/pubmed/25952317|882
Nierenzellkarzinom|"3.0"|2021|Eichelberg, Christian|Hintergrund|||Erstautor|Eichelberg C., Vervenne W. L., De Santis M., Fischer von Weikersthal L., Goebell P. J., Lerchenmuller C., et al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. . 2015;68:837-47|http://www.ncbi.nlm.nih.gov/pubmed/25952317|882
Nierenzellkarzinom|"3.0"|2021|Bex, Axel|Evidenzbasiertes Statement|0|False|Standard|Johannsen M., Florcken A., Bex A., Roigas J., Cosentino M., Ficarra V., et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. . 2009;55:1430-8|https://www.ncbi.nlm.nih.gov/pubmed/18950936|882
Nierenzellkarzinom|"3.0"|2021|Johannsen, Manfred|Evidenzbasiertes Statement|0|False|Erstautor|Johannsen M., Florcken A., Bex A., Roigas J., Cosentino M., Ficarra V., et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. . 2009;55:1430-8|https://www.ncbi.nlm.nih.gov/pubmed/18950936|882
Nierenzellkarzinom|"3.0"|2021|Roigas, Jan|Evidenzbasiertes Statement|0|False|Standard|Johannsen M., Florcken A., Bex A., Roigas J., Cosentino M., Ficarra V., et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. . 2009;55:1430-8|https://www.ncbi.nlm.nih.gov/pubmed/18950936|882
Nierenzellkarzinom|"3.0"|2021|Johannsen, Manfred|Hintergrund|||Erstautor|Johannsen M., Staehler M., Ohlmann C. H., Florcken A., Schmittel A., Otto T., et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. . 2011;22:657-63|http://www.ncbi.nlm.nih.gov/pubmed/20870911|882
Nierenzellkarzinom|"3.0"|2021|Staehler, Michael|Hintergrund|||Standard|Johannsen M., Staehler M., Ohlmann C. H., Florcken A., Schmittel A., Otto T., et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. . 2011;22:657-63|http://www.ncbi.nlm.nih.gov/pubmed/20870911|882
Nierenzellkarzinom|"3.0"|2021|Hallscheidt, Peter|Evidenzbasierte Empfehlung|A|False|Erstautor|Hallscheidt Peter J, Bock Michael, Riedasch Gerd, Zuna Ivan, Schoenberg Stefan O, Autschbach Frank, et al. Diagnostic accuracy of staging renal cell carcinomas using multidetector-row computed tomography and magnetic resonance imaging: a prospective study with histopathologic correlation. None. 2004;28:333-339||882
Nierenzellkarzinom|"3.0"|2021|Hallscheidt, Peter|Hintergrund|||Erstautor|Hallscheidt Peter J, Bock Michael, Riedasch Gerd, Zuna Ivan, Schoenberg Stefan O, Autschbach Frank, et al. Diagnostic accuracy of staging renal cell carcinomas using multidetector-row computed tomography and magnetic resonance imaging: a prospective study with histopathologic correlation. None. 2004;28:333-339||882
Nierenzellkarzinom|"3.0"|2021|Hallscheidt, Peter|Evidenzbasierte Empfehlung|A|False|Erstautor|Hallscheidt P., Schoenberg S., Schenk J. P., Zuna I., Petirsch O., Riedasch G. [Multi-slice CT in the planning of nephron-sparing interventions for renal cell carcinoma: Prospective study correlated with histopathology]. . 2002;174:898-903|http://www.ncbi.nlm.nih.gov/pubmed/12101482|882
Nierenzellkarzinom|"3.0"|2021|Staehler, Michael|Evidenzbasierte Empfehlung|B|False|Standard|Winter H., Meimarakis G., Angele M. K., Hummel M., Staehler M., Hoffmann R. T., et al. Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. . 2010;184:1888-94|http://www.ncbi.nlm.nih.gov/pubmed/20846691|882
Nierenzellkarzinom|"3.0"|2021|Staehler, Michael|Hintergrund|||Standard|Winter H., Meimarakis G., Angele M. K., Hummel M., Staehler M., Hoffmann R. T., et al. Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. . 2010;184:1888-94|http://www.ncbi.nlm.nih.gov/pubmed/20846691|882
Nierenzellkarzinom|"3.0"|2021|Pfannschmidt, Joachim|Hintergrund|||Erstautor|Pfannschmidt J., Hoffmann H., Muley T., Krysa S., Trainer C., Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. . 2002;74:1653-7|http://www.ncbi.nlm.nih.gov/pubmed/12440625|882
Nierenzellkarzinom|"3.0"|2021|Staehler, Michael|Hintergrund|||Standard|Meimarakis G., Angele M., Staehler M., Clevert D. A., Crispin A., Ruttinger D., et al. Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. . 2011;202:158-67|http://www.ncbi.nlm.nih.gov/pubmed/21810496|882
Nierenzellkarzinom|"3.0"|2021|Schirren, Joachim|Hintergrund|||Letztautor|Kudelin N., Boeluekbas S., Eberlein M., Schirren J. Metastasectomy with standardized lymph node dissection for metastatic renal cell carcinoma: an 11-year single-center experience. . 2013;96:265-70: discussion 270-1|http://www.ncbi.nlm.nih.gov/pubmed/23731615|882
Nierenzellkarzinom|"3.0"|2021|Schirren, Joachim|Hintergrund|||Letztautor|Boeluekbas S., Kudelin N., Eberlein M., Fisseler-Eckhoff A., Schirren J. The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma. . 2012;60:390-7|http://www.ncbi.nlm.nih.gov/pubmed/22207364|882
Nierenzellkarzinom|"3.0"|2021|Hallscheidt, Peter|Evidenzbasierte Empfehlung|B|False|Erstautor|Hallscheidt Peter J, Fink Christian, Haferkamp Axel, Bock Michael, Luburic Ante, Zuna Ivan, et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. . 2005;29:64-68|https://insights.ovid.com/crossref?an=00004728-200501000-00012|882
Nierenzellkarzinom|"3.0"|2021|Hallscheidt, Peter|Hintergrund|||Erstautor|Hallscheidt Peter J, Fink Christian, Haferkamp Axel, Bock Michael, Luburic Ante, Zuna Ivan, et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. . 2005;29:64-68|https://insights.ovid.com/crossref?an=00004728-200501000-00012|882
Nierenzellkarzinom|"3.0"|2021|Staehler, Michael|Hintergrund|||Erstautor|Staehler M., Haseke N., Nuhn P., Tullmann C., Karl A., Siebels M., et al. Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. . 2011;108:673-8|https://www.ncbi.nlm.nih.gov/pubmed/21156017|882
Nierenzellkarzinom|"3.0"|2021|Staehler, Michael|Hintergrund|||Erstautor|Staehler M. D., Kruse J., Haseke N., Stadler T., Roosen A., Karl A., et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. . 2010;28:543-7|https://www.ncbi.nlm.nih.gov/pubmed/20440505|882
Nierenzellkarzinom|"3.0"|2021|Bex, Axel|Evidenzbasiertes Statement||False|Erstautor|Bex A., van der Veldt A. A., Blank C., van den Eertwegh A. J., Boven E., Horenblas S., et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. . 2009;27:533-9||882
Nierenzellkarzinom|"3.0"|2021|Bex, Axel|Hintergrund|||Erstautor|Bex A., van der Veldt A. A., Blank C., van den Eertwegh A. J., Boven E., Horenblas S., et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. . 2009;27:533-9||882
Nierenzellkarzinom|"3.0"|2021|Bex, Axel|Evidenzbasiertes Statement||False|Erstautor|Bex A., Horenblas S., Meinhardt W., Verra N., de Gast G. C. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. . 2002;42:570-4; discussion 575-6||882
Nierenzellkarzinom|"3.0"|2021|Bex, Axel|Hintergrund|||Erstautor|Bex A., Horenblas S., Meinhardt W., Verra N., de Gast G. C. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. . 2002;42:570-4; discussion 575-6||882
Nierenzellkarzinom|"3.0"|2021|Hallscheidt, Peter|Hintergrund|||Erstautor|Hallscheidt P., Hansmann J., Schenk J. P., Radeleff B. A., Kauffmann G. W., Riedasch G. [Organ-sparing surgery of renal cell carcinoma - operative technique and findings in radiological follow-up]. . 2002;174:409-15|http://www.ncbi.nlm.nih.gov/pubmed/11960401|882
Nierenzellkarzinom|"3.0"|2021|Jones, Jon|Hintergrund|||Standard|Davis R., Jones J. S., Barocas D. A., Castle E. P., Lang E. K., Leveillee R. J., et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. . 2012;188:2473-81|https://www.ncbi.nlm.nih.gov/pubmed/23098784|882
Nierenzellkarzinom|"3.0"|2021|Junker, Kerstin|Hintergrund|||Standard|Wunderlich H., Hindermann W., Al Mustafa A. M., Reichelt O., Junker K., Schubert J. The accuracy of 250 fine needle biopsies of renal tumors. . 2005;174:44-6|http://www.ncbi.nlm.nih.gov/pubmed/15947574|882
Nierenzellkarzinom|"3.0"|2021|Wunderlich, Heiko|Hintergrund|||Erstautor|Wunderlich H., Hindermann W., Al Mustafa A. M., Reichelt O., Junker K., Schubert J. The accuracy of 250 fine needle biopsies of renal tumors. . 2005;174:44-6|http://www.ncbi.nlm.nih.gov/pubmed/15947574|882
Nierenzellkarzinom|"3.0"|2021|Micke, Oliver|Hintergrund|||Standard|Huebner J., Muenstedt K., Muecke R., Micke O., Stoll C., Kleeberg U. R., et al. Counseling cancer patients on complementary and alternative medicine. Background, theory, and implementation of nationwide counseling facilities. . 2013;189:613-7|https://www.ncbi.nlm.nih.gov/pubmed/23824107|882
Nierenzellkarzinom|"3.0"|2021|Stoll, Christoph|Hintergrund|||Standard|Huebner J., Muenstedt K., Muecke R., Micke O., Stoll C., Kleeberg U. R., et al. Counseling cancer patients on complementary and alternative medicine. Background, theory, and implementation of nationwide counseling facilities. . 2013;189:613-7|https://www.ncbi.nlm.nih.gov/pubmed/23824107|882
Nierenzellkarzinom|"3.0"|2021|Bedke, Jens|Evidenzbasierte Empfehlung|B|False|Standard|Retz M., Bedke J., Bogemann M., Grimm M. O., Zimmermann U., Muller L., et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). None. 2019;107:37-45|https://www.ncbi.nlm.nih.gov/pubmed/30529901|882
Nierenzellkarzinom|"3.0"|2021|Bedke, Jens|Hintergrund|||Standard|Retz M., Bedke J., Bogemann M., Grimm M. O., Zimmermann U., Muller L., et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). None. 2019;107:37-45|https://www.ncbi.nlm.nih.gov/pubmed/30529901|882
Nierenzellkarzinom|"3.0"|2021|Ihrig, Andreas|Hintergrund|||Standard|Sommerfeldt S., Ihrig A., Brechtel A., Keller M. Psychoonkologisches Screening in der Routineversorgung. . 2007;1:293-297|https://link.springer.com/article/10.1007%2Fs11800-007-0063-3|882
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Evidenzbasierte Empfehlung|A|False|Erstautor|Dieckmann K.P., Kulejewski M., Pichlmeier U., Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. . 2007;51:175-83; discussion 183-5||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Kulejewski M., Pichlmeier U., Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. . 2007;51:175-83; discussion 183-5||692
Hodentumoren|"1.1"|2020|Albers, Peter|Evidenzbasierte Empfehlung|A|False|Standard|Giannarini G., Dieckmann K. P., Albers P., Heidenreich A., Pizzocaro G. Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. . 2010;57:780-90||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Giannarini G., Dieckmann K. P., Albers P., Heidenreich A., Pizzocaro G. Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. . 2010;57:780-90||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Evidenzbasierte Empfehlung|A|False|Standard|Giannarini G., Dieckmann K. P., Albers P., Heidenreich A., Pizzocaro G. Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. . 2010;57:780-90||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Standard|Giannarini G., Dieckmann K. P., Albers P., Heidenreich A., Pizzocaro G. Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. . 2010;57:780-90||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Evidenzbasierte Empfehlung|A|False|Standard|Giannarini G., Dieckmann K. P., Albers P., Heidenreich A., Pizzocaro G. Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. . 2010;57:780-90||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Standard|Giannarini G., Dieckmann K. P., Albers P., Heidenreich A., Pizzocaro G. Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. . 2010;57:780-90||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Heidenreich A., Weissbach L., Holtl W., Albers P., Kliesch S., Kohrmann K. U., et al. Organ sparing surgery for malignant germ cell tumor of the testis. . 2001;166:2161-5||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Weissbach L., Holtl W., Albers P., Kliesch S., Kohrmann K. U., et al. Organ sparing surgery for malignant germ cell tumor of the testis. . 2001;166:2161-5||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Heidenreich A., Weissbach L., Holtl W., Albers P., Kliesch S., Kohrmann K. U., et al. Organ sparing surgery for malignant germ cell tumor of the testis. . 2001;166:2161-5||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Evidenzbasiertes Statement||False|Erstautor|Dieckmann K.P., Wilken S., Loy V., Matthies C., Kleinschmidt K., Bedke J., et al. Treatment of testicular intraepitelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: A survey of the German Testicular Cancer Study Group. None. 2013b;24:1332-1337||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Wilken S., Loy V., Matthies C., Kleinschmidt K., Bedke J., et al. Treatment of testicular intraepitelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: A survey of the German Testicular Cancer Study Group. None. 2013b;24:1332-1337||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Erstautor|Kliesch S., Thomaidis T., Schutte B., Puhse G., Kater B., Roth S., et al. Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). . 2003;111:70-4; discussion 75||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Erstautor|Kliesch S., Kamischke A., Cooper TG., Nieschlag E. Kryokonservierung menschlicher Spermien zur Zeugungsreserve. In: Nieschlag E, Behre HM, Nieschlag S, Hrsg. Andrologie: Grundlagen und Klinik der reproduktiven Gesundheit des Mannes. Springer Berlin Heidelberg. . 2009;:515-31||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Erstautor|Kliesch S., Behre H. M., Jurgens H., Nieschlag E. Cryopreservation of semen from adolescent patients with malignancies. . 1996;26:20-7||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Erstautor|Kliesch S., Bergmann M., Hertle L., Nieschlag E., Behre H. M. Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. . 1997;12:2830-2835||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P. Contralateral biopsies in patients with testicular germ-cell tumour-nuisance or new sense?. . 2015a;26:620-1||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Standard|Classen J., Dieckmann K., Bamberg M., Souchon R., Kliesch S., Kuehn M., et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. . 2003;88:828-31||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Classen J., Dieckmann K., Bamberg M., Souchon R., Kliesch S., Kuehn M., et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. . 2003;88:828-31||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Classen J., Dieckmann K., Bamberg M., Souchon R., Kliesch S., Kuehn M., et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. . 2003;88:828-31||692
Hodentumoren|"1.1"|2020|Schmidberger, Heinz|Hintergrund|||Standard|Classen J., Schmidberger H., Meisner C., Souchon R., Sautter-Bihl L., Sauer R., et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. . 2003a;21:1101-6||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Classen J., Schmidberger H., Meisner C., Souchon R., Sautter-Bihl L., Sauer R., et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. . 2003a;21:1101-6||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Heidenreich A., Albers P., Hartmann M., Kliesch S., Kohrmann K. U., Krege S., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. . 2003;169:1710-4||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Albers P., Hartmann M., Kliesch S., Kohrmann K. U., Krege S., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. . 2003;169:1710-4||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Heidenreich A., Albers P., Hartmann M., Kliesch S., Kohrmann K. U., Krege S., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. . 2003;169:1710-4||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Heidenreich A., Albers P., Hartmann M., Kliesch S., Kohrmann K. U., Krege S., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. . 2003;169:1710-4||692
Hodentumoren|"1.1"|2020|Albers, Peter|Evidenzbasierte Empfehlung|B|False|Letztautor|Heidenreich A., Pfister D., Witthuhn R., Thuer D., Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. . 2009;55:217-24||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Letztautor|Heidenreich A., Pfister D., Witthuhn R., Thuer D., Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. . 2009;55:217-24||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Evidenzbasierte Empfehlung|B|False|Erstautor|Heidenreich A., Pfister D., Witthuhn R., Thuer D., Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. . 2009;55:217-24||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Pfister D., Witthuhn R., Thuer D., Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. . 2009;55:217-24||692
Hodentumoren|"1.1"|2020|Pfister, David|Evidenzbasierte Empfehlung|B|False|Standard|Heidenreich A., Pfister D., Witthuhn R., Thuer D., Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. . 2009;55:217-24||692
Hodentumoren|"1.1"|2020|Pfister, David|Hintergrund|||Standard|Heidenreich A., Pfister D., Witthuhn R., Thuer D., Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. . 2009;55:217-24||692
Hodentumoren|"1.1"|2020|Wittekind, Christian|Hintergrund|||Erstautor|Wittekind C. TNM Klassifikation Maligner Tumoren. None. 2017;8. Auflage:None||692
Hodentumoren|"1.1"|2020|Albers, Peter|Evidenzbasiertes Statement||False|Erstautor|Albers P., Siener R., Kliesch S., Weissbach L., Krege S., Sparwasser C., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. . 2003;21:1505-12||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P., Siener R., Kliesch S., Weissbach L., Krege S., Sparwasser C., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. . 2003;21:1505-12||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Evidenzbasiertes Statement||False|Standard|Albers P., Siener R., Kliesch S., Weissbach L., Krege S., Sparwasser C., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. . 2003;21:1505-12||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Albers P., Siener R., Kliesch S., Weissbach L., Krege S., Sparwasser C., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. . 2003;21:1505-12||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Evidenzbasiertes Statement||False|Standard|Albers P., Siener R., Kliesch S., Weissbach L., Krege S., Sparwasser C., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. . 2003;21:1505-12||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Albers P., Siener R., Kliesch S., Weissbach L., Krege S., Sparwasser C., et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. . 2003;21:1505-12||692
Hodentumoren|"1.1"|2020|Ruf, Christian|Evidenzbasiertes Statement||False|Standard|Zengerling F., Kunath F., Jensen K., Ruf C., Schmidt S., Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - a systematic review. . 2017;pii: S1078-1439(17)30331-9:||692
Hodentumoren|"1.1"|2020|Ruf, Christian|Hintergrund|||Standard|Zengerling F., Kunath F., Jensen K., Ruf C., Schmidt S., Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - a systematic review. . 2017;pii: S1078-1439(17)30331-9:||692
Hodentumoren|"1.1"|2020|Schmidt, Stefanie|Evidenzbasiertes Statement||False|Standard|Zengerling F., Kunath F., Jensen K., Ruf C., Schmidt S., Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - a systematic review. . 2017;pii: S1078-1439(17)30331-9:||692
Hodentumoren|"1.1"|2020|Schmidt, Stefanie|Hintergrund|||Standard|Zengerling F., Kunath F., Jensen K., Ruf C., Schmidt S., Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - a systematic review. . 2017;pii: S1078-1439(17)30331-9:||692
Hodentumoren|"1.1"|2020|Zengerling, Friedemann|Evidenzbasiertes Statement||False|Erstautor|Zengerling F., Kunath F., Jensen K., Ruf C., Schmidt S., Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - a systematic review. . 2017;pii: S1078-1439(17)30331-9:||692
Hodentumoren|"1.1"|2020|Zengerling, Friedemann|Hintergrund|||Erstautor|Zengerling F., Kunath F., Jensen K., Ruf C., Schmidt S., Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - a systematic review. . 2017;pii: S1078-1439(17)30331-9:||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Boormans J.L., Mayor de Castro J., Marconi L., Yuan Y., Laguna Pes M.P., Bokemeyer C., et al. Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic review by the Testicular Cancer Guidelines Panel. . 2017;73:394–405||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P., Ulbright T.M., Albers J., Miller G.A., Orazi A., Crabtree W.N., et al. Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. . 1996;155:579-86||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Letztautor|Paffenholz P., Heidegger I. M., Kuhr K., Loosen S. H., Pfister D., Heidenreich A. Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival. . 2017;:||692
Hodentumoren|"1.1"|2020|Pfister, David|Hintergrund|||Standard|Paffenholz P., Heidegger I. M., Kuhr K., Loosen S. H., Pfister D., Heidenreich A. Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival. . 2017;:||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Anheuser P., Schmidt S., Soyka-Hundt B., Pichlmeier U., Schriefer P., et al. Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction. . 2015b;15:1-7||692
Hodentumoren|"1.1"|2020|Schmidt, Stefanie|Hintergrund|||Standard|Dieckmann K.P., Anheuser P., Schmidt S., Soyka-Hundt B., Pichlmeier U., Schriefer P., et al. Testicular prostheses in patients with testicular cancer - acceptance rate and patient satisfaction. . 2015b;15:1-7||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Skakkebaek N.E. Carcinoma in situ of the testis: A review of biological and clinical features. . 1999;83:815-822||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Schrader M., Weissbach L., Hartmann M., Krege S., Albers P., Miller K., et al. Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer?. . 2010;57:867-72||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Schrader M., Weissbach L., Hartmann M., Krege S., Albers P., Miller K., et al. Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer?. . 2010;57:867-72||692
Hodentumoren|"1.1"|2020|Schrader, Mark|Hintergrund|||Erstautor|Schrader M., Weissbach L., Hartmann M., Krege S., Albers P., Miller K., et al. Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer?. . 2010;57:867-72||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Standard|Rorth M., Rajpert-De Meyts E., Andersson L., Dieckmann K.P., Fossa S.D., Grigor K.M., et al. Carcinoma in situ in the testis. . 2000;suppl. 205:166-186||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. Guidelines on Testicular Cancer: 2015 Update. . 2015;68:1054-1068||692
Hodentumoren|"1.1"|2020|Albrecht, Walter|Hintergrund|||Standard|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. Guidelines on Testicular Cancer: 2015 Update. . 2015;68:1054-1068||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. Guidelines on Testicular Cancer: 2015 Update. . 2015;68:1054-1068||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Loy V. Paternity of a patient with testicular seminoma and contralateral testicular intraepithelial neoplasia. None. 1993;16:143-146||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Vorreuther R., Neubauer S., Zumbe J., Engelmann U.H. Paternity in patients with bilateral testicular germ cell tumors. None. 1997b;31:246-8||692
Hodentumoren|"1.1"|2020|Hakenberg, Oliver|Hintergrund|||Standard|Schrader M., Zengerling F., Hakenberg O. W., Protzel C. [German national second-opinion network for testicular cancer and penile carcinoma: Two sources for evidence-based information]. . 2016;55:1192-8||692
Hodentumoren|"1.1"|2020|Schrader, Mark|Hintergrund|||Erstautor|Schrader M., Zengerling F., Hakenberg O. W., Protzel C. [German national second-opinion network for testicular cancer and penile carcinoma: Two sources for evidence-based information]. . 2016;55:1192-8||692
Hodentumoren|"1.1"|2020|Zengerling, Friedemann|Hintergrund|||Standard|Schrader M., Zengerling F., Hakenberg O. W., Protzel C. [German national second-opinion network for testicular cancer and penile carcinoma: Two sources for evidence-based information]. . 2016;55:1192-8||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Anheuser P., Sattler F., Von Kügelgen T., Matthies C., Ruf C.G. Sequential bilateral testicular tumours presenting with intervals of 20 years and more. None. 2013a;13:71||692
Hodentumoren|"1.1"|2020|Ruf, Christian|Hintergrund|||Letztautor|Dieckmann K.P., Anheuser P., Sattler F., Von Kügelgen T., Matthies C., Ruf C.G. Sequential bilateral testicular tumours presenting with intervals of 20 years and more. None. 2013a;13:71||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Loy V. Intratesticular effects of cisplatin-based chemotherapy. . 1995;28:25-30||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Zengerling F., Krege S., Schrader A. J., Schrader M. [National second opinion network for testicular cancer patients - transferring guidelines into practice!]. . 2014;45:454-6||692
Hodentumoren|"1.1"|2020|Schrader, Mark|Hintergrund|||Letztautor|Zengerling F., Krege S., Schrader A. J., Schrader M. [National second opinion network for testicular cancer patients - transferring guidelines into practice!]. . 2014;45:454-6||692
Hodentumoren|"1.1"|2020|Zengerling, Friedemann|Hintergrund|||Erstautor|Zengerling F., Krege S., Schrader A. J., Schrader M. [National second opinion network for testicular cancer patients - transferring guidelines into practice!]. . 2014;45:454-6||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Lauke H., Michl U., Winter E., Loy V. Testicular germ cell cancer despite previous local radiotherapy to the testis. . 2002;41:643-649||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. . 2008a;53:478-96||692
Hodentumoren|"1.1"|2020|Albrecht, Walter|Hintergrund|||Standard|Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. . 2008a;53:478-96||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Erstautor|Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. . 2008a;53:478-96||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. . 2008a;53:478-96||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. . 2008b;53:497-513||692
Hodentumoren|"1.1"|2020|Albrecht, Walter|Hintergrund|||Standard|Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. . 2008b;53:497-513||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Erstautor|Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. . 2008b;53:497-513||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Krege S., Beyer J., Souchon R., Albers P., Albrecht W., Algaba F., et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. . 2008b;53:497-513||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Evidenzbasiertes Statement|0|False|Standard|Behre H.M., Kliesch S., Schadel F., Nieschlag E. Clinical relevance of scrotal and transrectal ultrasonography in andrological patients. . 1995;18 Suppl 2:27-31||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Behre H.M., Kliesch S., Schadel F., Nieschlag E. Clinical relevance of scrotal and transrectal ultrasonography in andrological patients. . 1995;18 Suppl 2:27-31||692
Hodentumoren|"1.1"|2020|Bedke, Jens|Hintergrund|||Standard|Dieckmann K.P., Dralle-Filiz I., Matthies C., Heinzelbecker J., Bedke J., Ellinger J., et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. . 2016;142:1599-607||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Dralle-Filiz I., Matthies C., Heinzelbecker J., Bedke J., Ellinger J., et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. . 2016;142:1599-607||692
Hodentumoren|"1.1"|2020|Heinzelbecker, Julia|Hintergrund|||Standard|Dieckmann K.P., Dralle-Filiz I., Matthies C., Heinzelbecker J., Bedke J., Ellinger J., et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. . 2016;142:1599-607||692
Hodentumoren|"1.1"|2020|Schmidberger, Heinz|Hintergrund|||Standard|Bamberg M., Schmidberger H., Meisner C. Radiotherapy for stage I, IIA/B testicular seminoma. . 1999a;83:823-27||692
Hodentumoren|"1.1"|2020|Schmidberger, Heinz|Hintergrund|||Standard|Bamberg M., Schmidberger H., Meisner C., Classen J., Souchon R., Weinknecht S., et al. Radiotherapy for stages I and IIA/B testicular seminoma. . 1999b;83:823-7||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Bamberg M., Schmidberger H., Meisner C., Classen J., Souchon R., Weinknecht S., et al. Radiotherapy for stages I and IIA/B testicular seminoma. . 1999b;83:823-7||692
Hodentumoren|"1.1"|2020|Schmidberger, Heinz|Hintergrund|||Standard|Classen J., Schmidberger H., Meisner C., Winkler C., Dunst J., Souchon R., et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). . 2004;90:2305-11||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Evidenzbasiertes Statement|0|False|Erstautor|Dieckmann K.P., Hartmann J.T., Classen J., Ludde R., Diederichs M., Pichlmeier U. Tallness is associated with risk of testicular cancer: evidence for the nutrition hypothesis. . 2008;99:1517-21||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Hartmann J.T., Classen J., Ludde R., Diederichs M., Pichlmeier U. Tallness is associated with risk of testicular cancer: evidence for the nutrition hypothesis. . 2008;99:1517-21||692
Hodentumoren|"1.1"|2020|Albers, Peter|Evidenzbasierte Empfehlung|B|False|Erstautor|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Evidenzbasierte Empfehlung|B|False|Standard|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Standard|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Evidenzbasierte Empfehlung|B|False|Standard|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Standard|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Evidenzbasierte Empfehlung|B|False|Standard|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Schmelz, Hans|Evidenzbasierte Empfehlung|B|False|Standard|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Schmelz, Hans|Hintergrund|||Standard|Albers P., Siener R., Krege S., Schmelz H.U., Dieckmann K.P., Heidenreich A., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. . 2008;26:2966-72||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Schenkmann N. S., Sesterhenn I. A., Mostofi F. K., McCarthy W. F., Heidenreich B., et al. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. . 1997a;158:620-5||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Beyer J., Albers P., Altena R., Aparicio J., Bokemeyer C., Busch J., et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. . 2013;24:878-88||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Beyer J., Albers P., Altena R., Aparicio J., Bokemeyer C., Busch J., et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. . 2013;24:878-88||692
Hodentumoren|"1.1"|2020|Busch, Jonas|Hintergrund|||Standard|Beyer J., Albers P., Altena R., Aparicio J., Bokemeyer C., Busch J., et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. . 2013;24:878-88||692
Hodentumoren|"1.1"|2020|Albrecht, Walter|Hintergrund|||Standard|Pont J., Albrecht W., Postner G., Sellner F., Angel K., Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. . 1996;14:441-8||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. EAU Guidelines on Testicular Cancer. European Association of Urology. None. 2018;None:None||692
Hodentumoren|"1.1"|2020|Albrecht, Walter|Hintergrund|||Standard|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. EAU Guidelines on Testicular Cancer. European Association of Urology. None. 2018;None:None||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. EAU Guidelines on Testicular Cancer. European Association of Urology. None. 2018;None:None||692
Hodentumoren|"1.1"|2020|Wittekind, Christian|Hintergrund|||Letztautor|Brierley J.D., Gospodarowicz M.K., Wittekind C. TNM Classification of Malignant Tumours. ed. 8 Oxford, UK: Wiley Blackwell; 2017. . 2017;:||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Standard|Krug B., Heidenreich A., Dietlein M. et al. Lymphknotenstaging maligner testikulärer Keimzelltumoren. None. 1999;171:87–94||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Leibovitch I., Foster R. S., Kopecky K. K., Albers P., Ulbright T. M., Donohue J. P. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. . 1998;16:261-8||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Krege S., Boergermann C., Baschek R., Hinke A., Pottek T., Kliesch S., et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). . 2006;17:276-80||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Erstautor|Krege S., Boergermann C., Baschek R., Hinke A., Pottek T., Kliesch S., et al. Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). . 2006;17:276-80||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Schmoll H.J., Souchon R., Krege S., Albers P., Beyer J., Kollmannsberger C., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). . 2004;15:1377-99||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Schmoll H.J., Souchon R., Krege S., Albers P., Beyer J., Kollmannsberger C., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). . 2004;15:1377-99||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Schmoll H.J., Souchon R., Krege S., Albers P., Beyer J., Kollmannsberger C., et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). . 2004;15:1377-99||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Letztautor|Ruf C.G., Isbarn H., Wagner W., Fisch M., Matthies C., Dieckmann K.P. Changes in epidemiologic features of testicular germ cell cancer: Age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. None. 2014;32:33.e1-6||692
Hodentumoren|"1.1"|2020|Ruf, Christian|Hintergrund|||Erstautor|Ruf C.G., Isbarn H., Wagner W., Fisch M., Matthies C., Dieckmann K.P. Changes in epidemiologic features of testicular germ cell cancer: Age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. None. 2014;32:33.e1-6||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|A|False|Erstautor|Bokemeyer C., Kollmannsberger C., Stenning S., Hartmann J.T., Horwich A., Clemm C., et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. . 2004;91:683-7||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Kollmannsberger C., Stenning S., Hartmann J.T., Horwich A., Clemm C., et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. . 2004;91:683-7||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Calabro F., Albers P., Bokemeyer C., Martin C., Einhorn L.H., Horwich A., et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. . 2012;61:1212-21||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Calabro F., Albers P., Bokemeyer C., Martin C., Einhorn L.H., Horwich A., et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. . 2012;61:1212-21||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|A|True|Letztautor|Beyer J., Bokemeyer C. [Chemotherapy for germ cell cancer]. . 2004;43:1507-13||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Letztautor|Beyer J., Bokemeyer C. [Chemotherapy for germ cell cancer]. . 2004;43:1507-13||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|A|False|Erstautor|Bokemeyer C., Kollmannsberger C., Meisner C., Harstrick A., Beyer J., Metzner B., et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. . 1999b;17:3450-6||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Kollmannsberger C., Meisner C., Harstrick A., Beyer J., Metzner B., et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. . 1999b;17:3450-6||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|A|False|Standard|Oechsle K., Bokemeyer C., Kollmannsberger C., Mayer F., Berger L. A., Oing C., et al. Bone metastases in germ cell tumor patients. . 2012;138:947-52||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Oechsle K., Bokemeyer C., Kollmannsberger C., Mayer F., Berger L. A., Oing C., et al. Bone metastases in germ cell tumor patients. . 2012;138:947-52||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Evidenzbasierte Empfehlung|A|False|Erstautor|Oechsle K., Bokemeyer C., Kollmannsberger C., Mayer F., Berger L. A., Oing C., et al. Bone metastases in germ cell tumor patients. . 2012;138:947-52||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Erstautor|Oechsle K., Bokemeyer C., Kollmannsberger C., Mayer F., Berger L. A., Oing C., et al. Bone metastases in germ cell tumor patients. . 2012;138:947-52||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Evidenzbasierte Empfehlung|A|False|Standard|Oing C., Oechsle K., Necchi A., Loriot Y., De Giorgi U., Flechon A., et al. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. . 2017;28:576-582||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Standard|Oing C., Oechsle K., Necchi A., Loriot Y., De Giorgi U., Flechon A., et al. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. . 2017;28:576-582||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Evidenzbasierte Empfehlung|A|False|Standard|Feldman D.R., Lorch A., Kramar A., Albany C., Einhorn L.H., Giannatempo P., et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options-an analysis from the global germ cell cancer group. . 2016;34:345-51||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Standard|Feldman D.R., Lorch A., Kramar A., Albany C., Einhorn L.H., Giannatempo P., et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options-an analysis from the global germ cell cancer group. . 2016;34:345-51||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Nichols C.R., Droz J.P., Schmoll H.J., Horwich A., Gerl A., et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. . 2002;20:1864-73||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|A|False|Letztautor|Oechsle K., Kollmannsberger C., Honecker F., Boehlke I., Bokemeyer C. Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. . 2008b;44:1663-9||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Letztautor|Oechsle K., Kollmannsberger C., Honecker F., Boehlke I., Bokemeyer C. Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. . 2008b;44:1663-9||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Evidenzbasierte Empfehlung|A|False|Erstautor|Oechsle K., Kollmannsberger C., Honecker F., Boehlke I., Bokemeyer C. Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. . 2008b;44:1663-9||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Erstautor|Oechsle K., Kollmannsberger C., Honecker F., Boehlke I., Bokemeyer C. Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. . 2008b;44:1663-9||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Nowak P., Haupt A., Metzner B., Kohne H., Hartmann J.T., et al. Treatment of brain metastases in patients with testicular cancer. . 1997;15:1449-54||692
Hodentumoren|"1.1"|2020|Albers, Peter|Evidenzbasierte Empfehlung|B|False|Letztautor|Nini A., Konieczny M., Winter C., Lusch A., Krauspe R., Albers P. Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. . 2018;36:82.e1-82.e5||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Letztautor|Nini A., Konieczny M., Winter C., Lusch A., Krauspe R., Albers P. Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. . 2018;36:82.e1-82.e5||692
Hodentumoren|"1.1"|2020|Winter, Christian|Evidenzbasierte Empfehlung|B|False|Standard|Nini A., Konieczny M., Winter C., Lusch A., Krauspe R., Albers P. Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. . 2018;36:82.e1-82.e5||692
Hodentumoren|"1.1"|2020|Winter, Christian|Hintergrund|||Standard|Nini A., Konieczny M., Winter C., Lusch A., Krauspe R., Albers P. Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. . 2018;36:82.e1-82.e5||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasiertes Statement|B|False|Erstautor|Bokemeyer C., Kohrmann O., Tischler J., Weissbach L., Rath U., Haupt A., et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. . 1996b;7:1015-21||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Kohrmann O., Tischler J., Weissbach L., Rath U., Haupt A., et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. . 1996b;7:1015-21||692
Hodentumoren|"1.1"|2020|Pfister, David|Evidenzbasiertes Statement|B|False|Standard|Bajorin D.F., Sarosdy M.F., Pfister D.G., Mazumdar M., Motzer R.J., Scher H.I., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. . 1993;11:598-606||692
Hodentumoren|"1.1"|2020|Pfister, David|Hintergrund|||Standard|Bajorin D.F., Sarosdy M.F., Pfister D.G., Mazumdar M., Motzer R.J., Scher H.I., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. . 1993;11:598-606||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Daneshmand S., Albers P., Fossa S.D., Heidenreich A., Kollmannsberger C., Krege S., et al. Contemporary management of postchemotherapy testis cancer. . 2012;62:867-76||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Standard|Daneshmand S., Albers P., Fossa S.D., Heidenreich A., Kollmannsberger C., Krege S., et al. Contemporary management of postchemotherapy testis cancer. . 2012;62:867-76||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Daneshmand S., Albers P., Fossa S.D., Heidenreich A., Kollmannsberger C., Krege S., et al. Contemporary management of postchemotherapy testis cancer. . 2012;62:867-76||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|De Santis M., Becherer A., Bokemeyer C., Stoiber F., Oechsle K., Sellner F., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. . 2004;22:1034-9||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Standard|De Santis M., Becherer A., Bokemeyer C., Stoiber F., Oechsle K., Sellner F., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. . 2004;22:1034-9||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Standard|Stang A., Bray F., Dieckmann K.P., Lortet-Tieulent J., Rusner C. Mortality of testicular cancer in East and West Germany 20 years after reunification: a gap not closed yet. None. 2015;95:160-166||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|B|False|Standard|Pfannenberg A.C., Oechsle K., Bokemeyer C., Kollmannsberger C., Dohmen B.M., Bares R., et al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. . 2004;22:132-9||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Pfannenberg A.C., Oechsle K., Bokemeyer C., Kollmannsberger C., Dohmen B.M., Bares R., et al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. . 2004;22:132-9||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Evidenzbasierte Empfehlung|B|False|Standard|Pfannenberg A.C., Oechsle K., Bokemeyer C., Kollmannsberger C., Dohmen B.M., Bares R., et al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. . 2004;22:132-9||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Standard|Pfannenberg A.C., Oechsle K., Bokemeyer C., Kollmannsberger C., Dohmen B.M., Bares R., et al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. . 2004;22:132-9||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Evidenzbasierte Empfehlung|B|False|Erstautor|Oechsle K., Hartmann M., Brenner W., Venz S., Weissbach L., Franzius C., et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. . 2008a;26:5930-5||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Erstautor|Oechsle K., Hartmann M., Brenner W., Venz S., Weissbach L., Franzius C., et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. . 2008a;26:5930-5||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Standard|Kollmannsberger C., Oechsle K., Dohmen B.M., Pfannenberg A., Bares R., Claussen C.D., et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. . 2002a;94:2353-62||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Letztautor|Hartmann J.T., Candelaria M., Kuczyk M.A., Schmoll H.J., Bokemeyer C. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. None. 1997;33:843-7||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|B|False|Standard|Rick O., Bokemeyer C., Weinknecht S., Schirren J., Pottek T., Hartmann J. T., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. . 2004;22:3713-9||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Rick O., Bokemeyer C., Weinknecht S., Schirren J., Pottek T., Hartmann J. T., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. . 2004;22:3713-9||692
Hodentumoren|"1.1"|2020|Rick, Oliver|Evidenzbasierte Empfehlung|B|False|Erstautor|Rick O., Bokemeyer C., Weinknecht S., Schirren J., Pottek T., Hartmann J. T., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. . 2004;22:3713-9||692
Hodentumoren|"1.1"|2020|Rick, Oliver|Hintergrund|||Erstautor|Rick O., Bokemeyer C., Weinknecht S., Schirren J., Pottek T., Hartmann J. T., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. . 2004;22:3713-9||692
Hodentumoren|"1.1"|2020|Schirren, Joachim|Evidenzbasierte Empfehlung|B|False|Standard|Rick O., Bokemeyer C., Weinknecht S., Schirren J., Pottek T., Hartmann J. T., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. . 2004;22:3713-9||692
Hodentumoren|"1.1"|2020|Schirren, Joachim|Hintergrund|||Standard|Rick O., Bokemeyer C., Weinknecht S., Schirren J., Pottek T., Hartmann J. T., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. . 2004;22:3713-9||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P. Resection of retroperitoneal residual tumor after chemotherapy for testicular cancer indication and surgical techniques. . 2004;50:79-85||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P., Ganz A., Hannig E., Miersch W.D., Muller S.C. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. . 2000;164:381-4||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Evidenzbasierte Empfehlung|A|False|Standard|Schirren J., Trainer S., Eberlein M., Lorch A., Beyer J., Bolukbas S. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. . 2012;60:405-12||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Standard|Schirren J., Trainer S., Eberlein M., Lorch A., Beyer J., Bolukbas S. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. . 2012;60:405-12||692
Hodentumoren|"1.1"|2020|Schirren, Joachim|Evidenzbasierte Empfehlung|A|False|Erstautor|Schirren J., Trainer S., Eberlein M., Lorch A., Beyer J., Bolukbas S. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. . 2012;60:405-12||692
Hodentumoren|"1.1"|2020|Schirren, Joachim|Hintergrund|||Erstautor|Schirren J., Trainer S., Eberlein M., Lorch A., Beyer J., Bolukbas S. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. . 2012;60:405-12||692
Hodentumoren|"1.1"|2020|Busch, Jonas|Hintergrund|||Standard|Winter C., Pfister D., Busch J., Bingol C., Ranft U., Schrader M., et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. . 2012;61:403-9||692
Hodentumoren|"1.1"|2020|Pfister, David|Hintergrund|||Standard|Winter C., Pfister D., Busch J., Bingol C., Ranft U., Schrader M., et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. . 2012;61:403-9||692
Hodentumoren|"1.1"|2020|Schrader, Mark|Hintergrund|||Standard|Winter C., Pfister D., Busch J., Bingol C., Ranft U., Schrader M., et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. . 2012;61:403-9||692
Hodentumoren|"1.1"|2020|Winter, Christian|Hintergrund|||Erstautor|Winter C., Pfister D., Busch J., Bingol C., Ranft U., Schrader M., et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. . 2012;61:403-9||692
Hodentumoren|"1.1"|2020|Busch, Jonas|Hintergrund|||Erstautor|Busch J., Magheli A., Erber B., Friedersdorff F., Hoffmann I., Kempkensteffen C., et al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis. . 2012;12:15||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Erstautor|Oechsle K., Kollmannsberger C., Honecker F., Mayer F., Waller C. F., Hartmann J. T., et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. None. 2011b;60:850-5||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Evidenzbasierte Empfehlung|A|False|Erstautor|Oechsle K., Kollmannsberger C., Honecker F., Mayer F., Waller C. F., Hartmann J. T., et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. . 2011b;60:850-5||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|B|False|Standard|Lorch A., Rick O., Wundisch T., Hartmann J. T., Bokemeyer C., Beyer J. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. . 2010b;184:168-73||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Lorch A., Rick O., Wundisch T., Hartmann J. T., Bokemeyer C., Beyer J. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. . 2010b;184:168-73||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Evidenzbasierte Empfehlung|B|False|Erstautor|Lorch A., Rick O., Wundisch T., Hartmann J. T., Bokemeyer C., Beyer J. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. . 2010b;184:168-73||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Erstautor|Lorch A., Rick O., Wundisch T., Hartmann J. T., Bokemeyer C., Beyer J. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. . 2010b;184:168-73||692
Hodentumoren|"1.1"|2020|Rick, Oliver|Evidenzbasierte Empfehlung|B|False|Standard|Lorch A., Rick O., Wundisch T., Hartmann J. T., Bokemeyer C., Beyer J. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. . 2010b;184:168-73||692
Hodentumoren|"1.1"|2020|Rick, Oliver|Hintergrund|||Standard|Lorch A., Rick O., Wundisch T., Hartmann J. T., Bokemeyer C., Beyer J. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. . 2010b;184:168-73||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. . 2004;22:2-14||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Erstautor|Lorch A., Beyer J., Bascoul-Mollevi C., Kramar A., Einhorn L. H., Necchi A., et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. . 2010a;28:4906-11||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|B|False|Standard|Berger L.A., Bokemeyer C., Lorch A., Hentrich M., Kopp H.G., Gauler T.C., et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). . 2014;140:1211-20||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Berger L.A., Bokemeyer C., Lorch A., Hentrich M., Kopp H.G., Gauler T.C., et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). . 2014;140:1211-20||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Evidenzbasierte Empfehlung|B|False|Standard|Berger L.A., Bokemeyer C., Lorch A., Hentrich M., Kopp H.G., Gauler T.C., et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). . 2014;140:1211-20||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Standard|Berger L.A., Bokemeyer C., Lorch A., Hentrich M., Kopp H.G., Gauler T.C., et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). . 2014;140:1211-20||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Erstautor|Lorch A., Bascoul-Mollevi C., Kramar A., Einhorn L., Necchi A., Massard C., et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. . 2011;29:2178-84||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Rick O., Bokemeyer C., Beyer J., Hartmann J. T., Schwella N., Kingreen D., et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. . 2001;19:81-8||692
Hodentumoren|"1.1"|2020|Rick, Oliver|Hintergrund|||Erstautor|Rick O., Bokemeyer C., Beyer J., Hartmann J. T., Schwella N., Kingreen D., et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. . 2001;19:81-8||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Erstautor|Lorch A., Kollmannsberger C., Hartmann J. T., Metzner B., Schmidt-Wolf I. G., Berdel W. E., et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. . 2007;25:2778-84||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Lorch A., Kleinhans A., Kramar A., Kollmannsberger C. K., Hartmann J. T., Bokemeyer C., et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. . 2012;30:800-5||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Erstautor|Lorch A., Kleinhans A., Kramar A., Kollmannsberger C. K., Hartmann J. T., Bokemeyer C., et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. . 2012;30:800-5||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Ohlmann C., Hegele A., Beyer J. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. . 2005;47:64-71||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Oing C., Lorch A., Bokemeyer C., Honecker F., Beyer J., Berger L. A., et al. First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database. . 2015;141:923-31||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Standard|Oing C., Lorch A., Bokemeyer C., Honecker F., Beyer J., Berger L. A., et al. First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database. . 2015;141:923-31||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Haidl F., Paffenholz P., Pape C., Neumann U., Pfister D. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. . 2017;28:362-367||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Dieckmann K.P., Albers P., Classen J., De Wit M., Pichlmeier U., Rick O., et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. . 2005;173:824-9||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Albers P., Classen J., De Wit M., Pichlmeier U., Rick O., et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. . 2005;173:824-9||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Gerl A., Schoffski P., Harstrick A., Niederle N., Beyer J., et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. . 1999a;17:512-6||692
Hodentumoren|"1.1"|2020|Rick, Oliver|Hintergrund|||Standard|Kollmannsberger C., Rick O., Derigs H.G., Schleucher N., Schoffski P., Beyer J., et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. . 2002b;20:2031-7||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Beyer J., Metzner B., Ruther U., Harstrick A., Weissbach L., et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. . 1996a;7:31-4||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Schmoll H.J., Natt F., Knoche M., Beyer J., Souchon R. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. . 1994;120:754-7||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Letztautor|Bokemeyer C., Schmoll H.J., Natt F., Knoche M., Beyer J., Souchon R. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. . 1994;120:754-7||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Erstautor|Oechsle K., Honecker F., Cheng T., Mayer F., Czaykowski P., Winquist E., et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. . 2011a;22:2654-60||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Evidenzbasierte Empfehlung|A|False|Erstautor|Bokemeyer C., Oechsle K., Honecker F., Mayer F., Hartmann J.T., Waller C.F., et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. . 2008;19:448-53||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Oechsle K., Honecker F., Mayer F., Hartmann J.T., Waller C.F., et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. . 2008;19:448-53||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Evidenzbasierte Empfehlung|A|False|Standard|Bokemeyer C., Oechsle K., Honecker F., Mayer F., Hartmann J.T., Waller C.F., et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. . 2008;19:448-53||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Standard|Bokemeyer C., Oechsle K., Honecker F., Mayer F., Hartmann J.T., Waller C.F., et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. . 2008;19:448-53||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Standard|Seidel C., Oechsle K., Lorch A., Dieing A., Hentrich M., Hornig M., et al. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group. . 2016;34:167.e21-8||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Standard|Seidel C., Oechsle K., Lorch A., Dieing A., Hentrich M., Hornig M., et al. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group. . 2016;34:167.e21-8||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Droz J. P., Horwich A., Gerl A., Fossa S.D., Beyer J., et al. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. . 2001;91:1394-401||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Letztautor|Lock G., Schroder C., Schmidt C., Anheuser P., Loening T., Dieckmann K. P. Contrast-enhanced ultrasound and real-time elastography for the diagnosis of benign Leydig cell tumors of the testis - a single center report on 13 cases. . 2014;35:534-9||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Loy V. Epidermoid cyst of the testis: a review of clinical and histogenetic considerations. . 1994;73:436-41||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Souchon R., Krege S., Schmoll H. J., Albers P., Beyer J., Bokemeyer C., et al. [Interdisciplinary consensus on diagnosis and therapy of testicular tumors. Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG)]. . 2000;176:388-405||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Souchon R., Krege S., Schmoll H. J., Albers P., Beyer J., Bokemeyer C., et al. [Interdisciplinary consensus on diagnosis and therapy of testicular tumors. Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG)]. . 2000;176:388-405||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Souchon R., Krege S., Schmoll H. J., Albers P., Beyer J., Bokemeyer C., et al. [Interdisciplinary consensus on diagnosis and therapy of testicular tumors. Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG)]. . 2000;176:388-405||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Erstautor|Souchon R., Krege S., Schmoll H. J., Albers P., Beyer J., Bokemeyer C., et al. [Interdisciplinary consensus on diagnosis and therapy of testicular tumors. Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG)]. . 2000;176:388-405||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Souchon R., Hartmann M., Krege S., Lorch A., Mayer F., De Santis M., et al. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. . 2011;187:158-66||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Standard|Souchon R., Hartmann M., Krege S., Lorch A., Mayer F., De Santis M., et al. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. . 2011;187:158-66||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Erstautor|Souchon R., Hartmann M., Krege S., Lorch A., Mayer F., De Santis M., et al. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. . 2011;187:158-66||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Hartmann M., Krege S., Souchon R., De Santis M., Gillessen S., Cathomas R. [Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations]. . 2011;50:830-5||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Hartmann M., Krege S., Souchon R., De Santis M., Gillessen S., Cathomas R. [Follow-up of testicular germ cell cancer patients: interdisciplinary evidence-based recommendations]. . 2011;50:830-5||692
Hodentumoren|"1.1"|2020|Krege, Susanne|Hintergrund|||Standard|Cathomas R., Hartmann M., Krege S., Souchon R., Lorch A., Mayer F., et al. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. . 2011;34:59-64||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Standard|Cathomas R., Hartmann M., Krege S., Souchon R., Lorch A., Mayer F., et al. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. . 2011;34:59-64||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Cathomas R., Hartmann M., Krege S., Souchon R., Lorch A., Mayer F., et al. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. . 2011;34:59-64||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Letztautor|Dohle G.R., Arver S., Bettocchi C., Jones T.H., Kliesch S. EAU-Leitlinie Männlicher Hypogonadismus. None. 2018;15:71-88||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Letztautor|Hartmann J.T., Albrecht C., Schmoll H.J., Kuczyk M.A., Kollmannsberger C., Bokemeyer C. Long-term effects on sexual function and fertility after treatment of testicular cancer. . 1999;80:801-7||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Letztautor|Puehse G., Secker A., Kemper S., Hertle L., Kliesch S. Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. . 2011;34:e351-7||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Puehse G., Wachsmuth J. U., Kemper S., Husstedt I. W., Kliesch S., Evers S. Phantom testis syndrome: prevalence, phenomenology and putative mechanisms. . 2010;33:e216-20||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Schmoll H. J. Treatment of testicular cancer and the development of secondary malignancies. . 1995;13:283-92||692
Hodentumoren|"1.1"|2020|Heidenreich, Axel|Hintergrund|||Standard|Heidegger I., Porres D., Veek N., Heidenreich A., Pfister D. Predictive factors for developing venous thrombosis during cisplatin-based chemotherapy in testicular cancer. . 2017;99:104-109||692
Hodentumoren|"1.1"|2020|Pfister, David|Hintergrund|||Letztautor|Heidegger I., Porres D., Veek N., Heidenreich A., Pfister D. Predictive factors for developing venous thrombosis during cisplatin-based chemotherapy in testicular cancer. . 2017;99:104-109||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Erstautor|Bokemeyer C., Berger C.C., Hartmann J.T., Kollmannsberger C., Schmoll H.J., Kuczyk M.A., et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. . 1998;77:1355-62||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Letztautor|Kollmannsberger C., Hartmann J.T., Kanz L., Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. . 1998b;124:207-14||692
Hodentumoren|"1.1"|2020|Rick, Oliver|Hintergrund|||Erstautor|Rick O. Oncological Rehabilitation. None. 2017;None:None||692
Hodentumoren|"1.1"|2020|Rick, Oliver|Hintergrund|||Erstautor|Rick O. Onkologische Rehabilitation als „Initialzünder“. None. 2016;(4):44-47||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Iversen K., Oechsle K., Oing C., Bokemeyer C., Seidel C. Specific characteristics of patients with advanced genitourinary cancer receiving specialized inpatient palliative care. . 2017;40:609-614||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Standard|Iversen K., Oechsle K., Oing C., Bokemeyer C., Seidel C. Specific characteristics of patients with advanced genitourinary cancer receiving specialized inpatient palliative care. . 2017;40:609-614||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Oechsle K., Hartmann M., Mehnert A., Oing C., Bokemeyer C., Vehling S. Symptom burden in long-term germ cell tumor survivors. . 2016;24:2243-2250||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Erstautor|Oechsle K., Hartmann M., Mehnert A., Oing C., Bokemeyer C., Vehling S. Symptom burden in long-term germ cell tumor survivors. . 2016;24:2243-2250||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Hartung T.J., Mehnert A., Friedrich M., Hartmann M., Vehling S., Bokemeyer C., et al. Age-related variation and predictors of long-term quality of life in germ cell tumor survivors. . 2016;34:60.e1-6||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Vehling S., Mehnert A., Hartmann M., Oing C., Bokemeyer C., Oechsle K. Anxiety and depression in long-term testicular germ cell tumor survivors. . 2016;38:21-5||692
Hodentumoren|"1.1"|2020|Oechsle, Karin|Hintergrund|||Letztautor|Vehling S., Mehnert A., Hartmann M., Oing C., Bokemeyer C., Oechsle K. Anxiety and depression in long-term testicular germ cell tumor survivors. . 2016;38:21-5||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Erstautor|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. EAU Guideline on testicular cancer. None. 2017;None:None||692
Hodentumoren|"1.1"|2020|Albrecht, Walter|Hintergrund|||Standard|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. EAU Guideline on testicular cancer. None. 2017;None:None||692
Hodentumoren|"1.1"|2020|Bokemeyer, Carsten|Hintergrund|||Standard|Albers P., Albrecht W., Algaba F., Bokemeyer C., Cohn-Cedermark G., Fizazi K., et al. EAU Guideline on testicular cancer. None. 2017;None:None||692
Hodentumoren|"1.1"|2020|Albers, Peter|Hintergrund|||Standard|Lorch A., Albers P., Beyer J., Cathomas R., Oing C., Souchon R., et al. Keimzelltumoren des Mannes. Leitlinie der DGHO. URL: https://www.onkopedia.com/de/onkopedia/guidelines/keimzelltumoren-des-mannes/@@view/pdf/index.pdf. Zugriff am 14.11.2017. None. 2016;None:None||692
Hodentumoren|"1.1"|2020|Lorch, Anja|Hintergrund|||Erstautor|Lorch A., Albers P., Beyer J., Cathomas R., Oing C., Souchon R., et al. Keimzelltumoren des Mannes. Leitlinie der DGHO. URL: https://www.onkopedia.com/de/onkopedia/guidelines/keimzelltumoren-des-mannes/@@view/pdf/index.pdf. Zugriff am 14.11.2017. None. 2016;None:None||692
Hodentumoren|"1.1"|2020|Souchon, Rainer|Hintergrund|||Standard|Lorch A., Albers P., Beyer J., Cathomas R., Oing C., Souchon R., et al. Keimzelltumoren des Mannes. Leitlinie der DGHO. URL: https://www.onkopedia.com/de/onkopedia/guidelines/keimzelltumoren-des-mannes/@@view/pdf/index.pdf. Zugriff am 14.11.2017. None. 2016;None:None||692
Hodentumoren|"1.1"|2020|Dieckmann, Klaus Peter|Hintergrund|||Erstautor|Dieckmann K.P., Radtke A., Spiekermann M., Balks T., Matthies C., Becker P., et al. Serum levels of microRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours. . 2017;71:213-220||692
Hodentumoren|"1.1"|2020|Kliesch, Sabine|Hintergrund|||Standard|Radtke A., Cremers J. F., Kliesch S., Riek S., Junker K., Mohamed S. A., et al. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?. . 2017;143:2383-2392||692
Endometriumkarzinom|"2.0"|2022|Weis, Joachim|Hintergrund|||Standard|Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol. 2013;31 (6):782-93|https://pubmed.ncbi.nlm.nih.gov/23319686/|3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn LC, Trost M, Bilek K. Staging of endometrial carcinoma: aspects of ovarian and cervical involvement. Int J Gynecol Pathol. 2010;29 (1):63-6|https://pubmed.ncbi.nlm.nih.gov/19952935/|3017
Endometriumkarzinom|"2.0"|2022|Kommoss, Stefan|Evidenzbasierte Empfehlung|0|False|Erstautor|Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29 (5):1180-1188|https://pubmed.ncbi.nlm.nih.gov/29432521/|3017
Endometriumkarzinom|"2.0"|2022|Kommoss, Stefan|Hintergrund|||Erstautor|Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29 (5):1180-1188|https://pubmed.ncbi.nlm.nih.gov/29432521/|3017
Endometriumkarzinom|"2.0"|2022|Mueller, Michael D.|Hintergrund|||Letztautor|Papadia A, Gasparri ML, Buda A, Mueller MD. Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue. J Cancer Res Clin Oncol. 2017;143 (10):2039-2048|https://pubmed.ncbi.nlm.nih.gov/28828528/|3017
Endometriumkarzinom|"2.0"|2022|Fleisch, Markus|Evidenzbasiertes Statement||False|Letztautor|Dörk T, Hillemanns P, Tempfer C, Breu J, Fleisch MC. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32854222/|3017
Endometriumkarzinom|"2.0"|2022|Fleisch, Markus|Hintergrund|||Letztautor|Dörk T, Hillemanns P, Tempfer C, Breu J, Fleisch MC. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32854222/|3017
Endometriumkarzinom|"2.0"|2022|Tempfer, Clemens|Evidenzbasiertes Statement||False|Standard|Dörk T, Hillemanns P, Tempfer C, Breu J, Fleisch MC. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32854222/|3017
Endometriumkarzinom|"2.0"|2022|Tempfer, Clemens|Hintergrund|||Standard|Dörk T, Hillemanns P, Tempfer C, Breu J, Fleisch MC. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32854222/|3017
Endometriumkarzinom|"2.0"|2022|Emons, Günter|Evidenzbasiertes Statement||False|Erstautor|Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Mustea, Alexander|Evidenzbasiertes Statement||False|Standard|Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Tempfer, Clemens|Evidenzbasiertes Statement||False|Letztautor|Emons G, Mustea A, Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Ortmann, Olaf|Evidenzbasiertes Statement||False|Letztautor|Ignatov A, Ortmann O. Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. Cancers (Basel). 2020;12 (7):|https://pubmed.ncbi.nlm.nih.gov/32630728/|3017
Endometriumkarzinom|"2.0"|2022|Ortmann, Olaf|Hintergrund|||Letztautor|Ignatov A, Ortmann O. Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. Cancers (Basel). 2020;12 (7):|https://pubmed.ncbi.nlm.nih.gov/32630728/|3017
Endometriumkarzinom|"2.0"|2022|Tempfer, Clemens|Evidenzbasiertes Statement||False|Erstautor|Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. Cancers (Basel). 2020;12 (8):|https://pubmed.ncbi.nlm.nih.gov/32781573/|3017
Endometriumkarzinom|"2.0"|2022|Tempfer, Clemens|Hintergrund|||Erstautor|Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. Cancers (Basel). 2020;12 (8):|https://pubmed.ncbi.nlm.nih.gov/32781573/|3017
Endometriumkarzinom|"2.0"|2022|Vordermark, Dirk|Hintergrund|||Erstautor|Vordermark D, Medenwald D, Izaguirre V, Sieker F, Marnitz S. The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus. Cancers (Basel). 2020;12 (12):|https://pubmed.ncbi.nlm.nih.gov/33265910/|3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn LC, Höhn AK, Krücken I, Stiller M, Obeck U, Brambs CE. Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma. J Cancer Res Clin Oncol. 2020;146 (4):971-983|https://pubmed.ncbi.nlm.nih.gov/31927619/|3017
Endometriumkarzinom|"2.0"|2022|Lax, Sigurd|Hintergrund|||Standard|Peters EEM, Bartosch C, McCluggage WG, Genestie C, Lax SF, Nout R, et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology. 2019;75 (1):128-136|https://pubmed.ncbi.nlm.nih.gov/31155736/|3017
Endometriumkarzinom|"2.0"|2022|Beckmann, Matthias W.|Hintergrund|||Standard|Emons G, Beckmann MW, Schmidt D, Mallmann P. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015;75 (2):135-136|https://pubmed.ncbi.nlm.nih.gov/25797956/|3017
Endometriumkarzinom|"2.0"|2022|Emons, Günter|Hintergrund|||Erstautor|Emons G, Beckmann MW, Schmidt D, Mallmann P. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015;75 (2):135-136|https://pubmed.ncbi.nlm.nih.gov/25797956/|3017
Endometriumkarzinom|"2.0"|2022|Mallmann, Peter|Hintergrund|||Letztautor|Emons G, Beckmann MW, Schmidt D, Mallmann P. New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015;75 (2):135-136|https://pubmed.ncbi.nlm.nih.gov/25797956/|3017
Endometriumkarzinom|"2.0"|2022|Mayr, Doris|Hintergrund|||Standard|Höhn AK, Brambs CE, Erber R, Hiller GGR, Mayr D, Schmidt D, et al. [Reporting and handling of lymphonodectomy specimens in gynecologic malignancies and sentinel lymph nodes]. Pathologe. 2021;42 (3):319-327|https://pubmed.ncbi.nlm.nih.gov/32700061/|3017
Endometriumkarzinom|"2.0"|2022|Kommoss, Stefan|Evidenzbasierte Empfehlung|A|False|Standard|Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019;154 (1):124-130|https://pubmed.ncbi.nlm.nih.gov/31103324/|3017
Endometriumkarzinom|"2.0"|2022|Kommoss, Stefan|Hintergrund|||Standard|Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger LFAG, Snijders MPML, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019;154 (1):124-130|https://pubmed.ncbi.nlm.nih.gov/31103324/|3017
Endometriumkarzinom|"2.0"|2022|Kommoss, Stefan|Hintergrund|||Standard|Marnitz S, Walter T, Schömig-Markiefka B, Engler T, Kommoss S, Brucker SY. A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?. Cancers (Basel). 2020;12 (9):|https://pubmed.ncbi.nlm.nih.gov/32927671/|3017
Endometriumkarzinom|"2.0"|2022|Beckmann, Matthias W.|Hintergrund|||Standard|Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, et al. [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology]. Pathologe. 2015;36 (6):585-93|https://pubmed.ncbi.nlm.nih.gov/26483249/|3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, et al. [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology]. Pathologe. 2015;36 (6):585-93|https://pubmed.ncbi.nlm.nih.gov/26483249/|3017
Endometriumkarzinom|"2.0"|2022|Mallmann, Peter|Hintergrund|||Standard|Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, et al. [S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology]. Pathologe. 2015;36 (6):585-93|https://pubmed.ncbi.nlm.nih.gov/26483249/|3017
Endometriumkarzinom|"2.0"|2022|Lax, Sigurd|Hintergrund|||Erstautor|Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol. 2000;24 (9):1201-8|https://pubmed.ncbi.nlm.nih.gov/10976693/|3017
Endometriumkarzinom|"2.0"|2022|Lax, Sigurd|Hintergrund|||Erstautor|Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444 (3):213-23|https://pubmed.ncbi.nlm.nih.gov/14747944/|3017
Endometriumkarzinom|"2.0"|2022|Lax, Sigurd|Hintergrund|||Erstautor|Lax SF. Pathology of Endometrial Carcinoma. Adv Exp Med Biol. 2017;943 ():75-96|https://pubmed.ncbi.nlm.nih.gov/PMID: 27910065/|3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Schnurrbusch U., Bilek K., Hentschel B., Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. . 2004;14:348-53|https://www.ncbi.nlm.nih.gov/pubmed/15086736|3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Dallacker M., Bilek K. [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors]. . 2009;30:292-301|https://www.ncbi.nlm.nih.gov/pubmed/19495763|3017
Endometriumkarzinom|"2.0"|2022|Mallmann, Peter|Hintergrund|||Standard|Denschlag D., Thiel F. C., Ackermann S., Harter P., Juhasz-Boess I., Mallmann P., et al. Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). . 2015;75:1028-1042|https://www.ncbi.nlm.nih.gov/pubmed/26640293|3017
Endometriumkarzinom|"2.0"|2022|Lax, Sigurd|Hintergrund|||Erstautor|Lax Sigurd F. Pathology of Endometrial Carcinoma. None. 2017;None:75-96|https://doi.org/10.1007/978-3-319-43139-0_3|3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Trost M., Bilek K. Staging of endometrial carcinoma: aspects of ovarian and cervical involvement. . 2009;29:63-6|https://www.ncbi.nlm.nih.gov/pubmed/19952935|3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Letztautor|Steiner E., Einenkel J., Schmidt D., Horn L. C. Prädiktive und prognostische Marker beim Endometriumkarzinom. . 2012;:|https://www.researchgate.net/publication/257455370_Pradiktive_und_prognostische_Marker_beim_Endometriumkarzinom|3017
Endometriumkarzinom|"2.0"|2022|Steiner, Eric|Hintergrund|||Erstautor|Steiner E., Einenkel J., Schmidt D., Horn L. C. Prädiktive und prognostische Marker beim Endometriumkarzinom. . 2012;:|https://www.researchgate.net/publication/257455370_Pradiktive_und_prognostische_Marker_beim_Endometriumkarzinom|3017
Endometriumkarzinom|"2.0"|2022|Mustea, Alexander|Hintergrund|||Standard|Polcher M., Hauptmann S., Fotopoulou C., Schmalfeldt B., Meinhold-Heerlein I., Mustea A., et al. Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO. . 2015;292:231-4|https://www.ncbi.nlm.nih.gov/pubmed/25914073|3017
Endometriumkarzinom|"2.0"|2022|Emons, Günter|Evidenzbasierte Empfehlung|0|False|Erstautor|Emons G., Mustea A., Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. . 2020;12:|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Emons, Günter|Hintergrund|||Erstautor|Emons G., Mustea A., Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. . 2020;12:|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Mustea, Alexander|Evidenzbasierte Empfehlung|0|False|Standard|Emons G., Mustea A., Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. . 2020;12:|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Mustea, Alexander|Hintergrund|||Standard|Emons G., Mustea A., Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. . 2020;12:|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Tempfer, Clemens|Evidenzbasierte Empfehlung|0|False|Letztautor|Emons G., Mustea A., Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. . 2020;12:|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Tempfer, Clemens|Hintergrund|||Letztautor|Emons G., Mustea A., Tempfer C. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. . 2020;12:|https://pubmed.ncbi.nlm.nih.gov/32906618/|3017
Endometriumkarzinom|"2.0"|2022|Weis, Joachim|Hintergrund|||Erstautor|Weis J Giesler J.M. Standards in der psychosozialen Versorgung von Krebspatienten. None. 2016;22:198-205|http://link.springer.com/article/10.1007/s00761-015-2938-9|3017
Endometriumkarzinom|"2.0"|2022|Weis, Joachim|Hintergrund|||Letztautor|Herschbach P., Weis J. Screeningverfahren in der Psychoonkologie. . 2010;:||3017
Endometriumkarzinom|"2.0"|2022|Weis, Joachim|Hintergrund|||Erstautor|Weis J., Giesler J. M. Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence. . 2008;73:511-8|https://www.ncbi.nlm.nih.gov/pubmed/18952394|3017
Endometriumkarzinom|"2.0"|2022|Battista, Marco J.|Hintergrund|||Standard|Baptiste C. G., Battista M. C., Trottier A., Baillargeon J. P. Insulin and hyperandrogenism in women with polycystic ovary syndrome. . 2009;122:42-52|https://www.ncbi.nlm.nih.gov/pubmed/20036327|3017
Endometriumkarzinom|"2.0"|2022|Beckmann, Matthias W.|Hintergrund|||Standard|Wesselmann S., Beckmann M. W., Winter A. The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care. . 2013;289:7-12|https://www.ncbi.nlm.nih.gov/pubmed/24220845|3017
Endometriumkarzinom|"2.0"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann M. W., Adler G., Albers P., Bruns J. Dreistufenmodell optimiert Behandlung unter Kostendeckung Wie die künftigen Strukturen der onkologischen Versorgung in Deutschland aussehen sollten. . 2007;104:3004-3009|https://www.aerzteblatt.de/archiv/57409/Onkologie-Dreistufenmodell-optimiert-Behandlung-unter-Kostendeckung-Wie-die-kuenftigen-Strukturen-der-onkologischen-Versorgung-in-Deutschland-aussehen-sollten|3017
Endometriumkarzinom|"2.0"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann M. W., et al. Der neue Schwerpunkt Gynäkologische Onkologie: nationale und internationale Chance?. . 2006;66:123-127||3017
Endometriumkarzinom|"2.0"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann M. W. Frauenarzt/-ärztin der Zukunft: müssen die Kliniken neu strukturiert werden?. . 2010;43:748-756|https://www.springermedizin.de/frauenarzt-aerztin-der-zukunft-muessen-die-kliniken-neu-struktur/8104622|3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn LC, Hoehn AK. Processing and Histopathological Workup of Hysterectomy Specimens. In: Alkatout I, Mettler L (Hrsg) Hysterectomy. A Comprehensive Surgical Approach. Springer International Publishing. Cham. 2018;None:259||3017
Endometriumkarzinom|"2.0"|2022|Horn, Lars-Christian|Hintergrund|||Letztautor|Mayr Doris, Schmoeckel Elisa, Höhn Anne Kathrin, Hiller Grit Gesine Ruth, Horn Lars-Christian. Aktuelle WHO-Klassifikation des weiblichen Genitale. None. 2021;42:259|https://doi.org/10.1007/s00292-021-00933-w|3017
Endometriumkarzinom|"2.0"|2022|Mayr, Doris|Hintergrund|||Erstautor|Mayr Doris, Schmoeckel Elisa, Höhn Anne Kathrin, Hiller Grit Gesine Ruth, Horn Lars-Christian. Aktuelle WHO-Klassifikation des weiblichen Genitale. None. 2021;42:259|https://doi.org/10.1007/s00292-021-00933-w|3017
Ösophaguskarzinom|"3.1"|2022|Ell, Christian|Hintergrund|||Letztautor|Pech Oliver, May Andrea, Gunter Erwin, Gossner Liebwin, Ell Christian. The Impact of Endoscopic Ultrasound and Computed Tomography on the TNM Staging of Early Cancer in Barrett's Esophagus. . 2006;101:2223-2229|https://pubmed.ncbi.nlm.nih.gov/17032186/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Erstautor|Pech Oliver, May Andrea, Gunter Erwin, Gossner Liebwin, Ell Christian. The Impact of Endoscopic Ultrasound and Computed Tomography on the TNM Staging of Early Cancer in Barrett's Esophagus. . 2006;101:2223-2229|https://pubmed.ncbi.nlm.nih.gov/17032186/|858
Ösophaguskarzinom|"3.1"|2022|Langer, Rupert|Hintergrund|||Standard|Heger U., Blank S., Wiecha C., Langer R., Weichert W., Lordick F., et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?. . 2014;21:1739-48|https://pubmed.ncbi.nlm.nih.gov/24419755/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Standard|Heger U., Blank S., Wiecha C., Langer R., Weichert W., Lordick F., et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?. . 2014;21:1739-48|https://pubmed.ncbi.nlm.nih.gov/24419755/|858
Ösophaguskarzinom|"3.1"|2022|Grenacher, Lars|Hintergrund|||Standard|Blank S., Lordick F., Dobritz M., Grenacher L., Burian M., Langer R., et al. A reliable risk score for stage IV esophagogastric cancer. . 2013;39:823-30|https://pubmed.ncbi.nlm.nih.gov/23375470/|858
Ösophaguskarzinom|"3.1"|2022|Langer, Rupert|Hintergrund|||Standard|Blank S., Lordick F., Dobritz M., Grenacher L., Burian M., Langer R., et al. A reliable risk score for stage IV esophagogastric cancer. . 2013;39:823-30|https://pubmed.ncbi.nlm.nih.gov/23375470/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Standard|Blank S., Lordick F., Dobritz M., Grenacher L., Burian M., Langer R., et al. A reliable risk score for stage IV esophagogastric cancer. . 2013;39:823-30|https://pubmed.ncbi.nlm.nih.gov/23375470/|858
Ösophaguskarzinom|"3.1"|2022|Grenacher, Lars|Hintergrund|||Standard|Blank S., Stange A., Sisic L., Roth W., Grenacher L., Sterzing F., et al. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. . 2013;398:211-20|https://pubmed.ncbi.nlm.nih.gov/23224565/|858
Ösophaguskarzinom|"3.1"|2022|Grenacher, Lars|Hintergrund|||Standard|Blank S., Blaker H., Schaible A., Lordick F., Grenacher L., Buechler M., et al. Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. . 2012;397:45-55|https://pubmed.ncbi.nlm.nih.gov/21598045/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Standard|Blank S., Blaker H., Schaible A., Lordick F., Grenacher L., Buechler M., et al. Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. . 2012;397:45-55|https://pubmed.ncbi.nlm.nih.gov/21598045/|858
Ösophaguskarzinom|"3.1"|2022|Porschen, Rainer|Hintergrund|||Standard|Sarbia M., Porschen R., Borchard F., Horstmann O., Willers R., Gabbert H. E. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. . 1994;74:2218-23|https://pubmed.ncbi.nlm.nih.gov/7922972/|858
Ösophaguskarzinom|"3.1"|2022|Langer, Rupert|Hintergrund|||Erstautor|Langer R., Ott K., Feith M., Lordick F., Siewert J. R., Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. . 2009;22:1555-63|https://pubmed.ncbi.nlm.nih.gov/19801967/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Standard|Langer R., Ott K., Feith M., Lordick F., Siewert J. R., Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. . 2009;22:1555-63|https://pubmed.ncbi.nlm.nih.gov/19801967/|858
Ösophaguskarzinom|"3.1"|2022|Langer, Rupert|Hintergrund|||Standard|Becker K., Langer R., Reim D., Novotny A., Meyer zum Buschenfelde C., Engel J., et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. . 2011;253:934-9|https://pubmed.ncbi.nlm.nih.gov/21490451/|858
Ösophaguskarzinom|"3.1"|2022|Meyer, Hans-Joachim|Hintergrund|||Standard|Weimann A., Meyer H. J., Muller M. J., Stenkhoff P., Miholic J., Jahne J., et al. Significance of preoperative weight loss for perioperative metabolic adaptation and surgical risk in patients with tumors of the upper gastrointestinal tract. . 1992;377:45-52|https://pubmed.ncbi.nlm.nih.gov/1569804/|858
Ösophaguskarzinom|"3.1"|2022|Weimann, Arved|Hintergrund|||Erstautor|Weimann A., Meyer H. J., Muller M. J., Stenkhoff P., Miholic J., Jahne J., et al. Significance of preoperative weight loss for perioperative metabolic adaptation and surgical risk in patients with tumors of the upper gastrointestinal tract. . 1992;377:45-52|https://pubmed.ncbi.nlm.nih.gov/1569804/|858
Ösophaguskarzinom|"3.1"|2022|Weimann, Arved|Hintergrund|||Letztautor|Falkner D., Plato R., Weimann A. Die Wertigkeit der Feinnadelkatheterjejunostomie in der postoperativen enteralen Ernährung nach Ösophagusresektion. Deutsche Gesellschaft für Chirurgie. 131. Kongress der Dt. Gesellschaft für Chirurgie. Berlin 25.-28.03.2014. None. None;None:None||858
Ösophaguskarzinom|"3.1"|2022|Weimann, Arved|Evidenzbasierte Empfehlung|A|False|Erstautor|Weimann A., Breitenstein S., Breuer J. P., Gabor S. E., Holland-Cunz S., Kemen M., et al. Clinical nutrition in surgery. Guidelines of the German Society for Nutritional Medicine. . 2014;85:320-6|https://pubmed.ncbi.nlm.nih.gov/24718444/|858
Ösophaguskarzinom|"3.1"|2022|Weimann, Arved|Hintergrund|||Erstautor|Weimann A., Breitenstein S., Breuer J. P., Gabor S. E., Holland-Cunz S., Kemen M., et al. Clinical nutrition in surgery. Guidelines of the German Society for Nutritional Medicine. . 2014;85:320-6|https://pubmed.ncbi.nlm.nih.gov/24718444/|858
Ösophaguskarzinom|"3.1"|2022|Ell, Christian|Hintergrund|||Standard|Pech O., Bollschweiler E., Manner H., Leers J., Ell C., Holscher A. H. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. . 2011;254:67-72|https://pubmed.ncbi.nlm.nih.gov/21532466/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Erstautor|Pech O., Bollschweiler E., Manner H., Leers J., Ell C., Holscher A. H. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. . 2011;254:67-72|https://pubmed.ncbi.nlm.nih.gov/21532466/|858
Ösophaguskarzinom|"3.1"|2022|Ell, Christian|Hintergrund|||Erstautor|Ell C., May A., Gossner L., Pech O., Gunter E., Mayer G., et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. . 2000;118:670-7|https://pubmed.ncbi.nlm.nih.gov/10734018/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Standard|Ell C., May A., Gossner L., Pech O., Gunter E., Mayer G., et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. . 2000;118:670-7|https://pubmed.ncbi.nlm.nih.gov/10734018/|858
Ösophaguskarzinom|"3.1"|2022|Ell, Christian|Hintergrund|||Erstautor|Ell C., May A., Pech O., Gossner L., Guenter E., Behrens A., et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). . 2007;65:3-10|https://pubmed.ncbi.nlm.nih.gov/17185072/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Standard|Ell C., May A., Pech O., Gossner L., Guenter E., Behrens A., et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). . 2007;65:3-10|https://pubmed.ncbi.nlm.nih.gov/17185072/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Erstautor|Pech O., Behrens A., May A., Nachbar L., Gossner L., Rabenstein T., et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. . 2008;57:1200-1206|https://pubmed.ncbi.nlm.nih.gov/18460553/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Erstautor|Pech O., May A., Manner H., Behrens A., Pohl J., Weferling M., et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. . 2014;146:652-660.e1|https://pubmed.ncbi.nlm.nih.gov/24269290/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Standard|Manner H., May A., Pech O., Gossner L., Rabenstein T., Gunter E., et al. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. . 2008;103:2589-97|https://pubmed.ncbi.nlm.nih.gov/18785950/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Standard|Manner H., Pech O., Heldmann Y., May A., Pohl J., Behrens A., et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. . 2013;11:630-5; quiz e45|https://pubmed.ncbi.nlm.nih.gov/23357492/|858
Ösophaguskarzinom|"3.1"|2022|Messmann, Helmut|Hintergrund|||Letztautor|Probst A., Maerkl B., Anthuber M., Messmann H. Endoskopische Submukosadissektion (ESD) im Ösophagus. . 2013;51:K233||858
Ösophaguskarzinom|"3.1"|2022|Ell, Christian|Hintergrund|||Standard|Zapletal Ch, Heesen Ch, Origer J., Pauthner M., Pech O., Ell Ch, et al. Quality of life after surgical treatment of early Barrett's cancer: a prospective comparison of the Ivor-Lewis resection versus the modified Merendino resection. None. 2014;38:1444-52|https://www.ncbi.nlm.nih.gov/pubmed/24378548|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Standard|Zapletal Ch, Heesen Ch, Origer J., Pauthner M., Pech O., Ell Ch, et al. Quality of life after surgical treatment of early Barrett's cancer: a prospective comparison of the Ivor-Lewis resection versus the modified Merendino resection. None. 2014;38:1444-52|https://www.ncbi.nlm.nih.gov/pubmed/24378548|858
Ösophaguskarzinom|"3.1"|2022|Ell, Christian|Hintergrund|||Standard|Zemler B., May A., Ell C., Stolte M. Early Barrett's carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion. . 2010;456:609-14|https://pubmed.ncbi.nlm.nih.gov/20449614/|858
Ösophaguskarzinom|"3.1"|2022|Lorenz, Dietmar|Hintergrund|||Erstautor|Lorenz D., Origer J., Pauthner M., Graupe F., Fisseler-Eckhoff A., Stolte M., et al. Prognostic risk factors of early esophageal adenocarcinomas. . 2014;259:469-76|https://pubmed.ncbi.nlm.nih.gov/24096754/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Standard|May A., Gossner L., Pech O., Fritz A., Gunter E., Mayer G., et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. . 2002;14:1085-91|https://pubmed.ncbi.nlm.nih.gov/12362099/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Erstautor|Pech O., Gossner L., May A., Rabenstein T., Vieth M., Stolte M., et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. . 2005;62:24-30|https://pubmed.ncbi.nlm.nih.gov/15990815/|858
Ösophaguskarzinom|"3.1"|2022|Stuschke, Martin|Evidenzbasierte Empfehlung|0|False|Letztautor|Pottgen C., Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials. . 2012;38:599-604|https://pubmed.ncbi.nlm.nih.gov/22116018/|858
Ösophaguskarzinom|"3.1"|2022|Stuschke, Martin|Hintergrund|||Letztautor|Pottgen C., Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials. . 2012;38:599-604|https://pubmed.ncbi.nlm.nih.gov/22116018/|858
Ösophaguskarzinom|"3.1"|2022|Weimann, Arved|Hintergrund|||Erstautor|Weimann A., Braga M., Harsanyi L., Laviano A., Ljungqvist O., Soeters P., et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. . 2006;25:224-44|https://pubmed.ncbi.nlm.nih.gov/16698152/|858
Ösophaguskarzinom|"3.1"|2022|Weimann, Arved|Hintergrund|||Erstautor|Weimann A Breitenstein S Breuer JP et al. S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin:  Klinische Ernährung in der Chirurgie. . 2013;38:e155-e197||858
Ösophaguskarzinom|"3.1"|2022|Ebert, Matthias|Evidenzbasierte Empfehlung|A|True|Standard|Moehler M., Baltin C. T., Ebert M., Fischbach W., Gockel I., Grenacher L., et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. . 2014;:|https://pubmed.ncbi.nlm.nih.gov/25192931/|858
Ösophaguskarzinom|"3.1"|2022|Fischbach, Wolfgang|Evidenzbasierte Empfehlung|A|True|Standard|Moehler M., Baltin C. T., Ebert M., Fischbach W., Gockel I., Grenacher L., et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. . 2014;:|https://pubmed.ncbi.nlm.nih.gov/25192931/|858
Ösophaguskarzinom|"3.1"|2022|Gockel, Ines|Evidenzbasierte Empfehlung|A|True|Standard|Moehler M., Baltin C. T., Ebert M., Fischbach W., Gockel I., Grenacher L., et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. . 2014;:|https://pubmed.ncbi.nlm.nih.gov/25192931/|858
Ösophaguskarzinom|"3.1"|2022|Meyer, Hans-Joachim|Hintergrund|||Standard|Stahl M., Walz M. K., Stuschke M., Lehmann N., Meyer H. J., Riera-Knorrenschild J., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. . 2009;27:851-6|https://pubmed.ncbi.nlm.nih.gov/19139439/|858
Ösophaguskarzinom|"3.1"|2022|Stahl, Michael|Hintergrund|||Erstautor|Stahl M., Walz M. K., Stuschke M., Lehmann N., Meyer H. J., Riera-Knorrenschild J., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. . 2009;27:851-6|https://pubmed.ncbi.nlm.nih.gov/19139439/|858
Ösophaguskarzinom|"3.1"|2022|Stuschke, Martin|Hintergrund|||Standard|Stahl M., Walz M. K., Stuschke M., Lehmann N., Meyer H. J., Riera-Knorrenschild J., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. . 2009;27:851-6|https://pubmed.ncbi.nlm.nih.gov/19139439/|858
Ösophaguskarzinom|"3.1"|2022|Jansen, Petra Lynen|Konsensbasiertes Statement||False|Standard|Koop H., Fuchs K. H., Labenz J., Lynen Jansen P., Messmann H., Miehlke S., et al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013. . 2014;52:1299-346|https://pubmed.ncbi.nlm.nih.gov/25390216/|858
Ösophaguskarzinom|"3.1"|2022|Jansen, Petra Lynen|Hintergrund|||Standard|Koop H., Fuchs K. H., Labenz J., Lynen Jansen P., Messmann H., Miehlke S., et al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013. . 2014;52:1299-346|https://pubmed.ncbi.nlm.nih.gov/25390216/|858
Ösophaguskarzinom|"3.1"|2022|Messmann, Helmut|Konsensbasiertes Statement||False|Standard|Koop H., Fuchs K. H., Labenz J., Lynen Jansen P., Messmann H., Miehlke S., et al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013. . 2014;52:1299-346|https://pubmed.ncbi.nlm.nih.gov/25390216/|858
Ösophaguskarzinom|"3.1"|2022|Messmann, Helmut|Hintergrund|||Standard|Koop H., Fuchs K. H., Labenz J., Lynen Jansen P., Messmann H., Miehlke S., et al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013. . 2014;52:1299-346|https://pubmed.ncbi.nlm.nih.gov/25390216/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Erstautor|Lordick F. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. . 2012;196:201-11|https://pubmed.ncbi.nlm.nih.gov/23129376/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Standard|Ott K., Weber W. A., Lordick F., Becker K., Busch R., Herrmann K., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. . 2006;24:4692-8|https://pubmed.ncbi.nlm.nih.gov/16966684/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Standard|Wieder H. A., Beer A. J., Lordick F., Ott K., Fischer M., Rummeny E. J., et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. . 2005;46:2029-34|https://pubmed.ncbi.nlm.nih.gov/16330567/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Erstautor|Lordick F., Ott K., Krause B. J., Weber W. A., Becker K., Stein H. J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. . 2007;8:797-805|https://pubmed.ncbi.nlm.nih.gov/17693134/|858
Ösophaguskarzinom|"3.1"|2022|Langer, Rupert|Hintergrund|||Standard|zum Buschenfelde C. M., Herrmann K., Schuster T., Geinitz H., Langer R., Becker K., et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. . 2011;52:1189-96|https://pubmed.ncbi.nlm.nih.gov/21764790/|858
Ösophaguskarzinom|"3.1"|2022|Stahl, Michael|Hintergrund|||Standard|Gkika E., Gauler T., Eberhardt W., Stahl M., Stuschke M., Pottgen C. Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. . 2014;27:678-84|https://pubmed.ncbi.nlm.nih.gov/24147973/|858
Ösophaguskarzinom|"3.1"|2022|Stuschke, Martin|Hintergrund|||Standard|Gkika E., Gauler T., Eberhardt W., Stahl M., Stuschke M., Pottgen C. Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. . 2014;27:678-84|https://pubmed.ncbi.nlm.nih.gov/24147973/|858
Ösophaguskarzinom|"3.1"|2022|Lordick, Florian|Hintergrund|||Standard|Ott K., Lordick F., Molls M., Bartels H., Biemer E., Siewert J. R. Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. . 2009;96:258-66|https://pubmed.ncbi.nlm.nih.gov/19224522/|858
Ösophaguskarzinom|"3.1"|2022|Meyer, Hans-Joachim|Hintergrund|||Standard|Stahl M., Stuschke M., Lehmann N., Meyer H. J., Walz M. K., Seeber S., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. . 2005;23:2310-7|https://pubmed.ncbi.nlm.nih.gov/15800321/|858
Ösophaguskarzinom|"3.1"|2022|Stahl, Michael|Hintergrund|||Erstautor|Stahl M., Stuschke M., Lehmann N., Meyer H. J., Walz M. K., Seeber S., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. . 2005;23:2310-7|https://pubmed.ncbi.nlm.nih.gov/15800321/|858
Ösophaguskarzinom|"3.1"|2022|Stuschke, Martin|Hintergrund|||Standard|Stahl M., Stuschke M., Lehmann N., Meyer H. J., Walz M. K., Seeber S., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. . 2005;23:2310-7|https://pubmed.ncbi.nlm.nih.gov/15800321/|858
Ösophaguskarzinom|"3.1"|2022|Weimann, Arved|Hintergrund|||Standard|Adiamah A., Skorepa P., Weimann A., Lobo D. N. The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis. None. 2019;270:247-256|https://www.ncbi.nlm.nih.gov/pubmed/30817349|858
Ösophaguskarzinom|"3.1"|2022|Vanhoefer, Udo|Hintergrund|||Standard|Lutz M. P., Wilke H., Wagener D. J., Vanhoefer U., Jeziorski K., Hegewisch-Becker S., et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. . 2007;25:2580-5|https://pubmed.ncbi.nlm.nih.gov/17577037/|858
Ösophaguskarzinom|"3.1"|2022|Weimann, Arved|Hintergrund|||Erstautor|Weimann A., Braga M., Carli F., Higashiguchi T., Hubner M., Klek S., et al. ESPEN guideline: Clinical nutrition in surgery. None. 2017;36:623-650|https://www.ncbi.nlm.nih.gov/pubmed/28385477|858
Ösophaguskarzinom|"3.1"|2022|Thuss-Patience, Peter|Evidenzbasierte Empfehlung|B|False|Erstautor|Thuss-Patience P. C., Kretzschmar A., Bichev D., Deist T., Hinke A., Breithaupt K., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). . 2011;47:2306-14|https://pubmed.ncbi.nlm.nih.gov/21742485/|858
Ösophaguskarzinom|"3.1"|2022|Thuss-Patience, Peter|Hintergrund|||Erstautor|Thuss-Patience P. C., Kretzschmar A., Bichev D., Deist T., Hinke A., Breithaupt K., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). . 2011;47:2306-14|https://pubmed.ncbi.nlm.nih.gov/21742485/|858
Ösophaguskarzinom|"3.1"|2022|Gockel, Ines|Evidenzbasierte Empfehlung|B|False|Standard|Sgourakis G., Gockel I., Karaliotas C., Moehler M., Schimanski C. C., Schmidberger H., et al. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. . 2012;12:70|https://pubmed.ncbi.nlm.nih.gov/22336151/|858
Ösophaguskarzinom|"3.1"|2022|Gockel, Ines|Hintergrund|||Standard|Sgourakis G., Gockel I., Karaliotas C., Moehler M., Schimanski C. C., Schmidberger H., et al. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. . 2012;12:70|https://pubmed.ncbi.nlm.nih.gov/22336151/|858
Ösophaguskarzinom|"3.1"|2022|Schmidberger, Heinz|Evidenzbasierte Empfehlung|B|False|Standard|Sgourakis G., Gockel I., Karaliotas C., Moehler M., Schimanski C. C., Schmidberger H., et al. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. . 2012;12:70|https://pubmed.ncbi.nlm.nih.gov/22336151/|858
Ösophaguskarzinom|"3.1"|2022|Schmidberger, Heinz|Hintergrund|||Standard|Sgourakis G., Gockel I., Karaliotas C., Moehler M., Schimanski C. C., Schmidberger H., et al. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. . 2012;12:70|https://pubmed.ncbi.nlm.nih.gov/22336151/|858
Ösophaguskarzinom|"3.1"|2022|Gockel, Ines|Evidenzbasierte Empfehlung|B|False|Standard|Sgourakis G., Gockel I., Radtke A., Dedemadi G., Goumas K., Mylona S., et al. The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. . 2010;55:3018-3030|https://pubmed.ncbi.nlm.nih.gov/20440646/|858
Ösophaguskarzinom|"3.1"|2022|Gockel, Ines|Hintergrund|||Standard|Sgourakis G., Gockel I., Radtke A., Dedemadi G., Goumas K., Mylona S., et al. The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. . 2010;55:3018-3030|https://pubmed.ncbi.nlm.nih.gov/20440646/|858
Ösophaguskarzinom|"3.1"|2022|Ell, Christian|Hintergrund|||Letztautor|Manner H., May A., Faerber M., Pech O., Plum N., Ell C. The tissue effect of second generation argon plasma coagulation (VIO APC) in comparison to standard APC and Nd:YAG laser in vitro. . 2007;70:352-6|https://pubmed.ncbi.nlm.nih.gov/18330091/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Standard|Manner H., May A., Faerber M., Pech O., Plum N., Ell C. The tissue effect of second generation argon plasma coagulation (VIO APC) in comparison to standard APC and Nd:YAG laser in vitro. . 2007;70:352-6|https://pubmed.ncbi.nlm.nih.gov/18330091/|858
Ösophaguskarzinom|"3.1"|2022|Pech, Oliver|Hintergrund|||Standard|Manner H., May A., Rabenstein T., Pech O., Nachbar L., Enderle M. D., et al. Prospective evaluation of a new high-power argon plasma coagulation system (hp-APC) in therapeutic gastrointestinal endoscopy. . 2007;42:397-405|https://pubmed.ncbi.nlm.nih.gov/17354121/|858
Ösophaguskarzinom|"3.1"|2022|Gockel, Ines|Hintergrund|||Erstautor|Gockel I., G&#246;nner U., Domeyer M., Lang H., Junginger Th. Long-term survivors of esophageal cancer: Disease-specific quality of life, general health and complications. . 2010;102:516-522|https://pubmed.ncbi.nlm.nih.gov/19877161/|858
Ösophaguskarzinom|"3.1"|2022|Thuss-Patience, Peter|Hintergrund|||Erstautor|Thuss-Patience P., Vecchione L., Keilholz U. Should cT2 esophageal cancer get neoadjuvant treatment before surgery?. . 2017;9:2819-2823|https://pubmed.ncbi.nlm.nih.gov/29221247/|858
Ösophaguskarzinom|"3.1"|2022|Lorenz, Dietmar|Hintergrund|||Letztautor|Nimptsch U., Haist T., Krautz C., Grutzmann R., Mansky T., Lorenz D. Hospital Volume, In-Hospital Mortality, and Failure to Rescue in Esophageal Surgery. None. 2018;115:793-800|https://www.ncbi.nlm.nih.gov/pubmed/30636674|858
Ösophaguskarzinom|"3.1"|2022|Thuss-Patience, Peter|Hintergrund|||Erstautor|Thuss-Patience P. C., Shah M. A., Ohtsu A., Van Cutsem E., Ajani J. A., Castro H., et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. . 2017;18:640-653|https://pubmed.ncbi.nlm.nih.gov/28343975/|858
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Standard|Ramroth H., Dietz A., Becher H. Interaction effects and population-attributable risks for smoking and alcohol on laryngeal cancer and its subsites. A case-control study from Germany. None. 2004;43:499-504||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Standard|Maier H., Gewelke U., Dietz A., Thamm H., Heller W. D., Weidauer H. Kehlkopfkarzinom und Berufstätigkeit - Ergebnisse der Heidelberger Kehlkopfkrebsstudie. [Laryngeal cancer and occupation - results of the Heidelberg laryngeal cancer study]. None. 1992;40:44-51||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Standard|Bayer O., Camara R., Zeissig S. R., Ressing M., Dietz A., Locati L. D., et al. Occupation and cancer of the larynx: a systematic review and meta-analysis. None. 2016;273:9-20||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Standard|Schröder U. Offene horizontale Kehlkopfteilresektion und Cricohyoidoglottopexie. None. 2010;None:93-99||838
Larynxkarzinom|"1.1"|2019|Ambrosch, Petra|Hintergrund|||Erstautor|Ambrosch P., Rödel R., Kron M., Steiner W. Die transorale Lasermikrochirurgie des Larynxkarzinoms. Eine retrospektive Analyse von 657 Patientenverläufen. None. 2001;7:505-512||838
Larynxkarzinom|"1.1"|2019|Ambrosch, Petra|Hintergrund|||Erstautor|Ambrosch P., Fazel A. Funktionserhaltende Therapie des Kehlkopf- und des Hypopharynxkarzinoms. [Functional organ preservation in laryngeal and hypopharyngeal cancer]. None. 2011;90 Suppl 1:S83-109||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Evidenzbasierte Empfehlung|B|False|Erstautor|Dietz Andreas, Wichmann Gunnar, Flentje Michael, Hagen Rudolf, Koelbl Oliver, Schreiber Frank, et al. Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC). None. 2016;34:6025-6025||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Erstautor|Dietz Andreas, Wichmann Gunnar, Flentje Michael, Hagen Rudolf, Koelbl Oliver, Schreiber Frank, et al. Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC). None. 2016;34:6025-6025||838
Larynxkarzinom|"1.1"|2019|Budach, Volker|Evidenzbasierte Empfehlung||False|Erstautor|Budach V., Stromberger C., Poettgen C., Baumann M., Budach W., Grabenbauer G., et al. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. None. 2015;91:916-24||838
Larynxkarzinom|"1.1"|2019|Budach, Volker|Hintergrund|||Erstautor|Budach V., Stromberger C., Poettgen C., Baumann M., Budach W., Grabenbauer G., et al. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. None. 2015;91:916-24||838
Larynxkarzinom|"1.1"|2019|Budach, Wilfried|Evidenzbasierte Empfehlung||False|Standard|Budach V., Stromberger C., Poettgen C., Baumann M., Budach W., Grabenbauer G., et al. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. None. 2015;91:916-24||838
Larynxkarzinom|"1.1"|2019|Budach, Wilfried|Hintergrund|||Standard|Budach V., Stromberger C., Poettgen C., Baumann M., Budach W., Grabenbauer G., et al. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. None. 2015;91:916-24||838
Larynxkarzinom|"1.1"|2019|Stromberger, Carmen|Evidenzbasierte Empfehlung||False|Standard|Budach V., Stromberger C., Poettgen C., Baumann M., Budach W., Grabenbauer G., et al. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. None. 2015;91:916-24||838
Larynxkarzinom|"1.1"|2019|Stromberger, Carmen|Hintergrund|||Standard|Budach V., Stromberger C., Poettgen C., Baumann M., Budach W., Grabenbauer G., et al. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. None. 2015;91:916-24||838
Larynxkarzinom|"1.1"|2019|Budach, Volker|Evidenzbasierte Empfehlung||False|Erstautor|Budach V., Stuschke M., Budach W., Baumann M., Geismar D., Grabenbauer G., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. None. 2005;23:1125-35||838
Larynxkarzinom|"1.1"|2019|Budach, Wilfried|Evidenzbasierte Empfehlung||False|Standard|Budach V., Stuschke M., Budach W., Baumann M., Geismar D., Grabenbauer G., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. None. 2005;23:1125-35||838
Larynxkarzinom|"1.1"|2019|Budach, Wilfried|Evidenzbasierte Empfehlung|A|False|Erstautor|Budach W., Bolke E., Kammers K., Gerber P. A., Orth K., Gripp S., et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. None. 2016;118:238-43||838
Larynxkarzinom|"1.1"|2019|Budach, Volker|Hintergrund|||Standard|Budach W., Hehr T., Budach V., Belka C., Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. None. 2006;6:28||838
Larynxkarzinom|"1.1"|2019|Budach, Wilfried|Hintergrund|||Erstautor|Budach W., Hehr T., Budach V., Belka C., Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. None. 2006;6:28||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Erstautor|Dietz A., Rudat V., Nollert J., Helbig M., Vanselow B., Weidauer H. Das chronische Larynxödem als Spätreaktion nach Radiochemotherapie. [Chronic laryngeal edema as a late reaction to radiochemotherapy]. None. 1998;46:731-8||838
Larynxkarzinom|"1.1"|2019|Budach, Wilfried|Hintergrund|||Standard|Gregoire V., Ang K., Budach W., Grau C., Hamoir M., Langendijk J. A., et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. None. 2014;110:172-81||838
Larynxkarzinom|"1.1"|2019|Budach, Wilfried|Hintergrund|||Standard|Brouwer C. L., Steenbakkers R. J., Bourhis J., Budach W., Grau C., Gregoire V., et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. None. 2015;117:83-90||838
Larynxkarzinom|"1.1"|2019|Fietkau, Rainer|Evidenzbasierte Empfehlung|B|False|Erstautor|Fietkau R., Lautenschläger C., Sauer R., Dunst J., Becker A., Baumann M., et al. Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96–3. None. 2006;24:5507-5507||838
Larynxkarzinom|"1.1"|2019|Fietkau, Rainer|Hintergrund|||Erstautor|Fietkau R., Lautenschläger C., Sauer R., Dunst J., Becker A., Baumann M., et al. Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96–3. None. 2006;24:5507-5507||838
Larynxkarzinom|"1.1"|2019|Nawka, Tadeus|Hintergrund|||Erstautor|Nawka T., Hosemann W. [Voice disorder. Surgical procedures]. None. 2005;84 Suppl 1:S201-12||838
Larynxkarzinom|"1.1"|2019|Nawka, Tadeus|Hintergrund|||Letztautor|Arens C., Herrmann I. F., Rohrbach S., Schwemmle C., Nawka T. Positionspapier der DGHNO und der DGPP - Stand der klinischen und endoskopischen Diagnostik, Evaluation und Therapie von Schluckstörungen bei Kindern und Erwachsenen. [Position paper of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery and the German Society of Phoniatrics and Pediatric Audiology - current state of clinical and endoscopic diagnostics, evaluation, and therapy of swallowing disorders in children and adults]. None. 2015;94 Suppl 1:S306-54||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Erstautor|Dietz A., Nollert J., Eckel H., Volling P., Schroder M., Staar S., et al. Organerhalt beim fortgeschrittenen Larynx- bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie. Ergebnisse einer multizentrischen Phase-II-Studie. [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study]. None. 2002;50:146-54||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Erstautor|Dietz A., Rudat V., Dreyhaupt J., Pritsch M., Hoppe F., Hagen R., et al. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). None. 2009;266:1291-300||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Erstautor|Dietz A. Kopf-Hals-Tumoren - Therapie des Larynx-/Hypopharynxkarzinoms unter besonderer Berücksichtigung des Larynxorganerhalts. None. 2008;None:None||838
Larynxkarzinom|"1.1"|2019|Bootz, Friedrich|Hintergrund|||Erstautor|Bootz F., Keiner S. Rekonstruktionsverfahren zum Wiederaufbau des Hypopharynx nach Tumorexstirpation. [Reconstructive procedures for restoring the hypopharynx after tumor excision]. None. 1998;46:87-9||838
Larynxkarzinom|"1.1"|2019|Remmert, Stephan|Hintergrund|||Erstautor|Remmert S., Müller G., Weerda H. Revaskularisierte überlange Jejunumsegmente in der einzeitigen Wiederherstellung von Stimm- und Schluckfunktion nach totaler Laryngopharyngektomie. [Revascularized over-long jejunum segments in single stage reconstruction of voice and deglutition function after total laryngopharyngectomy]. None. 1993;41:485-90||838
Larynxkarzinom|"1.1"|2019|Remmert, Stephan|Hintergrund|||Erstautor|Remmert S., Ahrens K. H., Sommer K., Muller G., Weerda H. Die Stimmrehabilitation mit dem Jejunumsprechsiphon: Der Biventerzugel, eine Modifikation zur Vermeidung von Aspirationen. [Voice rehabilitation with the jejunum speech siphon: the biventer rein, a modification for prevention of aspiration]. None. 1994;73:84-7||838
Larynxkarzinom|"1.1"|2019|Ambrosch, Petra|Hintergrund|||Standard|Rodrigo J. P., Suarez C., Silver C. E., Rinaldo A., Ambrosch P., Fagan J. J., et al. Transoral laser surgery for supraglottic cancer. None. 2008;30:658-66||838
Larynxkarzinom|"1.1"|2019|Nusser-Müller-Busch, Ricki|Hintergrund|||Letztautor|Seidl R. O., Nusser-Müller-Busch R. Trachealkanülen: Segen und Fluch. None. 2015;None:201-219||838
Larynxkarzinom|"1.1"|2019|Nusser-Müller-Busch, Ricki|Hintergrund|||Erstautor|Nusser-Müller-Busch R., Horst R. Die Manuelle Schlucktherapie – Reset the brain. None. 2011;25:6-13||838
Larynxkarzinom|"1.1"|2019|Nusser-Müller-Busch, Ricki|Hintergrund|||Letztautor|Seidl R. O., Nusser-Müller-Busch R. Schluckrehabilitation nach moderner Tumortherapie im Kopf-Hals-Bereich. [Posttreatment rehabilitation of swallowing in patients with head and neck cancer]. None. 2007;86:846-52||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Standard|Bindewald J., Herrmann E., Dietz A., Wulke C., Meister E., Wollbruck D., et al. Lebensqualität und Sprachverständlichkeit bei Patienten mit Kehlkopfkarzinom - Relevanz des "Zufriedenheitsparadoxes". [Quality of life and voice intelligibility in laryngeal cancer patients--relevance of the "satisfaction paradox"]. None. 2007;86:426-30||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Standard|Meyer A., Dietz A., Wollbruck D., Oeken J., Danker H., Meister E. F., et al. Schluckstörungen nach Kehlkopfteilresektion. Auftrittshäufigkeit und Prädiktoren. [Swallowing disorders after partial laryngectomy. Prevalence and predictors]. None. 2012;60:892-900||838
Larynxkarzinom|"1.1"|2019|Singer, Susanne|Hintergrund|||Letztautor|Wollbruck D., Danker H., Ullrich P., Pabich J., Singer S. Psychoonkologie für Logopäden und Sprechwissenschaftler: Begründung und Konzeption des Kurses PSYKOL. [Psycho-oncology for speech therapists: establishment and conception of the course PSYKOL]. None. 2013;61:1026-31||838
Larynxkarzinom|"1.1"|2019|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Arraras J. I., Baumann I., Boehm A., Chie W. C., Galalae R., et al. Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy--update of the EORTC QLQ-H&N35, Phase I. None. 2013;35:1331-8||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Standard|Singer S., Keszte J., Dietz A., Kluge A., Plontke S., Heim M., et al. Berufliche Rehabilitation nach Laryngektomie. [Vocational rehabilitation after total laryngectomy]. None. 2013;92:737-45||838
Larynxkarzinom|"1.1"|2019|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Keszte J., Dietz A., Kluge A., Plontke S., Heim M., et al. Berufliche Rehabilitation nach Laryngektomie. [Vocational rehabilitation after total laryngectomy]. None. 2013;92:737-45||838
Larynxkarzinom|"1.1"|2019|Dietz, Andreas|Hintergrund|||Standard|Singer S., Szalai C., Briest S., Brown A., Dietz A., Einenkel J., et al. Co-morbid mental health conditions in cancer patients at working age--prevalence, risk profiles, and care uptake. None. 2013;22:2291-7||838
Larynxkarzinom|"1.1"|2019|Singer, Susanne|Hintergrund|||Erstautor|Singer S., Szalai C., Briest S., Brown A., Dietz A., Einenkel J., et al. Co-morbid mental health conditions in cancer patients at working age--prevalence, risk profiles, and care uptake. None. 2013;22:2291-7||838
Larynxkarzinom|"1.1"|2019|Ambrosch, Petra|Evidenzbasierte Empfehlung|B|False|Standard|Jackel M. C., Ambrosch P., Martin A., Steiner W. Impact of re-resection for inadequate margins on the prognosis of upper aerodigestive tract cancer treated by laser microsurgery. None. 2007;117:350-6||838
Larynxkarzinom|"1.1"|2019|Ambrosch, Petra|Hintergrund|||Standard|Jackel M. C., Ambrosch P., Martin A., Steiner W. Impact of re-resection for inadequate margins on the prognosis of upper aerodigestive tract cancer treated by laser microsurgery. None. 2007;117:350-6||838
Larynxkarzinom|"1.1"|2019|Wittekind, Christian|Hintergrund|||Letztautor|Brierley J. D., Gospodarowicz M. K., Wittekind C. TNM Classification of Malignant Tumours. Eigth Edition. None. 2016;None:None||838
Larynxkarzinom|"1.1"|2019|Weichert, Wilko|Hintergrund|||Letztautor|Agaimy A., Weichert W. Grading von Tumoren der Kopf-Hals-Region. [Grading of head and neck neoplasms]. None. 2016;37:285-92||838
Larynxkarzinom|"1.1"|2019|Bootz, Friedrich|Hintergrund|||Standard|Lohler J., Gerstner A. O., Bootz F., Walther L. E. Incidence and localization of abnormal mucosa findings in patients consulting ENT outpatient clinics and data analysis of a cancer registry. None. 2014;271:1289-97||838
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Letztautor|Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. J Am Acad Dermatol. 2021;85 (6):1510-1519|https://pubmed.ncbi.nlm.nih.gov/33744350/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Standard|Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. J Am Acad Dermatol. 2021;85 (6):1510-1519|https://pubmed.ncbi.nlm.nih.gov/33744350/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Drexler, Hans|Hintergrund|||Standard|Voelter-Mahlknecht S, Scheriau R, Zwahr G, Koch B, Escobar Pinzon LC, Drexler H, et al. Skin tumors among employees of a tar refinery: the current data and their implications. Int Arch Occup Environ Health. 2007;80 (6):485-95|https://pubmed.ncbi.nlm.nih.gov/17093963/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Hauschild, Axel|Evidenzbasierte Empfehlung|B|False|Erstautor|Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160 (5):1066-74|https://pubmed.ncbi.nlm.nih.gov/19222455/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Hauschild, Axel|Hintergrund|||Erstautor|Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160 (5):1066-74|https://pubmed.ncbi.nlm.nih.gov/19222455/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Standard|Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160 (5):1066-74|https://pubmed.ncbi.nlm.nih.gov/19222455/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol. 2009;160 (5):1066-74|https://pubmed.ncbi.nlm.nih.gov/19222455/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Konsensbasiertes Statement||False|Letztautor|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Letztautor|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Konsensbasiertes Statement||False|Erstautor|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Hintergrund|||Erstautor|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Konsensbasiertes Statement||False|Standard|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Schmitz L, Kahl P, Majores M, Bierhoff E, Stockfleth E, Dirschka T. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30 (8):1303-7|https://pubmed.ncbi.nlm.nih.gov/26955898/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Hintergrund|||Erstautor|Schmitz L, Gambichler T, Gupta G, Stücker M, Stockfleth E, Szeimies RM, et al. Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. J Eur Acad Dermatol Venereol. 2018;32 (5):745-751|https://pubmed.ncbi.nlm.nih.gov/28796914/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Schmitz L, Gambichler T, Gupta G, Stücker M, Stockfleth E, Szeimies RM, et al. Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. J Eur Acad Dermatol Venereol. 2018;32 (5):745-751|https://pubmed.ncbi.nlm.nih.gov/28796914/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Standard|Schmitz L, Gambichler T, Gupta G, Stücker M, Stockfleth E, Szeimies RM, et al. Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. J Eur Acad Dermatol Venereol. 2018;32 (5):745-751|https://pubmed.ncbi.nlm.nih.gov/28796914/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Hintergrund|||Erstautor|Schmitz L, Gambichler T, Kost C, Gupta G, Stücker M, Stockfleth E, et al. Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses. Br J Dermatol. 2019;180 (4):916-921|https://pubmed.ncbi.nlm.nih.gov/29526028/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Schmitz L, Gambichler T, Kost C, Gupta G, Stücker M, Stockfleth E, et al. Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses. Br J Dermatol. 2019;180 (4):916-921|https://pubmed.ncbi.nlm.nih.gov/29526028/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Evidenzbasiertes Statement||False|Erstautor|Dirschka T, Pellacani G, Micali G, Malvehy J, Stratigos AJ, Casari A, et al. A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol. 2017;31 (8):1295-1302|https://pubmed.ncbi.nlm.nih.gov/28401585/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Erstautor|Dirschka T, Pellacani G, Micali G, Malvehy J, Stratigos AJ, Casari A, et al. A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol. 2017;31 (8):1295-1302|https://pubmed.ncbi.nlm.nih.gov/28401585/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Hintergrund|||Standard|Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128 ():83-102|https://pubmed.ncbi.nlm.nih.gov/32113942/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Gutzmer, Ralf|Hintergrund|||Standard|Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020;138 ():125-132|https://pubmed.ncbi.nlm.nih.gov/32882466/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Standard|Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020;138 ():125-132|https://pubmed.ncbi.nlm.nih.gov/32882466/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Loquai, Carmen|Hintergrund|||Standard|Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020;138 ():125-132|https://pubmed.ncbi.nlm.nih.gov/32882466/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Becker, Jürgen|Hintergrund|||Standard|Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Gutzmer, Ralf|Hintergrund|||Standard|Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Hillen, Uwe|Hintergrund|||Erstautor|Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Standard|Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, et al. Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96 ():34-43|https://pubmed.ncbi.nlm.nih.gov/29665511/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Gutzmer, Ralf|Hintergrund|||Letztautor|Kähler KC, Egberts F, Gutzmer R. Palliative treatment of skin metastases in dermato-oncology. J Dtsch Dermatol Ges. 2013;11 (11):1041-5; quiz 1046|https://pubmed.ncbi.nlm.nih.gov/24015966/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Evidenzbasiertes Statement||False|Erstautor|Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Hintergrund|||Erstautor|Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Welzel, Julia|Evidenzbasiertes Statement||False|Standard|Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Welzel, Julia|Hintergrund|||Standard|Schmitz L, Gupta G, Stücker M, Doerler M, Gambichler T, Welzel J, et al. Evaluation of two histological classifications for actinic keratoses - PRO classification scored highest inter-rater reliability. J Eur Acad Dermatol Venereol. 2019;33 (6):1092-1097|https://pubmed.ncbi.nlm.nih.gov/30887613/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Erstautor|Breuninger H, Eigentler T, Häfner HM, Leiter U. None. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31631533/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Hintergrund|||Standard|Breuninger H, Eigentler T, Häfner HM, Leiter U. None. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31631533/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Letztautor|Breuninger H, Eigentler T, Häfner HM, Leiter U. None. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31631533/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Erstautor|Breuninger H, Eigentler T, Häfner HM, Leiter U. Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31545559/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Hintergrund|||Standard|Breuninger H, Eigentler T, Häfner HM, Leiter U. Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31545559/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Letztautor|Breuninger H, Eigentler T, Häfner HM, Leiter U. Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. J Dtsch Dermatol Ges. 2019;17 (10):999-1004|https://pubmed.ncbi.nlm.nih.gov/31545559/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Hintergrund|||Standard|Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128 ():60-82|https://pubmed.ncbi.nlm.nih.gov/32113941/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Standard|Haug K, Breuninger H, Metzler G, Eigentler T, Eichner M, Häfner HM, et al. Prognostic Impact of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Results of a Prospective Study of 1,399 Tumors. J Invest Dermatol. 2020;140 (10):1968-1975|https://pubmed.ncbi.nlm.nih.gov/32169476/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Hintergrund|||Standard|Haug K, Breuninger H, Metzler G, Eigentler T, Eichner M, Häfner HM, et al. Prognostic Impact of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Results of a Prospective Study of 1,399 Tumors. J Invest Dermatol. 2020;140 (10):1968-1975|https://pubmed.ncbi.nlm.nih.gov/32169476/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Standard|Kofler L, Kofler K, Schulz C, Breuninger H, Häfner HM. Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma. Arch Dermatol Res. 2021;313 (2):119-126|https://pubmed.ncbi.nlm.nih.gov/32385689/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Kofler, Lukas|Hintergrund|||Erstautor|Kofler L, Kofler K, Schulz C, Breuninger H, Häfner HM. Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma. Arch Dermatol Res. 2021;313 (2):119-126|https://pubmed.ncbi.nlm.nih.gov/32385689/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Letztautor|Hoetzenecker W, Guenova E, Böttinger TU, Häfner HM, Breuninger H. Mapping of specific sentinel node locations for skin cancer of the head. Eur J Dermatol. ;21 (3):354-8|https://pubmed.ncbi.nlm.nih.gov/21680279/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Evidenzbasierte Empfehlung|B|False|Erstautor|Berking C, Herzinger T, Flaig MJ, Brenner M, Borelli C, Degitz K. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg. 2007;33 (7):825-30|https://pubmed.ncbi.nlm.nih.gov/17598848/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Erstautor|Berking C, Herzinger T, Flaig MJ, Brenner M, Borelli C, Degitz K. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg. 2007;33 (7):825-30|https://pubmed.ncbi.nlm.nih.gov/17598848/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Flaig, Michael|Evidenzbasierte Empfehlung|B|False|Standard|Berking C, Herzinger T, Flaig MJ, Brenner M, Borelli C, Degitz K. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg. 2007;33 (7):825-30|https://pubmed.ncbi.nlm.nih.gov/17598848/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Flaig, Michael|Hintergrund|||Standard|Berking C, Herzinger T, Flaig MJ, Brenner M, Borelli C, Degitz K. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg. 2007;33 (7):825-30|https://pubmed.ncbi.nlm.nih.gov/17598848/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Letztautor|Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017;137 (11):2309-2315|https://pubmed.ncbi.nlm.nih.gov/28736229/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Hintergrund|||Erstautor|Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017;137 (11):2309-2315|https://pubmed.ncbi.nlm.nih.gov/28736229/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Hintergrund|||Standard|Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017;137 (11):2309-2315|https://pubmed.ncbi.nlm.nih.gov/28736229/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Standard|Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017;137 (11):2309-2315|https://pubmed.ncbi.nlm.nih.gov/28736229/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Bechara, Falk G.|Hintergrund|||Erstautor|Bechara FG. [Healing by secondary intention after skin cancer surgery on the head and neck]. Hautarzt. 2013;64 (8):567-76|https://pubmed.ncbi.nlm.nih.gov/23868572/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Letztautor|Boehringer A, Adam P, Schnabl S, Häfner HM, Breuninger H. Analysis of incomplete excisions of basal-cell carcinomas after breadloaf microscopy compared with 3D-microscopy: a prospective randomized and blinded study. J Cutan Pathol. 2015;42 (8):542-53|https://pubmed.ncbi.nlm.nih.gov/25975523/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Standard|Kofler L, Breuninger H, Schreiber RH, Eichner M, Häfner HM, Schnabl SM. Three-dimensional histology vs. serial section histology in the treatment of primary basal cell carcinoma: a randomized, prospective, blinded study of 569 tumours. J Eur Acad Dermatol Venereol. 2021;35 (6):1323-1330|https://pubmed.ncbi.nlm.nih.gov/33539573/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Kofler, Lukas|Hintergrund|||Erstautor|Kofler L, Breuninger H, Schreiber RH, Eichner M, Häfner HM, Schnabl SM. Three-dimensional histology vs. serial section histology in the treatment of primary basal cell carcinoma: a randomized, prospective, blinded study of 569 tumours. J Eur Acad Dermatol Venereol. 2021;35 (6):1323-1330|https://pubmed.ncbi.nlm.nih.gov/33539573/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Standard|Kofler L, Breuninger H, Schulz C, Häfner HM, Kofler K. Local Recurrence Rates of Skin Tumors After Resection With Complete Circumferential Peripheral and Deep Margin Assessment-Identification of High-Risk Entities. Dermatol Surg. 2021;47 (2):e31-e36|https://pubmed.ncbi.nlm.nih.gov/33565775/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Kofler, Lukas|Hintergrund|||Erstautor|Kofler L, Breuninger H, Schulz C, Häfner HM, Kofler K. Local Recurrence Rates of Skin Tumors After Resection With Complete Circumferential Peripheral and Deep Margin Assessment-Identification of High-Risk Entities. Dermatol Surg. 2021;47 (2):e31-e36|https://pubmed.ncbi.nlm.nih.gov/33565775/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Konsensbasiertes Statement||False|Standard|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Hintergrund|||Standard|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Konsensbasiertes Statement||False|Erstautor|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Hintergrund|||Erstautor|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Konsensbasiertes Statement||False|Standard|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Hintergrund|||Standard|Schmitz L, Brehmer A, Falkenberg C, Gambichler T, Heppt MV, Steeb T, et al. Treatment-resistant actinic keratoses are characterized by distinct clinical and histological features. Ital J Dermatol Venerol. 2021;156 (2):213-219|https://pubmed.ncbi.nlm.nih.gov/33960752/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Evidenzbasierte Empfehlung|B|False|Standard|Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Standard|Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Evidenzbasierte Empfehlung|B|False|Standard|Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Hintergrund|||Standard|Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Evidenzbasierte Empfehlung|B|False|Erstautor|Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Hintergrund|||Erstautor|Steeb T, Wessely A, Schmitz L, Heppt F, Kirchberger MC, Berking C, et al. Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. J Invest Dermatol. 2021;141 (2):345-354.e8|https://pubmed.ncbi.nlm.nih.gov/32645365/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Evidenzbasierte Empfehlung|B|False|Letztautor|Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Letztautor|Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Evidenzbasierte Empfehlung|B|False|Erstautor|Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Hintergrund|||Erstautor|Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Evidenzbasierte Empfehlung|B|False|Standard|Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Hintergrund|||Standard|Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180 (4):740-748|https://pubmed.ncbi.nlm.nih.gov/30447074/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Evidenzbasierte Empfehlung|B|False|Letztautor|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Letztautor|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Evidenzbasierte Empfehlung|B|False|Erstautor|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Hintergrund|||Erstautor|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Evidenzbasierte Empfehlung|B|False|Standard|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Standard|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Evidenzbasierte Empfehlung|B|False|Standard|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Hintergrund|||Standard|Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33 (5):863-873|https://pubmed.ncbi.nlm.nih.gov/30710390/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Evidenzbasierte Empfehlung|B|False|Standard|Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Standard|Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Evidenzbasierte Empfehlung|B|False|Standard|Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Schmitz, Lutz|Hintergrund|||Standard|Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Evidenzbasierte Empfehlung|B|False|Erstautor|Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Hintergrund|||Erstautor|Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35 (3):641-649|https://pubmed.ncbi.nlm.nih.gov/32745330/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Evidenzbasierte Empfehlung|B|False|Letztautor|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Letztautor|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Evidenzbasierte Empfehlung|B|False|Standard|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Hintergrund|||Standard|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Evidenzbasierte Empfehlung|B|False|Erstautor|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Hintergrund|||Erstautor|Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80 (4):947-956|https://pubmed.ncbi.nlm.nih.gov/30267719/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Evidenzbasierte Empfehlung|B|False|Standard|Gollnick H, Dirschka T, Ostendorf R, Kerl H, Kunstfeld R. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2020;34 (1):82-89|https://pubmed.ncbi.nlm.nih.gov/31407414/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Standard|Gollnick H, Dirschka T, Ostendorf R, Kerl H, Kunstfeld R. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2020;34 (1):82-89|https://pubmed.ncbi.nlm.nih.gov/31407414/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Erstautor|Stockfleth E, Harwood CA, Serra-Guillén C, Larsson T, Østerdal ML, Skov T. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. Br J Dermatol. 2018;178 (2):433-442|https://pubmed.ncbi.nlm.nih.gov/29030864/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Erstautor|Stockfleth E, Harwood CA, Serra-Guillén C, Larsson T, Østerdal ML, Skov T. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp. Br J Dermatol. 2018;178 (2):433-442|https://pubmed.ncbi.nlm.nih.gov/29030864/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Letztautor|Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. J Am Acad Dermatol. 2021; ():|https://pubmed.ncbi.nlm.nih.gov/33744350/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Standard|Ulrich M, Reinhold U, Dominicus R, Aschoff R, Szeimies RM, Dirschka T. Red light photodynamic therapy with BF-200 ALA showed superior efficacy in the treatment of actinic keratosis on the extremities, trunk, and neck in a vehicle-controlled phase III study. J Am Acad Dermatol. 2021; ():|https://pubmed.ncbi.nlm.nih.gov/33744350/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Evidenzbasierte Empfehlung|B|False|Erstautor|Dirschka T, Ekanayake-Bohlig S, Dominicus R, Aschoff R, Herrera-Ceballos E, Botella-Estrada R, et al. A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J Eur Acad Dermatol Venereol. 2019;33 (2):288-297|https://pubmed.ncbi.nlm.nih.gov/30022544/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Erstautor|Dirschka T, Ekanayake-Bohlig S, Dominicus R, Aschoff R, Herrera-Ceballos E, Botella-Estrada R, et al. A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J Eur Acad Dermatol Venereol. 2019;33 (2):288-297|https://pubmed.ncbi.nlm.nih.gov/30022544/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Evidenzbasierte Empfehlung|B|False|Standard|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Hintergrund|||Standard|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Evidenzbasierte Empfehlung|B|False|Erstautor|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Heppt, Markus|Hintergrund|||Erstautor|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Evidenzbasierte Empfehlung|B|False|Standard|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Standard|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Evidenzbasierte Empfehlung|B|False|Standard|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Steeb, Theresa|Hintergrund|||Standard|Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2019;180 (1):43-50|https://pubmed.ncbi.nlm.nih.gov/30188570/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Hintergrund|||Letztautor|Leiter U., Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. . 2008;624:89-103|https://pubmed.ncbi.nlm.nih.gov/18348450/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Erstautor|Leiter U., Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. . 2008;624:89-103|https://pubmed.ncbi.nlm.nih.gov/18348450/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Evidenzbasierte Empfehlung|A|False|Standard|Stratigos A., Garbe C., Lebbe C., Malvehy J., del Marmol V., Pehamberger H., et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. . 2015;51:1989-2007|https://www.ncbi.nlm.nih.gov/pubmed/26219687|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Hintergrund|||Standard|Stratigos A., Garbe C., Lebbe C., Malvehy J., del Marmol V., Pehamberger H., et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. . 2015;51:1989-2007|https://www.ncbi.nlm.nih.gov/pubmed/26219687|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Drexler, Hans|Hintergrund|||Standard|Diepgen T. L., Drexler H., Elsner P., Schmitt J. [UV-irradiation-induced skin cancer as a new occupational disease]. None. 2015;66:154-9|https://www.ncbi.nlm.nih.gov/pubmed/25737435|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Werner R. N., Stockfleth E., Connolly S. M., Correia O., Erdmann R., Foley P., et al. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. None. 2015;29:2069-79|https://www.ncbi.nlm.nih.gov/pubmed/26370093|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breitbart, Eckhard W.|Hintergrund|||Standard|Waldmann A., Nolte S., Weinstock M. A., Breitbart E. W., Eisemann N., Geller A. C., et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. . 2012;106:970-974|https://pubmed.ncbi.nlm.nih.gov/22294187/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Augustin, Matthias|Hintergrund|||Erstautor|Augustin M., Stadler R., Reusch M., Schafer I., Kornek T., Luger T. Skin cancer screening in Germany - perception by the public. . 2012;10:42-9|https://pubmed.ncbi.nlm.nih.gov/21923730/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Letztautor|Krawtchenko N., Roewert-Huber J., Ulrich M., Mann I., Sterry W., Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. . 2007;157 Suppl 2:34-40|https://www.ncbi.nlm.nih.gov/pubmed/18067630|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Letztautor|Krawtchenko N., Roewert-Huber J., Ulrich M., Mann I., Sterry W., Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. . 2007;157 Suppl 2:34-40|https://www.ncbi.nlm.nih.gov/pubmed/18067630|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Evidenzbasierte Empfehlung|B|False|Standard|Kaufmann R., Spelman L., Weightman W., Reifenberger J., Szeimies R. M., Verhaeghe E., et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. . 2008;158:994-9|https://www.ncbi.nlm.nih.gov/pubmed/18341663|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Standard|Kaufmann R., Spelman L., Weightman W., Reifenberger J., Szeimies R. M., Verhaeghe E., et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. . 2008;158:994-9|https://www.ncbi.nlm.nih.gov/pubmed/18341663|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Erstautor|Szeimies R. M., Karrer S., Radakovic-Fijan S., Tanew A., Calzavara-Pinton P. G., Zane C., et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. . 2002;47:258-62|https://www.ncbi.nlm.nih.gov/pubmed/12140473|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Evidenzbasierte Empfehlung|B|False|Standard|Pflugfelder A., Welter A. K., Leiter U., Weide B., Held L., Eigentler T. K., et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. . 2012;26:48-53|https://www.ncbi.nlm.nih.gov/pubmed/21414035|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Hintergrund|||Standard|Pflugfelder A., Welter A. K., Leiter U., Weide B., Held L., Eigentler T. K., et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. . 2012;26:48-53|https://www.ncbi.nlm.nih.gov/pubmed/21414035|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Evidenzbasierte Empfehlung|B|False|Standard|Pflugfelder A., Welter A. K., Leiter U., Weide B., Held L., Eigentler T. K., et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. . 2012;26:48-53|https://www.ncbi.nlm.nih.gov/pubmed/21414035|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Standard|Pflugfelder A., Welter A. K., Leiter U., Weide B., Held L., Eigentler T. K., et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. . 2012;26:48-53|https://www.ncbi.nlm.nih.gov/pubmed/21414035|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Letztautor|Ulrich C., Johannsen A., Rowert-Huber J., Ulrich M., Sterry W., Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. . 2010;20:482-8|https://www.ncbi.nlm.nih.gov/pubmed/20507841|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Letztautor|Ulrich C., Johannsen A., Rowert-Huber J., Ulrich M., Sterry W., Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. . 2010;20:482-8|https://www.ncbi.nlm.nih.gov/pubmed/20507841|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Evidenzbasierte Empfehlung|B|False|Erstautor|Ulrich C., Johannsen A., Rowert-Huber J., Ulrich M., Sterry W., Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. . 2010;20:482-8|https://www.ncbi.nlm.nih.gov/pubmed/20507841|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Hintergrund|||Erstautor|Ulrich C., Johannsen A., Rowert-Huber J., Ulrich M., Sterry W., Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. . 2010;20:482-8|https://www.ncbi.nlm.nih.gov/pubmed/20507841|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Erstautor|Stockfleth E., Kerl H., Zwingers T., Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. . 2011;165:1101-8|https://www.ncbi.nlm.nih.gov/pubmed/21517801|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Erstautor|Stockfleth E., Kerl H., Zwingers T., Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. . 2011;165:1101-8|https://www.ncbi.nlm.nih.gov/pubmed/21517801|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Erstautor|Stockfleth E., Zwingers T., Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. . 2012;22:370-4|https://www.ncbi.nlm.nih.gov/pubmed/22494856|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Erstautor|Stockfleth E., Zwingers T., Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. . 2012;22:370-4|https://www.ncbi.nlm.nih.gov/pubmed/22494856|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Erstautor|Stockfleth E., von Kiedrowski R., Dominicus R., Ryan J., Ellery A., Falques M., et al. Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial. . 2017;7:81-96|https://www.ncbi.nlm.nih.gov/pubmed/27995485|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Erstautor|Stockfleth E., von Kiedrowski R., Dominicus R., Ryan J., Ellery A., Falques M., et al. Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial. . 2017;7:81-96|https://www.ncbi.nlm.nih.gov/pubmed/27995485|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|A|False|Erstautor|Stockfleth E., Sibbring G. C., Alarcon I. New Topical Treatment Options for Actinic Keratosis: A Systematic Review. . 2016;96:17-22|https://www.ncbi.nlm.nih.gov/pubmed/26068001|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Erstautor|Stockfleth E., Sibbring G. C., Alarcon I. New Topical Treatment Options for Actinic Keratosis: A Systematic Review. . 2016;96:17-22|https://www.ncbi.nlm.nih.gov/pubmed/26068001|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Evidenzbasierte Empfehlung|A|False|Erstautor|Garbe C., Basset-Seguin N., Poulin Y., Larsson T., Osterdal M. L., Venkata R., et al. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, controlled 12-month study. . 2016;174:505-13|https://www.ncbi.nlm.nih.gov/pubmed/26471889|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Augustin, Matthias|Hintergrund|||Letztautor|Schafer I., Reusch M., Siebert J., Spehr C., Augustin M. Health care characteristics of basal cell carcinoma in Germany: the role of insurance status and socio-demographic factors. . 2014;12:803-811|https://www.ncbi.nlm.nih.gov/pubmed/25176460|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Erstautor|Stockfleth E., Meyer T., Benninghoff B., Salasche S., Papadopoulos L., Ulrich C., et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. . 2002;138:1498-502|https://www.ncbi.nlm.nih.gov/pubmed/12437457|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Erstautor|Stockfleth E., Meyer T., Benninghoff B., Salasche S., Papadopoulos L., Ulrich C., et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. . 2002;138:1498-502|https://www.ncbi.nlm.nih.gov/pubmed/12437457|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Evidenzbasierte Empfehlung|B|False|Standard|Stockfleth E., Meyer T., Benninghoff B., Salasche S., Papadopoulos L., Ulrich C., et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. . 2002;138:1498-502|https://www.ncbi.nlm.nih.gov/pubmed/12437457|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Hintergrund|||Standard|Stockfleth E., Meyer T., Benninghoff B., Salasche S., Papadopoulos L., Ulrich C., et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. . 2002;138:1498-502|https://www.ncbi.nlm.nih.gov/pubmed/12437457|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Evidenzbasierte Empfehlung|B|False|Erstautor|Szeimies R. M., Gerritsen M. J., Gupta G., Ortonne J. P., Serresi S., Bichel J., et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. . 2004;51:547-55|https://www.ncbi.nlm.nih.gov/pubmed/15389189|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Erstautor|Szeimies R. M., Gerritsen M. J., Gupta G., Ortonne J. P., Serresi S., Bichel J., et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. . 2004;51:547-55|https://www.ncbi.nlm.nih.gov/pubmed/15389189|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Evidenzbasierte Empfehlung|0|False|Erstautor|Ulrich C., Bichel J., Euvrard S., Guidi B., Proby C. M., van de Kerkhof P. C., et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. . 2007;157 Suppl 2:25-31|https://www.ncbi.nlm.nih.gov/pubmed/18067628|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Hintergrund|||Erstautor|Ulrich C., Bichel J., Euvrard S., Guidi B., Proby C. M., van de Kerkhof P. C., et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. . 2007;157 Suppl 2:25-31|https://www.ncbi.nlm.nih.gov/pubmed/18067628|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Standard|Hanke C. W., Beer K. R., Stockfleth E., Wu J., Rosen T., Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. . 2010;62:573-81|https://www.ncbi.nlm.nih.gov/pubmed/20133012|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Hanke C. W., Beer K. R., Stockfleth E., Wu J., Rosen T., Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. . 2010;62:573-81|https://www.ncbi.nlm.nih.gov/pubmed/20133012|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Evidenzbasierte Empfehlung|B|False|Standard|Peris K., Stockfleth E., Gupta G., Aractingi S., Dakovic R., Dirschka T., et al. Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions. . 2015;29:2470-3|https://www.ncbi.nlm.nih.gov/pubmed/26954313|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Peris K., Stockfleth E., Gupta G., Aractingi S., Dakovic R., Dirschka T., et al. Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions. . 2015;29:2470-3|https://www.ncbi.nlm.nih.gov/pubmed/26954313|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Evidenzbasierte Empfehlung|B|False|Letztautor|Giehl K. A., Kriz M., Grahovac M., Ruzicka T., Berking C. A controlled trial of photodynamic therapy of actinic keratosis comparing different red light sources. . 2014;24:335-41|https://www.ncbi.nlm.nih.gov/pubmed/24876164|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Letztautor|Giehl K. A., Kriz M., Grahovac M., Ruzicka T., Berking C. A controlled trial of photodynamic therapy of actinic keratosis comparing different red light sources. . 2014;24:335-41|https://www.ncbi.nlm.nih.gov/pubmed/24876164|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Evidenzbasierte Empfehlung|B|False|Standard|Szeimies R. M., Radny P., Sebastian M., Borrosch F., Dirschka T., Krahn-Senftleben G., et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. . 2010;163:386-94|https://www.ncbi.nlm.nih.gov/pubmed/20518784|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Standard|Szeimies R. M., Radny P., Sebastian M., Borrosch F., Dirschka T., Krahn-Senftleben G., et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. . 2010;163:386-94|https://www.ncbi.nlm.nih.gov/pubmed/20518784|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Evidenzbasierte Empfehlung|B|False|Erstautor|Szeimies R. M., Radny P., Sebastian M., Borrosch F., Dirschka T., Krahn-Senftleben G., et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. . 2010;163:386-94|https://www.ncbi.nlm.nih.gov/pubmed/20518784|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Erstautor|Szeimies R. M., Radny P., Sebastian M., Borrosch F., Dirschka T., Krahn-Senftleben G., et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. . 2010;163:386-94|https://www.ncbi.nlm.nih.gov/pubmed/20518784|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Evidenzbasierte Empfehlung|B|False|Erstautor|Dirschka T., Radny P., Dominicus R., Mensing H., Bruning H., Jenne L., et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. . 2013;168:825-36|https://www.ncbi.nlm.nih.gov/pubmed/23252768|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Erstautor|Dirschka T., Radny P., Dominicus R., Mensing H., Bruning H., Jenne L., et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. . 2013;168:825-36|https://www.ncbi.nlm.nih.gov/pubmed/23252768|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Evidenzbasierte Empfehlung|B|False|Erstautor|Dirschka T., Radny P., Dominicus R., Mensing H., Bruning H., Jenne L., et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. . 2012;166:137-46|https://www.ncbi.nlm.nih.gov/pubmed/21910711|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Erstautor|Dirschka T., Radny P., Dominicus R., Mensing H., Bruning H., Jenne L., et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. . 2012;166:137-46|https://www.ncbi.nlm.nih.gov/pubmed/21910711|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Evidenzbasierte Empfehlung|B|False|Standard|Reinhold U., Dirschka T., Ostendorf R., Aschoff R., Berking C., Philipp-Dormston W. G., et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz((R)) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED((R)) lamp. . 2016;175:696-705|https://pubmed.ncbi.nlm.nih.gov/26921093/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Standard|Reinhold U., Dirschka T., Ostendorf R., Aschoff R., Berking C., Philipp-Dormston W. G., et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz((R)) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED((R)) lamp. . 2016;175:696-705|https://pubmed.ncbi.nlm.nih.gov/26921093/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Evidenzbasierte Empfehlung|B|False|Standard|Reinhold U., Dirschka T., Ostendorf R., Aschoff R., Berking C., Philipp-Dormston W. G., et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz((R)) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED((R)) lamp. . 2016;175:696-705|https://pubmed.ncbi.nlm.nih.gov/26921093/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Standard|Reinhold U., Dirschka T., Ostendorf R., Aschoff R., Berking C., Philipp-Dormston W. G., et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz((R)) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED((R)) lamp. . 2016;175:696-705|https://pubmed.ncbi.nlm.nih.gov/26921093/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Evidenzbasierte Empfehlung|B|False|Erstautor|Szeimies R. M., Matheson R. T., Davis S. A., Bhatia A. C., Frambach Y., Klovekorn W., et al. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. . 2009;35:586-92|https://www.ncbi.nlm.nih.gov/pubmed/19309347|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Erstautor|Szeimies R. M., Matheson R. T., Davis S. A., Bhatia A. C., Frambach Y., Klovekorn W., et al. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. . 2009;35:586-92|https://www.ncbi.nlm.nih.gov/pubmed/19309347|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Hauschild, Axel|Hintergrund|||Erstautor|Hauschild A., Popp G., Stockfleth E., Meyer K. G., Imberger D., Mohr P., et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. . 2009;18:116-21|https://www.ncbi.nlm.nih.gov/pubmed/18643849|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Mohr, Peter|Hintergrund|||Standard|Hauschild A., Popp G., Stockfleth E., Meyer K. G., Imberger D., Mohr P., et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. . 2009;18:116-21|https://www.ncbi.nlm.nih.gov/pubmed/18643849|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Hauschild A., Popp G., Stockfleth E., Meyer K. G., Imberger D., Mohr P., et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. . 2009;18:116-21|https://www.ncbi.nlm.nih.gov/pubmed/18643849|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Szeimies R. M., Stockfleth E., Popp G., Borrosch F., Bruning H., Dominicus R., et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. None. 2010;162:410-4|https://www.ncbi.nlm.nih.gov/pubmed/19804593|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Erstautor|Szeimies R. M., Stockfleth E., Popp G., Borrosch F., Bruning H., Dominicus R., et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. None. 2010;162:410-4|https://www.ncbi.nlm.nih.gov/pubmed/19804593|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Evidenzbasierte Empfehlung|B|False|Standard|Lacour J. P., Ulrich C., Gilaberte Y., Von Felbert V., Basset-Seguin N., Dreno B., et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. . 2015;29:2342-8|https://www.ncbi.nlm.nih.gov/pubmed/26435363|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Hintergrund|||Standard|Lacour J. P., Ulrich C., Gilaberte Y., Von Felbert V., Basset-Seguin N., Dreno B., et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. . 2015;29:2342-8|https://www.ncbi.nlm.nih.gov/pubmed/26435363|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Letztautor|Strunk T., Szeimies R. M. [Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options]. None. 2014;65:241-52; quiz 253-4||647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Standard|Pflugfelder A., Andonov E., Weide B., Dirschka T., Schempp C., Stockfleth E., et al. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. . 2015;172:926-32|https://www.ncbi.nlm.nih.gov/pubmed/25124939/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Pflugfelder A., Andonov E., Weide B., Dirschka T., Schempp C., Stockfleth E., et al. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. . 2015;172:926-32|https://www.ncbi.nlm.nih.gov/pubmed/25124939/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Szeimies R. M., Bichel J., Ortonne J. P., Stockfleth E., Lee J., Meng T. C. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. . 2008;159:205-10|https://www.ncbi.nlm.nih.gov/pubmed/18476957|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Szeimies, Rolf-Markus|Hintergrund|||Erstautor|Szeimies R. M., Bichel J., Ortonne J. P., Stockfleth E., Lee J., Meng T. C. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. . 2008;159:205-10|https://www.ncbi.nlm.nih.gov/pubmed/18476957|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Wennberg A. M., Stenquist B., Stockfleth E., Keohane S., Lear J. T., Jemec G., et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: A randomized study. . 2008;86:423-429|https://pubmed.ncbi.nlm.nih.gov/18698246/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Erstautor|Breuninger H., Schaumburg-Lever G., Holzschuh J., Horny H. P. Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. . 1997;79:915-9|https://www.ncbi.nlm.nih.gov/pubmed/9041153|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Erstautor|Breuninger H., Black B., Rassner G. Microstaging of squamous cell carcinomas. . 1990;94:624-7|https://www.ncbi.nlm.nih.gov/pubmed/2239827|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Wermker, Kai|Hintergrund|||Erstautor|Wermker K., Belok F., Schipmann S., Klein M., Schulze H. J., Hallermann C. Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. . 2015;43:545-52|https://www.ncbi.nlm.nih.gov/pubmed/25753473|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Erstautor|Breuninger H., Brantsch K., Eigentler T., Häfner H.-M. Comparison and evaluation of the current staging of cutaneous carcinomas. . 2012;10:579-586|http://dx.doi.org/10.1111/j.1610-0387.2012.07896.x|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Hintergrund|||Standard|Breuninger H., Brantsch K., Eigentler T., Häfner H.-M. Comparison and evaluation of the current staging of cutaneous carcinomas. . 2012;10:579-586|http://dx.doi.org/10.1111/j.1610-0387.2012.07896.x|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Erstautor|Breuninger Helmut, Eigentler Thomas, Bootz Friedrich, Hauschild Axel, Kortmann Rolf-Dieter, Wolff Klaus, et al. Brief S2k guidelines – Cutaneous squamous cell carcinoma. . 2013;11:37-45|http://dx.doi.org/10.1111/ddg.12015_7|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Hintergrund|||Standard|Breuninger Helmut, Eigentler Thomas, Bootz Friedrich, Hauschild Axel, Kortmann Rolf-Dieter, Wolff Klaus, et al. Brief S2k guidelines – Cutaneous squamous cell carcinoma. . 2013;11:37-45|http://dx.doi.org/10.1111/ddg.12015_7|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Hauschild, Axel|Hintergrund|||Standard|Breuninger Helmut, Eigentler Thomas, Bootz Friedrich, Hauschild Axel, Kortmann Rolf-Dieter, Wolff Klaus, et al. Brief S2k guidelines – Cutaneous squamous cell carcinoma. . 2013;11:37-45|http://dx.doi.org/10.1111/ddg.12015_7|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Standard|Hafner H. M., Breuninger H., Moehrle M., Trilling B., Krimmel M. 3D histology-guided surgery for basal cell carcinoma and squamous cell carcinoma: recurrence rates and clinical outcome. . 2011;40:943-8|https://www.ncbi.nlm.nih.gov/pubmed/21600736|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Erstautor|Breuninger H., Schaumburg-Lever G. Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique. None. 1988;154:167-71|http://onlinelibrary.wiley.com/doi/10.1002/path.1711540209/abstract|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Letztautor|Ulrich C., Schmook T., Nindl I., Meyer T., Sterry W., Stockfleth E. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. . 2003;149 Suppl 66:40-42|https://www.ncbi.nlm.nih.gov/pubmed/14616348|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Hintergrund|||Erstautor|Ulrich C., Schmook T., Nindl I., Meyer T., Sterry W., Stockfleth E. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. . 2003;149 Suppl 66:40-42|https://www.ncbi.nlm.nih.gov/pubmed/14616348|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Standard|Moehrle M., Breuninger H., Röcken M. A confusing world: what to call histology of three-dimensional tumour margins?. . 2007;21:591-595|https://www.ncbi.nlm.nih.gov/pubmed/17447971|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Krediet J. T., Beyer M., Lenz K., Ulrich C., Lange-Asschenfeldt B., Stockfleth E., et al. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. . 2015;172:1029-36|https://www.ncbi.nlm.nih.gov/pubmed/25362868|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Hintergrund|||Standard|Krediet J. T., Beyer M., Lenz K., Ulrich C., Lange-Asschenfeldt B., Stockfleth E., et al. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. . 2015;172:1029-36|https://www.ncbi.nlm.nih.gov/pubmed/25362868|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Alter, Mareike|Hintergrund|||Standard|Leiter U., Gutzmer R., Alter M., Ulrich C., Lonsdorf A. S., Sachse M. M., et al. Kutanes Plattenepithelkarzinom. None. 2016;67:857-866|https://doi.org/10.1007/s00105-016-3875-2|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Gutzmer, Ralf|Hintergrund|||Standard|Leiter U., Gutzmer R., Alter M., Ulrich C., Lonsdorf A. S., Sachse M. M., et al. Kutanes Plattenepithelkarzinom. None. 2016;67:857-866|https://doi.org/10.1007/s00105-016-3875-2|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Erstautor|Leiter U., Gutzmer R., Alter M., Ulrich C., Lonsdorf A. S., Sachse M. M., et al. Kutanes Plattenepithelkarzinom. None. 2016;67:857-866|https://doi.org/10.1007/s00105-016-3875-2|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Ulrich, Claas|Hintergrund|||Standard|Leiter U., Gutzmer R., Alter M., Ulrich C., Lonsdorf A. S., Sachse M. M., et al. Kutanes Plattenepithelkarzinom. None. 2016;67:857-866|https://doi.org/10.1007/s00105-016-3875-2|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Erstautor|Stockfleth E., Ferrandiz C., Grob J. J., Leigh I., Pehamberger H., Kerl H. Development of a treatment algorithm for actinic keratoses: a European Consensus. None. 2008;18:651-9|http://www.ncbi.nlm.nih.gov/pubmed/18955209|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Evidenzbasierte Empfehlung|A|False|Standard|Schweinzer K., Kofler L., Bauer J., Metzler G., Breuninger H., Hafner H. M. Cytokeratin AE1/AE3 immunostaining and 3D-histology: improvement of diagnosis in desmoplastic squamous cell carcinoma of the skin. . 2017;309:43-46|https://www.ncbi.nlm.nih.gov/pubmed/27864629|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Breuninger, Helmut|Hintergrund|||Standard|Schweinzer K., Kofler L., Bauer J., Metzler G., Breuninger H., Hafner H. M. Cytokeratin AE1/AE3 immunostaining and 3D-histology: improvement of diagnosis in desmoplastic squamous cell carcinoma of the skin. . 2017;309:43-46|https://www.ncbi.nlm.nih.gov/pubmed/27864629|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Kofler, Lukas|Evidenzbasierte Empfehlung|A|False|Standard|Schweinzer K., Kofler L., Bauer J., Metzler G., Breuninger H., Hafner H. M. Cytokeratin AE1/AE3 immunostaining and 3D-histology: improvement of diagnosis in desmoplastic squamous cell carcinoma of the skin. . 2017;309:43-46|https://www.ncbi.nlm.nih.gov/pubmed/27864629|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Kofler, Lukas|Hintergrund|||Standard|Schweinzer K., Kofler L., Bauer J., Metzler G., Breuninger H., Hafner H. M. Cytokeratin AE1/AE3 immunostaining and 3D-histology: improvement of diagnosis in desmoplastic squamous cell carcinoma of the skin. . 2017;309:43-46|https://www.ncbi.nlm.nih.gov/pubmed/27864629|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Konsensbasiertes Statement||False|Standard|Werner R. N., Sammain A., Erdmann R., Hartmann V., Stockfleth E., Nast A. The natural history of actinic keratosis: a systematic review. None. 2013;169:502-18|https://www.ncbi.nlm.nih.gov/pubmed/23647091|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Werner R. N., Sammain A., Erdmann R., Hartmann V., Stockfleth E., Nast A. The natural history of actinic keratosis: a systematic review. None. 2013;169:502-18|https://www.ncbi.nlm.nih.gov/pubmed/23647091|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Evidenzbasiertes Statement||False|Standard|Dreno B., Cerio R., Dirschka T., Nart I. F., Lear J. T., Peris K., et al. A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity. None. 2017;97:1108-1113|http://www.ncbi.nlm.nih.gov/pubmed/28536731|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Standard|Dreno B., Cerio R., Dirschka T., Nart I. F., Lear J. T., Peris K., et al. A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity. None. 2017;97:1108-1113|http://www.ncbi.nlm.nih.gov/pubmed/28536731|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Bauer, Andrea|Hintergrund|||Letztautor|Schmitt J., Seidler A., Diepgen T. L., Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. . 2011;164:291-307|https://www.ncbi.nlm.nih.gov/pubmed/21054335|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Wermker, Kai|Evidenzbasiertes Statement||False|Erstautor|Wermker K., Kluwig J., Schipmann S., Klein M., Schulze H. J., Hallermann C. Prediction score for lymph node metastasis from cutaneous squamous cell carcinoma of the external ear. . 2015;41:128-35|https://www.ncbi.nlm.nih.gov/pubmed/25182221|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Wermker, Kai|Hintergrund|||Erstautor|Wermker K., Kluwig J., Schipmann S., Klein M., Schulze H. J., Hallermann C. Prediction score for lymph node metastasis from cutaneous squamous cell carcinoma of the external ear. . 2015;41:128-35|https://www.ncbi.nlm.nih.gov/pubmed/25182221|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Eigentler, Thomas|Hintergrund|||Standard|Leiter U., Keim U., Eigentler T., Katalinic A., Holleczek B., Martus P., et al. Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. . 2017;:|https://www.ncbi.nlm.nih.gov/pubmed/28487088|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Erstautor|Leiter U., Keim U., Eigentler T., Katalinic A., Holleczek B., Martus P., et al. Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. . 2017;:|https://www.ncbi.nlm.nih.gov/pubmed/28487088|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Erstautor|Dirschka T., Gupta G., Micali G., Stockfleth E., Basset-Seguin N., Del Marmol V., et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. None. 2017;28:431-442|https://www.ncbi.nlm.nih.gov/pubmed/27796187|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Dirschka T., Gupta G., Micali G., Stockfleth E., Basset-Seguin N., Del Marmol V., et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. None. 2017;28:431-442|https://www.ncbi.nlm.nih.gov/pubmed/27796187|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Stockfleth, Eggert|Hintergrund|||Standard|Roewert-Huber J., Stockfleth E., Kerl H. Pathology and pathobiology of actinic (solar) keratosis - an update. None. 2007;157 Suppl 2:18-20|https://www.ncbi.nlm.nih.gov/pubmed/18067626|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Dirschka, Thomas|Hintergrund|||Standard|Figueras Nart I., Cerio R., Dirschka T., Dreno B., Lear J. T., Pellacani G., et al. Defining the actinic keratosis field: a literature review and discussion. None. 2017;None:None|https://www.ncbi.nlm.nih.gov/pubmed/29055153|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Welzel, Julia|Hintergrund|||Erstautor|Welzel J., Ulrich M., Lange-Aschenfeldt S., Stolz W., Sattler E. S1-Leitlinie 013-076: Konfokale Lasermikroskopie in der Dermatologie. None. 2017;None:None||647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Welzel, Julia|Hintergrund|||Letztautor|Schuh S., Kaestle R., Sattler E. C., Welzel J. Optical coherence tomography of actinic keratoses and basal cell carcinomas - differentiation by quantification of signal intensity and layer thickness. None. 2016;30:1321-6|https://www.ncbi.nlm.nih.gov/pubmed/26915996|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Berking, Carola|Hintergrund|||Letztautor|Maier T., Cekovic D., Ruzicka T., Sattler E. C., Berking C. Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. None. 2015;172:816-8|https://www.ncbi.nlm.nih.gov/pubmed/25070046|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Garbe, Claus|Hintergrund|||Standard|Amaral T, Osewold M, Presser D, Meiwes A, Garbe C, Leiter U. Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. J Eur Acad Dermatol Venereol. 2019;33 Suppl 8 ():44-51|https://pubmed.ncbi.nlm.nih.gov/31658392/|647
Aktinische Keratose und Plattenepithelkarzinom der Haut|"2.0"|2022|Leiter, Ulrike|Hintergrund|||Letztautor|Amaral T, Osewold M, Presser D, Meiwes A, Garbe C, Leiter U. Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. J Eur Acad Dermatol Venereol. 2019;33 Suppl 8 ():44-51|https://pubmed.ncbi.nlm.nih.gov/31658392/|647
Analkarzinom|"1.2"|2020|Wieland, Ulrike|Hintergrund|||Letztautor|Kreuter A., Siorokos C., Oellig F., Silling S., Pfister H., Wieland U. High-grade Dysplasia in Anogenital Warts of HIV-Positive Men. None. 2016;152:1225-1230|https://www.ncbi.nlm.nih.gov/pubmed/27463201|535
Analkarzinom|"1.2"|2020|Wieland, Ulrike|Hintergrund|||Standard|Rodel F., Wieland U., Fraunholz I., Kitz J., Rave-Frank M., Wolff H. A., et al. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. None. 2015;136:278-88|https://www.ncbi.nlm.nih.gov/pubmed/24839133|535
Analkarzinom|"1.2"|2020|Koswig, Stephan|Hintergrund|||Standard|Matzinger O., Roelofsen F., Mineur L., Koswig S., Van Der Steen-Banasik E. M., Van Houtte P., et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). None. 2009;45:2782-91|https://www.ncbi.nlm.nih.gov/pubmed/19643599|535
Analkarzinom|"1.2"|2020|Aigner, Felix|Hintergrund|||Erstautor|Aigner F., Boeckle E., Albright J., Kilo J., Boesmueller C., Conrad F., et al. Malignancies of the colorectum and anus in solid organ recipients. None. 2007;20:497-504|https://www.ncbi.nlm.nih.gov/pubmed/17343685|535
Analkarzinom|"1.2"|2020|Esser, Stefan|Hintergrund|||Standard|Gross G. E., Werner R. N., Becker J. C., Brockmeyer N. H., Esser S., Hampl M., et al. S2k-Leitlinie: HPV-assoziierte Lasionen der ausseren Genitalregion und des Anus - Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (Kurzfassung). None. 2018;16:242-256|https://www.ncbi.nlm.nih.gov/pubmed/29418090|535
Analkarzinom|"1.2"|2020|Werner, Ricardo N.|Hintergrund|||Standard|Gross G. E., Werner R. N., Becker J. C., Brockmeyer N. H., Esser S., Hampl M., et al. S2k-Leitlinie: HPV-assoziierte Lasionen der ausseren Genitalregion und des Anus - Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (Kurzfassung). None. 2018;16:242-256|https://www.ncbi.nlm.nih.gov/pubmed/29418090|535
Analkarzinom|"1.2"|2020|Esser, Stefan|Konsensbasierte Empfehlung|A|False|Erstautor|Esser S., Kreuter A., Oette M., Gingelmaier A., Mosthaf F., Sautter-Bihl M. L., et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. None. 2015;13:1302-19|https://www.ncbi.nlm.nih.gov/pubmed/26612810|535
Analkarzinom|"1.2"|2020|Esser, Stefan|Hintergrund|||Erstautor|Esser S., Kreuter A., Oette M., Gingelmaier A., Mosthaf F., Sautter-Bihl M. L., et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. None. 2015;13:1302-19|https://www.ncbi.nlm.nih.gov/pubmed/26612810|535
Analkarzinom|"1.2"|2020|Mosthaf, Franz|Konsensbasierte Empfehlung|A|False|Standard|Esser S., Kreuter A., Oette M., Gingelmaier A., Mosthaf F., Sautter-Bihl M. L., et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. None. 2015;13:1302-19|https://www.ncbi.nlm.nih.gov/pubmed/26612810|535
Analkarzinom|"1.2"|2020|Mosthaf, Franz|Hintergrund|||Standard|Esser S., Kreuter A., Oette M., Gingelmaier A., Mosthaf F., Sautter-Bihl M. L., et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. None. 2015;13:1302-19|https://www.ncbi.nlm.nih.gov/pubmed/26612810|535
Analkarzinom|"1.2"|2020|Oette, Mark|Konsensbasierte Empfehlung|A|False|Standard|Esser S., Kreuter A., Oette M., Gingelmaier A., Mosthaf F., Sautter-Bihl M. L., et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. None. 2015;13:1302-19|https://www.ncbi.nlm.nih.gov/pubmed/26612810|535
Analkarzinom|"1.2"|2020|Oette, Mark|Hintergrund|||Standard|Esser S., Kreuter A., Oette M., Gingelmaier A., Mosthaf F., Sautter-Bihl M. L., et al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. None. 2015;13:1302-19|https://www.ncbi.nlm.nih.gov/pubmed/26612810|535
Analkarzinom|"1.2"|2020|Oette, Mark|Hintergrund|||Erstautor|Oette M., Wieland U., Schunemann M., Haes J., Reuter S., Jensen B. E., et al. Anal chromoendoscopy using gastroenterological video-endoscopes: A new method to perform high resolution anoscopy for diagnosing intraepithelial neoplasia and anal carcinoma in HIV-infected patients. None. 2017;55:23-31|https://www.ncbi.nlm.nih.gov/pubmed/27806411|535
Analkarzinom|"1.2"|2020|Wieland, Ulrike|Hintergrund|||Standard|Oette M., Wieland U., Schunemann M., Haes J., Reuter S., Jensen B. E., et al. Anal chromoendoscopy using gastroenterological video-endoscopes: A new method to perform high resolution anoscopy for diagnosing intraepithelial neoplasia and anal carcinoma in HIV-infected patients. None. 2017;55:23-31|https://www.ncbi.nlm.nih.gov/pubmed/27806411|535
Analkarzinom|"1.2"|2020|Wieland, Ulrike|Hintergrund|||Letztautor|Silling S., Kreuter A., Hellmich M., Swoboda J., Pfister H., Wieland U. Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men. None. 2012;53:325-31|https://www.ncbi.nlm.nih.gov/pubmed/22261122|535
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019;9 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31525824/|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2020;1 ():CD012643|https://pubmed.ncbi.nlm.nih.gov/31930780/|560
Hodgkin Lymphom|"3.2"|2022|Hentrich, Marcus|Hintergrund|||Standard|Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med. 2015;16 (4):261-4|https://pubmed.ncbi.nlm.nih.gov/25252101/|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Erstautor|Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132 (14):1519-1525|https://pubmed.ncbi.nlm.nih.gov/30064977/|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132 (14):1519-1525|https://pubmed.ncbi.nlm.nih.gov/30064977/|560
Hodgkin Lymphom|"3.2"|2022|von Tresckow, Bastian|Hintergrund|||Standard|Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood. 2018;132 (14):1519-1525|https://pubmed.ncbi.nlm.nih.gov/30064977/|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|Gillessen Sarah, Plütschow Annette, Fuchs Michael, Markova Jana, Greil Richard, Topp Max S., et al. Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2019;134:129|https://doi.org/10.1182/blood-2019-125249|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Armand P., Engert A., Younes A., Fanale M., Santoro A., Zinzani P. L., et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. None. 2018;36:1428-1439|https://pubmed.ncbi.nlm.nih.gov/29584546/|560
Hodgkin Lymphom|"3.2"|2022|Skoetz, Nicole|Hintergrund|||Letztautor|Knips L., Bergenthal N., Streckmann F., Monsef I., Elter T., Skoetz N. Aerobic physical exercise for adult patients with haematological malignancies. None. 2019;1:Cd009075|https://pubmed.ncbi.nlm.nih.gov/30702150/|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Erstautor|Fuchs M. Hodgkin-Lymphome. Available from: https://www.onkopedia.com/de/onkopedia/guidelines/hodgkin-lymphom/@@view/html/index.html. . 2016;:|https://www.onkopedia.com/de/onkopedia/guidelines/hodgkin-lymphom/@@view/html/index.html|560
Hodgkin Lymphom|"3.2"|2022|Skoetz, Nicole|Hintergrund|||Standard|Herbst C., Rehan F. A., Skoetz N., Bohlius J., Brillant C., Schulz H., et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. . 2011;:CD007110|https://www.ncbi.nlm.nih.gov/pubmed/21328291|560
Hodgkin Lymphom|"3.2"|2022|Dietlein, Markus|Hintergrund|||Standard|Kobe C., Dietlein M., Franklin J., Markova J., Lohri A., Amthauer H., et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. None. 2008;112:3989-94|http://www.bloodjournal.org/content/bloodjournal/112/10/3989.full.pdf|560
Hodgkin Lymphom|"3.2"|2022|Kobe, Carsten|Hintergrund|||Erstautor|Kobe C., Dietlein M., Franklin J., Markova J., Lohri A., Amthauer H., et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. None. 2008;112:3989-94|http://www.bloodjournal.org/content/bloodjournal/112/10/3989.full.pdf|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Skoetz N., Trelle S., Rancea M., Haverkamp H., Diehl V., Engert A., et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. . 2013;14:943-52|https://www.ncbi.nlm.nih.gov/pubmed/23948348|560
Hodgkin Lymphom|"3.2"|2022|Rancea, Michaela|Hintergrund|||Standard|Skoetz N., Trelle S., Rancea M., Haverkamp H., Diehl V., Engert A., et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. . 2013;14:943-52|https://www.ncbi.nlm.nih.gov/pubmed/23948348|560
Hodgkin Lymphom|"3.2"|2022|Skoetz, Nicole|Hintergrund|||Erstautor|Skoetz N., Trelle S., Rancea M., Haverkamp H., Diehl V., Engert A., et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. . 2013;14:943-52|https://www.ncbi.nlm.nih.gov/pubmed/23948348|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert A., Haverkamp H., Kobe C., Markova J., Renner C., Ho A., et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. . 2012;:1791-9|http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/655/CN-00880655/frame.html, http://ac.els-cdn.com/S0140673611619405/1-s2.0-S0140673611619405-main.pdf?_tid=dc23364a-9507-11e6-ae67-00000aab0f6b&acdnat=1476777347_7bbee63f0430e63c4218a37237d2cfb6|560
Hodgkin Lymphom|"3.2"|2022|Kobe, Carsten|Hintergrund|||Standard|Engert A., Haverkamp H., Kobe C., Markova J., Renner C., Ho A., et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. . 2012;:1791-9|http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/655/CN-00880655/frame.html, http://ac.els-cdn.com/S0140673611619405/1-s2.0-S0140673611619405-main.pdf?_tid=dc23364a-9507-11e6-ae67-00000aab0f6b&acdnat=1476777347_7bbee63f0430e63c4218a37237d2cfb6|560
Hodgkin Lymphom|"3.2"|2022|Borchmann, Peter|Hintergrund|||Erstautor|Borchmann P., Haverkamp H., Diehl V., Cerny T., Markova J., Ho A. D., et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. . 2011;29:4234-42|https://www.ncbi.nlm.nih.gov/pubmed/21990399|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Erstautor|Eichenauer Dennis A., Plütschow Annette, Kreissl Stefanie, Sökler Martin, Hellmuth Johannes C., Meissner Julia, et al. Randomized phase II study of targeted BEACOPP variants incorporating Brentuximab vedotin in the first-line treatment of advanced classical Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). None. 2017 accepted, not published;None:None||560
Hodgkin Lymphom|"3.2"|2022|Kreissl, Stefanie|Hintergrund|||Standard|Eichenauer Dennis A., Plütschow Annette, Kreissl Stefanie, Sökler Martin, Hellmuth Johannes C., Meissner Julia, et al. Randomized phase II study of targeted BEACOPP variants incorporating Brentuximab vedotin in the first-line treatment of advanced classical Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). None. 2017 accepted, not published;None:None||560
Hodgkin Lymphom|"3.2"|2022|Rosenwald, Andreas|Hintergrund|||Erstautor|Rosenwald A. Pathology and Molecular Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma - A Comprehensive Update On Diagnostics and Clinics (Engert A., ed.). None. 2011;None:33 -48||560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert A., Ballova V., Haverkamp H., Pfistner B., Josting A., Duhmke E., et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. . 2005;23:5052-60|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Boll B., Bredenfeld H., Gorgen H., Halbsguth T., Eich H. T., Soekler M., et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. . 2011;118:6292-8|https://www.ncbi.nlm.nih.gov/pubmed/21917759|560
Hodgkin Lymphom|"3.2"|2022|Borchmann, Peter|Hintergrund|||Standard|Boll B., Borchmann P., Topp M. S., Hanel M., Reiners K. S., Engert A., et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. . 2010;148:480-2|https://www.ncbi.nlm.nih.gov/pubmed/19863533|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Boll B., Borchmann P., Topp M. S., Hanel M., Reiners K. S., Engert A., et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. . 2010;148:480-2|https://www.ncbi.nlm.nih.gov/pubmed/19863533|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Standard|Klimm B., Reineke T., Haverkamp H., Behringer K., Eich H. T., Josting A., et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. . 2005;23:8003-11|https://www.ncbi.nlm.nih.gov/pubmed/16204002|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Klimm B., Reineke T., Haverkamp H., Behringer K., Eich H. T., Josting A., et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. . 2005;23:8003-11|https://www.ncbi.nlm.nih.gov/pubmed/16204002|560
Hodgkin Lymphom|"3.2"|2022|Klimm, Beate|Hintergrund|||Erstautor|Klimm B., Reineke T., Haverkamp H., Behringer K., Eich H. T., Josting A., et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. . 2005;23:8003-11|https://www.ncbi.nlm.nih.gov/pubmed/16204002|560
Hodgkin Lymphom|"3.2"|2022|Hentrich, Marcus|Hintergrund|||Erstautor|Hentrich M., Maretta L., Chow K. U., Bogner J. R., Schurmann D., Neuhoff P., et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. . 2006;17:914-9|https://www.ncbi.nlm.nih.gov/pubmed/16565210|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Erstautor|Eichenauer D. A., Engert A., Andre M., Federico M., Illidge T., Hutchings M., et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. . 2014;25 Suppl 3:iii70-5|https://www.ncbi.nlm.nih.gov/pubmed/25185243|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Eichenauer D. A., Engert A., Andre M., Federico M., Illidge T., Hutchings M., et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. . 2014;25 Suppl 3:iii70-5|https://www.ncbi.nlm.nih.gov/pubmed/25185243|560
Hodgkin Lymphom|"3.2"|2022|Hentrich, Marcus|Hintergrund|||Erstautor|Hentrich M., Berger M., Wyen C., Siehl J., Rockstroh J. K., Muller M., et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. . 2012;30:4117-23|https://www.ncbi.nlm.nih.gov/pubmed/23045592|560
Hodgkin Lymphom|"3.2"|2022|Wyen, Christoph|Hintergrund|||Standard|Hentrich M., Berger M., Wyen C., Siehl J., Rockstroh J. K., Muller M., et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. . 2012;30:4117-23|https://www.ncbi.nlm.nih.gov/pubmed/23045592|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Standard|Eichenauer D. A., Plutschow A., Fuchs M., von Tresckow B., Boll B., Behringer K., et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. . 2015;33:2857-62|https://www.ncbi.nlm.nih.gov/pubmed/26240235|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Erstautor|Eichenauer D. A., Plutschow A., Fuchs M., von Tresckow B., Boll B., Behringer K., et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. . 2015;33:2857-62|https://www.ncbi.nlm.nih.gov/pubmed/26240235|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|Eichenauer D. A., Plutschow A., Fuchs M., von Tresckow B., Boll B., Behringer K., et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. . 2015;33:2857-62|https://www.ncbi.nlm.nih.gov/pubmed/26240235|560
Hodgkin Lymphom|"3.2"|2022|von Tresckow, Bastian|Hintergrund|||Standard|Eichenauer D. A., Plutschow A., Fuchs M., von Tresckow B., Boll B., Behringer K., et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. . 2015;33:2857-62|https://www.ncbi.nlm.nih.gov/pubmed/26240235|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Standard|Eichenauer D. A., Goergen H., Plutschow A., Wongso D., Behringer K., Kreissl S., et al. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. None. 2016;30:1425-7|http://www.nature.com/leu/journal/v30/n6/pdf/leu2015321a.pdf|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Erstautor|Eichenauer D. A., Goergen H., Plutschow A., Wongso D., Behringer K., Kreissl S., et al. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. None. 2016;30:1425-7|http://www.nature.com/leu/journal/v30/n6/pdf/leu2015321a.pdf|560
Hodgkin Lymphom|"3.2"|2022|Kreissl, Stefanie|Hintergrund|||Standard|Eichenauer D. A., Goergen H., Plutschow A., Wongso D., Behringer K., Kreissl S., et al. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. None. 2016;30:1425-7|http://www.nature.com/leu/journal/v30/n6/pdf/leu2015321a.pdf|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert Andreas, Haverkamp Heinz, Kobe Carsten, Markova Jana, Renner Christoph, Ho Anthony D., et al. Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results. . 2011;118:589-|http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/589|560
Hodgkin Lymphom|"3.2"|2022|Kobe, Carsten|Hintergrund|||Standard|Engert Andreas, Haverkamp Heinz, Kobe Carsten, Markova Jana, Renner Christoph, Ho Anthony D., et al. Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results. . 2011;118:589-|http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/589|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|Hay A. E., Klimm B., Chen B. E., Goergen H., Shepherd L. E., Fuchs M., et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. None. 2013;24:3065-9|https://pubmed.ncbi.nlm.nih.gov/24121121/|560
Hodgkin Lymphom|"3.2"|2022|Klimm, Beate|Hintergrund|||Standard|Hay A. E., Klimm B., Chen B. E., Goergen H., Shepherd L. E., Fuchs M., et al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. None. 2013;24:3065-9|https://pubmed.ncbi.nlm.nih.gov/24121121/|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Rancea Michaela, Monsef Ina, von Tresckow Bastian, Engert Andreas, Skoetz Nicole. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. . 2013;:|https://www.ncbi.nlm.nih.gov/pubmed/23784872|560
Hodgkin Lymphom|"3.2"|2022|Rancea, Michaela|Hintergrund|||Erstautor|Rancea Michaela, Monsef Ina, von Tresckow Bastian, Engert Andreas, Skoetz Nicole. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. . 2013;:|https://www.ncbi.nlm.nih.gov/pubmed/23784872|560
Hodgkin Lymphom|"3.2"|2022|von Tresckow, Bastian|Hintergrund|||Standard|Rancea Michaela, Monsef Ina, von Tresckow Bastian, Engert Andreas, Skoetz Nicole. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. . 2013;:|https://www.ncbi.nlm.nih.gov/pubmed/23784872|560
Hodgkin Lymphom|"3.2"|2022|Borchmann, Peter|Hintergrund|||Standard|Josting A., Muller H., Borchmann P., Baars J. W., Metzner B., Dohner H., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. None. 2010;28:5074-80|http://www.ncbi.nlm.nih.gov/pubmed/20975066|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|Boll Boris, Gorgen Helen, Arndt Nils, Plutschow Annette, Fuchs Michael, Diehl Volker, et al. Relapsed Hodgkin Lymphoma in Elderly Patients: A Comprehensive Analysis From the German Hodgkin Study Group (GHSG). . 2011;118:92-|http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/92|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Standard|Kreissl S., Mueller H., Goergen H., Mayer A., Brillant C., Behringer K., et al. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. None. 2016;17:1453-1462|https://pubmed.ncbi.nlm.nih.gov/27612583/|560
Hodgkin Lymphom|"3.2"|2022|Kreissl, Stefanie|Hintergrund|||Erstautor|Kreissl S., Mueller H., Goergen H., Mayer A., Brillant C., Behringer K., et al. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. None. 2016;17:1453-1462|https://pubmed.ncbi.nlm.nih.gov/27612583/|560
Hodgkin Lymphom|"3.2"|2022|Baues, Christian|Hintergrund|||Erstautor|Baues C., Marnitz S., Engert A., Baus W., Jablonska K., Fogliata A., et al. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY. . 2018;13:122|https://ro-journal.biomedcentral.com/track/pdf/10.1186/s13014-018-1066-2|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Baues C., Marnitz S., Engert A., Baus W., Jablonska K., Fogliata A., et al. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY. . 2018;13:122|https://ro-journal.biomedcentral.com/track/pdf/10.1186/s13014-018-1066-2|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Standard|Engert A., Eichenauer D. A., Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. . 2010c;21 Suppl 5:v168-71|http://www.ncbi.nlm.nih.gov/pubmed/20555072|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert A., Eichenauer D. A., Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. . 2010c;21 Suppl 5:v168-71|http://www.ncbi.nlm.nih.gov/pubmed/20555072|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Standard|Sasse S., Rothe A., Goergen H., Eichenauer D. A., Lohri A., Kreher S., et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. None. 2013;54:2144-8|http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.775434?needAccess=true|560
Hodgkin Lymphom|"3.2"|2022|Sasse, Stephanie|Hintergrund|||Erstautor|Sasse S., Rothe A., Goergen H., Eichenauer D. A., Lohri A., Kreher S., et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. None. 2013;54:2144-8|http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.775434?needAccess=true|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Josting A., Nogova L., Franklin J., Glossmann J. P., Eich H. T., Sieber M., et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. None. 2005;23:1522-9|http://www.ncbi.nlm.nih.gov/pubmed/15632410|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Specht L., Yahalom J., Illidge T., Berthelsen A. K., Constine L. S., Eich H. T., et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). . 2014;89:854-62|https://www.ncbi.nlm.nih.gov/pubmed/23790512|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Letztautor|Bohlius J., Herbst C., Reiser M., Schwarzer G., Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. . 2008;:CD003189|http://www.ncbi.nlm.nih.gov/pubmed/18843642|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert A., Bredenfeld H., Dohner H., Ho A. D., Schmitz N., Berger D., et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. None. 2006;91:546-9|http://www.haematologica.org/content/haematol/91/4/546.full.pdf|560
Hodgkin Lymphom|"3.2"|2022|Borchmann, Peter|Hintergrund|||Erstautor|Borchmann P., Haverkamp H., Lohri A., Mey U., Kreissl S., Greil R., et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. . 2017;18:454-463|https://www.sciencedirect.com/science/article/pii/S1470204517301031|560
Hodgkin Lymphom|"3.2"|2022|Kreissl, Stefanie|Hintergrund|||Standard|Borchmann P., Haverkamp H., Lohri A., Mey U., Kreissl S., Greil R., et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. . 2017;18:454-463|https://www.sciencedirect.com/science/article/pii/S1470204517301031|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Glossmann J. P., Engert A., Wassmer G., Flechtner H., Ko Y., Rudolph C., et al. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial. None. 2003;82:469-75|https://link.springer.com/content/pdf/10.1007%2Fs00277-003-0695-0.pdf|560
Hodgkin Lymphom|"3.2"|2022|Flechtner, Hans-Henning|Hintergrund|||Standard|Glossmann J. P., Engert A., Wassmer G., Flechtner H., Ko Y., Rudolph C., et al. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial. None. 2003;82:469-75|https://link.springer.com/content/pdf/10.1007%2Fs00277-003-0695-0.pdf|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Muller H., Gorgen H., Flechtner H. H., Brillant C., Halbsguth T. V., et al. Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group. . 2013;108:49-57|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553532/|560
Hodgkin Lymphom|"3.2"|2022|Flechtner, Hans-Henning|Hintergrund|||Standard|Behringer K., Muller H., Gorgen H., Flechtner H. H., Brillant C., Halbsguth T. V., et al. Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group. . 2013;108:49-57|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553532/|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Thielen I., Mueller H., Goergen H., Eibi A. S., Rosenbrock J. Fertlity and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. None. 2012;None:1818-25|http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/402/CN-00853402/frame.html|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Kobe C., Kuhnert G., Kahraman D., Haverkamp H., Eich H. T., Franke M., et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. . 2014;32:1776-81|https://www.ncbi.nlm.nih.gov/pubmed/24799482|560
Hodgkin Lymphom|"3.2"|2022|Kobe, Carsten|Hintergrund|||Erstautor|Kobe C., Kuhnert G., Kahraman D., Haverkamp H., Eich H. T., Franke M., et al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. . 2014;32:1776-81|https://www.ncbi.nlm.nih.gov/pubmed/24799482|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Wildt L., Mueller H., Mattle V., Ganitis P., van den Hoonaard B., et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. . 2010;21:2052-60|https://www.ncbi.nlm.nih.gov/pubmed/20305034|560
Hodgkin Lymphom|"3.2"|2022|Borchmann, Peter|Hintergrund|||Erstautor|Borchmann P., Goergen H., Kobe C., Lohri A., Greil R., Eichenauer D. A., et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. None. 2018;390:2790-2802|https://pubmed.ncbi.nlm.nih.gov/29061295/|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Standard|Borchmann P., Goergen H., Kobe C., Lohri A., Greil R., Eichenauer D. A., et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. None. 2018;390:2790-2802|https://pubmed.ncbi.nlm.nih.gov/29061295/|560
Hodgkin Lymphom|"3.2"|2022|Kobe, Carsten|Hintergrund|||Standard|Borchmann P., Goergen H., Kobe C., Lohri A., Greil R., Eichenauer D. A., et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. None. 2018;390:2790-2802|https://pubmed.ncbi.nlm.nih.gov/29061295/|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Standard|Haverkamp H., Boll B., Eichenauer D. A., Sasse S., Fuchs M., Borchmann P., et al. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials. None. 2015;33:2430-6|https://pubmed.ncbi.nlm.nih.gov/26101245/|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|Haverkamp H., Boll B., Eichenauer D. A., Sasse S., Fuchs M., Borchmann P., et al. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials. None. 2015;33:2430-6|https://pubmed.ncbi.nlm.nih.gov/26101245/|560
Hodgkin Lymphom|"3.2"|2022|Sasse, Stephanie|Hintergrund|||Standard|Haverkamp H., Boll B., Eichenauer D. A., Sasse S., Fuchs M., Borchmann P., et al. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials. None. 2015;33:2430-6|https://pubmed.ncbi.nlm.nih.gov/26101245/|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Thielen I., Mueller H., Goergen H., Eibl A. D., Rosenbrock J., et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. . 2012;23:1818-25|https://www.ncbi.nlm.nih.gov/pubmed/22228451|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Standard|Balcerek M., Behringer K., Borgmann-Staudt A., Bürkle C., Fehm T., Fey M., et al. Perspektive Fertilität Indikation und Durchführung fertilitätsprotektiver Massnahmen bei onkologischen und nicht-onkologischen Erkrankungen. None. 2016;None:None|https://www.ferring.de/assets/Uploads/FG004750-von-Wolff-Perspektive-Fertilitaet-Fertilitaetsprotektive-Massnahmen.pdf|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Standard|Sieniawski M., Reineke T., Josting A., Nogova L., Behringer K., Halbsguth T., et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. . 2008;19:1795-801|https://www.ncbi.nlm.nih.gov/pubmed/18544558|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Blank O., von Tresckow B., Monsef I., Specht L., Engert A., Skoetz N. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. . 2017;4:Cd007110|https://www.ncbi.nlm.nih.gov/pubmed/28447341|560
Hodgkin Lymphom|"3.2"|2022|Skoetz, Nicole|Hintergrund|||Letztautor|Blank O., von Tresckow B., Monsef I., Specht L., Engert A., Skoetz N. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. . 2017;4:Cd007110|https://www.ncbi.nlm.nih.gov/pubmed/28447341|560
Hodgkin Lymphom|"3.2"|2022|von Tresckow, Bastian|Hintergrund|||Standard|Blank O., von Tresckow B., Monsef I., Specht L., Engert A., Skoetz N. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. . 2017;4:Cd007110|https://www.ncbi.nlm.nih.gov/pubmed/28447341|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Standard|Franklin J., Eichenauer D. A., Becker I., Monsef I., Engert A. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. . 2017;9:Cd008814|https://www.ncbi.nlm.nih.gov/pubmed/28901021|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Letztautor|Franklin J., Eichenauer D. A., Becker I., Monsef I., Engert A. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. . 2017;9:Cd008814|https://www.ncbi.nlm.nih.gov/pubmed/28901021|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Standard|Eichenauer D. A., Thielen I., Haverkamp H., Franklin J., Behringer K., Halbsguth T., et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. . 2014;123:1658-64|https://www.ncbi.nlm.nih.gov/pubmed/24478403|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Erstautor|Eichenauer D. A., Thielen I., Haverkamp H., Franklin J., Behringer K., Halbsguth T., et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. . 2014;123:1658-64|https://www.ncbi.nlm.nih.gov/pubmed/24478403|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Josting A., Schiller P., Eich H. T., Bredenfeld H., Diehl V., et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. . 2004;15:1079-85|https://www.ncbi.nlm.nih.gov/pubmed/15205202|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Behringer K., Josting A., Schiller P., Eich H. T., Bredenfeld H., Diehl V., et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. . 2004;15:1079-85|https://www.ncbi.nlm.nih.gov/pubmed/15205202|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Engert A., Franklin J., Eich H. T., Brillant C., Sehlen S., Cartoni C., et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. . 2007;25:3495-502|https://www.ncbi.nlm.nih.gov/pubmed/17606976|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert A., Franklin J., Eich H. T., Brillant C., Sehlen S., Cartoni C., et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. . 2007;25:3495-502|https://www.ncbi.nlm.nih.gov/pubmed/17606976|560
Hodgkin Lymphom|"3.2"|2022|Eichenauer, Dennis|Hintergrund|||Standard|Franklin Jeremy, Eichenauer Dennis, Becker I., Monsef Ina, Engert Andreas. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival. . 2016;:|https://www.ncbi.nlm.nih.gov/pubmed/28901021|560
Hodgkin Lymphom|"3.2"|2022|Leibbrand, Birgit|Hintergrund|||Letztautor|Kähnert H, Exner AK, Brand S, Leibbrand B. Entwicklung und Bewertung der beruflich-orientierten Intervention “Perspektive Job” für die onkologische Rehabilitation. None. 2016;55:155-156|https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0042-104451|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Goergen H., Hitz F., Zijlstra J. M., Greil R., Markova J., et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. None. 2015;None:1418-27|http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/269/CN-01071269/frame.html, http://ac.els-cdn.com/S0140673614614690/1-s2.0-S0140673614614690-main.pdf?_tid=adc0e348-491f-11e7-ac8a-00000aacb35e&acdnat=1496578786_01c7ccf921527e5e5346aeb17f859e7d|560
Hodgkin Lymphom|"3.2"|2022|Leibbrand, Birgit|Hintergrund|||Standard|Mehnert A., Barth J., Gaspar M., Leibbrand B., Kegel C. D., Bootsveld W., et al. Predictors of early retirement after cancer rehabilitation-a longitudinal study. None. 2016;26:None|https://onlinelibrary.wiley.com/doi/pdf/10.1111/ecc.12528|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert Andreas, Goergen Helen, Markova Jana, Pabst Thomas, Meissner Julia, Zijlstra Josée M., et al. Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group. None. 2017;1:e5-e5|https://pubmed.ncbi.nlm.nih.gov/31723734, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745969/|560
Hodgkin Lymphom|"3.2"|2022|Borchmann, Peter|Hintergrund|||Standard|Engert A., Plutschow A., Eich H. T., Lohri A., Dorken B., Borchmann P., et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. None. 2010b;363:640-52|http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000067|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Engert A., Plutschow A., Eich H. T., Lohri A., Dorken B., Borchmann P., et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. None. 2010b;363:640-52|http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000067|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert A., Plutschow A., Eich H. T., Lohri A., Dorken B., Borchmann P., et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. None. 2010b;363:640-52|http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000067|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Breuer K., Reineke T., May M., Nogova L., Klimm B., et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. None. 2005;23:7555-64|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16234521, http://jco.ascopubs.org/content/23/30/7555.full.pdf|560
Hodgkin Lymphom|"3.2"|2022|Klimm, Beate|Hintergrund|||Standard|Behringer K., Breuer K., Reineke T., May M., Nogova L., Klimm B., et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. None. 2005;23:7555-64|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16234521, http://jco.ascopubs.org/content/23/30/7555.full.pdf|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Goergen H., Muller H., Thielen I., Brillant C., Kreissl S., et al. Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. . 2016;34:4329-4337|https://www.ncbi.nlm.nih.gov/pubmed/27998235|560
Hodgkin Lymphom|"3.2"|2022|Flechtner, Hans-Henning|Hintergrund|||Standard|Ruffer J. U., Flechtner H., Tralls P., Josting A., Sieber M., Lathan B., et al. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). None. 2003;39:2179-86|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14522376, http://ac.els-cdn.com/S0959804903005458/1-s2.0-S0959804903005458-main.pdf?_tid=e6fce8f8-4d2c-11e7-8450-00000aacb362&acdnat=1497024270_0f553c1d0e2121bde5924259c42954a7|560
Hodgkin Lymphom|"3.2"|2022|Flechtner, Hans-Henning|Hintergrund|||Standard|Heutte N., Flechtner H. H., Mounier N., Mellink W. A., Meerwaldt J. H., Eghbali H., et al. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. None. 2009;10:1160-70|http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19828373, http://ac.els-cdn.com/S147020450970258X/1-s2.0-S147020450970258X-main.pdf?_tid=62494b42-4d2c-11e7-8735-00000aacb362&acdnat=1497024048_27176fe0325f73e2447ed2a2799770e6|560
Hodgkin Lymphom|"3.2"|2022|Baues, Christian|Hintergrund|||Standard|Kobe C., Goergen H., Baues C., Kuhnert G., Voltin C. A., Zijlstra J., et al. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. . 2018;132:2273-2279|https://www.tandfonline.com/doi/full/10.1080/10428190903040048|560
Hodgkin Lymphom|"3.2"|2022|Kobe, Carsten|Hintergrund|||Erstautor|Kobe C., Goergen H., Baues C., Kuhnert G., Voltin C. A., Zijlstra J., et al. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. . 2018;132:2273-2279|https://www.tandfonline.com/doi/full/10.1080/10428190903040048|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Erstautor|Fuchs M., Goergen H., Kobe C., Kuhnert G., Lohri A., Greil R., et al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. None. 2019;None:Jco1900964|https://pubmed.ncbi.nlm.nih.gov/31498753/|560
Hodgkin Lymphom|"3.2"|2022|Kobe, Carsten|Hintergrund|||Standard|Fuchs M., Goergen H., Kobe C., Kuhnert G., Lohri A., Greil R., et al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. None. 2019;None:Jco1900964|https://pubmed.ncbi.nlm.nih.gov/31498753/|560
Hodgkin Lymphom|"3.2"|2022|Dietlein, Markus|Hintergrund|||Standard|Weihrauch M. R., Re D., Scheidhauer K., Ansen S., Dietlein M., Bischoff S., et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. . 2001;98:2930-4|https://www.ncbi.nlm.nih.gov/pubmed/11698273|560
Hodgkin Lymphom|"3.2"|2022|Kreissl, Stefanie|Hintergrund|||Standard|Sasse S., Brockelmann P. J., Goergen H., Plutschow A., Muller H., Kreissl S., et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. . 2017;35:1999-2007|https://pubmed.ncbi.nlm.nih.gov/28418763/|560
Hodgkin Lymphom|"3.2"|2022|Sasse, Stephanie|Hintergrund|||Erstautor|Sasse S., Brockelmann P. J., Goergen H., Plutschow A., Muller H., Kreissl S., et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. . 2017;35:1999-2007|https://pubmed.ncbi.nlm.nih.gov/28418763/|560
Hodgkin Lymphom|"3.2"|2022|Borchmann, Peter|Hintergrund|||Erstautor|Borchmann Peter. POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG. None. 2020;None:None||560
Hodgkin Lymphom|"3.2"|2022|Naumann, Ralph|Hintergrund|||Erstautor|Naumann R., Vaic A., Beuthien-Baumann B., Bredow J., Kropp J., Kittner T., et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. . 2001;115:793-800|https://www.ncbi.nlm.nih.gov/pubmed/11843811|560
Hodgkin Lymphom|"3.2"|2022|Kreissl, Stefanie|Hintergrund|||Standard|von Tresckow B., Kreissl S., Goergen H., Bröckelmann P. J., Pabst T., Fridrik M., et al. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. None. 2018;5:e462-e473|https://pubmed.ncbi.nlm.nih.gov/30290903/|560
Hodgkin Lymphom|"3.2"|2022|von Tresckow, Bastian|Hintergrund|||Erstautor|von Tresckow B., Kreissl S., Goergen H., Bröckelmann P. J., Pabst T., Fridrik M., et al. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. None. 2018;5:e462-e473|https://pubmed.ncbi.nlm.nih.gov/30290903/|560
Hodgkin Lymphom|"3.2"|2022|Borchmann, Peter|Hintergrund|||Standard|Sickinger Marie-Therese, von Tresckow Bastian, Kobe Carsten, Engert Andreas, Borchmann Peter, Skoetz Nicole. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. None. 2015;None:None|http://dx.doi.org/10.1002/14651858.CD010533.pub2|560
Hodgkin Lymphom|"3.2"|2022|Kobe, Carsten|Hintergrund|||Standard|Sickinger Marie-Therese, von Tresckow Bastian, Kobe Carsten, Engert Andreas, Borchmann Peter, Skoetz Nicole. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. None. 2015;None:None|http://dx.doi.org/10.1002/14651858.CD010533.pub2|560
Hodgkin Lymphom|"3.2"|2022|Skoetz, Nicole|Hintergrund|||Letztautor|Sickinger Marie-Therese, von Tresckow Bastian, Kobe Carsten, Engert Andreas, Borchmann Peter, Skoetz Nicole. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. None. 2015;None:None|http://dx.doi.org/10.1002/14651858.CD010533.pub2|560
Hodgkin Lymphom|"3.2"|2022|von Tresckow, Bastian|Hintergrund|||Standard|Sickinger Marie-Therese, von Tresckow Bastian, Kobe Carsten, Engert Andreas, Borchmann Peter, Skoetz Nicole. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. None. 2015;None:None|http://dx.doi.org/10.1002/14651858.CD010533.pub2|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert A., Schiller P., Josting A., Herrmann R., Koch P., Sieber M., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. . 2003;21:3601-8|https://www.ncbi.nlm.nih.gov/pubmed/12913100|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|Sasse S., Klimm B., Görgen H., Fuchs M., Heyden-Honerkamp A., Lohri A., et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. None. 2012;23:2953-2959|http://dx.doi.org/10.1093/annonc/mds110|560
Hodgkin Lymphom|"3.2"|2022|Klimm, Beate|Hintergrund|||Standard|Sasse S., Klimm B., Görgen H., Fuchs M., Heyden-Honerkamp A., Lohri A., et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. None. 2012;23:2953-2959|http://dx.doi.org/10.1093/annonc/mds110|560
Hodgkin Lymphom|"3.2"|2022|Sasse, Stephanie|Hintergrund|||Erstautor|Sasse S., Klimm B., Görgen H., Fuchs M., Heyden-Honerkamp A., Lohri A., et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. None. 2012;23:2953-2959|http://dx.doi.org/10.1093/annonc/mds110|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Erstautor|Eich H. T., Diehl V., Gorgen H., Pabst T., Markova J., Debus J., et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. . 2010;28:4199-206|https://www.ncbi.nlm.nih.gov/pubmed/20713848|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|von Tresckow B., Plutschow A., Fuchs M., Klimm B., Markova J., Lohri A., et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. . 2012;30:907-13|https://www.ncbi.nlm.nih.gov/pubmed/20713848|560
Hodgkin Lymphom|"3.2"|2022|Klimm, Beate|Hintergrund|||Standard|von Tresckow B., Plutschow A., Fuchs M., Klimm B., Markova J., Lohri A., et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. . 2012;30:907-13|https://www.ncbi.nlm.nih.gov/pubmed/20713848|560
Hodgkin Lymphom|"3.2"|2022|von Tresckow, Bastian|Hintergrund|||Erstautor|von Tresckow B., Plutschow A., Fuchs M., Klimm B., Markova J., Lohri A., et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. . 2012;30:907-13|https://www.ncbi.nlm.nih.gov/pubmed/20713848|560
Hodgkin Lymphom|"3.2"|2022|Eich, Hans-Theodor|Hintergrund|||Standard|Koeck J., Abo-Madyan Y., Eich H. T., Stieler F., Fleckenstein J., Kriz J., et al. Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin's disease. . 2012;188:653-9|https://www.springermedizin.de/clinical-relevance-of-different-dose-calculation-strategies-for-/7992990|560
Hodgkin Lymphom|"3.2"|2022|Kriz, Jan|Hintergrund|||Erstautor|Kriz J., Spickermann M., Lehrich P., Schmidberger H., Reinartz G., Eich H., et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. . 2015;191:717-25|https://www.ncbi.nlm.nih.gov/pubmed/25876905|560
Hodgkin Lymphom|"3.2"|2022|Schmidberger, Heinz|Hintergrund|||Standard|Kriz J., Spickermann M., Lehrich P., Schmidberger H., Reinartz G., Eich H., et al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. . 2015;191:717-25|https://www.ncbi.nlm.nih.gov/pubmed/25876905|560
Hodgkin Lymphom|"3.2"|2022|Kreissl, Stefanie|Hintergrund|||Standard|Sasse S., Brockelmann P. J., Goergen H., Plutschow A., Muller H., Kreissl S., et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. . 2017;:Jco2016709410|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131364/|560
Hodgkin Lymphom|"3.2"|2022|Sasse, Stephanie|Hintergrund|||Erstautor|Sasse S., Brockelmann P. J., Goergen H., Plutschow A., Muller H., Kreissl S., et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. . 2017;:Jco2016709410|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131364/|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Standard|Skoetz N., Will A., Monsef I., Brillant C., Engert A., von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. . 2017;5:Cd007941|https://www.ncbi.nlm.nih.gov/pubmed/28541603|560
Hodgkin Lymphom|"3.2"|2022|Skoetz, Nicole|Hintergrund|||Erstautor|Skoetz N., Will A., Monsef I., Brillant C., Engert A., von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. . 2017;5:Cd007941|https://www.ncbi.nlm.nih.gov/pubmed/28541603|560
Hodgkin Lymphom|"3.2"|2022|von Tresckow, Bastian|Hintergrund|||Letztautor|Skoetz N., Will A., Monsef I., Brillant C., Engert A., von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. . 2017;5:Cd007941|https://www.ncbi.nlm.nih.gov/pubmed/28541603|560
Hodgkin Lymphom|"3.2"|2022|Engert, Andreas|Hintergrund|||Erstautor|Engert A., Diehl V., Franklin J., Lohri A., Dorken B., Ludwig W. D., et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. None. 2009;27:4548-54|http://jco.ascopubs.org/content/27/27/4548.full.pdf|560
Hodgkin Lymphom|"3.2"|2022|Fuchs, Michael|Hintergrund|||Standard|Wongso D., Fuchs M., Plutschow A., Klimm B., Sasse S., Hertenstein B., et al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. . 2013;31:2819-24|https://www.ncbi.nlm.nih.gov/pubmed/23796987|560
Hodgkin Lymphom|"3.2"|2022|Klimm, Beate|Hintergrund|||Standard|Wongso D., Fuchs M., Plutschow A., Klimm B., Sasse S., Hertenstein B., et al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. . 2013;31:2819-24|https://www.ncbi.nlm.nih.gov/pubmed/23796987|560
Hodgkin Lymphom|"3.2"|2022|Sasse, Stephanie|Hintergrund|||Standard|Wongso D., Fuchs M., Plutschow A., Klimm B., Sasse S., Hertenstein B., et al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. . 2013;31:2819-24|https://www.ncbi.nlm.nih.gov/pubmed/23796987|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Standard|Boll B., Goergen H., Behringer K., Brockelmann P. J., Hitz F., Kerkhoff A., et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. None. 2016;127:2189-92|http://www.bloodjournal.org/content/bloodjournal/127/18/2189.full.pdf|560
Hodgkin Lymphom|"3.2"|2022|Behringer, Karolin|Hintergrund|||Erstautor|Behringer K., Goergen H., Hitz F., Zijlstra J. M., Greil R., Markova J., et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. . 2015;385:1418-27|https://www.ncbi.nlm.nih.gov/pubmed/25539730|560
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Evidenzbasierte Empfehlung|A|False|Standard|Saad F., Cella D., Basch E., Hadaschik B.A., Mainwaring P.N., Oudard S., et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer. . 2018;19:1404-1416|https://pubmed.ncbi.nlm.nih.gov/30213449/|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Hintergrund|||Standard|Saad F., Cella D., Basch E., Hadaschik B.A., Mainwaring P.N., Oudard S., et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer. . 2018;19:1404-1416|https://pubmed.ncbi.nlm.nih.gov/30213449/|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Evidenzbasierte Empfehlung|A|False|Standard|Valerio M., Donaldson I., Emberton M., Ehdaie B., Hadaschik B.A., Marks L.S., et al. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. . 2015;68:8-19|http://www.ncbi.nlm.nih.gov/pubmed/25454618|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Hintergrund|||Standard|Valerio M., Donaldson I., Emberton M., Ehdaie B., Hadaschik B.A., Marks L.S., et al. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. . 2015;68:8-19|http://www.ncbi.nlm.nih.gov/pubmed/25454618|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Evidenzbasiertes Statement||False|Standard|Tilki D., Preisser F., Graefen M., Huland H., Pompe R.S. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. . 2019;75:896-900|https://pubmed.ncbi.nlm.nih.gov/30955970/|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Standard|Tilki D., Preisser F., Graefen M., Huland H., Pompe R.S. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. . 2019;75:896-900|https://pubmed.ncbi.nlm.nih.gov/30955970/|1631
Prostatakarzinom|"6.2"|2021|Asbach, Patrick|Hintergrund|||Standard|Franiel T., Quentin M., Mueller-Lisse U.G., Schimmoeller L., Asbach P., Rodel S., et al. MRT der Prostata: Empfehlungen zur Vorbereitung und Durchführung. None. 2017;189:21-28|http://www.ncbi.nlm.nih.gov/pubmed/28002857|1631
Prostatakarzinom|"6.2"|2021|Franiel, Tobias|Hintergrund|||Erstautor|Franiel T., Quentin M., Mueller-Lisse U.G., Schimmoeller L., Asbach P., Rodel S., et al. MRT der Prostata: Empfehlungen zur Vorbereitung und Durchführung. None. 2017;189:21-28|http://www.ncbi.nlm.nih.gov/pubmed/28002857|1631
Prostatakarzinom|"6.2"|2021|Krause, Bernd|Evidenzbasierte Empfehlung|A|False|Erstautor|Krause B.J., Souvatzoglou M., Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. . 2011;:|http://www.ncbi.nlm.nih.gov/pubmed/21388835|1631
Prostatakarzinom|"6.2"|2021|Krause, Bernd|Hintergrund|||Erstautor|Krause B.J., Souvatzoglou M., Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. . 2011;:|http://www.ncbi.nlm.nih.gov/pubmed/21388835|1631
Prostatakarzinom|"6.2"|2021|Penzkofer, Tobias|Hintergrund|||Standard|Collettini F., Enders J., Stephan C., Fischer T., Baur A. D. J., Penzkofer T., et al. Image-guided Irreversible Electroporation of Localized Prostate Cancer. . 2019;292:250-257|https://pubmed.ncbi.nlm.nih.gov/31161973/|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasierte Empfehlung|B|True|Letztautor|Bartkowiak D., Thamm R., Siegmann A., Böhmer D., Budach V., Wiegel T. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. . 2020;154:255-259|https://pubmed.ncbi.nlm.nih.gov/32920006/|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Letztautor|Bartkowiak D., Thamm R., Siegmann A., Böhmer D., Budach V., Wiegel T. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer. . 2020;154:255-259|https://pubmed.ncbi.nlm.nih.gov/32920006/|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Evidenzbasierte Empfehlung|A|False|Standard|Steuber T., Graefen M., Haese A., Erbersdobler A., Chun F.K., Schlom T., et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. . 2006;175:939-944|http://www.ncbi.nlm.nih.gov/pubmed/16469587|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Standard|Steuber T., Graefen M., Haese A., Erbersdobler A., Chun F.K., Schlom T., et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. . 2006;175:939-944|http://www.ncbi.nlm.nih.gov/pubmed/16469587|1631
Prostatakarzinom|"6.2"|2021|Steuber, Thomas|Evidenzbasierte Empfehlung|A|False|Erstautor|Steuber T., Graefen M., Haese A., Erbersdobler A., Chun F.K., Schlom T., et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. . 2006;175:939-944|http://www.ncbi.nlm.nih.gov/pubmed/16469587|1631
Prostatakarzinom|"6.2"|2021|Steuber, Thomas|Hintergrund|||Erstautor|Steuber T., Graefen M., Haese A., Erbersdobler A., Chun F.K., Schlom T., et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. . 2006;175:939-944|http://www.ncbi.nlm.nih.gov/pubmed/16469587|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Evidenzbasierte Empfehlung|A|False|Standard|Chun F.K., Briganti A., Graefen M., Montorsi F., Porter C., Scattoni V., et al. Development and external validation of an extended 10-core biopsy nomogram. . 2007;52:436-444|http://www.ncbi.nlm.nih.gov/pubmed/17010505|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Standard|Chun F.K., Briganti A., Graefen M., Montorsi F., Porter C., Scattoni V., et al. Development and external validation of an extended 10-core biopsy nomogram. . 2007;52:436-444|http://www.ncbi.nlm.nih.gov/pubmed/17010505|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Evidenzbasierte Empfehlung|A|False|Standard|Pfister D., Porres D., Heidenreich A., Heidegger I., Knuechel R., Steib F., et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-Fluoroethylcholine PET/CT. . 2016;:|http://www.ncbi.nlm.nih.gov/pubmed/26993315|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Standard|Pfister D., Porres D., Heidenreich A., Heidegger I., Knuechel R., Steib F., et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-Fluoroethylcholine PET/CT. . 2016;:|http://www.ncbi.nlm.nih.gov/pubmed/26993315|1631
Prostatakarzinom|"6.2"|2021|Afshar-Oromieh, Ali|Evidenzbasierte Empfehlung|A|False|Erstautor|Afshar-Oromieh A., Zechmann C.M., Malcher A., Eder M., Eisenhut M., Linhart H.G., et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. . 2014;41:11-20|http://www.ncbi.nlm.nih.gov/pubmed/24072344|1631
Prostatakarzinom|"6.2"|2021|Afshar-Oromieh, Ali|Hintergrund|||Erstautor|Afshar-Oromieh A., Zechmann C.M., Malcher A., Eder M., Eisenhut M., Linhart H.G., et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. . 2014;41:11-20|http://www.ncbi.nlm.nih.gov/pubmed/24072344|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasierte Empfehlung|B|False|Standard|Ploussard G., Fossati N., Wiegel T., D'Amico A., Hofman M. S., Gillessen S., et al. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy. . 2021;:[Epub ahead of print]|https://pubmed.ncbi.nlm.nih.gov/33574012/|1631
Prostatakarzinom|"6.2"|2021|Kristiansen, Glen|Hintergrund|||Erstautor|Kristiansen G. Diagnostic and prognostic molecular biomarkers for prostate cancer. None. 2012;60:125-141|http://www.ncbi.nlm.nih.gov/pubmed/22212082|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasierte Empfehlung|B|False|Erstautor|Wiegel T., Bartkowiak D., Bottke D., Thamm R., Hinke A., Stöckle M., et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival. . 2015;91:288-294|www.ncbi.nlm.nih.gov/pubmed/25445556|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Erstautor|Wiegel T., Bartkowiak D., Bottke D., Thamm R., Hinke A., Stöckle M., et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival. . 2015;91:288-294|www.ncbi.nlm.nih.gov/pubmed/25445556|1631
Prostatakarzinom|"6.2"|2021|Ghadjar, Pirus|Hintergrund|||Erstautor|Ghadjar P., Wiegel T. Re. . 2021;:|https://pubmed.ncbi.nlm.nih.gov/33612373/|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Letztautor|Ghadjar P., Wiegel T. Re. . 2021;:|https://pubmed.ncbi.nlm.nih.gov/33612373/|1631
Prostatakarzinom|"6.2"|2021|Albers, Peter|Hintergrund|||Standard|Wiegel T., Albers P., Bartkowiak D., Bussar-Maatz R., Härter M., Kristiansen G., et al. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). . 2021;147:235-242|www.ncbi.nlm.nih.gov/pubmed/32886212|1631
Prostatakarzinom|"6.2"|2021|Kristiansen, Glen|Hintergrund|||Standard|Wiegel T., Albers P., Bartkowiak D., Bussar-Maatz R., Härter M., Kristiansen G., et al. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). . 2021;147:235-242|www.ncbi.nlm.nih.gov/pubmed/32886212|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Erstautor|Wiegel T., Albers P., Bartkowiak D., Bussar-Maatz R., Härter M., Kristiansen G., et al. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). . 2021;147:235-242|www.ncbi.nlm.nih.gov/pubmed/32886212|1631
Prostatakarzinom|"6.2"|2021|Hakenberg, Oliver|Hintergrund|||Standard|Froehner M., Koch R., Litz R.J., Hakenberg O.W., Wirth M.P. Which patients are at the highest risk of dying from competing causes </= 10 years after radical prostatectomy?. None. 2012;110:206-210|http://www.ncbi.nlm.nih.gov/pubmed/22044591|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Hintergrund|||Letztautor|Froehner M., Koch R., Litz R.J., Hakenberg O.W., Wirth M.P. Which patients are at the highest risk of dying from competing causes </= 10 years after radical prostatectomy?. None. 2012;110:206-210|http://www.ncbi.nlm.nih.gov/pubmed/22044591|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasierte Empfehlung|B|False|Letztautor|Bartkowiak D., Siegmann A., Böhmer D., Budach V., Wiegel T. The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer. . 2019;124:785-791|https://pubmed.ncbi.nlm.nih.gov/31220400/|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Letztautor|Bartkowiak D., Siegmann A., Böhmer D., Budach V., Wiegel T. The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer. . 2019;124:785-791|https://pubmed.ncbi.nlm.nih.gov/31220400/|1631
Prostatakarzinom|"6.2"|2021|Asbach, Patrick|Hintergrund|||Standard|Franiel T., Asbach P. , Beyersdorff D. , Blondin D., Kaufmann S. , Mueller-Lisse U.G. , et al. mpMRI of the Prostate (MR-Prostatography): Updated Recommendations of the DRG and BDR on Patient Preparation and Scanning Protocol. . 2021;Online ahead of print:|https://pubmed.ncbi.nlm.nih.gov/33735931/|1631
Prostatakarzinom|"6.2"|2021|Beyersdorff, Dirk|Hintergrund|||Standard|Franiel T., Asbach P. , Beyersdorff D. , Blondin D., Kaufmann S. , Mueller-Lisse U.G. , et al. mpMRI of the Prostate (MR-Prostatography): Updated Recommendations of the DRG and BDR on Patient Preparation and Scanning Protocol. . 2021;Online ahead of print:|https://pubmed.ncbi.nlm.nih.gov/33735931/|1631
Prostatakarzinom|"6.2"|2021|Franiel, Tobias|Hintergrund|||Erstautor|Franiel T., Asbach P. , Beyersdorff D. , Blondin D., Kaufmann S. , Mueller-Lisse U.G. , et al. mpMRI of the Prostate (MR-Prostatography): Updated Recommendations of the DRG and BDR on Patient Preparation and Scanning Protocol. . 2021;Online ahead of print:|https://pubmed.ncbi.nlm.nih.gov/33735931/|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Erstautor|Graefen M., Ahyai S., Heuer R., Salomon G., Schlomm T., Isbarn H., et al. Aktive Uberwachung des Prostatakarzinoms. None. 2008;47:261-269|http://www.ncbi.nlm.nih.gov/pubmed/18273597|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Standard|Augustin H., Hammerer P.G., Graefen M., Erbersdobler A., Blonski J., Palisaar J., et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. None. 2003;43:455-460|http://www.ncbi.nlm.nih.gov/pubmed/12705986|1631
Prostatakarzinom|"6.2"|2021|Hammerer, Peter|Hintergrund|||Standard|Augustin H., Hammerer P.G., Graefen M., Erbersdobler A., Blonski J., Palisaar J., et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. None. 2003;43:455-460|http://www.ncbi.nlm.nih.gov/pubmed/12705986|1631
Prostatakarzinom|"6.2"|2021|Aebersold, Daniel|Evidenzbasierte Empfehlung|A|False|Standard|Ghadjar P., Aebersold D. M., Albrecht C., Böhmer D., Flentje M., Ganswindt U., et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. . 2018;194:619-626|https://pubmed.ncbi.nlm.nih.gov/29383406/|1631
Prostatakarzinom|"6.2"|2021|Aebersold, Daniel|Hintergrund|||Standard|Ghadjar P., Aebersold D. M., Albrecht C., Böhmer D., Flentje M., Ganswindt U., et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. . 2018;194:619-626|https://pubmed.ncbi.nlm.nih.gov/29383406/|1631
Prostatakarzinom|"6.2"|2021|Albrecht, Clemens|Evidenzbasierte Empfehlung|A|False|Standard|Ghadjar P., Aebersold D. M., Albrecht C., Böhmer D., Flentje M., Ganswindt U., et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. . 2018;194:619-626|https://pubmed.ncbi.nlm.nih.gov/29383406/|1631
Prostatakarzinom|"6.2"|2021|Albrecht, Clemens|Hintergrund|||Standard|Ghadjar P., Aebersold D. M., Albrecht C., Böhmer D., Flentje M., Ganswindt U., et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. . 2018;194:619-626|https://pubmed.ncbi.nlm.nih.gov/29383406/|1631
Prostatakarzinom|"6.2"|2021|Flentje, Michael|Evidenzbasierte Empfehlung|A|False|Standard|Ghadjar P., Aebersold D. M., Albrecht C., Böhmer D., Flentje M., Ganswindt U., et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. . 2018;194:619-626|https://pubmed.ncbi.nlm.nih.gov/29383406/|1631
Prostatakarzinom|"6.2"|2021|Flentje, Michael|Hintergrund|||Standard|Ghadjar P., Aebersold D. M., Albrecht C., Böhmer D., Flentje M., Ganswindt U., et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. . 2018;194:619-626|https://pubmed.ncbi.nlm.nih.gov/29383406/|1631
Prostatakarzinom|"6.2"|2021|Ghadjar, Pirus|Evidenzbasierte Empfehlung|A|False|Erstautor|Ghadjar P., Aebersold D. M., Albrecht C., Böhmer D., Flentje M., Ganswindt U., et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. . 2018;194:619-626|https://pubmed.ncbi.nlm.nih.gov/29383406/|1631
Prostatakarzinom|"6.2"|2021|Ghadjar, Pirus|Hintergrund|||Erstautor|Ghadjar P., Aebersold D. M., Albrecht C., Böhmer D., Flentje M., Ganswindt U., et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. . 2018;194:619-626|https://pubmed.ncbi.nlm.nih.gov/29383406/|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Standard|Suardi N., Capitanio U., Chun F.K., Graefen M., Perrotte P., Schlomm T., et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. None. 2008;113:2068-2072|http://www.ncbi.nlm.nih.gov/pubmed/18792067|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Letztautor|Stöckle M., Wiegel T. Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk (PREFERE). None. 2013;None:None|http://clinicaltrials.gov/ct2/show/record/NCT01717677|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Evidenzbasiertes Statement||False|Erstautor|Heidenreich A., Bolla M., Joniau S., Mason M.D., Matveev V., Mottet N., et al. EAU guidelines on prostate cancer. . 2011;:||1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Bolla M., Joniau S., Mason M.D., Matveev V., Mottet N., et al. EAU guidelines on prostate cancer. . 2011;:||1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Standard|Michl U., Graefen M., Noldus J., Eggert T., Huland H. Funktionelle Ergebnisse unterschiedlicher Operationstechniken der radikalen Prostatektomie. None. 2003;42:1196-1202|http://www.ncbi.nlm.nih.gov/pubmed/14504752|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasierte Empfehlung|A|False|Standard|Koontz B.F., Bossi A., Cozzarini C., Wiegel T., D'Amico A. A systematic review of hypofractionation for primary management of prostate cancer. . 2015;68:683-691|http://www.ncbi.nlm.nih.gov/pubmed/25171903|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Standard|Koontz B.F., Bossi A., Cozzarini C., Wiegel T., D'Amico A. A systematic review of hypofractionation for primary management of prostate cancer. . 2015;68:683-691|http://www.ncbi.nlm.nih.gov/pubmed/25171903|1631
Prostatakarzinom|"6.2"|2021|Ghadjar, Pirus|Hintergrund|||Erstautor|Ghadjar P., Hayoz S., Bernhard J., Zwahlen D. R., Hölscher T., Gut P., et al. Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy. . 2015;33:4158-4166|https://pubmed.ncbi.nlm.nih.gov/26527774/|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasiertes Statement||False|Standard|Deger S., Boehmer D., Roigas J., Schink T., Wernecke K.D., Wiegel T., et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. . 2005;47:441-448|http://www.ncbi.nlm.nih.gov/pubmed/15774239|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Standard|Deger S., Boehmer D., Roigas J., Schink T., Wernecke K.D., Wiegel T., et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. . 2005;47:441-448|http://www.ncbi.nlm.nih.gov/pubmed/15774239|1631
Prostatakarzinom|"6.2"|2021|Loch, Tillmann|Evidenzbasiertes Statement||False|Standard|Galalae R.M., Kovacs G., Schultze J., Loch T., Rzehak P., Wilhelm R., et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. . 2002;52:81-90|http://www.ncbi.nlm.nih.gov/pubmed/11777625|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Hintergrund|||Erstautor|Wirth M.P., Hermann T., Alken P., Kovacs G., Muller R.P., Hakenberg O.W., et al. Empfehlungen zur Durchführung der alleinigen, permanenten, interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom. None. 2002;178:115-119|http://www.ncbi.nlm.nih.gov/pubmed/11942038|1631
Prostatakarzinom|"6.2"|2021|Loch, Tillmann|Hintergrund|||Standard|Kovacs G., Potter R., Loch T., Hammer J., Kolkman-Deurloo I.K., de la Rosette J.J., et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. None. 2005;74:137-148|http://www.ncbi.nlm.nih.gov/pubmed/15734201|1631
Prostatakarzinom|"6.2"|2021|Wawroschek, Friedhelm|Evidenzbasiertes Statement||False|Standard|Weckermann D., Goppelt M., Dorn R., Wawroschek F., Harzmann R. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy. . 2006;97:1173-1178|http://www.ncbi.nlm.nih.gov/pubmed/16686707|1631
Prostatakarzinom|"6.2"|2021|Wawroschek, Friedhelm|Evidenzbasiertes Statement||False|Standard|Weckermann D., Dorn R., Trefz M., Wagner T., Wawroschek F., Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. . 2007;177:916-920|http://www.ncbi.nlm.nih.gov/pubmed/17296375|1631
Prostatakarzinom|"6.2"|2021|Wawroschek, Friedhelm|Hintergrund|||Standard|Weckermann D., Dorn R., Trefz M., Wagner T., Wawroschek F., Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. . 2007;177:916-920|http://www.ncbi.nlm.nih.gov/pubmed/17296375|1631
Prostatakarzinom|"6.2"|2021|Blana, Andreas|Hintergrund|||Erstautor|Blana A., Rogenhofer S., Ganzer R., Lunz J.C., Schostak M., Wieland W.F., et al. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. None. 2008;72:1329-1333|http://www.ncbi.nlm.nih.gov/pubmed/18829078|1631
Prostatakarzinom|"6.2"|2021|Ganzer, Roman|Hintergrund|||Standard|Blana A., Rogenhofer S., Ganzer R., Lunz J.C., Schostak M., Wieland W.F., et al. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. None. 2008;72:1329-1333|http://www.ncbi.nlm.nih.gov/pubmed/18829078|1631
Prostatakarzinom|"6.2"|2021|Schostak, Martin|Hintergrund|||Standard|Blana A., Rogenhofer S., Ganzer R., Lunz J.C., Schostak M., Wieland W.F., et al. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. None. 2008;72:1329-1333|http://www.ncbi.nlm.nih.gov/pubmed/18829078|1631
Prostatakarzinom|"6.2"|2021|Ganzer, Roman|Evidenzbasierte Empfehlung|A|True|Erstautor|Ganzer R., Fritsche H.M., Brandtner A., Brundl J., Koch D., Wieland W.F., et al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. . 2013;112:322-329|http://www.ncbi.nlm.nih.gov/pubmed/23356910|1631
Prostatakarzinom|"6.2"|2021|Ganzer, Roman|Hintergrund|||Erstautor|Ganzer R., Fritsche H.M., Brandtner A., Brundl J., Koch D., Wieland W.F., et al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. . 2013;112:322-329|http://www.ncbi.nlm.nih.gov/pubmed/23356910|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Bolla M., Joniau S., Mason M.D., Matveev V., Mottet N., et al. EAU guidelines on prostate cancer. . 2010;:|https://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2010.pdf|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Evidenzbasiertes Statement||False|Standard|Tyrrell C.J., Payne H., See W.A., McLeod D.G., Wirth M.P., Iversen P., et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. . 2005;76:4-10|http://www.ncbi.nlm.nih.gov/pubmed/16145740|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Hintergrund|||Standard|Tyrrell C.J., Payne H., See W.A., McLeod D.G., Wirth M.P., Iversen P., et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. . 2005;76:4-10|http://www.ncbi.nlm.nih.gov/pubmed/16145740|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasierte Empfehlung|B|False|Erstautor|Wiegel T., Bartkowiak D., Bottke D., Bronner C., Steiner U., Siegmann A., et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy. . 2014;66:243-250|www.ncbi.nlm.nih.gov/pubmed/24680359|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Erstautor|Wiegel T., Bartkowiak D., Bottke D., Bronner C., Steiner U., Siegmann A., et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy. . 2014;66:243-250|www.ncbi.nlm.nih.gov/pubmed/24680359|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasiertes Statement||False|Standard|Deger S., Boehmer D., Turk I., Roigas J., Wernecke K.D., Wiegel T., et al. High dose rate brachytherapy of localized prostate cancer. . 2002;41:420-426|http://www.ncbi.nlm.nih.gov/pubmed/12074814|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Standard|Deger S., Boehmer D., Turk I., Roigas J., Wernecke K.D., Wiegel T., et al. High dose rate brachytherapy of localized prostate cancer. . 2002;41:420-426|http://www.ncbi.nlm.nih.gov/pubmed/12074814|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Standard|Rades D., Schwarz R., Todorovic M., Thurmann H., Graefen M., Walz J., et al. Experiences with a new high-dose-rate brachytherapy (HDR-BT) boost technique for T3b prostate cancer. None. 2007;183:398-402|http://www.ncbi.nlm.nih.gov/pubmed/17609874|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Varga Z., von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. . 2002;167:1681-1686|http://www.ncbi.nlm.nih.gov/pubmed/11912387|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Bolla M., Joniau S., Mason M.D., Matveev V., Mottet N., et al. EAU guidelines on prostate cancer. . 2013;:|https://uroweb.org/wp-content/uploads/09_Prostate_Cancer_LR.pdf|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Hintergrund|||Standard|Iversen P., Wirth M.P., See W.A., McLeod D.G., Klimberg I., Gleason D., et al. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. None. 2004;63:928-933|http://www.ncbi.nlm.nih.gov/pubmed/15134983|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Evidenzbasierte Empfehlung|A|False|Erstautor|Wirth M.P., Weissbach L., Marx F.J., Heckl W., Jellinghaus W., Riedmiller H., et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. . 2004;45:267-270|http://www.ncbi.nlm.nih.gov/pubmed/15036669|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Hintergrund|||Erstautor|Wirth M.P., Weissbach L., Marx F.J., Heckl W., Jellinghaus W., Riedmiller H., et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. . 2004;45:267-270|http://www.ncbi.nlm.nih.gov/pubmed/15036669|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Evidenzbasierte Empfehlung|A|False|Letztautor|McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., Wirth M.P. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. . 2006;97:247-254|http://www.ncbi.nlm.nih.gov/pubmed/16430622|1631
Prostatakarzinom|"6.2"|2021|Wirth, Manfred P.|Hintergrund|||Letztautor|McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., Wirth M.P. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. . 2006;97:247-254|http://www.ncbi.nlm.nih.gov/pubmed/16430622|1631
Prostatakarzinom|"6.2"|2021|Semjonow, Axel|Hintergrund|||Standard|Lilja H., Semjonow A., Sibley P., Babaian R., Dowell B., Rittenhouse H., et al. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Prostate Cancer. None. 2006;None:None||1631
Prostatakarzinom|"6.2"|2021|Semjonow, Axel|Hintergrund|||Erstautor|Semjonow A., Zechel C., Brandt B., Flammang F., Pepping B., Hertle L. Teststreifenuntersuchungen: prostataspezifisches Antigen (PSA). None. 1995;34:S91||1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Evidenzbasierte Empfehlung|A|False|Erstautor|Heidenreich A., Bolla M., Joniau S., van der Kwast T.H., Matveev V., Mason M.D., et al. EAU guidelines on prostate cancer. . 2009;:||1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Bolla M., Joniau S., van der Kwast T.H., Matveev V., Mason M.D., et al. EAU guidelines on prostate cancer. . 2009;:||1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Evidenzbasierte Empfehlung|A|False|Erstautor|Wiegel T., Lohm G., Bottke D., Hocht S., Miller K., Siegmann A., et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. . 2009;73:1009-1016|http://www.ncbi.nlm.nih.gov/pubmed/18963539|1631
Prostatakarzinom|"6.2"|2021|Wiegel, Thomas|Hintergrund|||Erstautor|Wiegel T., Lohm G., Bottke D., Hocht S., Miller K., Siegmann A., et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. . 2009;73:1009-1016|http://www.ncbi.nlm.nih.gov/pubmed/18963539|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Evidenzbasierte Empfehlung|A|False|Standard|Small E.J., Saad F., Chowdhury S., Oudard S., Hadaschik B.A., Graff J.N., et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. . 2019;30:1813-1820|https://pubmed.ncbi.nlm.nih.gov/31560066/|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Hintergrund|||Standard|Small E.J., Saad F., Chowdhury S., Oudard S., Hadaschik B.A., Graff J.N., et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. . 2019;30:1813-1820|https://pubmed.ncbi.nlm.nih.gov/31560066/|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Evidenzbasiertes Statement||False|Erstautor|Heidenreich A., Richter S., Thuer D., Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. . 2010;57:437-443|http://www.ncbi.nlm.nih.gov/pubmed/19303197|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Richter S., Thuer D., Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. . 2010;57:437-443|http://www.ncbi.nlm.nih.gov/pubmed/19303197|1631
Prostatakarzinom|"6.2"|2021|Blana, Andreas|Evidenzbasierte Empfehlung|A|False|Standard|Crouzet S., Blana A., Murat F.J., Pasticier G., Brown S.C., Conti G.N., et al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. . 2017;119:896-904|http://www.ncbi.nlm.nih.gov/pubmed/28063191|1631
Prostatakarzinom|"6.2"|2021|Blana, Andreas|Hintergrund|||Standard|Crouzet S., Blana A., Murat F.J., Pasticier G., Brown S.C., Conti G.N., et al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. . 2017;119:896-904|http://www.ncbi.nlm.nih.gov/pubmed/28063191|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Evidenzbasierte Empfehlung|A|False|Standard|Smith M.R., Saad F., Chowdhury S., Oudard S., Hadaschik B.A., Graff J.N., et al. Apalutamide and Overall Survival in Prostate Cancer. . 2020;79:150-158|https://pubmed.ncbi.nlm.nih.gov/32907777/|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Hintergrund|||Standard|Smith M.R., Saad F., Chowdhury S., Oudard S., Hadaschik B.A., Graff J.N., et al. Apalutamide and Overall Survival in Prostate Cancer. . 2020;79:150-158|https://pubmed.ncbi.nlm.nih.gov/32907777/|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Semrau R., Thuer D., Pfister D. Die radikale Salvageprostatektomie: Therapie der lokalen Prostatarezidivs nach Strahlentherapie. None. 2008;47:1441-1446|http://www.ncbi.nlm.nih.gov/pubmed/18806991|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Evidenzbasierte Empfehlung|A|False|Standard|Smith M.R., Saad F., Chowdhury S., Oudard S., Hadaschik B.A., Graff J.N., et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. . 2018;378:1408-1418|https://pubmed.ncbi.nlm.nih.gov/29420164/|1631
Prostatakarzinom|"6.2"|2021|Hadaschik, Boris|Hintergrund|||Standard|Smith M.R., Saad F., Chowdhury S., Oudard S., Hadaschik B.A., Graff J.N., et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. . 2018;378:1408-1418|https://pubmed.ncbi.nlm.nih.gov/29420164/|1631
Prostatakarzinom|"6.2"|2021|Wedding, Ulrich|Hintergrund|||Standard|Friedrich C., Kolb G., Wedding U., Pientka L. Comprehensive geriatric assessment in the elderly cancer patient. None. 2003;26:355-360|http://www.ncbi.nlm.nih.gov/pubmed/12972703|1631
Prostatakarzinom|"6.2"|2021|Wedding, Ulrich|Hintergrund|||Standard|Pallis A.G., Fortpied C., Wedding U., Van Nes M.C., Penninckx B., Ring A., et al. EORTC elderly task force position paper: approach to the older cancer patient. None. 2010;46:1502-1513|http://www.ncbi.nlm.nih.gov/pubmed/20227872|1631
Prostatakarzinom|"6.2"|2021|Wedding, Ulrich|Hintergrund|||Standard|Pallis A.G., Wedding U., Lacombe D., Soubeyran P., Wildiers H. Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?. None. 2010;46:1019-1025|http://www.ncbi.nlm.nih.gov/pubmed/20138506|1631
Prostatakarzinom|"6.2"|2021|Rahbar, Kambiz|Hintergrund|||Erstautor|Rahbar K., Ahmadzadehfar H., Kratochwil C., Haberkorn U., Schafers M., Essler M., et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. . 2017;58:85-90|http://www.ncbi.nlm.nih.gov/pubmed/27765862|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Scholz H.J., Rogenhofer S., Arsov C., Retz M., Muller S.C., et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. None. 2013;63:977-982|http://www.ncbi.nlm.nih.gov/pubmed/23116658|1631
Prostatakarzinom|"6.2"|2021|Semjonow, Axel|Hintergrund|||Erstautor|Semjonow A., Hamm M., Rathert P., Hertle L. Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. None. 1994;73:538-543|http://www.ncbi.nlm.nih.gov/pubmed/7516808|1631
Prostatakarzinom|"6.2"|2021|Hakenberg, Oliver|Hintergrund|||Standard|Beyer J., Wessela S., Hakenberg O.W., Kuhlisch E., Halbritter K., Froehner M., et al. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery. None. 2009;7:597-604|http://www.ncbi.nlm.nih.gov/pubmed/19143928|1631
Prostatakarzinom|"6.2"|2021|Otto, Ullrich|Hintergrund|||Erstautor|Otto U., Dombo O. Studie zur Identifikation von Prädiktoren für die individuelle Rehabilitationsdauer und den langfristigen Rehabilitationserfolg. Patienten mit Prostatacarcinom. None. 2002;None:85-138||1631
Prostatakarzinom|"6.2"|2021|Hoffmann, Wilfried|Hintergrund|||Standard|Vahlensieck W., Gack M., Gleissner J., Hoffmann W., Liedke S., Otto U., et al. Struktur- und Prozessqualität der stationären urologischen Rehabilitation. None. 2005;44:51-56|http://www.ncbi.nlm.nih.gov/pubmed/15602650|1631
Prostatakarzinom|"6.2"|2021|Otto, Ullrich|Hintergrund|||Standard|Vahlensieck W., Gack M., Gleissner J., Hoffmann W., Liedke S., Otto U., et al. Struktur- und Prozessqualität der stationären urologischen Rehabilitation. None. 2005;44:51-56|http://www.ncbi.nlm.nih.gov/pubmed/15602650|1631
Prostatakarzinom|"6.2"|2021|Otto, Ullrich|Hintergrund|||Letztautor|Dombo O., Otto U. Rehabilitation. Allgemeine Grundlagen. None. 2007;None:203-218||1631
Prostatakarzinom|"6.2"|2021|Otto, Ullrich|Hintergrund|||Letztautor|Dombo O., Otto U. Stress-Inkontinenz beim Mann: Anatomische und funktionelle Besonderheiten. None. 2004;None:7-12||1631
Prostatakarzinom|"6.2"|2021|Hoffmann, Wilfried|Hintergrund|||Standard|Otto U., Grosemans P., Hoffmann W., Dombo O. Rehabilitation in der urologischen Onkologie. None. 1998;38:35-40||1631
Prostatakarzinom|"6.2"|2021|Otto, Ullrich|Hintergrund|||Erstautor|Otto U., Grosemans P., Hoffmann W., Dombo O. Rehabilitation in der urologischen Onkologie. None. 1998;38:35-40||1631
Prostatakarzinom|"6.2"|2021|Hoffmann, Wilfried|Hintergrund|||Erstautor|Hoffmann W., Liedtke S., Otto U. Das videoendoskopische Biofeedback-Sphinktertraining zur Therapie der postoperativen Harninkontinenz nach radikalchirurgischen Operationen. None. 2002;3:32-33||1631
Prostatakarzinom|"6.2"|2021|Otto, Ullrich|Hintergrund|||Letztautor|Hoffmann W., Liedtke S., Otto U. Das videoendoskopische Biofeedback-Sphinktertraining zur Therapie der postoperativen Harninkontinenz nach radikalchirurgischen Operationen. None. 2002;3:32-33||1631
Prostatakarzinom|"6.2"|2021|Hoffmann, Wilfried|Hintergrund|||Erstautor|Hoffmann W., Liedke S., Dombo O., Otto U. Die Elektrostimulation in der Therapie der postoperativen Harninkontinenz. Therapeutischer Nutzen unter Berücksichtigung der Lebensqualität. None. 2005;44:33-40|http://www.ncbi.nlm.nih.gov/pubmed/15580472|1631
Prostatakarzinom|"6.2"|2021|Otto, Ullrich|Hintergrund|||Letztautor|Hoffmann W., Liedke S., Dombo O., Otto U. Die Elektrostimulation in der Therapie der postoperativen Harninkontinenz. Therapeutischer Nutzen unter Berücksichtigung der Lebensqualität. None. 2005;44:33-40|http://www.ncbi.nlm.nih.gov/pubmed/15580472|1631
Prostatakarzinom|"6.2"|2021|Volkmer, Björn|Hintergrund|||Letztautor|Herkommer K., Niespodziany S., Zorn C., Gschwend J.E., Volkmer B.G. Versorgung der erektilen Dysfunktion nach radikaler Prostatektomie in Deutschland. Einschätzung durch den Urologen vs. Patientenbefragung. None. 2006;45:336, 338-336, 342|http://www.ncbi.nlm.nih.gov/pubmed/16341512|1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Standard|Montorsi F., Brock G., Lee J., Shapiro J., Van Poppel H., Graefen M., et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. None. 2008;54:924-931|http://www.ncbi.nlm.nih.gov/pubmed/18640769|1631
Prostatakarzinom|"6.2"|2021|Semjonow, Axel|Hintergrund|||Standard|Soletormos G., Semjonow A., Sibley P.E., Lamerz R., Petersen P.H., Albrecht W., et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. None. 2005;51:1342-1351|http://www.ncbi.nlm.nih.gov/pubmed/15961552|1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Evidenzbasierte Empfehlung|A|False|Erstautor|Heidenreich A., Aus G., Abbou C.C., Bolla M., Joniau S., Matveev V., et al. EAU guidelines on prostate cancer. None. 2007;None:None||1631
Prostatakarzinom|"6.2"|2021|Heidenreich, Axel|Hintergrund|||Erstautor|Heidenreich A., Aus G., Abbou C.C., Bolla M., Joniau S., Matveev V., et al. EAU guidelines on prostate cancer. None. 2007;None:None||1631
Prostatakarzinom|"6.2"|2021|Graefen, Markus|Hintergrund|||Letztautor|Beyer B., Huland H., Feick G., Graefen M. "Expanded prostate cancer index composite"(EPIC-26): Funktionelles Behandlungsergebnis bei Patienten mit lokalisiertem Prostatakarzinom. None. 2015;54:1591-1595|http://www.ncbi.nlm.nih.gov/pubmed/26347350|1631
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Schellhaas, Barbara|Hintergrund|||Erstautor|Schellhaas B., Gortz R. S., Pfeifer L., Kielisch C., Neurath M. F., Strobel D. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. None. 2017;29:1036-1044|https://www.ncbi.nlm.nih.gov/pubmed/28562394|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Lang, Hauke|Hintergrund|||Erstautor|Lang H., Sotiropoulos G. C., Brokalaki E. I., Schmitz K. J., Bertona C., Meyer G., et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. None. 2007;205:27-36||807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Roeb, Elke|Hintergrund|||Erstautor|Roeb E., Steffen H. M., Bantel H., Baumann U., Canbay A., Demir M., et al. [S2k Guideline non-alcoholic fatty liver disease]. None. 2015;53:668-723|https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0035-1553193|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Geier, Andreas|Hintergrund|||Letztautor|Roeb E., Geier A. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. None. 2019;57:508-517|https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-0784-8827|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Roeb, Elke|Hintergrund|||Erstautor|Roeb E., Geier A. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. None. 2019;57:508-517|https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-0784-8827|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Vogl, Thomas J.|Evidenzbasierte Empfehlung|A|False|Standard|Lammer J., Malagari K., Vogl T., Pilleul F., Denys A., Watkinson A., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. None. 2010;33:41-52|https://www.zora.uzh.ch/id/eprint/24207/1/Lammer_CardiovascInterventRadiol_2010_V.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Vogel, Arndt|Hintergrund|||Erstautor|Vogel A., Cervantes A., Chau I., Daniele B., Llovet J. M., Meyer T., et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. None. 2018;29:iv238-iv255||807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Galle, Peter|Evidenzbasierte Empfehlung|A|False|Standard|Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. None. 2020;382:1894-1905|https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915745?articleTools=true|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Galle, Peter|Hintergrund|||Standard|Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T. Y., et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. None. 2020;382:1894-1905|https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915745?articleTools=true|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Galle, Peter|Evidenzbasierte Empfehlung|A|False|Standard|Zhu A. X., Kang Y. K., Yen C. J., Finn R. S., Galle P. R., Llovet J. M., et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. None. 2019;20:282-296||807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Galle, Peter|Hintergrund|||Standard|Zhu Andrew X., Kang Yoon-Koo, Yen Chia-Jui, Finn Richard S., Galle Peter R., Llovet Josep M., et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. None. 2019;20:282-296||807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Galle, Peter|Evidenzbasierte Empfehlung|0|False|Standard|Ganten T. M., Stauber R. E., Schott E., Malfertheiner P., Buder R., Galle P. R., et al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. None. 2017;23:5720-5728|https://clincancerres.aacrjournals.org/content/clincanres/23/19/5720.full.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Galle, Peter|Hintergrund|||Standard|Ganten T. M., Stauber R. E., Schott E., Malfertheiner P., Buder R., Galle P. R., et al. Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. None. 2017;23:5720-5728|https://clincancerres.aacrjournals.org/content/clincanres/23/19/5720.full.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Schmid, Irene|Hintergrund|||Erstautor|Schmid I., von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. . 2017;4:15-21|https://pubmed.ncbi.nlm.nih.gov/28144610/|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Schmid, Irene|Hintergrund|||Erstautor|Schmid I., Häberle B., Albert M. H., Corbacioglu S., Fröhlich B., Graf N., et al. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. None. 2012;58:539-44|https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.23295|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Plauth, Mathias|Hintergrund|||Erstautor|Plauth M., Bernal W., Dasarathy S., Merli M., Plank L. D., Schütz T., et al. ESPEN guideline on clinical nutrition in liver disease. None. 2019;38:485-521|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686849/pdf/nihms-1529826.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Schuler, Andreas|Hintergrund|||Standard|Kratzer W., Schmid A., Akinli A. S., Thiel R., Mason R. A., Schuler A., et al. [Gallbladder polyps: prevalence and risk factors]. None. 2011;32 Suppl 1:S68-73|https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0029-1245265.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Wildner, Daniel|Hintergrund|||Erstautor|Wildner D., Bernatik T., Greis C., Seitz K., Neurath M. F., Strobel D. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. None. 2015;36:132-9|https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0034-1399147.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Galle, Peter|Hintergrund|||Standard|Bridgewater J., Galle P. R., Khan S. A., Llovet J. M., Park J. W., Patel T., et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. None. 2014;60:1268-89|https://www.ncbi.nlm.nih.gov/pubmed/24681130|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Albert, Jörg|Hintergrund|||Standard|Aabakken L., Karlsen T. H., Albert J., Arvanitakis M., Chazouilleres O., Dumonceau J. M., et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. None. 2017;49:588-608|https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-107029.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Lang, Hauke|Hintergrund|||Erstautor|Lang H., Sotiropoulos G. C., Sgourakis G., Schmitz K. J., Paul A., Hilgard P., et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. None. 2009;208:218-28||807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Lang, Hauke|Hintergrund|||Letztautor|Bartsch F., Tripke V., Baumgart J., Hoppe-Lotichius M., Heinrich S., Lang H. Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study. None. 2019;67:62-69|https://www.sciencedirect.com/science/article/abs/pii/S1743919119301116?via%3Dihub|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Lang, Hauke|Hintergrund|||Letztautor|Bartsch F., Paschold M., Baumgart J., Hoppe-Lotichius M., Heinrich S., Lang H. Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma. None. 2019;43:1105-1116|https://link.springer.com/content/pdf/10.1007/s00268-018-04876-x.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Seehofer, Daniel|Hintergrund|||Standard|Mantel H. T., Westerkamp A. C., Adam R., Bennet W. F., Seehofer D., Settmacher U., et al. Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. None. 2016;11:e0156127|https://air.unimi.it/retrieve/handle/2434/465540/799026/journal.pone.0156127.PDF|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Vogl, Thomas J.|Hintergrund|||Standard|Koch C., Franzke C., Bechstein W. O., Schnitzbauer A. A., Filmann N., Vogl T., et al. Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center. None. 2019;None:1-8||807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Trojan, Jörg|Hintergrund|||Standard|Vogl T. J., Naguib N. N., Nour-Eldin N. E., Bechstein W. O., Zeuzem S., Trojan J., et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. None. 2012;131:733-40|https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.26407|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Vogl, Thomas J.|Hintergrund|||Erstautor|Vogl T. J., Naguib N. N., Nour-Eldin N. E., Bechstein W. O., Zeuzem S., Trojan J., et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. None. 2012;131:733-40|https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.26407|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Reimer, Peter|Hintergrund|||Erstautor|Reimer P., Virarkar M. K., Binnenhei M., Justinger M., Schön M. R., Tatsch K. Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-Naïve Patients. None. 2018;41:744-752|https://link.springer.com/content/pdf/10.1007/s00270-017-1871-2.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Brunner, Thomas|Hintergrund|||Erstautor|Brunner T. B., Blanck O., Lewitzki V., Abbasi-Senger N., Momm F., Riesterer O., et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. None. 2019;132:42-47|https://www.sciencedirect.com/science/article/abs/pii/S0167814018336089?via%3Dihub|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Seehofer, Daniel|Hintergrund|||Standard|Schnapauff D., Denecke T., Grieser C., Collettini F., Seehofer D., Sinn M., et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. None. 2012;35:581-7|https://link.springer.com/content/pdf/10.1007/s00270-011-0249-0.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Vogel, Arndt|Hintergrund|||Erstautor|Vogel A., Wege H., Caca K., Nashan B., Neumann U. The diagnosis and treatment of cholangiocarcinoma. None. 2014;111:748-54|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239580/pdf/Dtsch_Arztebl_Int-111-0748.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Wege, Henning|Hintergrund|||Standard|Vogel A., Wege H., Caca K., Nashan B., Neumann U. The diagnosis and treatment of cholangiocarcinoma. None. 2014;111:748-54|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239580/pdf/Dtsch_Arztebl_Int-111-0748.pdf|807
Hepatozelluläres Karzinom und biliäre Karzinome|"3.0"|2022|Schirmacher, Peter|Hintergrund|||Standard|Czink E., Heining C., Weber T. F., Lasitschka F., Schemmer P., Schirmacher P., et al. [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]. None. 2016;54:426-30|https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0042-103498|807
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Evidenzbasierte Empfehlung|B|False|Erstautor|Bausewein C., Booth S., Gysels M., Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. None. 2008;None:CD005623||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein C., Booth S., Gysels M., Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. . 2008;:CD005623||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Evidenzbasierte Empfehlung||False|Standard|Mucke M., Carter C., Cuhls H., Pruss M., Radbruch L., Hauser W. [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety]. None. 2016;30:25-36|https://www.ncbi.nlm.nih.gov/pubmed/26809975|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Mucke M., Carter C., Cuhls H., Pruss M., Radbruch L., Hauser W. [Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety]. None. 2016;30:25-36|https://www.ncbi.nlm.nih.gov/pubmed/26809975|2899
Palliativmedizin|"2.2"|2020|Wirz, Stefan|Hintergrund|||Erstautor|Wirz S., Nadstawek J., Kuhn K. U., Vater S., Junker U., Wartenberg H. C. [Modafinil for the treatment of cancer-related fatigue : an intervention study]. None. 2010;24:587-95|https://www.ncbi.nlm.nih.gov/pubmed/21046171|2899
Palliativmedizin|"2.2"|2020|Lorenzl, Stefan|Hintergrund|||Letztautor|Hensler M., Remi J., Nubling G. S., Lorenzl S. Prospective evaluation of the frequency and treatment of restless legs syndrome in a palliative care unit. None. 2012;44:e3-5|https://www.ncbi.nlm.nih.gov/pubmed/23131706|2899
Palliativmedizin|"2.2"|2020|Frohnhofen, Helmut|Hintergrund|||Erstautor|Frohnhofen H, Bibl M, Nickel B, Popp R. Der Essener Fragebogen Alter und Schläfrigkeit ( EFAS ) – ein neues Assessmentinstrument zur Messung von Tagesschläfrigkeit bei alten. None. 2010;12:84-90||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Letztautor|Simon S. T., Weingartner V., Higginson I. J., Voltz R., Bausewein C. Definition, Categorization, and Terminology of Episodic Breathlessness: Consensus by an International Delphi Survey. None. 2013;None:None||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Erstautor|Simon S. T., Weingartner V., Higginson I. J., Voltz R., Bausewein C. Definition, Categorization, and Terminology of Episodic Breathlessness: Consensus by an International Delphi Survey. None. 2013;None:None||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Standard|Simon S. T., Weingartner V., Higginson I. J., Voltz R., Bausewein C. Definition, Categorization, and Terminology of Episodic Breathlessness: Consensus by an International Delphi Survey. None. 2013;None:None||2899
Palliativmedizin|"2.2"|2020|Eychmüller, Steffen|Evidenzbasierte Empfehlung||False|Erstautor|Eychmüller S., Domeisen Benedetti F., Latten R., Tal K., Walker J., Costantini M., et al. “Diagnosing dying” in cancer patients - a systematic literature review. None. 2013;20:292-296||2899
Palliativmedizin|"2.2"|2020|Eychmüller, Steffen|Hintergrund|||Erstautor|Eychmüller S., Domeisen Benedetti F., Latten R., Tal K., Walker J., Costantini M., et al. “Diagnosing dying” in cancer patients - a systematic literature review. None. 2013;20:292-296||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Erstautor|Alt-Epping B., Nauck F., Schneider N. Leben bis zuletzt. Hausärztliche und spezialisierte Palliativversorgung bei schwerstkranken Patienten. None. 2012;11:43-46||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Alt-Epping B., Nauck F., Schneider N. Leben bis zuletzt. Hausärztliche und spezialisierte Palliativversorgung bei schwerstkranken Patienten. None. 2012;11:43-46||2899
Palliativmedizin|"2.2"|2020|Schneider, Nils|Hintergrund|||Letztautor|Alt-Epping B., Nauck F., Schneider N. Leben bis zuletzt. Hausärztliche und spezialisierte Palliativversorgung bei schwerstkranken Patienten. None. 2012;11:43-46||2899
Palliativmedizin|"2.2"|2020|Holtmann, Martin H.|Hintergrund|||Letztautor|Zorn M., Domagk D., Auerbauch T., Mais J., Brauckhoff T., Holtmann M. H. Malignant bowel obstruction. . 2010;48:264-73||2899
Palliativmedizin|"2.2"|2020|Wirz, Stefan|Hintergrund|||Erstautor|Wirz S., Nadstawek J., Elsen C., Junker U., Wartenberg H. C. Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. . 2012;21:131-40||2899
Palliativmedizin|"2.2"|2020|Doll, Axel|Hintergrund|||Erstautor|Doll A. Übelkeit und Erbrechen. None. 2008;None:161-70||2899
Palliativmedizin|"2.2"|2020|Frick, Eckhard|Hintergrund|||Erstautor|Weber S. Frick E. Zur Bedeutung der Spiritualität von Patienten und Betreuern in der  Onkologie. None. 2002;None:106-109||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Standard|Frick E., Riedner C., Fegg M. J., Hauf S., Borasio G. D. A clinical interview assessing cancer patients' spiritual needs and preferences. None. 2006;15:238-43||2899
Palliativmedizin|"2.2"|2020|Frick, Eckhard|Hintergrund|||Erstautor|Frick E., Riedner C., Fegg M. J., Hauf S., Borasio G. D. A clinical interview assessing cancer patients' spiritual needs and preferences. None. 2006;15:238-43||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Standard|Ninnemann B. Somatopsychische Symptome. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Gramm, Jan|Hintergrund|||Standard|Ninnemann B. Somatopsychische Symptome. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Galushko, Maren|Hintergrund|||Standard|Voltz R., Galushko M., Walisko J., Karbach U., Ernstmann N., Pfaff H., et al. Issues of "life" and "death" for patients receiving palliative care--comments when confronted with a research tool. None. 2011;19:771-7||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Erstautor|Voltz R., Galushko M., Walisko J., Karbach U., Ernstmann N., Pfaff H., et al. Issues of "life" and "death" for patients receiving palliative care--comments when confronted with a research tool. None. 2011;19:771-7||2899
Palliativmedizin|"2.2"|2020|Galushko, Maren|Hintergrund|||Standard|Voltz R., Galushko M., Walisko J., Karbach U., Ernstmann N., Pfaff H., et al. Issues of "life" and "death" for patients receiving palliative care--comments when confronted with a research tool. . 2011;19:771-7||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Erstautor|Voltz R., Galushko M., Walisko J., Karbach U., Ernstmann N., Pfaff H., et al. Issues of "life" and "death" for patients receiving palliative care--comments when confronted with a research tool. . 2011;19:771-7||2899
Palliativmedizin|"2.2"|2020|Wirz, Stefan|Hintergrund|||Erstautor|Wirz S., Wittmann M., Schenk M., Schroeck A., Schaefer N., Mueller M., et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. None. 2009;13:737-43|https://www.ncbi.nlm.nih.gov/pubmed/18977159|2899
Palliativmedizin|"2.2"|2020|Wirz, Stefan|Hintergrund|||Standard|Wittmann M., Schaaf T., Peters I., Wirz S., Urban B. W., Barann M. The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptors. None. 2008;107:107-12|https://www.ncbi.nlm.nih.gov/pubmed/18635474|2899
Palliativmedizin|"2.2"|2020|Magnussen, Helgo|Hintergrund|||Letztautor|von Leupoldt A., Taube K., Lehmann K., Fritzsche A., Magnussen H. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. . 2011;140:730-6||2899
Palliativmedizin|"2.2"|2020|von Leupoldt, Andreas|Hintergrund|||Erstautor|von Leupoldt A., Taube K., Lehmann K., Fritzsche A., Magnussen H. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. . 2011;140:730-6||2899
Palliativmedizin|"2.2"|2020|von Leupoldt, Andreas|Hintergrund|||Letztautor|Fritzsche A., Clamor A., von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD--a review. . 2011;105:1422-33||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Standard|Murtagh F. E., Bausewein C., Verne J., Groeneveld E. I., Kaloki Y. E., Higginson I. J. How many people need palliative care? A study developing and comparing methods for population-based estimates. None. 2014;28:49-58||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Erstautor|Fegg M. J., Brandstatter M., Kogler M., Hauke G., Rechenberg-Winter P., Fensterer V., et al. Existential behavioural therapy for informal caregivers of palliative patients: a randomised controlled trial. . 2013;22:2079-86||2899
Palliativmedizin|"2.2"|2020|Thomas, Michael|Hintergrund|||Standard|Goeckenjan G., Sitter H., Thomas M., Branscheid D., Flentje M., Griesinger F., et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer]. . 2010;64 Suppl 2:e1-164||2899
Palliativmedizin|"2.2"|2020|Frerich, Gerrit|Hintergrund|||Letztautor|Perrar K. M., Eisenmann Y., Frerich G. Suizidalität in der Palliativmedizin. None. 2014;11:27-42||2899
Palliativmedizin|"2.2"|2020|Perrar, Klaus Maria|Hintergrund|||Erstautor|Perrar K. M., Eisenmann Y., Frerich G. Suizidalität in der Palliativmedizin. None. 2014;11:27-42||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Erstautor|Alt-Epping B., Staritz A. E., Simon S. T., Altfelder N., Hotz T., Lindena G., et al. What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey. None. 2012;15:971-7||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Standard|Alt-Epping B., Staritz A. E., Simon S. T., Altfelder N., Hotz T., Lindena G., et al. What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey. None. 2012;15:971-7||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Standard|Simon S. T., Altfelder N., Alt-Epping B., Bausewein C., Weingartner V., Voltz R., et al. Is breathlessness what the professional says it is? Analysis of patient and professionals' assessments from a German nationwide register. None. 2014;22:1825-32||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Standard|Simon S. T., Altfelder N., Alt-Epping B., Bausewein C., Weingartner V., Voltz R., et al. Is breathlessness what the professional says it is? Analysis of patient and professionals' assessments from a German nationwide register. None. 2014;22:1825-32||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Erstautor|Simon S. T., Altfelder N., Alt-Epping B., Bausewein C., Weingartner V., Voltz R., et al. Is breathlessness what the professional says it is? Analysis of patient and professionals' assessments from a German nationwide register. None. 2014;22:1825-32||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Standard|Simon S. T., Altfelder N., Alt-Epping B., Bausewein C., Weingartner V., Voltz R., et al. Is breathlessness what the professional says it is? Analysis of patient and professionals' assessments from a German nationwide register. None. 2014;22:1825-32||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Letztautor|Simon ST., Weingaertner V., Voltz R., Bausewein C. Atemnotattacken: Übersetzung und Konsentierung der internationalen Definition im Rahmen einer Delphi-Befragung; Episodic breathlessness: Translation of the international definition using the Delphi-method. None. accepted;None:None||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Erstautor|Simon ST., Weingaertner V., Voltz R., Bausewein C. Atemnotattacken: Übersetzung und Konsentierung der internationalen Definition im Rahmen einer Delphi-Befragung; Episodic breathlessness: Translation of the international definition using the Delphi-method. None. accepted;None:None||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Standard|Simon ST., Weingaertner V., Voltz R., Bausewein C. Atemnotattacken: Übersetzung und Konsentierung der internationalen Definition im Rahmen einer Delphi-Befragung; Episodic breathlessness: Translation of the international definition using the Delphi-method. None. accepted;None:None||2899
Palliativmedizin|"2.2"|2020|Schuler, Ulrich|Hintergrund|||Standard|Dittrich A., Schubert B., Kramer M., Lenz F., Kast K., Schuler U., et al. Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction. None. 2017;25:2849-2856|https://www.ncbi.nlm.nih.gov/pubmed/28434096|2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Standard|Rémi C., Bausewein C., Twycross R., Wilcock A., Howard P. Arzneimitteltherapie in der Palliativmedizin. None. 2015;None:None||2899
Palliativmedizin|"2.2"|2020|Rémi, Constanze|Hintergrund|||Erstautor|Rémi C., Bausewein C., Twycross R., Wilcock A., Howard P. Arzneimitteltherapie in der Palliativmedizin. None. 2015;None:None||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Letztautor|Simon S. T., Muller-Busch C., Bausewein C. [Symptom management of pain and breathlessness]. None. 2011;52:28, 30-5||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Erstautor|Simon S. T., Muller-Busch C., Bausewein C. [Symptom management of pain and breathlessness]. None. 2011;52:28, 30-5||2899
Palliativmedizin|"2.2"|2020|Schneider, Nils|Hintergrund|||Erstautor|Schneider N., Mitchell G. K., Murray S. A. Palliative care in urgent need of recognition and development in general practice: the example of Germany. None. 2010;11:66||2899
Palliativmedizin|"2.2"|2020|Uebach, Barbara|Hintergrund|||Erstautor|Uebach Barbara. Wundversorgung in der Palliative Care (Teil 2). None. 2012;13:280-283||2899
Palliativmedizin|"2.2"|2020|Uebach, Barbara|Hintergrund|||Erstautor|Uebach Barbara, Kern Martina. Wunden sind nicht immer heilbar - Palliative Wundbehandlung exulzerierender Tumorwunden. None. 2010;None:None||2899
Palliativmedizin|"2.2"|2020|Rades, Dirk|Hintergrund|||Erstautor|Rades D., Stalpers L. J., Veninga T., Schulte R., Hoskin P. J., Obralic N., et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. . 2005;23:3366-75||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein C., Booth S., Gysels M., Kuhnbach R., Haberland B., Higginson I. J. Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study. None. 2010;24:777-86||2899
Palliativmedizin|"2.2"|2020|Haberland, Birgit|Hintergrund|||Standard|Bausewein C., Booth S., Gysels M., Kuhnbach R., Haberland B., Higginson I. J. Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study. None. 2010;24:777-86||2899
Palliativmedizin|"2.2"|2020|Nieland, Peter|Hintergrund|||Letztautor|Clemens K. E., Jaspers B., Klaschik E., Nieland P. Evaluation of the clinical effectiveness of physiotherapeutic management of lymphoedema in palliative care patients. None. 2010;40:1068-72|https://www.ncbi.nlm.nih.gov/pubmed/20558463|2899
Palliativmedizin|"2.2"|2020|Vasel-Biergans, Anette|Hintergrund|||Erstautor|Vasel-Biergans Anette. Wundauflagen, Band 1- konventionelle und hydroaktive Wundauflagen. None. 2018;None:None||2899
Palliativmedizin|"2.2"|2020|Vasel-Biergans, Anette|Hintergrund|||Erstautor|Vasel-Biergans Anette. Wundauflagen, Band 2 - spezielle Wundversorgung und Produkte für den Handverkauf. None. 2018;None:None||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Letztautor|Mehnert A., Nauck F. Psychotherapie in der palliativen Versorgung. . 2016;17:289–301||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Aulbert E., Nauck F., Radbruch L. Lehrbuch der Palliativmedizin. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Letztautor|Aulbert E., Nauck F., Radbruch L. Lehrbuch der Palliativmedizin. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Standard|Schulz C. Angst. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Gramm, Jan|Hintergrund|||Standard|Schulz C. Angst. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Schulz, Christian|Hintergrund|||Erstautor|Schulz C. Angst. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Gramm, Jan|Hintergrund|||Letztautor|Schramm A., Berthold D., Gramm J. Dignity Therapy. Psychologische Kurzintervention für Würde am Lebensende. None. 2013;None:None||2899
Palliativmedizin|"2.2"|2020|Gaspar, Manfred|Hintergrund|||Standard|Sonntag R.F. Akzeptanz- und Commitment-Therapie, Akzeptanz und Engagement bis zuletzt. None. 2017;None:71-84||2899
Palliativmedizin|"2.2"|2020|Gramm, Jan|Hintergrund|||Standard|Sonntag R.F. Akzeptanz- und Commitment-Therapie, Akzeptanz und Engagement bis zuletzt. None. 2017;None:71-84||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Erstautor|Fegg M. J., Kramer M., L'Hoste S., Borasio G. D. The Schedule for Meaning in Life Evaluation (SMiLE): validation of a new instrument for meaning-in-life research. None. 2008;35:356-64|https://www.ncbi.nlm.nih.gov/pubmed/18222629|2899
Palliativmedizin|"2.2"|2020|Jentschke, Elisabeth|Hintergrund|||Letztautor|Hardoerfer K., Jentschke E. Effect of Yoga Therapy on Symptoms of Anxiety in Cancer Patients. None. 2018;41:526-532|https://www.ncbi.nlm.nih.gov/pubmed/30086538|2899
Palliativmedizin|"2.2"|2020|von Leupoldt, Andreas|Hintergrund|||Erstautor|von Leupoldt A., Sommer T., Kegat S., Baumann H. J., Klose H., Dahme B., et al. Dyspnea and pain share emotion-related brain network. . 2009;48:200-6||2899
Palliativmedizin|"2.2"|2020|Lorenzl, Stefan|Evidenzbasierte Empfehlung|B|False|Letztautor|Nubling G., Allmendinger S., Lorenzl S. [Drug therapy of anxiety and fear in palliative care patients with cancer or other illnesses : a systematic review]. None. 2012;26:537-49|https://www.ncbi.nlm.nih.gov/pubmed/22968367|2899
Palliativmedizin|"2.2"|2020|Lorenzl, Stefan|Hintergrund|||Letztautor|Nubling G., Allmendinger S., Lorenzl S. [Drug therapy of anxiety and fear in palliative care patients with cancer or other illnesses : a systematic review]. None. 2012;26:537-49|https://www.ncbi.nlm.nih.gov/pubmed/22968367|2899
Palliativmedizin|"2.2"|2020|Keller, Monika|Hintergrund|||Erstautor|Keller M. Depression. None. 2011;None:1109–27||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Keller M. Depression. None. 2011;None:1109–27||2899
Palliativmedizin|"2.2"|2020|von Leupoldt, Andreas|Hintergrund|||Erstautor|von Leupoldt A., Sommer T., Kegat S., Baumann H. J., Klose H., Dahme B., et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. . 2008;177:1026-32||2899
Palliativmedizin|"2.2"|2020|Lindner, Reinhard|Hintergrund|||Erstautor|Lindner R. Suizidale Männer in der psychoanalytisch orientierten Psychotherapie. Eine systematische qualitative Untersuchung. None. 2006;None:None||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Standard|Altfelder N., Nauck F., Alt-Epping B., Bausewein C., Simon S. T. Characteristics of patients with breathlessness - a German national survey on palliative care in-patient units. None. 2010;24:37||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Standard|Altfelder N., Nauck F., Alt-Epping B., Bausewein C., Simon S. T. Characteristics of patients with breathlessness - a German national survey on palliative care in-patient units. None. 2010;24:37||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Altfelder N., Nauck F., Alt-Epping B., Bausewein C., Simon S. T. Characteristics of patients with breathlessness - a German national survey on palliative care in-patient units. None. 2010;24:37||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Letztautor|Altfelder N., Nauck F., Alt-Epping B., Bausewein C., Simon S. T. Characteristics of patients with breathlessness - a German national survey on palliative care in-patient units. None. 2010;24:37||2899
Palliativmedizin|"2.2"|2020|Bernhart-Just, Alexandra|Hintergrund|||Erstautor|Bernhart-Just A. Weiterleben oder sterben? Entscheidungsprozesse leidender Menschen. None. 2015;None:None||2899
Palliativmedizin|"2.2"|2020|Frerich, Gerrit|Hintergrund|||Erstautor|Frerich G. Der Umgang mit Todeswünschen von Patienten in der spezialisierten Palliativmedizin. None. 2017;None:None||2899
Palliativmedizin|"2.2"|2020|Frerich, Gerrit|Hintergrund|||Standard|Galushko M., Frerich G., Perrar K. M., Golla H., Radbruch L., Nauck F., et al. Desire for hastened death: how do professionals in specialized palliative care react?. None. 2016;25:536-43|https://www.ncbi.nlm.nih.gov/pubmed/26374399|2899
Palliativmedizin|"2.2"|2020|Galushko, Maren|Hintergrund|||Erstautor|Galushko M., Frerich G., Perrar K. M., Golla H., Radbruch L., Nauck F., et al. Desire for hastened death: how do professionals in specialized palliative care react?. None. 2016;25:536-43|https://www.ncbi.nlm.nih.gov/pubmed/26374399|2899
Palliativmedizin|"2.2"|2020|Golla, Heidrun|Hintergrund|||Standard|Galushko M., Frerich G., Perrar K. M., Golla H., Radbruch L., Nauck F., et al. Desire for hastened death: how do professionals in specialized palliative care react?. None. 2016;25:536-43|https://www.ncbi.nlm.nih.gov/pubmed/26374399|2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Galushko M., Frerich G., Perrar K. M., Golla H., Radbruch L., Nauck F., et al. Desire for hastened death: how do professionals in specialized palliative care react?. None. 2016;25:536-43|https://www.ncbi.nlm.nih.gov/pubmed/26374399|2899
Palliativmedizin|"2.2"|2020|Perrar, Klaus Maria|Hintergrund|||Standard|Galushko M., Frerich G., Perrar K. M., Golla H., Radbruch L., Nauck F., et al. Desire for hastened death: how do professionals in specialized palliative care react?. None. 2016;25:536-43|https://www.ncbi.nlm.nih.gov/pubmed/26374399|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Galushko M., Frerich G., Perrar K. M., Golla H., Radbruch L., Nauck F., et al. Desire for hastened death: how do professionals in specialized palliative care react?. None. 2016;25:536-43|https://www.ncbi.nlm.nih.gov/pubmed/26374399|2899
Palliativmedizin|"2.2"|2020|Sperling, Uwe|Hintergrund|||Erstautor|Sperling U., Thüler C., Burkhardt H., Gladisch R. Äußerungen eines Todesverlangens - Suizidalität in einer geriatrischen Population. None. 2009;36:29-35||2899
Palliativmedizin|"2.2"|2020|Sperling, Uwe|Hintergrund|||Standard|Burkhardt H., Sperling U., Gladisch R., Kruse A. Todesverlangen – Ergebnisse einer Pilotstudie mit geriatrischen Akutpatienten. None. 2003;36:392-400||2899
Palliativmedizin|"2.2"|2020|von Leupoldt, Andreas|Hintergrund|||Erstautor|von Leupoldt A., Sommer T., Kegat S., Eippert F., Baumann H. J., Klose H., et al. Down-regulation of insular cortex responses to dyspnea and pain in asthma. . 2009;180:232-8||2899
Palliativmedizin|"2.2"|2020|Roser, Traugott|Hintergrund|||Erstautor|Roser T. Lebenssättigung als Programm. Praktisch-theologische Überlegungen zu Seelsorge und Liturgie an der Grenze. None. 2012;109:397-414||2899
Palliativmedizin|"2.2"|2020|Galushko, Maren|Hintergrund|||Standard|Voltz R., Galushko M., Walisko J., Pfaff H., Nauck F., Radbruch L., et al. End-of-life research on patients' attitudes in Germany: a feasibility study. None. 2010;18:317-20|https://www.ncbi.nlm.nih.gov/pubmed/19479283|2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Voltz R., Galushko M., Walisko J., Pfaff H., Nauck F., Radbruch L., et al. End-of-life research on patients' attitudes in Germany: a feasibility study. None. 2010;18:317-20|https://www.ncbi.nlm.nih.gov/pubmed/19479283|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Voltz R., Galushko M., Walisko J., Pfaff H., Nauck F., Radbruch L., et al. End-of-life research on patients' attitudes in Germany: a feasibility study. None. 2010;18:317-20|https://www.ncbi.nlm.nih.gov/pubmed/19479283|2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Erstautor|Voltz R., Galushko M., Walisko J., Pfaff H., Nauck F., Radbruch L., et al. End-of-life research on patients' attitudes in Germany: a feasibility study. None. 2010;18:317-20|https://www.ncbi.nlm.nih.gov/pubmed/19479283|2899
Palliativmedizin|"2.2"|2020|Galushko, Maren|Hintergrund|||Erstautor|Galushko Maren, Strupp Julia, Walisko-Waniek Johanna, Hahn Moritz, Löffert Sabine, Ernstmann Nicole, et al. Validation of the German version of the Schedule of Attitudes Toward Hastened Death (SAHD–D) with patients in palliative care. None. 2015;13:713-723||2899
Palliativmedizin|"2.2"|2020|Galushko, Maren|Hintergrund|||Standard|Buecken R., Galushko M., Golla H., Strupp J., Hahn M., Ernstmann N., et al. Patients feeling severely affected by multiple sclerosis: how do patients want to communicate about end-of-life issues?. None. 2012;88:318-24|https://www.ncbi.nlm.nih.gov/pubmed/22480629|2899
Palliativmedizin|"2.2"|2020|Golla, Heidrun|Hintergrund|||Standard|Buecken R., Galushko M., Golla H., Strupp J., Hahn M., Ernstmann N., et al. Patients feeling severely affected by multiple sclerosis: how do patients want to communicate about end-of-life issues?. None. 2012;88:318-24|https://www.ncbi.nlm.nih.gov/pubmed/22480629|2899
Palliativmedizin|"2.2"|2020|Lindner, Reinhard|Hintergrund|||Erstautor|Lindner R., Foerster R., von Renteln-Kruse W. Physical distress and relationship problems: exploring the psychosocial and intrapsychic world of suicidal geriatric patients. None. 2014;47:502-7|https://www.ncbi.nlm.nih.gov/pubmed/24202298|2899
Palliativmedizin|"2.2"|2020|Lindner, Reinhard|Hintergrund|||Standard|Gerisch B., Fiedler G., Gans I., Götze P., Lindner R., Richter M. "Ich sehe dieses Elendes kein Ende als das Grab": Zur psychoanalytischen Konzeption und der Behandlung Suizidgefährdeter. None. 2000;None:9-64||2899
Palliativmedizin|"2.2"|2020|Lindner, Reinhard|Hintergrund|||Erstautor|Lindner R., Schneider B. [Psychotherapy of suicidality]. None. 2016;87:488-95|https://www.ncbi.nlm.nih.gov/pubmed/27056189|2899
Palliativmedizin|"2.2"|2020|Schneider, Barbara|Hintergrund|||Letztautor|Lindner R., Schneider B. [Psychotherapy of suicidality]. None. 2016;87:488-95|https://www.ncbi.nlm.nih.gov/pubmed/27056189|2899
Palliativmedizin|"2.2"|2020|Lindner, Reinhard|Hintergrund|||Erstautor|Lindner R. „Media vita in morte sumus“. Psychodynamische Psychotherapie am Lebensende. None. 2017;14:195-208||2899
Palliativmedizin|"2.2"|2020|Lindner, Reinhard|Hintergrund|||Letztautor|Hirsch R.D., Lindner R. Teamkoordination in stationären Einrichtungen. None. 2014;None:123-130||2899
Palliativmedizin|"2.2"|2020|Schneider, Barbara|Hintergrund|||Standard|Hirsch R.D., Lindner R. Teamkoordination in stationären Einrichtungen. None. 2014;None:123-130||2899
Palliativmedizin|"2.2"|2020|Sperling, Uwe|Hintergrund|||Standard|Hirsch R.D., Lindner R. Teamkoordination in stationären Einrichtungen. None. 2014;None:123-130||2899
Palliativmedizin|"2.2"|2020|Lindner, Reinhard|Hintergrund|||Erstautor|Lindner R., Foerster R., Von Renteln-Kruse W. Idealtypische Interaktionsmuster psychosomatischer Patienten in stationär-geriatrischer Behandlung. . 2013;46:441-448||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Erstautor|Alt-Epping B. KLUG ENTSCHEIDEN. . . in der Palliativmedizin. Vor den Rahmenbedingungen von Endlichkeit und komplexer Belastung sind die Behandlungsziele auf die bestmögliche Symptomlinderung und umfassende Unterstützung zu richten. None. 2016;Jg. 113:A1870-A5||2899
Palliativmedizin|"2.2"|2020|Schneider, Barbara|Hintergrund|||Standard|Prigerson H. G., Bao Y., Shah M. A., Paulk M. E., LeBlanc T. W., Schneider B. J., et al. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. None. 2015;1:778-84|https://www.ncbi.nlm.nih.gov/pubmed/26203912|2899
Palliativmedizin|"2.2"|2020|Neitzke, Gerald|Hintergrund|||Erstautor|Neitzke G., Boll B., Burchardi H., Dannenberg K., Duttge G., Erchinger R., et al. [Documentation of decisions to withhold or withdraw life-sustaining therapies : Recommendation of the Ethics Section of the German Interdisciplinary Association of Critical Care and Emergency Medicine (DIVI) in collaboration with the Ethics Section of the German Society for Medical Intensive Care and Emergency Medicine (DGIIN)]. None. 2017;112:527-530|https://www.ncbi.nlm.nih.gov/pubmed/28730421|2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Standard|Waltenberger J., Schöne-Seifert B., Friedrich D. R., Alt-Epping B., Bestehorn M., Dutzmann J., et al. Verantwortlicher Umgang mit ICDs. None. 2017;11:383-397||2899
Palliativmedizin|"2.2"|2020|Nieland, Peter|Hintergrund|||Standard|Mehne S, Nieland P, Simander R. Basiscurriculum Physiotherapie in Palliative Care Palliativmedizin und Hospizwesen. . 2007;:||2899
Palliativmedizin|"2.2"|2020|Roser, Traugott|Hintergrund|||Standard|Hagen T., Roser T, Reigber H., Fittgau-T&#246;nnesmann B. Qualifizierungskurs Palliative Care f&#252;r Seelsorgende. . 2010;:74||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Standard|Higginson I. J., Bausewein C., Reilly C. C., Gao W., Gysels M., Dzingina M., et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. . 2014;2:979-87||2899
Palliativmedizin|"2.2"|2020|Magnussen, Helgo|Hintergrund|||Erstautor|Magnussen H., Kirsten A. M., Kohler D., Morr H., Sitter H., Worth H. [Guidelines for long-term oxygen therapy. German Society for Pneumology and Respiratory Medicine]. . 2008;62:748-56||2899
Palliativmedizin|"2.2"|2020|Magnussen, Helgo|Hintergrund|||Standard|von Leupoldt A., Balewski S., Petersen S., Taube K., Schubert-Heukeshoven S., Magnussen H., et al. Verbal descriptors of dyspnea in patients with COPD at different intensity levels of dyspnea. . 2007;132:141-7||2899
Palliativmedizin|"2.2"|2020|von Leupoldt, Andreas|Hintergrund|||Erstautor|von Leupoldt A., Balewski S., Petersen S., Taube K., Schubert-Heukeshoven S., Magnussen H., et al. Verbal descriptors of dyspnea in patients with COPD at different intensity levels of dyspnea. . 2007;132:141-7||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein C., Jolley C., Reilly C., Lobo P., Kelly J., Bellas H., et al. Development, effectiveness and cost-effectiveness of a new out-patient Breathlessness Support Service: study protocol of a phase III fast-track randomised controlled trial. . 2012;12:58||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Erstautor|Simon S. T., Higginson I. J., Benalia H., Gysels M., Murtagh F. E., Spicer J., et al. Episodic and continuous breathlessness – a new categorization of breathlessness. None. 2013;45:1019-1029||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein C., Roller S., Voltz R. Leitfaden Palliativmedizin. . 2007;:||2899
Palliativmedizin|"2.2"|2020|Roller, Susanne|Hintergrund|||Standard|Bausewein C., Roller S., Voltz R. Leitfaden Palliativmedizin. . 2007;:||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Letztautor|Bausewein C., Roller S., Voltz R. Leitfaden Palliativmedizin. . 2007;:||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Erstautor|Alt-Epping B., Staritz A. E., Simon S. T., Altfelder N., Hotz T., Lindena G., et al. What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey. . 2012;15:971-7||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Standard|Alt-Epping B., Staritz A. E., Simon S. T., Altfelder N., Hotz T., Lindena G., et al. What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey. . 2012;15:971-7||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Evidenzbasierte Empfehlung||False|Letztautor|Klein C., Stiel S., Bukki J., Ostgathe C. [Pharmacological treatment of malignant bowel obstruction in severely ill and dying patients : a systematic literature review]. . 2012;26:587-99|https://www.ncbi.nlm.nih.gov/pubmed/23052994|2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Letztautor|Klein C., Stiel S., Bukki J., Ostgathe C. [Pharmacological treatment of malignant bowel obstruction in severely ill and dying patients : a systematic literature review]. . 2012;26:587-99|https://www.ncbi.nlm.nih.gov/pubmed/23052994|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Erstautor|Radbruch L., Trottenberg P., Elsner F., Kaasa S., Caraceni A. Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. . 2011;25:578-96||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Evidenzbasierte Empfehlung|A|False|Erstautor|Radbruch L., Trottenberg P., Elsner F., Kaasa S., Caraceni A. Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. None. 2011;25:578-96||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein Claudia, Booth Sara, Gysels Marjolein, Kuhnbach Robert, Higginson Irene J. Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. . 2010;9:22||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Evidenzbasierte Empfehlung|B|False|Erstautor|Bausewein Claudia, Booth Sara, Gysels Marjolein, Kuhnbach Robert, Higginson Irene J. Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. None. 2010;9:22||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Letztautor|Gaertner J., Wolf J., Hallek M., Glossmann J. P., Voltz R. Standardizing integration of palliative care into comprehensive cancer therapy--a disease specific approach. . 2011;19:1037-43||2899
Palliativmedizin|"2.2"|2020|Wolf, Jürgen|Hintergrund|||Standard|Gaertner J., Wolf J., Hallek M., Glossmann J. P., Voltz R. Standardizing integration of palliative care into comprehensive cancer therapy--a disease specific approach. . 2011;19:1037-43||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Erstautor|Radbruch L., Payne S. White Paper on standards and norms for hospice and palliative care in Europe: part 1. None. 2009;16:278-289||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Erstautor|Radbruch L., Payne S. White Paper on standards and norms for hospice and palliative care in Europe: part 2. None. 2010;17:22-33||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Letztautor|Gaertner J., Wolf J., Voltz R. Early palliative care for patients with metastatic cancer. . 2012;24:357-62||2899
Palliativmedizin|"2.2"|2020|Wolf, Jürgen|Hintergrund|||Standard|Gaertner J., Wolf J., Voltz R. Early palliative care for patients with metastatic cancer. . 2012;24:357-62||2899
Palliativmedizin|"2.2"|2020|Siemens, Waldemar|Evidenzbasierte Empfehlung|A|False|Standard|Gaertner J., Siemens W., Meerpohl J. J., Antes G., Meffert C., Xander C., et al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis. . 2017;357:j2925|https://www.ncbi.nlm.nih.gov/pubmed/28676557|2899
Palliativmedizin|"2.2"|2020|Siemens, Waldemar|Hintergrund|||Standard|Gaertner J., Siemens W., Meerpohl J. J., Antes G., Meffert C., Xander C., et al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis. . 2017;357:j2925|https://www.ncbi.nlm.nih.gov/pubmed/28676557|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Grond S., Zech D., Lehmann K. A., Radbruch L., Breitenbach H., Hertel D. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. . 1997;69:191-8||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Elsner F., Radbruch L., Loick G., Gaertner J., Sabatowski R. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. . 2005;8:743-50||2899
Palliativmedizin|"2.2"|2020|Sabatowski, Rainer|Hintergrund|||Letztautor|Elsner F., Radbruch L., Loick G., Gaertner J., Sabatowski R. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. . 2005;8:743-50||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Mercadante S., Radbruch L., Davies A., Poulain P., Sitte T., Perkins P., et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. . 2009;25:2805-15||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Erstautor|Radbruch L., Loick G., Kiencke P., Lindena G., Sabatowski R., Grond S., et al. Validation of the German version of the Brief Pain Inventory. . 1999;18:180-7||2899
Palliativmedizin|"2.2"|2020|Sabatowski, Rainer|Hintergrund|||Standard|Radbruch L., Loick G., Kiencke P., Lindena G., Sabatowski R., Grond S., et al. Validation of the German version of the Brief Pain Inventory. . 1999;18:180-7||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Standard|Stiel S., Matthes M. E., Bertram L., Ostgathe C., Elsner F., Radbruch L. [Validation of the new version of the minimal documentation system (MIDOS) for patients in palliative care : the German version of the edmonton symptom assessment scale (ESAS)]. . 2010;24:596-604||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Stiel S., Pollok A., Elsner F., Lindena G., Ostgathe C., Nauck F., et al. Validation of the Symptom and Problem Checklist of the German Hospice and Palliative Care Evaluation (HOPE). . 2012;43:593-605||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Standard|Stiel S., Pollok A., Elsner F., Lindena G., Ostgathe C., Nauck F., et al. Validation of the Symptom and Problem Checklist of the German Hospice and Palliative Care Evaluation (HOPE). . 2012;43:593-605||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Evidenzbasierte Empfehlung||False|Standard|Domeisen Benedetti F., Ostgathe C., Clark J., Costantini M., Daud M. L., Grossenbacher-Gschwend B., et al. International palliative care experts' view on phenomena indicating the last hours and days of life. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Standard|Domeisen Benedetti F., Ostgathe C., Clark J., Costantini M., Daud M. L., Grossenbacher-Gschwend B., et al. International palliative care experts' view on phenomena indicating the last hours and days of life. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Letztautor|Cherny N. I., Radbruch L. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. None. 2009;23:581-93||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Letztautor|Cherny N. I., Radbruch L. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. . 2009;23:581-93||2899
Palliativmedizin|"2.2"|2020|Schulz, Christian|Evidenzbasierte Empfehlung|B|False|Letztautor|Dietz I., Schmitz A., Lampey I., Schulz C. Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review. . 2013;12:2||2899
Palliativmedizin|"2.2"|2020|Schulz, Christian|Hintergrund|||Letztautor|Dietz I., Schmitz A., Lampey I., Schulz C. Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review. . 2013;12:2||2899
Palliativmedizin|"2.2"|2020|Golla, Heidrun|Hintergrund|||Standard|Perrar K. M., Golla H., Voltz R. Medikamentöse Behandlung des Delirs bei Palliativpatienten. Eine systematische Literaturübersicht. None. 2013;None:None||2899
Palliativmedizin|"2.2"|2020|Perrar, Klaus Maria|Hintergrund|||Erstautor|Perrar K. M., Golla H., Voltz R. Medikamentöse Behandlung des Delirs bei Palliativpatienten. Eine systematische Literaturübersicht. None. 2013;None:None||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Letztautor|Perrar K. M., Golla H., Voltz R. Medikamentöse Behandlung des Delirs bei Palliativpatienten. Eine systematische Literaturübersicht. None. 2013;None:None||2899
Palliativmedizin|"2.2"|2020|Weber, Martin|Hintergrund|||Standard|Escobar Pinzon L. C., Weber M., Claus M., Fischbeck S., Unrath M., Martini T., et al. Factors influencing place of death in Germany. None. 2011;41:893-903||2899
Palliativmedizin|"2.2"|2020|Becker, Gerhild|Hintergrund|||Letztautor|Bader S., Weber M., Becker G. Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review. . 2012;26:568-86||2899
Palliativmedizin|"2.2"|2020|Weber, Martin|Hintergrund|||Standard|Bader S., Weber M., Becker G. Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review. . 2012;26:568-86||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Standard|Owusu Boakye S., Nauck F., Alt-Epping B., Marx G. Selbstbestimmung braucht Vertrauen – Entscheidungsfindung am Lebensende. . 2016;:101-132||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Owusu Boakye S., Nauck F., Alt-Epping B., Marx G. Selbstbestimmung braucht Vertrauen – Entscheidungsfindung am Lebensende. . 2016;:101-132||2899
Palliativmedizin|"2.2"|2020|Wirz, Stefan|Hintergrund|||Erstautor|Wirz S., Klaschik E. Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option?. . 2005;22:375-81||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Ahmedzai S. H., Nauck F., Bar-Sela G., Bosse B., Leyendecker P., Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. . 2012;26:50-60||2899
Palliativmedizin|"2.2"|2020|Frieling, Thomas|Hintergrund|||Erstautor|Frieling T. Acute abdomen from the internal medicine point of view. . 2009;134:246-50||2899
Palliativmedizin|"2.2"|2020|Schulz, Christian|Hintergrund|||Erstautor|Schulz C. Diversitätskompetenz am Lebensende. None. 2010;None:242-256||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Standard|Heußner P., Besseler M., Dietzfelbinger H., Fegg M., Lang K., Mehl U., et al. Psychoonkologie. None. 2009;None:None||2899
Palliativmedizin|"2.2"|2020|Heußner, Pia|Hintergrund|||Erstautor|Heußner P., Besseler M., Dietzfelbinger H., Fegg M., Lang K., Mehl U., et al. Psychoonkologie. None. 2009;None:None||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Erstautor|Fegg M., Gramm J., Pestinger M. Psychologie und Palliative Care. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Gramm, Jan|Hintergrund|||Standard|Fegg M., Gramm J., Pestinger M. Psychologie und Palliative Care. None. 2012;None:None||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Standard|Schulz C. Interventionen bei Kernsymptomen - Angst. None. 2012;None:191-197||2899
Palliativmedizin|"2.2"|2020|Gramm, Jan|Hintergrund|||Standard|Schulz C. Interventionen bei Kernsymptomen - Angst. None. 2012;None:191-197||2899
Palliativmedizin|"2.2"|2020|Schulz, Christian|Hintergrund|||Erstautor|Schulz C. Interventionen bei Kernsymptomen - Angst. None. 2012;None:191-197||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Erstautor|Nauck F., Klaschik E., Ostgathe C. Symptom control during the last three days of life. None. 2000;7:81-84||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Letztautor|Nauck F., Klaschik E., Ostgathe C. Symptom control during the last three days of life. None. 2000;7:81-84||2899
Palliativmedizin|"2.2"|2020|Winkler, Eva|Hintergrund|||Letztautor|Hauke D., Reiter-Theil S., Hoster E., Hiddemann W., Winkler E. C. The role of relatives in decisions concerning life-prolonging treatment in patients with end-stage malignant disorders: informants, advocates or surrogate decision-makers?. . 2011;22:2667-74|https://www.ncbi.nlm.nih.gov/pubmed/21427061|2899
Palliativmedizin|"2.2"|2020|Kloke, Marianne|Hintergrund|||Erstautor|Kloke M. SOP Tagesklinik des Zentrums für Palliativmedizin der Kliniken Essen-Mitte. None. 2013;None:None||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Radbruch L., Stiel S., Nauck F., Jaspers B., Ostgathe C., Voltz R. Das Lebensende gestalten. None. 2008;9:27-31||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Standard|Radbruch L., Stiel S., Nauck F., Jaspers B., Ostgathe C., Voltz R. Das Lebensende gestalten. None. 2008;9:27-31||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Erstautor|Radbruch L., Stiel S., Nauck F., Jaspers B., Ostgathe C., Voltz R. Das Lebensende gestalten. None. 2008;9:27-31||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Letztautor|Radbruch L., Stiel S., Nauck F., Jaspers B., Ostgathe C., Voltz R. Das Lebensende gestalten. None. 2008;9:27-31||2899
Palliativmedizin|"2.2"|2020|Weis, Joachim|Hintergrund|||Standard|Faller H., Schuler M., Richard M., Heckl U., Weis J., Kuffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. None. 2013;31:782-93||2899
Palliativmedizin|"2.2"|2020|Ujeyl, Mariam|Evidenzbasiertes Statement||False|Erstautor|Ujeyl M., Muller-Oerlinghausen B. [Antidepressants for treatment of depression in palliative patients : a systematic literature review]. None. 2012;26:523-36||2899
Palliativmedizin|"2.2"|2020|Ujeyl, Mariam|Hintergrund|||Erstautor|Ujeyl M., Muller-Oerlinghausen B. [Antidepressants for treatment of depression in palliative patients : a systematic literature review]. None. 2012;26:523-36||2899
Palliativmedizin|"2.2"|2020|Simon, Alfred|Hintergrund|||Standard|van Oorschot B., Schuler M., Simon A., Schleicher U., Geinitz H. Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis. None. 2011;187:461-6||2899
Palliativmedizin|"2.2"|2020|van Oorschot, Birgit|Hintergrund|||Erstautor|van Oorschot B., Schuler M., Simon A., Schleicher U., Geinitz H. Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis. None. 2011;187:461-6||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein C., Fegg M., Radbruch L., Nauck F., von Mackensen S., Borasio G. D., et al. Validation and clinical application of the german version of the palliative care outcome scale. . 2005;30:51-62||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Standard|Bausewein C., Fegg M., Radbruch L., Nauck F., von Mackensen S., Borasio G. D., et al. Validation and clinical application of the german version of the palliative care outcome scale. . 2005;30:51-62||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Bausewein C., Fegg M., Radbruch L., Nauck F., von Mackensen S., Borasio G. D., et al. Validation and clinical application of the german version of the palliative care outcome scale. . 2005;30:51-62||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Bausewein C., Fegg M., Radbruch L., Nauck F., von Mackensen S., Borasio G. D., et al. Validation and clinical application of the german version of the palliative care outcome scale. . 2005;30:51-62||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Augustyn B., Kern M. Symptomorientierte Pflege bei Übelkeit und Erbrechen. . 2007;:976-977||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Augustyn B., Kern M. Symptomorientierte Pflege bei Übelkeit und Erbrechen. . 2007;:976-977||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Evidenzbasierte Empfehlung|B|False|Standard|Benze G., Alt-Epping B., Geyer A., Nauck F. [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review]. . 2012;26:500-14|https://www.ncbi.nlm.nih.gov/pubmed/22968365|2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Standard|Benze G., Alt-Epping B., Geyer A., Nauck F. [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review]. . 2012;26:500-14|https://www.ncbi.nlm.nih.gov/pubmed/22968365|2899
Palliativmedizin|"2.2"|2020|Benze, Gesine|Evidenzbasierte Empfehlung|B|False|Erstautor|Benze G., Alt-Epping B., Geyer A., Nauck F. [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review]. . 2012;26:500-14|https://www.ncbi.nlm.nih.gov/pubmed/22968365|2899
Palliativmedizin|"2.2"|2020|Benze, Gesine|Hintergrund|||Erstautor|Benze G., Alt-Epping B., Geyer A., Nauck F. [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review]. . 2012;26:500-14|https://www.ncbi.nlm.nih.gov/pubmed/22968365|2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Evidenzbasierte Empfehlung|B|False|Letztautor|Benze G., Alt-Epping B., Geyer A., Nauck F. [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review]. . 2012;26:500-14|https://www.ncbi.nlm.nih.gov/pubmed/22968365|2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Letztautor|Benze G., Alt-Epping B., Geyer A., Nauck F. [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review]. . 2012;26:500-14|https://www.ncbi.nlm.nih.gov/pubmed/22968365|2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Evidenzbasierte Empfehlung||False|Standard|Benze G., Geyer A., Alt-Epping B., Nauck F. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review]. . 2012;26:481-99|https://www.ncbi.nlm.nih.gov/pubmed/22983450|2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Standard|Benze G., Geyer A., Alt-Epping B., Nauck F. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review]. . 2012;26:481-99|https://www.ncbi.nlm.nih.gov/pubmed/22983450|2899
Palliativmedizin|"2.2"|2020|Benze, Gesine|Evidenzbasierte Empfehlung||False|Erstautor|Benze G., Geyer A., Alt-Epping B., Nauck F. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review]. . 2012;26:481-99|https://www.ncbi.nlm.nih.gov/pubmed/22983450|2899
Palliativmedizin|"2.2"|2020|Benze, Gesine|Hintergrund|||Erstautor|Benze G., Geyer A., Alt-Epping B., Nauck F. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review]. . 2012;26:481-99|https://www.ncbi.nlm.nih.gov/pubmed/22983450|2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Evidenzbasierte Empfehlung||False|Letztautor|Benze G., Geyer A., Alt-Epping B., Nauck F. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review]. . 2012;26:481-99|https://www.ncbi.nlm.nih.gov/pubmed/22983450|2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Letztautor|Benze G., Geyer A., Alt-Epping B., Nauck F. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review]. . 2012;26:481-99|https://www.ncbi.nlm.nih.gov/pubmed/22983450|2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Standard|Remi C., Bausewein C., Twycross R., Wilcock A., Howard P. Arzneimitteltherapie in der Palliativmedizin. . 2018;:||2899
Palliativmedizin|"2.2"|2020|Schildmann, Jan|Hintergrund|||Letztautor|Jox R. J., Michalowski S., Lorenz J., Schildmann J. Substitute decision making in medicine: comparative analysis of the ethico-legal discourse in England and Germany. . 2008;11:153-63||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein C., Farquhar M., Booth S., Gysels M., Higginson I. J. Measurement of breathlessness in advanced disease: a systematic review. None. 2007;101:399-410||2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein C., Booth S., Higginson I. J. Measurement of dyspnoea in the clinical rather than the research setting. None. 2008;2:95-9||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Erstautor|Nauck F., Ostgathe C., Dickerson E. D. A German model for methadone conversion. . 2001;18:200-2||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Standard|Nauck F., Ostgathe C., Dickerson E. D. A German model for methadone conversion. . 2001;18:200-2||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Erstautor|Alt-Epping B., Sitte T., Nauck F., Radbruch L. Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC). . 2010;24:342-54||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Alt-Epping B., Sitte T., Nauck F., Radbruch L. Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC). . 2010;24:342-54||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Letztautor|Alt-Epping B., Sitte T., Nauck F., Radbruch L. Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC). . 2010;24:342-54||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Erstautor|Alt-Epping B., Sitte T., Nauck F., Radbruch L. Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC). None. 2010;24:342-54||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Standard|Alt-Epping B., Sitte T., Nauck F., Radbruch L. Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC). None. 2010;24:342-54||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Letztautor|Alt-Epping B., Sitte T., Nauck F., Radbruch L. Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC). None. 2010;24:342-54||2899
Palliativmedizin|"2.2"|2020|Fegg, Martin|Hintergrund|||Erstautor|Fegg M Pestinger M Lampe H Jünger S Berger H Gramm J Brandstätter M. Berufsbild für Psychologen in Palliative Care. None. 2008;None:None||2899
Palliativmedizin|"2.2"|2020|Gramm, Jan|Hintergrund|||Erstautor|Fegg M Pestinger M Lampe H Jünger S Berger H Gramm J Brandstätter M. Berufsbild für Psychologen in Palliative Care. None. 2008;None:None||2899
Palliativmedizin|"2.2"|2020|Gaspar, Manfred|Hintergrund|||Erstautor|Gaspar M.; Weber M. Kommunikation in der Palliativmedizin. None. 2010;None:None||2899
Palliativmedizin|"2.2"|2020|Weber, Martin|Hintergrund|||Erstautor|Gaspar M.; Weber M. Kommunikation in der Palliativmedizin. None. 2010;None:None||2899
Palliativmedizin|"2.2"|2020|Gramm, Jan|Hintergrund|||Erstautor|Gramm Jan. Das Familiengespräch. . 2012;:||2899
Palliativmedizin|"2.2"|2020|Keller, Monika|Hintergrund|||Erstautor|Keller M. Krebspatienten im Sterbeprozess - Perspektiven und Erfahrungen in der Psychoonkologie. None. 2013;None:765-799||2899
Palliativmedizin|"2.2"|2020|Keller, Monika|Hintergrund|||Erstautor|Keller M. & Barthel Y. Patientenzentrierte Kommunikation in der Onkologie - Erfahrungen mit dem KOMPASS Training. None. 2013;None:147-65||2899
Palliativmedizin|"2.2"|2020|Weis, Joachim|Hintergrund|||Standard|Keller M. & Barthel Y. Patientenzentrierte Kommunikation in der Onkologie - Erfahrungen mit dem KOMPASS Training. None. 2013;None:147-65||2899
Palliativmedizin|"2.2"|2020|Becker, Gerhild|Evidenzbasierte Empfehlung|A|True|Letztautor|Bader S., Weber M., Becker G. Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review. None. 2012;26:568-86||2899
Palliativmedizin|"2.2"|2020|Weber, Martin|Evidenzbasierte Empfehlung|A|True|Standard|Bader S., Weber M., Becker G. Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review. None. 2012;26:568-86||2899
Palliativmedizin|"2.2"|2020|Becker, Gerhild|Hintergrund|||Erstautor|Becker G., Blum H. E. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. . 2009;373:1198-206||2899
Palliativmedizin|"2.2"|2020|Winkler, Eva|Hintergrund|||Erstautor|Winkler E. C., Reiter-Theil S., Lange-Riess D., Schmahl-Menges N., Hiddemann W. Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient. None. 2009;27:2225-30|https://www.ncbi.nlm.nih.gov/pubmed/19307508|2899
Palliativmedizin|"2.2"|2020|Winkler, Eva|Hintergrund|||Letztautor|Laryionava K., Heussner P., Hiddemann W., Winkler E. C. Framework for timing of the discussion about forgoing cancer-specific treatment based on a qualitative study with oncologists. None. 2015;23:715-21|https://www.ncbi.nlm.nih.gov/pubmed/25172311|2899
Palliativmedizin|"2.2"|2020|Wirz, Stefan|Hintergrund|||Erstautor|Wirz S., Klaschik E. Laxative use and efficacy in palliative care of patients with cancer pain and morphine therapy. A retrospective study with special regard to polyethylene glycol. . 2003;17:233-9||2899
Palliativmedizin|"2.2"|2020|Wirz, Stefan|Hintergrund|||Erstautor|Wirz S.; Beck D. Obstipation in der Palliativmedizin. None. 2008;9:13-26||2899
Palliativmedizin|"2.2"|2020|Simon, Alfred|Hintergrund|||Standard|Coors M., Simon A., Stiemerling M. Ethikberatung in Pflege und ambulanter Versorgung: Modelle und theoretische Grundlagen. None. 2014;None:None||2899
Palliativmedizin|"2.2"|2020|Janssens, Uwe|Hintergrund|||Erstautor|Janssens U., Burchardi H., Duttge G. Therapiezieländerung und Therapiebegrenzung in der Intensivmedizin. Positionspapier der Sektion Ethik der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin. None. 2013;62:47–52||2899
Palliativmedizin|"2.2"|2020|Neitzke, Gerald|Hintergrund|||Erstautor|Neitzke Gerald, Riedel Annette, Dinges Stefan, Fahr Uwe, May Arnd T. Empfehlungen zur Evaluation von Ethikberatung in Einrichtungen des Gesundheitswesens. None. 2012;25:149-156||2899
Palliativmedizin|"2.2"|2020|Schildmann, Jan|Hintergrund|||Erstautor|Schildmann J., Vollmann J. Evaluation klinischer Ethikberatung: eine systematische Übersichtsarbeit. None. 2009;None:71-86||2899
Palliativmedizin|"2.2"|2020|Simon, Alfred|Hintergrund|||Standard|Schildmann J., Vollmann J. Evaluation klinischer Ethikberatung: eine systematische Übersichtsarbeit. None. 2009;None:71-86||2899
Palliativmedizin|"2.2"|2020|Lipp, Volker|Hintergrund|||Erstautor|Lipp V. Die medizinische Indikation – ein „Kernstück ärztlicher Legitimation“?. None. 2015;33:762-766||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Standard|Sahm S. Autonomie, ärztliche Indikation und Entscheidungsfindung. None. 2008;None:121–131||2899
Palliativmedizin|"2.2"|2020|Heußner, Pia|Hintergrund|||Erstautor|Heußner P., Winkler E. C. Leitlinie zur Therapiebegrenzung der Medizinischen Klinik und Poliklinik III des Klinikums der Universität München. None. 2015;None:None|http://www.ethikkomitee.de/downloads/leitlinie-zur-therapiebegrenzung.pdf 2015. Zugriff 31.01.2018|2899
Palliativmedizin|"2.2"|2020|Winkler, Eva|Hintergrund|||Letztautor|Heußner P., Winkler E. C. Leitlinie zur Therapiebegrenzung der Medizinischen Klinik und Poliklinik III des Klinikums der Universität München. None. 2015;None:None|http://www.ethikkomitee.de/downloads/leitlinie-zur-therapiebegrenzung.pdf 2015. Zugriff 31.01.2018|2899
Palliativmedizin|"2.2"|2020|Winkler, Eva|Hintergrund|||Erstautor|Winkler E. C. Ist ein Therapieverzicht gegen den Willen des Patienten ethisch begründbar?. None. 2010;22:89–102||2899
Palliativmedizin|"2.2"|2020|Winkler, Eva|Hintergrund|||Erstautor|Winkler E. C., Hiddemann W., Marckmann G. Ethical assessment of life-prolonging treatment. None. 2011;12:720-2|https://www.ncbi.nlm.nih.gov/pubmed/21807335|2899
Palliativmedizin|"2.2"|2020|Winkler, Eva|Hintergrund|||Erstautor|Winkler E. C., Markmann G. Therapieverzicht gegen den Patientenwillen?. None. 2012;4:140-144||2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Erstautor|Alt-Epping B., Nauck F. Der Wunsch des Patienten – ein eigenständiger normativer Faktor in der klinischen Therapieentscheidung?. None. 2012;24:19-28||2899
Palliativmedizin|"2.2"|2020|Nauck, Friedemann|Hintergrund|||Letztautor|Alt-Epping B., Nauck F. Der Wunsch des Patienten – ein eigenständiger normativer Faktor in der klinischen Therapieentscheidung?. None. 2012;24:19-28||2899
Palliativmedizin|"2.2"|2020|Neitzke, Gerald|Hintergrund|||Erstautor|Neitzke G., Burchardi H., Duttge G. Grenzen der Sinnhaftigkeit von Intensivmedizin. Positionspapier der Sektion Ethik der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin. None. 2016;None:None||2899
Palliativmedizin|"2.2"|2020|Magnussen, Helgo|Evidenzbasierte Empfehlung||False|Letztautor|Worth H., Forster K., Eriksson G., Nihlen U., Peterson S., Magnussen H. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. None. 2010;104:1450-9||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Erstautor|Simon S. T., Weingartner V., Higginson I. J., Benalia H., Gysels M., Murtagh F. E., et al. "I Can Breathe Again!" Patients' Self-Management Strategies for Episodic Breathlessness in Advanced Disease, Derived From Qualitative Interviews. None. 2016;52:228-34|https://www.ncbi.nlm.nih.gov/pubmed/27220949|2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Evidenzbasierte Empfehlung|A|False|Standard|Simon S. T., Kloke M., Alt-Epping B., Gartner J., Hellmich M., Hein R., et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. None. 2016;52:617-625|https://www.ncbi.nlm.nih.gov/pubmed/27693898|2899
Palliativmedizin|"2.2"|2020|Alt-Epping, Bernd|Hintergrund|||Standard|Simon S. T., Kloke M., Alt-Epping B., Gartner J., Hellmich M., Hein R., et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. None. 2016;52:617-625|https://www.ncbi.nlm.nih.gov/pubmed/27693898|2899
Palliativmedizin|"2.2"|2020|Kloke, Marianne|Evidenzbasierte Empfehlung|A|False|Standard|Simon S. T., Kloke M., Alt-Epping B., Gartner J., Hellmich M., Hein R., et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. None. 2016;52:617-625|https://www.ncbi.nlm.nih.gov/pubmed/27693898|2899
Palliativmedizin|"2.2"|2020|Kloke, Marianne|Hintergrund|||Standard|Simon S. T., Kloke M., Alt-Epping B., Gartner J., Hellmich M., Hein R., et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. None. 2016;52:617-625|https://www.ncbi.nlm.nih.gov/pubmed/27693898|2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Evidenzbasierte Empfehlung|A|False|Erstautor|Simon S. T., Kloke M., Alt-Epping B., Gartner J., Hellmich M., Hein R., et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. None. 2016;52:617-625|https://www.ncbi.nlm.nih.gov/pubmed/27693898|2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Erstautor|Simon S. T., Kloke M., Alt-Epping B., Gartner J., Hellmich M., Hein R., et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. None. 2016;52:617-625|https://www.ncbi.nlm.nih.gov/pubmed/27693898|2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Letztautor|Simon S. T., Higginson I. J., Booth S., Harding R., Weingartner V., Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. None. 2016;10:CD007354|https://www.ncbi.nlm.nih.gov/pubmed/27764523|2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Hintergrund|||Erstautor|Simon S. T., Higginson I. J., Booth S., Harding R., Weingartner V., Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. None. 2016;10:CD007354|https://www.ncbi.nlm.nih.gov/pubmed/27764523|2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Standard|Gaertner J., Wolf J., Ostgathe C., Toepelt K., Glossmann J. P., Hallek M., et al. Specifying WHO recommendation: moving toward disease-specific guidelines. None. 2010;13:1273-6||2899
Palliativmedizin|"2.2"|2020|Wolf, Jürgen|Hintergrund|||Standard|Gaertner J., Wolf J., Ostgathe C., Toepelt K., Glossmann J. P., Hallek M., et al. Specifying WHO recommendation: moving toward disease-specific guidelines. None. 2010;13:1273-6||2899
Palliativmedizin|"2.2"|2020|Ostgathe, Christoph|Hintergrund|||Standard|Gaertner J., Frechen S., Sladek M., Ostgathe C., Voltz R. Palliative care consultation service and palliative care unit: why do we need both?. None. 2012;17:428-35||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Letztautor|Gaertner J., Frechen S., Sladek M., Ostgathe C., Voltz R. Palliative care consultation service and palliative care unit: why do we need both?. None. 2012;17:428-35||2899
Palliativmedizin|"2.2"|2020|Becker, Gerhild|Evidenzbasierte Empfehlung|A|False|Letztautor|Siemens W., Becker G. Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. None. 2016;12:401-12|https://www.ncbi.nlm.nih.gov/pubmed/27042082|2899
Palliativmedizin|"2.2"|2020|Becker, Gerhild|Hintergrund|||Letztautor|Siemens W., Becker G. Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. None. 2016;12:401-12|https://www.ncbi.nlm.nih.gov/pubmed/27042082|2899
Palliativmedizin|"2.2"|2020|Siemens, Waldemar|Evidenzbasierte Empfehlung|A|False|Erstautor|Siemens W., Becker G. Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. None. 2016;12:401-12|https://www.ncbi.nlm.nih.gov/pubmed/27042082|2899
Palliativmedizin|"2.2"|2020|Siemens, Waldemar|Hintergrund|||Erstautor|Siemens W., Becker G. Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. None. 2016;12:401-12|https://www.ncbi.nlm.nih.gov/pubmed/27042082|2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Hintergrund|||Erstautor|Bausewein C., Roller S., Voltz R. Leitfaden Palliative Care. . 2018;:||2899
Palliativmedizin|"2.2"|2020|Roller, Susanne|Hintergrund|||Standard|Bausewein C., Roller S., Voltz R. Leitfaden Palliative Care. . 2018;:||2899
Palliativmedizin|"2.2"|2020|Voltz, Raymond|Hintergrund|||Letztautor|Bausewein C., Roller S., Voltz R. Leitfaden Palliative Care. . 2018;:||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Evidenzbasierte Empfehlung|0|False|Standard|Schuchen R. H., Mucke M., Marinova M., Kravchenko D., Hauser W., Radbruch L., et al. Systematic review and meta-analysis on non-opioid analgesics in palliative medicine. None. 2018;9:1235-1254|https://www.ncbi.nlm.nih.gov/pubmed/30375188|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Standard|Schuchen R. H., Mucke M., Marinova M., Kravchenko D., Hauser W., Radbruch L., et al. Systematic review and meta-analysis on non-opioid analgesics in palliative medicine. None. 2018;9:1235-1254|https://www.ncbi.nlm.nih.gov/pubmed/30375188|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Erstautor|Radbruch L., Strasser F., Elsner F., Goncalves J. F., Loge J., Kaasa S., et al. Fatigue in palliative care patients -- an EAPC approach. None. 2008;22:13-32|https://www.ncbi.nlm.nih.gov/pubmed/18216074|2899
Palliativmedizin|"2.2"|2020|Bausewein, Claudia|Evidenzbasierte Empfehlung||False|Letztautor|Simon S. T., Higginson I. J., Booth S., Harding R., Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. None. 2010;None:CD007354||2899
Palliativmedizin|"2.2"|2020|Simon, Steffen|Evidenzbasierte Empfehlung||False|Erstautor|Simon S. T., Higginson I. J., Booth S., Harding R., Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. None. 2010;None:CD007354||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Erstautor|Radbruch L., Sabatowski R., Elsner F., Everts J., Mendoza T., Cleeland C. Validation of the German version of the brief fatigue inventory. None. 2003;25:449-58|https://www.ncbi.nlm.nih.gov/pubmed/12727043|2899
Palliativmedizin|"2.2"|2020|Sabatowski, Rainer|Hintergrund|||Standard|Radbruch L., Sabatowski R., Elsner F., Everts J., Mendoza T., Cleeland C. Validation of the German version of the brief fatigue inventory. None. 2003;25:449-58|https://www.ncbi.nlm.nih.gov/pubmed/12727043|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Letztautor|Thiem A., Rolke R., Radbruch L. [Glucocorticoids and androgens for treatment of tiredness and weakness in palliative care patients : a systematic review]. None. 2012;26:550-67|https://www.ncbi.nlm.nih.gov/pubmed/22956074|2899
Palliativmedizin|"2.2"|2020|Rolke, Roman|Hintergrund|||Standard|Thiem A., Rolke R., Radbruch L. [Glucocorticoids and androgens for treatment of tiredness and weakness in palliative care patients : a systematic review]. None. 2012;26:550-67|https://www.ncbi.nlm.nih.gov/pubmed/22956074|2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Erstautor|Radbruch L., Sabatowski R., Loick G., Jonen-Thielemann I., Elsner F., Hörmann E. MIDOS - Validierung eines minimalen Dokumentationssystems für die Palliativmedizin. None. 2000;14:231-239||2899
Palliativmedizin|"2.2"|2020|Sabatowski, Rainer|Hintergrund|||Standard|Radbruch L., Sabatowski R., Loick G., Jonen-Thielemann I., Elsner F., Hörmann E. MIDOS - Validierung eines minimalen Dokumentationssystems für die Palliativmedizin. None. 2000;14:231-239||2899
Palliativmedizin|"2.2"|2020|Radbruch, Lukas|Hintergrund|||Letztautor|Sabatowski R., Schwalen S., Rettig K., Herberg K. W., Kasper S. M., Radbruch L. Driving ability under long-term treatment with transdermal fentanyl. None. 2003;25:38-47|https://www.ncbi.nlm.nih.gov/pubmed/12565187|2899
Palliativmedizin|"2.2"|2020|Sabatowski, Rainer|Hintergrund|||Erstautor|Sabatowski R., Schwalen S., Rettig K., Herberg K. W., Kasper S. M., Radbruch L. Driving ability under long-term treatment with transdermal fentanyl. None. 2003;25:38-47|https://www.ncbi.nlm.nih.gov/pubmed/12565187|2899
Palliativmedizin|"2.2"|2020|Jentschke, Elisabeth|Hintergrund|||Standard|Cuhls H., Mochamat, Mücke M., Jaspers B., Jentschke E., Hense J., et al. SOP - Fatigue. None. 2017;23:462-468||2899
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Einenkel J., Hockel M., Kolbl H., Kommoss F., Lax S. F., et al. Pathoanatomical preparation and reporting for dysplasias and cancers of the cervix uteri: cervical biopsy, conization, radical hysterectomy and exenteration. None. 2007;28:249-60||2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Einenkel J., Hockel M., Kolbl H., Kommoss F., Lax S. F., et al. Pathoanatomical preparation and reporting for dysplasias and cancers of the cervix uteri: cervical biopsy, conization, radical hysterectomy and exenteration. . 2007;28:249-60|https://www.ncbi.nlm.nih.gov/pubmed/16838175|2340
Zervixkarzinom|"2.2"|2022|Küppers, Volkmar|Hintergrund|||Standard|Girardi F., Frey Tirri B., Küppers V., Menton M., Quaas J, Reich O. Neue kolposkopische IFCPC-Nomenklatur der Cervix uteri (Rio de Janeiro 2011) - Approbierte Darstellung und Erläuterung für Deutschland, Österreich und die deutschsprachige Schweiz. None. 2012;53:1064-1066||2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Klostermann K. Precancerous lesions of the uterine cervix: morphology and molecular pathology. None. 2011;32 Suppl 2:242-54||2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Klostermann K. Precancerous lesions of the uterine cervix: morphology and molecular pathology. . 2011;32 Suppl 2:242-54|https://www.ncbi.nlm.nih.gov/pubmed/21909794|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Einenkel J., Hockel M., Kolbl H., Kommoss F., Lax S. F., et al. Recommendations for the handling and oncologic pathology report of lymph node specimens submitted for evaluation of metastatic disease in gynecologic malignancies. None. 2005;26:266-72||2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Einenkel J., Hockel M., Kolbl H., Kommoss F., Lax S. F., et al. Recommendations for the handling and oncologic pathology report of lymph node specimens submitted for evaluation of metastatic disease in gynecologic malignancies. . 2005;26:266-72|https://www.ncbi.nlm.nih.gov/pubmed/15915329|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Kellner C., Scherling R., Hockel M., Einenkel J. Ultrastaging for micrometastases in para-aortic lymph nodes in patients with carcinoma of the uterine cervix. None. 2012;124:374-5; author reply 375-6||2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Kellner C., Scherling R., Hockel M., Einenkel J. Ultrastaging for micrometastases in para-aortic lymph nodes in patients with carcinoma of the uterine cervix. . 2012;124:374-5; author reply 375-6|https://www.ncbi.nlm.nih.gov/pubmed/22040833|2340
Zervixkarzinom|"2.2"|2022|Wittekind, Christian|Hintergrund|||Letztautor|Hermanek P., Hutter R. V., Sobin L. H., Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. None. 1999;86:2668-73||2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Standard|Hockel M., Horn L. C., Tetsch E., Einenkel J. Pattern analysis of regional spread and therapeutic lymph node dissection in cervical cancer based on ontogenetic anatomy. . 2012;125:168-74|https://www.ncbi.nlm.nih.gov/pubmed/22155677|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Meinel A., Fischer U., Bilek K., Hentschel B. Perineural invasion in carcinoma of the cervix uteri-prognostic impact. . 2010;136:1557-62|https://www.ncbi.nlm.nih.gov/pubmed/20169362|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Hohn A. K., Hentschel B., Fischer U., Bilek K., Brambs C. E. Prognostic relevance of low-grade versus high-grade FIGO IB1 squamous cell uterine cervical carcinomas. None. 2019;145:457-462|https://www.ncbi.nlm.nih.gov/pubmed/30603900|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Letztautor|Brambs C. E., Hohn A. K., Hentschel B., Fischer U., Bilek K., Horn L. C. The Prognostic Impact of Grading in FIGO IB and IIB Squamous Cell Cervical Carcinomas. None. 2019;79:198-204|https://www.ncbi.nlm.nih.gov/pubmed/30792550|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Mayr D., Brambs C. E., Einenkel J., Sandig I., Schierle K. [Grading of gynecological tumors : Current aspects]. None. 2016;37:337-51|https://www.ncbi.nlm.nih.gov/pubmed/27379622|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Hentschel B., Fischer U., Peter D., Bilek K. Detection of micrometastases in pelvic lymph nodes in patients with carcinoma of the cervix uteri using step sectioning: Frequency, topographic distribution and prognostic impact. . 2008;111:276-81|https://www.ncbi.nlm.nih.gov/pubmed/18722005|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Standard|McCluggage W. G., Judge M. J., Alvarado-Cabrero I., Duggan M. A., Horn L. C., Hui P., et al. Data Set for the Reporting of Carcinomas of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR). None. 2018;37:205-228|https://www.ncbi.nlm.nih.gov/pubmed/28700433|2340
Zervixkarzinom|"2.2"|2022|Denschlag, Dominik|Hintergrund|||Erstautor|Denschlag D., Woll J., Schneider A. Stellenwert des Sentinel-Lymphknoten-Konzepts bei uterinen Karzinomen. None. 2011;52:46-51||2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Letztautor|Mehlhorn G., Lanowska M., Thiel F., Köhler C., Beckmann M.W. GebFra-Refresher: Organerhaltende operative Methoden im Bereich der Cervix uteri. None. 2008;68:R121-R144||2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Standard|Koch M. C., Hautmann S., Thiel F., Beckmann M. W., Mehlhorn G. Ist die Messerkonisation mit anschließender Sturmdorfnaht Out? Gilt die Meinung: „Eine Messerkonisation macht heute kein Mensch mehr!?“ Wie ist der Stellenwert der Laserkonisation? Wie ist es mit der Bewertung der Schnittränder beim Lasern? Ist nicht beim Lasern der Aufwand viel zu hoch und teuer?. None. 2014;None:None||2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Höhn A. K. Processing and Histopathological Workup of Hysterectomy Specimens. None. 2017;None:None|https://link.springer.com/chapter/10.1007/978-3-319-22497-8_18|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Handzel R., Borte G., Siebolts U., Haak A., Brambs C. E. Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma. None. 2019;145:2573-2582|https://www.ncbi.nlm.nih.gov/pubmed/31385027|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Brambs C. E., Handzel R., Lax S., Sandig I., Schmidt D., et al. [Cervical cancer : Update on morphology]. None. 2016;37:542-548|https://www.ncbi.nlm.nih.gov/pubmed/27766382|2340
Zervixkarzinom|"2.2"|2022|Schmittel, Alexander|Hintergrund|||Standard|Marnitz S., Kohler C., Oppelt P., Schmittel A., Favero G., Hasenbein K., et al. Cisplatin application in pregnancy: first in vivo analysis of 7 patients. None. 2010;79:72-7|https://www.ncbi.nlm.nih.gov/pubmed/21071993|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Bilek K., Fischer U., Einenkel J., Hentschel B. A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer. None. 2014;134:42-6|https://www.ncbi.nlm.nih.gov/pubmed/24768850|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Standard|Stolnicu S., Boros M., Segura S., Horn L. C., Parra-Herran C., Oliva E., et al. Invasive Stratified Mucinous Carcinoma (iSMC) of the Cervix Often Presents With High-risk Features That Are Determinants of Poor Outcome: An International Multicenter Study. None. 2020;None:None||2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann M. W., Brucker C., Hanf V., Rauh C., Bani M. R., Knob S., et al. Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. None. 2011;34:362-7|https://www.ncbi.nlm.nih.gov/pubmed/21734422|2340
Zervixkarzinom|"2.2"|2022|Wittekind, Christian|Hintergrund|||Erstautor|Wittekind C. TNM Klassifikation maligner Tumoren - Korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den Jahren 2017 bis 2019. None. 2020;None:None||2340
Zervixkarzinom|"2.2"|2022|Grimm, Christoph|Hintergrund|||Standard|Kranawetter M., Rohrich S., Mullauer L., Obermair H., Reinthaller A., Grimm C., et al. Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data. None. 2018;28:1196-1202|https://www.ncbi.nlm.nih.gov/pubmed/29787422|2340
Zervixkarzinom|"2.2"|2022|Hillemanns, Peter|Hintergrund|||Standard|Lecuru F. R., McCormack M., Hillemanns P., Anota A., Leitao M., Mathevet P., et al. SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study. None. 2019;29:829-834|https://www.ncbi.nlm.nih.gov/pubmed/30898938|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Standard|Hockel M., Horn L. C., Manthey N., Braumann U. D., Wolf U., Teichmann G., et al. Resection of the embryologically defined uterovaginal (Mullerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis. None. 2009;10:683-92||2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Letztautor|Hockel M., Hentschel B., Horn L. C. Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis. None. 2014;15:445-56|https://www.ncbi.nlm.nih.gov/pubmed/24656439|2340
Zervixkarzinom|"2.2"|2022|Hillemanns, Peter|Hintergrund|||Erstautor|Hillemanns P., Brucker S., Holthaus B., Kimmig R., Lampe B., Runnebaum I., et al. Updated Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO) and the Gynecological Endoscopy Working Group (AGE) of the German Society of Gynecology and Obstetrics (DGGG) on the Randomized Study Comparing Minimally Invasive with Abdominal Radical Hysterectomy for Early-stage Cervical Cancer (LACC). None. 2019;79:145-147|https://www.ncbi.nlm.nih.gov/pubmed/30792544|2340
Zervixkarzinom|"2.2"|2022|Mallmann, Peter|Hintergrund|||Standard|Kohler C., Hertel H., Herrmann J., Marnitz S., Mallmann P., Favero G., et al. Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff - a multicenter analysis. None. 2019;29:845-850|https://www.ncbi.nlm.nih.gov/pubmed/31155516|2340
Zervixkarzinom|"2.2"|2022|Mallmann, Peter|Hintergrund|||Standard|Marnitz S., Martus P., Kohler C., Stromberger C., Asse E., Mallmann P., et al. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group. None. 2016;94:243-53|https://www.ncbi.nlm.nih.gov/pubmed/26853333|2340
Zervixkarzinom|"2.2"|2022|Stromberger, Carmen|Hintergrund|||Standard|Marnitz S., Martus P., Kohler C., Stromberger C., Asse E., Mallmann P., et al. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group. None. 2016;94:243-53|https://www.ncbi.nlm.nih.gov/pubmed/26853333|2340
Zervixkarzinom|"2.2"|2022|Sturdza, Alina|Hintergrund|||Standard|Tanderup K., Fokdal L. U., Sturdza A., Haie-Meder C., Mazeron R., van Limbergen E., et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. None. 2016;120:441-446|https://www.ncbi.nlm.nih.gov/pubmed/27350396|2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann Matthias W., Jud S.M. Gynäkologische Krebszentren- Kompetenzbündelung zur Qualitätsbesserung. None. 2009;3:71-74||2340
Zervixkarzinom|"2.2"|2022|Hillemanns, Peter|Hintergrund|||Erstautor|Hillemanns Peter. HPV-Impfstoff der Zweiten Generation: Gegen neun Virustypen gerichtet. None. 2013;110:2479-80|https://www.aerzteblatt.de/int/article.asp?id=152479|2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann Matthias W., Adler Guido, Albers Peter, Bruns Johannes, Ehninger Gerhard, Hauschild Axel, et al. Dreistufenmodell optimiert Behandlung unter Kostendeckung. None. 2007;104:3004-3009||2340
Zervixkarzinom|"2.2"|2022|Hillemanns, Peter|Hintergrund|||Letztautor|Geyer S., Jaunzeme J., Hillemanns P. Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data. None. 2014;None:623–629|http://www.ncbi.nlm.nih.gov/pubmed/25138124|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Standard|Hockel M., Horn L. C., Einenkel J. (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy. . 2012;127:297-302|https://www.ncbi.nlm.nih.gov/pubmed/22864112|2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann M. W., Gitsch G., Emons G., Berg D., Ortmann O., Jonat W., et al. Der neue Schwerpunkt Gynäkologische Onkologie: nationale und internationale Chance?. None. 2006;66:123-127||2340
Zervixkarzinom|"2.2"|2022|Ortmann, Olaf|Hintergrund|||Standard|Beckmann M. W., Gitsch G., Emons G., Berg D., Ortmann O., Jonat W., et al. Der neue Schwerpunkt Gynäkologische Onkologie: nationale und internationale Chance?. None. 2006;66:123-127||2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Standard|Fleisch M. C., Pantke P., Beckmann M. W., Schnuerch H. G., Ackermann R., Grimm M. O., et al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. None. 2007;95:476-84||2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann M. W. Frauenarzt/-ärztin der Zukunft: müssen die Kliniken neu strukturiert werden?. None. 2010;43:748-756||2340
Zervixkarzinom|"2.2"|2022|Sturdza, Alina|Hintergrund|||Standard|Fokdal L., Sturdza A., Mazeron R., Haie-Meder C., Tan L. T., Gillham C., et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. None. 2016;120:434-440|https://www.ncbi.nlm.nih.gov/pubmed/27113795|2340
Zervixkarzinom|"2.2"|2022|Wittekind, Christian|Hintergrund|||Erstautor|Wittekind C, Meyer HJ. TNM-Klassifikation maligner Tumoren. None. 2010;None:None||2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Standard|Van der Ven H., Liebenthron J., Beckmann M., Toth B., Korell M., Krussel J., et al. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. None. 2016;31:2031-41|https://www.ncbi.nlm.nih.gov/pubmed/27378768|2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Letztautor|Dittrich R., Hackl J., Lotz L., Hoffmann I., Beckmann M. W. Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center. None. 2015;103:462-8|https://www.ncbi.nlm.nih.gov/pubmed/25487750|2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Standard|Wesselmann S., Beckmann M. W., Winter A. The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care. None. 2014;289:7-12|https://www.ncbi.nlm.nih.gov/pubmed/24220845|2340
Zervixkarzinom|"2.2"|2022|Beckmann, Matthias W.|Hintergrund|||Erstautor|Beckmann M. W., Quaas J., Bischofberger A., Kammerle A., Lux M. P., Wesselmann S. Establishment of the Certification System "Gynaecological Dysplasia" in Germany. None. 2014;74:860-867|https://www.ncbi.nlm.nih.gov/pubmed/25278628|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Brambs C. E., Opitz S., Ulrich U. A., Hohn A. K. [The 2019 FIGO classification for cervical carcinoma-what's new?]. None. 2019;40:629-635|https://www.ncbi.nlm.nih.gov/pubmed/31612260|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Erstautor|Horn L. C., Hentschel B., Bilek K., Richter C. E., Einenkel J., Leo C. Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index. . 2006;10:140-3|https://www.ncbi.nlm.nih.gov/pubmed/16730307|2340
Zervixkarzinom|"2.2"|2022|Horn, Lars-Christian|Hintergrund|||Standard|Schmidt D., Horn L. C., Kommoss F. Neuroendocrine carcinomas of the cervix. . 2005;26:262-5|https://www.ncbi.nlm.nih.gov/pubmed/15915327|2340
Zervixkarzinom|"2.2"|2022|Wittekind, Christian|Hintergrund|||Erstautor|Wittekind C, Compton CC, Brirley J, Sobin LH. TNM Supplement. A Comentary on Uniform USe. None. 2012;None:None||2340
Maligne Ovarialtumoren|"5.1"|2022|Schmalfeldt, Barbara|Hintergrund|||Standard|Polcher M., Hauptmann S., Fotopoulou C., Schmalfeldt B., Meinhold-Heerlein I., Mustea A., et al. Should Fallopian Tubes Be Removed During Hysterectomy Procedures?- A Statement by AGO Ovar. . 2015;75:339-341|https://pubmed.ncbi.nlm.nih.gov/26028692/|736
Maligne Ovarialtumoren|"5.1"|2022|Schmalfeldt, Barbara|Hintergrund|||Standard|Polcher M., Hauptmann S., Fotopoulou C., Schmalfeldt B., Meinhold-Heerlein I., Mustea A., et al. Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO. . 2015;292:231-4|https://pubmed.ncbi.nlm.nih.gov/25914073/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Ray-Coquard I., Cibula D., Mirza M. R., Reuss A., Ricci C., Colombo N., et al. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. . 2020;146:439-448|https://pubmed.ncbi.nlm.nih.gov/31381147/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|Grabowski J. P., Harter P., Buhrmann C., Lorenz D., Hils R., Kommoss S., et al. Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. . 2012;21:31-5|https://pubmed.ncbi.nlm.nih.gov/20875732/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). . 2009;115:1234-44|https://pubmed.ncbi.nlm.nih.gov/19189349/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Hintergrund|||Letztautor|du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). . 2009;115:1234-44|https://pubmed.ncbi.nlm.nih.gov/19189349/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). . 2009;115:1234-44|https://pubmed.ncbi.nlm.nih.gov/19189349/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Hintergrund|||Standard|du Bois A., Rochon J., Pfisterer J., Hoskins W. J. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. . 2009;112:422-36|https://pubmed.ncbi.nlm.nih.gov/18990435/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|du Bois A., Reuss A., Harter P., Pujade-Lauraine E., Ray-Coquard I., Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. . 2010;28:1733-9|https://pubmed.ncbi.nlm.nih.gov/20194855/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Hintergrund|||Letztautor|du Bois A., Reuss A., Harter P., Pujade-Lauraine E., Ray-Coquard I., Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. . 2010;28:1733-9|https://pubmed.ncbi.nlm.nih.gov/20194855/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|du Bois A., Reuss A., Harter P., Pujade-Lauraine E., Ray-Coquard I., Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. . 2010;28:1733-9|https://pubmed.ncbi.nlm.nih.gov/20194855/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Erstautor|Harter P., Gnauert K., Hils R., Lehmann T. G., Fisseler-Eckhoff A., Traut A., et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. . 2007;17:1238-44|https://pubmed.ncbi.nlm.nih.gov/17433064/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Erstautor|Harter Philipp, Sehouli Jalid, Lorusso Domenica, Reuss Alexander, Vergote Ignace, Marth Christian, et al. LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. . 2017;:|https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5500|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Harter Philipp, Sehouli Jalid, Lorusso Domenica, Reuss Alexander, Vergote Ignace, Marth Christian, et al. LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. . 2017;:|https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5500|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Hintergrund|||Standard|Harter Philipp, Sehouli Jalid, Lorusso Domenica, Reuss Alexander, Vergote Ignace, Marth Christian, et al. LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. . 2017;:|https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5500|736
Maligne Ovarialtumoren|"5.1"|2022|Schmalfeldt, Barbara|Evidenzbasierte Empfehlung|A|True|Standard|Wimberger P., Wehling M., Lehmann N., Kimmig R., Schmalfeldt B., Burges A., et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). . 2010;17:1642-8|https://pubmed.ncbi.nlm.nih.gov/20165986/|736
Maligne Ovarialtumoren|"5.1"|2022|Burges, Alexander|Hintergrund|||Standard|Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). . 2007;106:69-74|https://pubmed.ncbi.nlm.nih.gov/17397910/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Hintergrund|||Standard|Perren T. J., Swart A. M., Pfisterer J., Ledermann J. A., Pujade-Lauraine E., Kristensen G., et al. A phase 3 trial of bevacizumab in ovarian cancer. . 2011;365:2484-96|https://pubmed.ncbi.nlm.nih.gov/22204725/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Evidenzbasierte Empfehlung|A|False|Standard|Perren T. J., Swart A. M., Pfisterer J., Ledermann J. A., Pujade-Lauraine E., Kristensen G., et al. A phase 3 trial of bevacizumab in ovarian cancer. . 2011;365:2484-96|https://pubmed.ncbi.nlm.nih.gov/22204725/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Hintergrund|||Standard|Oza A. M., Cook A. D., Pfisterer J., Embleton A., Ledermann J. A., Pujade-Lauraine E., et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. . 2015;16:928-36|https://pubmed.ncbi.nlm.nih.gov/26115797/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Evidenzbasierte Empfehlung|B|False|Standard|Oza A. M., Cook A. D., Pfisterer J., Embleton A., Ledermann J. A., Pujade-Lauraine E., et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. . 2015;16:928-36|https://pubmed.ncbi.nlm.nih.gov/26115797/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|du Bois A., Kristensen G., Ray-Coquard I., Reuss A., Pignata S., Colombo N., et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. . 2016;17:78-89|https://pubmed.ncbi.nlm.nih.gov/26590673/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|Fotopoulou C., Sehouli J., Mahner S., Harter P., Van Nieuwenhuysen E., Gonzalez-Martin A., et al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?. . 2018;29:1610-1613|https://pubmed.ncbi.nlm.nih.gov/29873689/|736
Maligne Ovarialtumoren|"5.1"|2022|Mahner, Sven|Hintergrund|||Standard|Fotopoulou C., Sehouli J., Mahner S., Harter P., Van Nieuwenhuysen E., Gonzalez-Martin A., et al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?. . 2018;29:1610-1613|https://pubmed.ncbi.nlm.nih.gov/29873689/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Hintergrund|||Standard|Fotopoulou C., Sehouli J., Mahner S., Harter P., Van Nieuwenhuysen E., Gonzalez-Martin A., et al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?. . 2018;29:1610-1613|https://pubmed.ncbi.nlm.nih.gov/29873689/|736
Maligne Ovarialtumoren|"5.1"|2022|Frickhofen, Norbert|Hintergrund|||Standard|Mobus V., Wandt H., Frickhofen N., Bengala C., Champion K., Kimmig R., et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. . 2007;25:4187-93|https://pubmed.ncbi.nlm.nih.gov/17698804/|736
Maligne Ovarialtumoren|"5.1"|2022|Frickhofen, Norbert|Evidenzbasierte Empfehlung|B|False|Standard|Mobus V., Wandt H., Frickhofen N., Bengala C., Champion K., Kimmig R., et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. . 2007;25:4187-93|https://pubmed.ncbi.nlm.nih.gov/17698804/|736
Maligne Ovarialtumoren|"5.1"|2022|Burges, Alexander|Evidenzbasierte Empfehlung|A|True|Standard|Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). . 2007;106:69-74|https://pubmed.ncbi.nlm.nih.gov/17397910/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Evidenzbasierte Empfehlung|A|True|Standard|du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). . 2009;115:1234-44|https://pubmed.ncbi.nlm.nih.gov/19189349/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Evidenzbasierte Empfehlung|A|True|Letztautor|du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). . 2009;115:1234-44|https://pubmed.ncbi.nlm.nih.gov/19189349/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Evidenzbasierte Empfehlung|A|True|Standard|du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). . 2009;115:1234-44|https://pubmed.ncbi.nlm.nih.gov/19189349/|736
Maligne Ovarialtumoren|"5.1"|2022|Burges, Alexander|Hintergrund|||Standard|van Dalen A., Favier J., Burges A., Hasholzner U., de Bruijn H. W., Dobler-Girdziunaite D., et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. . 2000;79:444-50|https://pubmed.ncbi.nlm.nih.gov/11104617/|736
Maligne Ovarialtumoren|"5.1"|2022|Arnold, Norbert|Hintergrund|||Standard|Riener E. K., Arnold N., Kommoss F., Lauinger S., Pfisterer J. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. . 2004;95:89-94|https://pubmed.ncbi.nlm.nih.gov/15385115/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Hintergrund|||Letztautor|Riener E. K., Arnold N., Kommoss F., Lauinger S., Pfisterer J. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. . 2004;95:89-94|https://pubmed.ncbi.nlm.nih.gov/15385115/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|Kommoss S., Schmidt D., Kommoss F., Hedderich J., Harter P., Pfisterer J., et al. Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). . 2009;454:249-56|https://pubmed.ncbi.nlm.nih.gov/19172293/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Mackay H. J., Brady M. F., Oza A. M., Reuss A., Pujade-Lauraine E., Swart A. M., et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. . 2010;20:945-52|https://pubmed.ncbi.nlm.nih.gov/20683400/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Meier W., du Bois A., Reuss A., Kuhn W., Olbricht S., Gropp M., et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). . 2009;114:199-205|https://pubmed.ncbi.nlm.nih.gov/19446314/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Evidenzbasiertes Statement||False|Standard|Meier W., du Bois A., Reuss A., Kuhn W., Olbricht S., Gropp M., et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). . 2009;114:199-205|https://pubmed.ncbi.nlm.nih.gov/19446314/|736
Maligne Ovarialtumoren|"5.1"|2022|Emons, Günter|Evidenzbasiertes Statement||False|Standard|du Bois A., Meier W., Luck H. J., Emons G., Moebus V., Schroeder W., et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. . 2002;:|https://pubmed.ncbi.nlm.nih.gov/11886002/|736
Maligne Ovarialtumoren|"5.1"|2022|Emons, Günter|Hintergrund|||Standard|du Bois A., Meier W., Luck H. J., Emons G., Moebus V., Schroeder W., et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. . 2002;:|https://pubmed.ncbi.nlm.nih.gov/11886002/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Hintergrund|||Erstautor|Sehouli J., Stengel D., Oskay-Oezcelik G., Zeimet A. G., Sommer H., Klare P., et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. . 2008;26:3176-82|https://pubmed.ncbi.nlm.nih.gov/18591555/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Evidenzbasiertes Statement||False|Erstautor|Sehouli J., Stengel D., Oskay-Oezcelik G., Zeimet A. G., Sommer H., Klare P., et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. . 2008;26:3176-82|https://pubmed.ncbi.nlm.nih.gov/18591555/|736
Maligne Ovarialtumoren|"5.1"|2022|Hilpert, Felix|Evidenzbasierte Empfehlung|0|False|Standard|Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. . 2014;32:1302-8|https://pubmed.ncbi.nlm.nih.gov/24637997/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Evidenzbasierte Empfehlung|0|False|Standard|Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. . 2014;32:1302-8|https://pubmed.ncbi.nlm.nih.gov/24637997/|736
Maligne Ovarialtumoren|"5.1"|2022|Hilpert, Felix|Hintergrund|||Standard|Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). . 2012;30:|https://ascopubs.org/doi/abs/10.1200/jco.2012.30.18_suppl.lba5002|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). . 2012;30:|https://ascopubs.org/doi/abs/10.1200/jco.2012.30.18_suppl.lba5002|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Hintergrund|||Erstautor|Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A. J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. . 2006;24:4699-707|https://pubmed.ncbi.nlm.nih.gov/16966687/|736
Maligne Ovarialtumoren|"5.1"|2022|Wagner, Uwe|Hintergrund|||Standard|Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., Gebski V., Heywood M., Vasey P. A., et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. . 2010;28:3323-9|https://pubmed.ncbi.nlm.nih.gov/20498395/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|Sehouli J., Chekerov R., Reinthaller A., Richter R., Gonzalez-Martin A., Harter P., et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). . 2016;27:2236-2241|https://pubmed.ncbi.nlm.nih.gov/27789470/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Hintergrund|||Erstautor|Sehouli J., Chekerov R., Reinthaller A., Richter R., Gonzalez-Martin A., Harter P., et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). . 2016;27:2236-2241|https://pubmed.ncbi.nlm.nih.gov/27789470/|736
Maligne Ovarialtumoren|"5.1"|2022|Wagner, Uwe|Hintergrund|||Standard|Pignata S., Scambia G., Bologna A., Signoriello S., Vergote I. B., Wagner U., et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. . 2017;:JCO2017734293|https://pubmed.ncbi.nlm.nih.gov/28825853/|736
Maligne Ovarialtumoren|"5.1"|2022|Burges, Alexander|Evidenzbasiertes Statement||False|Standard|Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. . 2006;:|https://pubmed.ncbi.nlm.nih.gov/17009163/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Evidenzbasiertes Statement||False|Erstautor|Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. . 2006;:|https://pubmed.ncbi.nlm.nih.gov/17009163/|736
Maligne Ovarialtumoren|"5.1"|2022|Hasenburg, Annette|Evidenzbasiertes Statement||False|Standard|Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. . 2006;:|https://pubmed.ncbi.nlm.nih.gov/17009163/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Hintergrund|||Erstautor|Sehouli J., Richter R., Braicu E. I., Buhling K. J., Bahra M., Neuhaus P., et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. . 2010;102:656-62|https://pubmed.ncbi.nlm.nih.gov/20734422/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Evidenzbasiertes Statement||False|Erstautor|Sehouli J., Richter R., Braicu E. I., Buhling K. J., Bahra M., Neuhaus P., et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. . 2010;102:656-62|https://pubmed.ncbi.nlm.nih.gov/20734422/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Evidenzbasiertes Statement||False|Erstautor|Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. . 2011;21:289-95|https://pubmed.ncbi.nlm.nih.gov/21270612/|736
Maligne Ovarialtumoren|"5.1"|2022|Hasenburg, Annette|Evidenzbasiertes Statement||False|Standard|Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. . 2011;21:289-95|https://pubmed.ncbi.nlm.nih.gov/21270612/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Evidenzbasiertes Statement||False|Standard|Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. . 2011;21:289-95|https://pubmed.ncbi.nlm.nih.gov/21270612/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Evidenzbasiertes Statement||False|Standard|Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. . 2011;21:289-95|https://pubmed.ncbi.nlm.nih.gov/21270612/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Erstautor|Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. . 2011;21:289-95|https://pubmed.ncbi.nlm.nih.gov/21270612/|736
Maligne Ovarialtumoren|"5.1"|2022|Hasenburg, Annette|Hintergrund|||Standard|Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. . 2011;21:289-95|https://pubmed.ncbi.nlm.nih.gov/21270612/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. . 2011;21:289-95|https://pubmed.ncbi.nlm.nih.gov/21270612/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Hintergrund|||Standard|Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. . 2011;21:289-95|https://pubmed.ncbi.nlm.nih.gov/21270612/|736
Maligne Ovarialtumoren|"5.1"|2022|Burges, Alexander|Hintergrund|||Standard|Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. . 2006;13:1702-10|https://pubmed.ncbi.nlm.nih.gov/17009163/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Erstautor|Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. . 2006;13:1702-10|https://pubmed.ncbi.nlm.nih.gov/17009163/|736
Maligne Ovarialtumoren|"5.1"|2022|Hasenburg, Annette|Hintergrund|||Standard|Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. . 2006;13:1702-10|https://pubmed.ncbi.nlm.nih.gov/17009163/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Du Bois Andreas, Vergote Ignace, Ferron Gwenael, Reuss Alexander, Meier Werner, Greggi Stefano, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. None. 2017;None:None||736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Evidenzbasierte Empfehlung|B|False|Standard|Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. . 2012;366:1382-92|https://pubmed.ncbi.nlm.nih.gov/22452356/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. . 2012;366:1382-92|https://pubmed.ncbi.nlm.nih.gov/22452356/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Evidenzbasierte Empfehlung|B|False|Standard|Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. . 2014;15:852-61|https://pubmed.ncbi.nlm.nih.gov/24882434/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. . 2014;15:852-61|https://pubmed.ncbi.nlm.nih.gov/24882434/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Evidenzbasierte Empfehlung|B|False|Standard|Ledermann J. A., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. . 2016;17:1579-1589|https://pubmed.ncbi.nlm.nih.gov/27617661/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Standard|Ledermann J. A., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. . 2016;17:1579-1589|https://pubmed.ncbi.nlm.nih.gov/27617661/|736
Maligne Ovarialtumoren|"5.1"|2022|Mahner, Sven|Hintergrund|||Standard|Mirza M. R., Monk B. J., Herrstedt J., Oza A. M., Mahner S., Redondo A., et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. . 2016;375:2154-2164|https://pubmed.ncbi.nlm.nih.gov/27717299/|736
Maligne Ovarialtumoren|"5.1"|2022|Mahner, Sven|Evidenzbasierte Empfehlung|B|False|Standard|Mirza M. R., Monk B. J., Herrstedt J., Oza A. M., Mahner S., Redondo A., et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. . 2016;375:2154-2164|https://pubmed.ncbi.nlm.nih.gov/27717299/|736
Maligne Ovarialtumoren|"5.1"|2022|Weis, Joachim|Hintergrund|||Letztautor|Herschbach P., Weis J. Screeningverfahren in der Psychoonkologie: Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten, 2. Auflage. . 2010;:|https://www.dapo-ev.de/wp-content/uploads/2017/04/pso_broschuere2.pdf|736
Maligne Ovarialtumoren|"5.1"|2022|Mahner, Sven|Hintergrund|||Standard|Trillsch F., Mahner S., Woelber L., Vettorazzi E., Reuss A., Ewald-Riegler N., et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. . 2014;25:1320-7|https://pubmed.ncbi.nlm.nih.gov/24618151/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Trillsch F., Mahner S., Woelber L., Vettorazzi E., Reuss A., Ewald-Riegler N., et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. . 2014;25:1320-7|https://pubmed.ncbi.nlm.nih.gov/24618151/|736
Maligne Ovarialtumoren|"5.1"|2022|Mahner, Sven|Evidenzbasierte Empfehlung|A|True|Standard|Trillsch F., Mahner S., Woelber L., Vettorazzi E., Reuss A., Ewald-Riegler N., et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. . 2014;25:1320-7|https://pubmed.ncbi.nlm.nih.gov/24618151/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Evidenzbasierte Empfehlung|A|True|Standard|Trillsch F., Mahner S., Woelber L., Vettorazzi E., Reuss A., Ewald-Riegler N., et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. . 2014;25:1320-7|https://pubmed.ncbi.nlm.nih.gov/24618151/|736
Maligne Ovarialtumoren|"5.1"|2022|Mahner, Sven|Hintergrund|||Standard|du Bois A., Ewald-Riegler N., de Gregorio N., Reuss A., Mahner S., Fotopoulou C., et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. . 2013;49:1905-14|https://pubmed.ncbi.nlm.nih.gov/23490647/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|du Bois A., Ewald-Riegler N., de Gregorio N., Reuss A., Mahner S., Fotopoulou C., et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. . 2013;49:1905-14|https://pubmed.ncbi.nlm.nih.gov/23490647/|736
Maligne Ovarialtumoren|"5.1"|2022|Mahner, Sven|Evidenzbasierte Empfehlung|A|False|Standard|du Bois A., Ewald-Riegler N., de Gregorio N., Reuss A., Mahner S., Fotopoulou C., et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. . 2013;49:1905-14|https://pubmed.ncbi.nlm.nih.gov/23490647/|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Evidenzbasierte Empfehlung|A|False|Standard|du Bois A., Ewald-Riegler N., de Gregorio N., Reuss A., Mahner S., Fotopoulou C., et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. . 2013;49:1905-14|https://pubmed.ncbi.nlm.nih.gov/23490647/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Hintergrund|||Erstautor|Sehouli J., Drescher F. S., Mustea A., Elling D., Friedmann W., Kuhn W., et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. . 2004;24:1223-9|https://pubmed.ncbi.nlm.nih.gov/15154651/|736
Maligne Ovarialtumoren|"5.1"|2022|Sehouli, Jalid|Evidenzbasierte Empfehlung|A|False|Erstautor|Sehouli J., Drescher F. S., Mustea A., Elling D., Friedmann W., Kuhn W., et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. . 2004;24:1223-9|https://pubmed.ncbi.nlm.nih.gov/15154651/|736
Maligne Ovarialtumoren|"5.1"|2022|Calaminus, Gabriele|Hintergrund|||Standard|Gobel U., Haas R. J., Calaminus G., Bamberg M., Bokkerink E. B., Engert J., et al. Treatment of germ cell tumors in children: results of European trials for testicular and non-testicular primary sites. . 1990;10:89-98|https://pubmed.ncbi.nlm.nih.gov/1694438/|736
Maligne Ovarialtumoren|"5.1"|2022|Calaminus, Gabriele|Evidenzbasiertes Statement||False|Standard|Gobel U., Haas R. J., Calaminus G., Bamberg M., Bokkerink E. B., Engert J., et al. Treatment of germ cell tumors in children: results of European trials for testicular and non-testicular primary sites. . 1990;10:89-98|https://pubmed.ncbi.nlm.nih.gov/1694438/|736
Maligne Ovarialtumoren|"5.1"|2022|Pfisterer, Jacobus|Evidenzbasierte Empfehlung|A|True|Standard|du Bois A., Rochon J., Pfisterer J., Hoskins W. J. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. . 2009;112:422-36|https://pubmed.ncbi.nlm.nih.gov/18990435/|736
Maligne Ovarialtumoren|"5.1"|2022|Weis, Joachim|Hintergrund|||Erstautor|Weis J., Giesler J. M. Subjective dimensions of patient competence: relationships with selected healthcare usage behaviors and general features of self-rated competence. . 2008;73:511-8|https://pubmed.ncbi.nlm.nih.gov/18952394/|736
Maligne Ovarialtumoren|"5.1"|2022|Wagner, Uwe|Hintergrund|||Standard|Albert U. S., Koller M., Wagner U., Schulz K. D. Survival chances and psychological aspects of quality of life in patients with localized early stage breast cancer. . 2004;53 Suppl 2:S136-41|https://pubmed.ncbi.nlm.nih.gov/15338065/|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Evidenzbasierte Empfehlung|A|True|Erstautor|Harter P., Hauke J., Heitz F., Reuss A., Kommoss S., Marme F., et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). . 2017;12:e0186043|https://www.ncbi.nlm.nih.gov/pubmed/29053726|736
Maligne Ovarialtumoren|"5.1"|2022|Harter, Philipp|Hintergrund|||Erstautor|Harter P., Hauke J., Heitz F., Reuss A., Kommoss S., Marme F., et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). . 2017;12:e0186043|https://www.ncbi.nlm.nih.gov/pubmed/29053726|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Evidenzbasierte Empfehlung|A|True|Standard|Harter P., Hauke J., Heitz F., Reuss A., Kommoss S., Marme F., et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). . 2017;12:e0186043|https://www.ncbi.nlm.nih.gov/pubmed/29053726|736
Maligne Ovarialtumoren|"5.1"|2022|Reuss, Alexander|Hintergrund|||Standard|Harter P., Hauke J., Heitz F., Reuss A., Kommoss S., Marme F., et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). . 2017;12:e0186043|https://www.ncbi.nlm.nih.gov/pubmed/29053726|736
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Evidenzbasierte Empfehlung|A|True|Standard|Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, et al. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory . JTO Clin Res Rep. 2022;3 (9):100385|https://pubmed.ncbi.nlm.nih.gov/36065449/|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Hintergrund|||Standard|Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, et al. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory . JTO Clin Res Rep. 2022;3 (9):100385|https://pubmed.ncbi.nlm.nih.gov/36065449/|2269
Lungenkarzinom|"2.1"|2022|Griesinger, Frank|Evidenzbasierte Empfehlung|A|False|Erstautor|Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; ():|https://pubmed.ncbi.nlm.nih.gov/35973665/|2269
Lungenkarzinom|"2.1"|2022|Griesinger, Frank|Hintergrund|||Erstautor|Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; ():|https://pubmed.ncbi.nlm.nih.gov/35973665/|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Evidenzbasierte Empfehlung|A|False|Standard|Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; ():|https://pubmed.ncbi.nlm.nih.gov/35973665/|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Standard|Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; ():|https://pubmed.ncbi.nlm.nih.gov/35973665/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Standard|Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G, Reck M, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135 ():188-195|https://pubmed.ncbi.nlm.nih.gov/31446994/|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Erstautor|Thomas M, Rübe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9 (7):636-48|https://pubmed.ncbi.nlm.nih.gov/18583190/|2269
Lungenkarzinom|"2.1"|2022|Junker, Klaus|Evidenzbasierte Empfehlung|A|True|Erstautor|Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. 2001;120 (5):1584-91|https://pubmed.ncbi.nlm.nih.gov/11713138/|2269
Lungenkarzinom|"2.1"|2022|Junker, Klaus|Hintergrund|||Erstautor|Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. 2001;120 (5):1584-91|https://pubmed.ncbi.nlm.nih.gov/11713138/|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Evidenzbasierte Empfehlung|A|True|Letztautor|Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. 2001;120 (5):1584-91|https://pubmed.ncbi.nlm.nih.gov/11713138/|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Letztautor|Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest. 2001;120 (5):1584-91|https://pubmed.ncbi.nlm.nih.gov/11713138/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|True|Erstautor|Eberhardt WE, Stamatis G, Stuschke M. Surgery in stage III non-small-cell lung cancer. Lancet. 2009;374 (9687):359-60|https://pubmed.ncbi.nlm.nih.gov/19632715/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Erstautor|Eberhardt WE, Stamatis G, Stuschke M. Surgery in stage III non-small-cell lung cancer. Lancet. 2009;374 (9687):359-60|https://pubmed.ncbi.nlm.nih.gov/19632715/|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Evidenzbasierte Empfehlung|A|True|Letztautor|Eberhardt WE, Stamatis G, Stuschke M. Surgery in stage III non-small-cell lung cancer. Lancet. 2009;374 (9687):359-60|https://pubmed.ncbi.nlm.nih.gov/19632715/|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Hintergrund|||Letztautor|Eberhardt WE, Stamatis G, Stuschke M. Surgery in stage III non-small-cell lung cancer. Lancet. 2009;374 (9687):359-60|https://pubmed.ncbi.nlm.nih.gov/19632715/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|True|Standard|Pöttgen C, Eberhardt W, Bildat S, Stüben G, Stamatis G, Hillejan L, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol. 2002;13 (3):403-11|https://pubmed.ncbi.nlm.nih.gov/11996471/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Pöttgen C, Eberhardt W, Bildat S, Stüben G, Stamatis G, Hillejan L, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol. 2002;13 (3):403-11|https://pubmed.ncbi.nlm.nih.gov/11996471/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|True|Standard|Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6 ():vi89-98|https://pubmed.ncbi.nlm.nih.gov/23860613/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6 ():vi89-98|https://pubmed.ncbi.nlm.nih.gov/23860613/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|True|Standard|Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8 (25):41670-41678|https://pubmed.ncbi.nlm.nih.gov/28415831/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8 (25):41670-41678|https://pubmed.ncbi.nlm.nih.gov/28415831/|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Evidenzbasierte Empfehlung|A|True|Letztautor|Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8 (25):41670-41678|https://pubmed.ncbi.nlm.nih.gov/28415831/|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Hintergrund|||Letztautor|Pöttgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8 (25):41670-41678|https://pubmed.ncbi.nlm.nih.gov/28415831/|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Evidenzbasierte Empfehlung|0|False|Standard|Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, et al. Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. BMC Cancer. 2015;15 ():363|https://pubmed.ncbi.nlm.nih.gov/25943191/|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Hintergrund|||Standard|Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, et al. Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors. BMC Cancer. 2015;15 ():363|https://pubmed.ncbi.nlm.nih.gov/25943191/|2269
Lungenkarzinom|"2.1"|2022|Flentje, Michael|Konsensbasierte Empfehlung|A|True|Erstautor|Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/|2269
Lungenkarzinom|"2.1"|2022|Flentje, Michael|Hintergrund|||Erstautor|Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Konsensbasierte Empfehlung|A|True|Standard|Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Hintergrund|||Standard|Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/|2269
Lungenkarzinom|"2.1"|2022|Kollmeier, Jens|Konsensbasierte Empfehlung|A|True|Standard|Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/|2269
Lungenkarzinom|"2.1"|2022|Kollmeier, Jens|Hintergrund|||Standard|Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192 (4):216-22|https://pubmed.ncbi.nlm.nih.gov/26809652/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Konsensbasierte Empfehlung|A|True|Erstautor|Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21 (4):581-592|https://pubmed.ncbi.nlm.nih.gov/32171429/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Hintergrund|||Erstautor|Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21 (4):581-592|https://pubmed.ncbi.nlm.nih.gov/32171429/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Evidenzbasierte Empfehlung|B|False|Erstautor|Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018;127 (1):1-5|https://pubmed.ncbi.nlm.nih.gov/29605476/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Hintergrund|||Erstautor|Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018;127 (1):1-5|https://pubmed.ncbi.nlm.nih.gov/29605476/|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Evidenzbasierte Empfehlung|B|False|Standard|Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280 ():163-175|https://pubmed.ncbi.nlm.nih.gov/30661849/|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Hintergrund|||Standard|Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280 ():163-175|https://pubmed.ncbi.nlm.nih.gov/30661849/|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Evidenzbasierte Empfehlung|A|True|Erstautor|Huber RM, Reck M, Thomas M. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. Eur Respir J. 2013;42 (4):1119-33|https://pubmed.ncbi.nlm.nih.gov/23429914/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Evidenzbasierte Empfehlung|A|True|Standard|Huber RM, Reck M, Thomas M. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. Eur Respir J. 2013;42 (4):1119-33|https://pubmed.ncbi.nlm.nih.gov/23429914/|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Evidenzbasierte Empfehlung|A|True|Letztautor|Huber RM, Reck M, Thomas M. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. Eur Respir J. 2013;42 (4):1119-33|https://pubmed.ncbi.nlm.nih.gov/23429914/|2269
Lungenkarzinom|"2.1"|2022|Guckenberger, Matthias|Hintergrund|||Standard|Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer. 2019;133 ():83-87|https://pubmed.ncbi.nlm.nih.gov/31200833/|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Standard|Haun MW, Estel S, Rücker G, Friederich HC, Villalobos M, Thomas M, et al. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev. 2017;6 ():CD011129|https://pubmed.ncbi.nlm.nih.gov/28603881/|2269
Lungenkarzinom|"2.1"|2022|Kraywinkel, Klaus|Hintergrund|||Erstautor|Kraywinkel Klaus, Barnes Benjamin. Epidemiologie des kleinzelligen Lungenkarzinoms in Deutschland. None. 2017/4;23:334||2269
Lungenkarzinom|"2.1"|2022|Flentje, Michael|Hintergrund|||Standard|Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/|2269
Lungenkarzinom|"2.1"|2022|Griesinger, Frank|Hintergrund|||Standard|Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Standard|Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65 (8):e51-75|https://pubmed.ncbi.nlm.nih.gov/21830177/|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Evidenzbasierte Empfehlung|A|False|Standard|Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with . N Engl J Med. 2021;384 (25):2371-2381|https://pubmed.ncbi.nlm.nih.gov/34096690/|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Hintergrund|||Standard|Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with . N Engl J Med. 2021;384 (25):2371-2381|https://pubmed.ncbi.nlm.nih.gov/34096690/|2269
Lungenkarzinom|"2.1"|2022|Reinmuth, Niels|Evidenzbasierte Empfehlung|A|False|Standard|Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383 (14):1328-1339|https://pubmed.ncbi.nlm.nih.gov/32997907/|2269
Lungenkarzinom|"2.1"|2022|Reinmuth, Niels|Hintergrund|||Standard|Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383 (14):1328-1339|https://pubmed.ncbi.nlm.nih.gov/32997907/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|True|Erstautor|Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33 (35):4194-201|https://pubmed.ncbi.nlm.nih.gov/26527789/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Erstautor|Eberhardt WE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33 (35):4194-201|https://pubmed.ncbi.nlm.nih.gov/26527789/|2269
Lungenkarzinom|"2.1"|2022|Sebastian, Martin|Evidenzbasierte Empfehlung|A|False|Standard|Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/|2269
Lungenkarzinom|"2.1"|2022|Sebastian, Martin|Hintergrund|||Standard|Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol. 2019;14 (7):1266-1276|https://pubmed.ncbi.nlm.nih.gov/30978502/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Wiesweg M, Eberhardt WEE, Reis H, Ting S, Savvidou N, Skiba C, et al. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. J Thorac Oncol. 2017;12 (1):54-64|https://pubmed.ncbi.nlm.nih.gov/27575422/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M, Wehler T, Orlandi F, Nogami N, Barone C, Moro-Sibilot D, et al. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38 (22):2530-2542|https://pubmed.ncbi.nlm.nih.gov/32459597/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021; ():JCO2100174|https://pubmed.ncbi.nlm.nih.gov/33872070/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Standard|Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376 (25):2415-2426|https://pubmed.ncbi.nlm.nih.gov/28636851/|2269
Lungenkarzinom|"2.1"|2022|Guckenberger, Matthias|Evidenzbasierte Empfehlung|A|False|Erstautor|Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190 (1):26-33|https://pubmed.ncbi.nlm.nih.gov/24052011/|2269
Lungenkarzinom|"2.1"|2022|Guckenberger, Matthias|Hintergrund|||Erstautor|Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190 (1):26-33|https://pubmed.ncbi.nlm.nih.gov/24052011/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Evidenzbasierte Empfehlung|A|False|Standard|Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190 (1):26-33|https://pubmed.ncbi.nlm.nih.gov/24052011/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Hintergrund|||Standard|Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190 (1):26-33|https://pubmed.ncbi.nlm.nih.gov/24052011/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Evidenzbasierte Empfehlung|B|False|Standard|De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Péchoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124 (1):1-10|https://pubmed.ncbi.nlm.nih.gov/28666551/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Hintergrund|||Standard|De Ruysscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Péchoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017;124 (1):1-10|https://pubmed.ncbi.nlm.nih.gov/28666551/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, et al. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 2018;102 ():23-30|https://pubmed.ncbi.nlm.nih.gov/30103096/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Evidenzbasierte Empfehlung|A|False|Erstautor|Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019;37 (7):537-546|https://pubmed.ncbi.nlm.nih.gov/30620668/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Evidenzbasierte Empfehlung|A|False|Standard|De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28 (36):5301-10|https://pubmed.ncbi.nlm.nih.gov/21079134/|2269
Lungenkarzinom|"2.1"|2022|Nestle, Ursula|Hintergrund|||Standard|De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010;28 (36):5301-10|https://pubmed.ncbi.nlm.nih.gov/21079134/|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Evidenzbasierte Empfehlung|B|False|Standard|Palade E, Passlick B, Osei-Agyemang T, Günter J, Wiesemann S. Video-assisted vs open mediastinal lymphadenectomy for Stage I non-small-cell lung cancer: results of a prospective randomized trial. Eur J Cardiothorac Surg. 2013;44 (2):244-9; discussion 249|https://pubmed.ncbi.nlm.nih.gov/23295451/|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Hintergrund|||Standard|Palade E, Passlick B, Osei-Agyemang T, Günter J, Wiesemann S. Video-assisted vs open mediastinal lymphadenectomy for Stage I non-small-cell lung cancer: results of a prospective randomized trial. Eur J Cardiothorac Surg. 2013;44 (2):244-9; discussion 249|https://pubmed.ncbi.nlm.nih.gov/23295451/|2269
Lungenkarzinom|"2.1"|2022|Guckenberger, Matthias|Hintergrund|||Standard|Schanne DH, Heitmann J, Guckenberger M, Andratschke NHJ. Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature. Cancer Treat Rev. 2019;80 ():101892|https://pubmed.ncbi.nlm.nih.gov/31522079/|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Hintergrund|||Erstautor|De Wolf J, Bellier J, Lepimpec-Barthes F, Tronc F, Peillon C, Bernard A, et al. Exhaustive preoperative staging increases survival in resected adrenal oligometastatic non-small-cell lung cancer: a multicentre study. Eur J Cardiothorac Surg. 2017;52 (4):698-703|https://pubmed.ncbi.nlm.nih.gov/29156014/|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Hintergrund|||Standard|Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012;7 (9):1432-9|https://pubmed.ncbi.nlm.nih.gov/22895140/|2269
Lungenkarzinom|"2.1"|2022|Waller, Cornelius|Hintergrund|||Standard|Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012;7 (9):1432-9|https://pubmed.ncbi.nlm.nih.gov/22895140/|2269
Lungenkarzinom|"2.1"|2022|Reinmuth, Niels|Hintergrund|||Standard|Paz-Ares Luis G., Dvorkin Mikhail, Chen Yuanbin, Reinmuth Niels, Hotta Katsuyuki, Trukhin Dmytro, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study. None. 2020;38:9002|https://doi.org/10.1200/JCO.2020.38.15_suppl.9002|2269
Lungenkarzinom|"2.1"|2022|Reinmuth, Niels|Hintergrund|||Standard|Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394 (10212):1929-1939|https://pubmed.ncbi.nlm.nih.gov/31590988/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016;34 (31):3740-3748|https://pubmed.ncbi.nlm.nih.gov/27458307/|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Standard|Owonikoko T.K., Kim H.R., Govindan R., Ready N., Reck M., Peters S., et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. None. 2019;30:ii77|https://doi.org/10.1093/annonc/mdz094|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M., Liu S.V., Mansfield A.S., Mok T.S.K., Scherpereel A., Reinmuth N., et al. IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). None. 2019;30:v710|https://doi.org/10.1093/annonc/mdz264|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Konsensbasierte Empfehlung|A|False|Standard|De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45 (5):787-98|https://pubmed.ncbi.nlm.nih.gov/24578407/|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Hintergrund|||Standard|De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45 (5):787-98|https://pubmed.ncbi.nlm.nih.gov/24578407/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|False|Standard|Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015;33 (34):4007-14|https://pubmed.ncbi.nlm.nih.gov/26324372/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015;33 (34):4007-14|https://pubmed.ncbi.nlm.nih.gov/26324372/|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Hintergrund|||Standard|De Leyn P, Lardinois D, Van Schil P, Rami-Porta R, Passlick B, Zielinski M, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol. 2007;2 (4):357-61|https://pubmed.ncbi.nlm.nih.gov/17409811/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|True|Erstautor|Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26 (8):1573-88|https://pubmed.ncbi.nlm.nih.gov/25897013/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Erstautor|Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26 (8):1573-88|https://pubmed.ncbi.nlm.nih.gov/25897013/|2269
Lungenkarzinom|"2.1"|2022|Griesinger, Frank|Evidenzbasierte Empfehlung|A|True|Standard|Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/|2269
Lungenkarzinom|"2.1"|2022|Griesinger, Frank|Hintergrund|||Standard|Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/|2269
Lungenkarzinom|"2.1"|2022|Reinmuth, Niels|Evidenzbasierte Empfehlung|A|True|Standard|Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/|2269
Lungenkarzinom|"2.1"|2022|Reinmuth, Niels|Hintergrund|||Standard|Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/|2269
Lungenkarzinom|"2.1"|2022|Sebastian, Martin|Evidenzbasierte Empfehlung|A|True|Standard|Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/|2269
Lungenkarzinom|"2.1"|2022|Sebastian, Martin|Hintergrund|||Standard|Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/|2269
Lungenkarzinom|"2.1"|2022|Serke, Monika|Evidenzbasierte Empfehlung|A|True|Standard|Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/|2269
Lungenkarzinom|"2.1"|2022|Serke, Monika|Hintergrund|||Standard|Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, et al. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 2021;13 ():1758835921996506|https://pubmed.ncbi.nlm.nih.gov/34104223/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|True|Erstautor|Eberhardt WE, Gauler TC, Lepechoux C, Stamatis G, Bildat S, Krbek T, et al. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). Lung Cancer. 2013;82 (1):83-9|https://pubmed.ncbi.nlm.nih.gov/23957964/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Erstautor|Eberhardt WE, Gauler TC, Lepechoux C, Stamatis G, Bildat S, Krbek T, et al. 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). Lung Cancer. 2013;82 (1):83-9|https://pubmed.ncbi.nlm.nih.gov/23957964/|2269
Lungenkarzinom|"2.1"|2022|Griesinger, Frank|Evidenzbasierte Empfehlung|A|True|Standard|Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/|2269
Lungenkarzinom|"2.1"|2022|Griesinger, Frank|Hintergrund|||Standard|Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/|2269
Lungenkarzinom|"2.1"|2022|Hoffmann, Hans|Evidenzbasierte Empfehlung|A|True|Standard|Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/|2269
Lungenkarzinom|"2.1"|2022|Hoffmann, Hans|Hintergrund|||Standard|Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007;7 ():77|https://pubmed.ncbi.nlm.nih.gov/17488518/|2269
Lungenkarzinom|"2.1"|2022|Kraywinkel, Klaus|Hintergrund|||Standard|Barnes Benjamin, Kraywinkel Klaus, Nowossadeck Enno, Schönfeld Ina, Starker Anne, Wienecke Antje, et al. Bericht zum Krebsgeschehen  in Deutschland 2016. None. 2016;None:None||2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|False|Standard|Weder W, Collaud S, Eberhardt WE, Hillinger S, Welter S, Stahel R, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg. 2010;139 (6):1424-30|https://pubmed.ncbi.nlm.nih.gov/20416887/|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Weder W, Collaud S, Eberhardt WE, Hillinger S, Welter S, Stahel R, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg. 2010;139 (6):1424-30|https://pubmed.ncbi.nlm.nih.gov/20416887/|2269
Lungenkarzinom|"2.1"|2022|Guckenberger, Matthias|Evidenzbasierte Empfehlung|A|False|Standard|Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012;7 (9):1382-93|https://pubmed.ncbi.nlm.nih.gov/22843086/|2269
Lungenkarzinom|"2.1"|2022|Guckenberger, Matthias|Hintergrund|||Standard|Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012;7 (9):1382-93|https://pubmed.ncbi.nlm.nih.gov/22843086/|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Hintergrund|||Standard|Gärtner J, Daun M, Wolf J, von Bergwelt-Baildon M, Hallek M. Early Palliative Care: Pro, but Please Be Precise!. Oncol Res Treat. 2019;42 (1-2):11-18|https://pubmed.ncbi.nlm.nih.gov/30685764/|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Evidenzbasierte Empfehlung|B|False|Erstautor|Wolf M., Havemann K., Holle R., Gropp C., Drings P., Hans K., et al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. . 1987;5:1880-1889|https://www.ncbi.nlm.nih.gov/pubmed/2824710|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Hintergrund|||Erstautor|Wolf M., Havemann K., Holle R., Gropp C., Drings P., Hans K., et al. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. . 1987;5:1880-1889|https://www.ncbi.nlm.nih.gov/pubmed/2824710|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Hintergrund|||Letztautor|Hautmann H., Gamarra F., Pfeifer K. J., Huber R. M. Fiberoptic bronchoscopic balloon dilatation in malignant tracheobronchial disease: indications and results. . 2001;120:43-49|https://www.ncbi.nlm.nih.gov/pubmed/11451814|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Hintergrund|||Standard|Vergnon J. M., Huber R. M., Moghissi K. Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. . 2006;28:200-218|https://www.ncbi.nlm.nih.gov/pubmed/16816349|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Standard|Freitag L., Ernst A., Thomas M., Prenzel R., Wahlers B., Macha H. N. Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma. . 2004;59:790-793|https://www.ncbi.nlm.nih.gov/pubmed/15333857|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Hintergrund|||Standard|Rieger J., Linsenmaier U., Hautmann H., Fedorowski A., Huber R. M., Pfeifer K. J. [Interdisciplinary interventional therapy for tracheobronchial stenosis with modern metal net stents]. . 2002;174:1009-1014|https://www.ncbi.nlm.nih.gov/pubmed/12142979|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Hintergrund|||Erstautor|Huber R. M., Fischer R., Hautmann H., Pollinger B., Haussinger K., Wendt T. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. . 1997;38:533-540|https://www.ncbi.nlm.nih.gov/pubmed/9231677|2269
Lungenkarzinom|"2.1"|2022|Huber, Rudolf M.|Hintergrund|||Standard|Horneber M. A., Bueschel G., Huber R., Linde K., Rostock M. Mistletoe therapy in oncology. . 2008;:CD003297|https://www.ncbi.nlm.nih.gov/pubmed/18425885|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M., Ciuleanu T. E., Lee J. S., Schenker M., Audigier-Valette C., Zurawski B., et al. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. None. 2021;16:665-676||2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M., Mok T. S. K., Nishio M., Jotte R. M., Cappuzzo F., Orlandi F., et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. None. 2019;7:387-401||2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Evidenzbasierte Empfehlung|A|False|Erstautor|Reck Martin, Mok Tony S. K., Nishio Makoto, Jotte Robert M., Cappuzzo Federico, Orlandi Francisco, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with <em>EGFR</em> mutations or baseline liver metastases in a randomised, open-label phase 3 trial. None. 2019;7:387-401|https://doi.org/10.1016/S2213-2600(19)30084-0|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck Martin, Mok Tony S. K., Nishio Makoto, Jotte Robert M., Cappuzzo Federico, Orlandi Francisco, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with <em>EGFR</em> mutations or baseline liver metastases in a randomised, open-label phase 3 trial. None. 2019;7:387-401|https://doi.org/10.1016/S2213-2600(19)30084-0|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Evidenzbasierte Empfehlung|A|False|Erstautor|Reck M., Schenker M., Lee K. H., Provencio M., Nishio M., Lesniewski-Kmak K., et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. None. 2019;116:137-147||2269
Lungenkarzinom|"2.1"|2022|Kauczor, Hans-Ulrich|Hintergrund|||Erstautor|Kauczor Hans-Ulrich, Bonomo Lorenzo, Gaga Mina, Nackaerts Kristiaan, Peled Nir, Prokop Mathias, et al. ESR/ERS white paper on lung cancer screening. None. 2015;None:None||2269
Lungenkarzinom|"2.1"|2022|Gröschel, Andreas|Hintergrund|||Letztautor|Herth F J F, Hoffmann H., Heussel C P, Biederer J., Gröschel A. Lungenkrebs-Screening – Update 2014. None. 2014;68:781-783||2269
Lungenkarzinom|"2.1"|2022|Hoffmann, Hans|Hintergrund|||Standard|Herth F J F, Hoffmann H., Heussel C P, Biederer J., Gröschel A. Lungenkrebs-Screening – Update 2014. None. 2014;68:781-783||2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Erstautor|Thomas M., et al. Empfehlungen zur Diagnostik des Bronchialkarzinoms. . 2000;54:361-371||2269
Lungenkarzinom|"2.1"|2022|Nowak, Dennis|Hintergrund|||Standard|Kolb S., Bruckner U., Nowak D., Radon K. Quantification of ETS exposure in hospitality workers who have never smoked. None. 2010;9:49||2269
Lungenkarzinom|"2.1"|2022|Wittekind, Christian|Hintergrund|||Erstautor|Wittekind C. TNM: Klassifikation maligner Tumoren. . 2017;:||2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Evidenzbasierte Empfehlung|A|False|Erstautor|Wolf J., Seto T., Han J. Y., Reguart N., Garon E. B., Groen H. J. M., et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. . 2020;383:944-957|https://www.nejm.org/doi/full/10.1056/NEJMoa2002787|2269
Lungenkarzinom|"2.1"|2022|Hellwig, Dirk|Hintergrund|||Erstautor|Hellwig D., Ukena D., Paulsen F., Bamberg M., Kirsch C. M. Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren. Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000. . 2001;55:367-377|https://www.researchgate.net/publication/247463168_Metaanalyse_zum_Stellenwert_der_Positronen-Emissions-Tomographie_mit_F-18-Fluorodesoxyglukose_FDG-PET_bei_Lungentumoren1_-_Diskussionsbasis_der_deutschen_Konsensus-Konferenz_Onko-PET_2000_-|2269
Lungenkarzinom|"2.1"|2022|Hellwig, Dirk|Hintergrund|||Erstautor|Hellwig D. R., Baum P., Kirsch C. M. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: A systematic review. . 2009;:|https://www.ncbi.nlm.nih.gov/pubmed/19333516|2269
Lungenkarzinom|"2.1"|2022|Hoffmann, Hans|Evidenzbasierte Empfehlung|A|False|Standard|Dienemann H., Trainer C., Hoffmann H., Bulzebruck H., Muley T., Kayser K., et al. [Incomplete resections in bronchial carcinoma: morbidity and prognosis]. None. 1997;68:1014-9||2269
Lungenkarzinom|"2.1"|2022|Hoffmann, Hans|Hintergrund|||Standard|Dienemann H., Trainer C., Hoffmann H., Bulzebruck H., Muley T., Kayser K., et al. [Incomplete resections in bronchial carcinoma: morbidity and prognosis]. None. 1997;68:1014-9||2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Hintergrund|||Erstautor|Passlick B., Sitar I., Sienel W., Thetter O., Morresi-Hauf A. Significance of lymphangiosis carcinomatosa at the bronchial resection margin in patients with non-small cell lung cancer. . 2001;72:1160-4|https://www.ncbi.nlm.nih.gov/pubmed/11603430|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Evidenzbasierte Empfehlung|A|True|Erstautor|Thomas M., Rube C., Semik M., von Eiff M., Freitag L., Macha H. N., et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. . 1999;17:1185|https://www.ncbi.nlm.nih.gov/pubmed/10561177|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Erstautor|Thomas M., Rube C., Semik M., von Eiff M., Freitag L., Macha H. N., et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. . 1999;17:1185|https://www.ncbi.nlm.nih.gov/pubmed/10561177|2269
Lungenkarzinom|"2.1"|2022|Junker, Klaus|Hintergrund|||Erstautor|Junker K. Therapieinduzierte Tumorregression und Regressionsgrading bei Lungenkarzinomen. . 2014;35:574-577|https://www.springermedizin.de/therapieinduzierte-tumorregression-und-regressionsgrading-bei-lu/8301204|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Hintergrund|||Erstautor|Wolf J., Seto T., Han J. Y., Reguart N., Garon E. B., Groen H. J. M., et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. . 2020;383:944-957|https://pubmed.ncbi.nlm.nih.gov/32877583/|2269
Lungenkarzinom|"2.1"|2022|Kollmeier, Jens|Hintergrund|||Standard|Nehls W., Gabrijel S., Kiss A., Kollmeier J., Schmalz O., Albrecht H., et al. Physician Communication in a Lung Cancer Center – Does the Message Come Across ?. . 2013;67:688-693|https://www.ncbi.nlm.nih.gov/pubmed/24323560|2269
Lungenkarzinom|"2.1"|2022|Nehls, Wiebke|Hintergrund|||Erstautor|Nehls W., Gabrijel S., Kiss A., Kollmeier J., Schmalz O., Albrecht H., et al. Physician Communication in a Lung Cancer Center – Does the Message Come Across ?. . 2013;67:688-693|https://www.ncbi.nlm.nih.gov/pubmed/24323560|2269
Lungenkarzinom|"2.1"|2022|Delis, Sandra|Hintergrund|||Standard|Nehls W., Gabrijel S., Kiss A., Delis S., Black N.B., al et. Communication Skills Training Significantly Improves Lung Cancer Patient`s Understanding. . 2014;4:182|https://www.ncbi.nlm.nih.gov/pubmed/15106217|2269
Lungenkarzinom|"2.1"|2022|Nehls, Wiebke|Hintergrund|||Erstautor|Nehls W., Gabrijel S., Kiss A., Delis S., Black N.B., al et. Communication Skills Training Significantly Improves Lung Cancer Patient`s Understanding. . 2014;4:182|https://www.ncbi.nlm.nih.gov/pubmed/15106217|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Hintergrund|||Standard|Gaertner J., Wolf J., Voltz R. Early palliative care for patients with metastatic cancer. . 2012;24:357-62|https://www.ncbi.nlm.nih.gov/pubmed/22476189|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Hintergrund|||Standard|Gaertner J., Wolf J., Hallek M., Glossmann J. P., Voltz R. Standardizing integration of palliative care into comprehensive cancer therapy--a disease specific approach. . 2011;19:1037-43|https://www.ncbi.nlm.nih.gov/pubmed/21432009|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Evidenzbasierte Empfehlung|A|False|Standard|Izbicki J. R., Thetter O., Habekost M., Karg O., Passlick B., Kubuschok B., et al. Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial. . 1994;81:229-235|https://www.ncbi.nlm.nih.gov/pubmed/8156344|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Hintergrund|||Standard|Izbicki J. R., Thetter O., Habekost M., Karg O., Passlick B., Kubuschok B., et al. Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial. . 1994;81:229-235|https://www.ncbi.nlm.nih.gov/pubmed/8156344|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Hintergrund|||Standard|Izbicki J. R., Passlick B., Pantel K., Pichlmeier U., Hosch S. B., Karg O., et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. . 1998;227:138-144|https://www.ncbi.nlm.nih.gov/pubmed/9445122|2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Evidenzbasierte Empfehlung|A|False|Standard|Izbicki J. R., Passlick B., Karg O., Bloechle C., Pantel K., Knoefel W. T., et al. Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. None. 1995;59:209-214||2269
Lungenkarzinom|"2.1"|2022|Passlick, Bernward|Hintergrund|||Standard|Izbicki J. R., Passlick B., Karg O., Bloechle C., Pantel K., Knoefel W. T., et al. Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. None. 1995;59:209-214||2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Marra A., Eberhardt W., Pottgen C., Theegarten D., Korfee S., Gauler T., et al. Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour. . 2007;29:117-126|https://www.ncbi.nlm.nih.gov/pubmed/16971407|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Konsensbasierte Empfehlung|A|False|Erstautor|Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. . 1998;16:622-634|https://www.ncbi.nlm.nih.gov/pubmed/9469351|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Erstautor|Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. . 1998;16:622-634|https://www.ncbi.nlm.nih.gov/pubmed/9469351|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Konsensbasierte Empfehlung|A|False|Standard|Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. . 1998;16:622-634|https://www.ncbi.nlm.nih.gov/pubmed/9469351|2269
Lungenkarzinom|"2.1"|2022|Stuschke, Martin|Hintergrund|||Standard|Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. . 1998;16:622-634|https://www.ncbi.nlm.nih.gov/pubmed/9469351|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|False|Standard|Stamatis G., Djuric D., Eberhardt W., Pottken C., Zaboura G., Fechner S., et al. Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients. . 2002;22:292-297|https://www.ncbi.nlm.nih.gov/pubmed/12142202|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Stamatis G., Djuric D., Eberhardt W., Pottken C., Zaboura G., Fechner S., et al. Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients. . 2002;22:292-297|https://www.ncbi.nlm.nih.gov/pubmed/12142202|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Evidenzbasierte Empfehlung|A|True|Standard|Friedel G., Hruska D., Budach W., Wolf M., Kyriss T., Hurtgen M., et al. Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer. . 2000;30:175-185|https://www.ncbi.nlm.nih.gov/pubmed/11137202|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Hintergrund|||Standard|Friedel G., Hruska D., Budach W., Wolf M., Kyriss T., Hurtgen M., et al. Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer. . 2000;30:175-185|https://www.ncbi.nlm.nih.gov/pubmed/11137202|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Hintergrund|||Standard|Hamilton M., Wolf J. L., Rusk J., Beard S. E., Clark G. M., Witt K., et al. Effects of smoking on the pharmacokinetics of erlotinib. . 2006;12:2166-2171|https://www.ncbi.nlm.nih.gov/pubmed/16609030|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|True|Standard|Pottgen C., Eberhardt W., Grannass A., Korfee S., Stuben G., Teschler H., et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. . 2007;25:4987-92||2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Pottgen C., Eberhardt W., Grannass A., Korfee S., Stuben G., Teschler H., et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. . 2007;25:4987-92||2269
Lungenkarzinom|"2.1"|2022|Griesinger, Frank|Hintergrund|||Standard|Crino L., Dansin E., Garrido P., Griesinger F., Laskin J., Pavlakis N., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. . 2010;11:733-40|https://www.ncbi.nlm.nih.gov/pubmed/20650686|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Evidenzbasierte Empfehlung|A|False|Erstautor|Reck M., Rodriguez-Abreu D., Robinson A. G., Hui R., Csoszi T., Fulop A., et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. . 2016;:|https://www.ncbi.nlm.nih.gov/pubmed/27718847|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M., Rodriguez-Abreu D., Robinson A. G., Hui R., Csoszi T., Fulop A., et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. . 2016;:|https://www.ncbi.nlm.nih.gov/pubmed/27718847|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M., Socinski M. A., Luft A., Szczesna A., Dediu M., Ramlau R., et al. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. . 2016;11:808-18|https://www.ncbi.nlm.nih.gov/pubmed/26980471|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Evidenzbasierte Empfehlung|A|False|Standard|Pujol J. L., Paz-Ares L., de Marinis F., Dediu M., Thomas M., Bidoli P., et al. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. . 2014;15:418-25|https://www.ncbi.nlm.nih.gov/pubmed/25104617|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Standard|Pujol J. L., Paz-Ares L., de Marinis F., Dediu M., Thomas M., Bidoli P., et al. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. . 2014;15:418-25|https://www.ncbi.nlm.nih.gov/pubmed/25104617|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Evidenzbasierte Empfehlung|A|False|Erstautor|Reck M., Paz-Ares L. G., de Marinis F., Molinier O., Sahoo T. P., Laack E., et al. PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. . 2014;9:205-13|https://www.ncbi.nlm.nih.gov/pubmed/24419418|2269
Lungenkarzinom|"2.1"|2022|Reck, Martin|Hintergrund|||Erstautor|Reck M., Paz-Ares L. G., de Marinis F., Molinier O., Sahoo T. P., Laack E., et al. PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. . 2014;9:205-13|https://www.ncbi.nlm.nih.gov/pubmed/24419418|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Evidenzbasierte Empfehlung|A|False|Standard|Paz-Ares L. G., de Marinis F., Dediu M., Thomas M., Pujol J. L., Bidoli P., et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. . 2013;31:2895-902|https://www.ncbi.nlm.nih.gov/pubmed/23835707|2269
Lungenkarzinom|"2.1"|2022|Thomas, Michael|Hintergrund|||Standard|Paz-Ares L. G., de Marinis F., Dediu M., Thomas M., Pujol J. L., Bidoli P., et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. . 2013;31:2895-902|https://www.ncbi.nlm.nih.gov/pubmed/23835707|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasierte Empfehlung|A|False|Standard|Brahmer J., Reckamp K. L., Baas P., Crino L., Eberhardt W. E., Poddubskaya E., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. . 2015;373:123-35|https://www.ncbi.nlm.nih.gov/pubmed/26028407|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Brahmer J., Reckamp K. L., Baas P., Crino L., Eberhardt W. E., Poddubskaya E., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. . 2015;373:123-35|https://www.ncbi.nlm.nih.gov/pubmed/26028407|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Schuette W., Schirmacher P., Eberhardt W. E., Fischer J. R., von der Schulenburg J. M., Mezger J., et al. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. . 2015;24:1254-61|https://www.ncbi.nlm.nih.gov/pubmed/26070531|2269
Lungenkarzinom|"2.1"|2022|Sebastian, Martin|Evidenzbasierte Empfehlung|A|True|Standard|Yang J. C., Wu Y. L., Schuler M., Sebastian M., Popat S., Yamamoto N., et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. . 2015;16:141-51|https://www.ncbi.nlm.nih.gov/pubmed/25589191|2269
Lungenkarzinom|"2.1"|2022|Sebastian, Martin|Hintergrund|||Standard|Yang J. C., Wu Y. L., Schuler M., Sebastian M., Popat S., Yamamoto N., et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. . 2015;16:141-51|https://www.ncbi.nlm.nih.gov/pubmed/25589191|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Evidenzbasierte Empfehlung|A|True|Standard|Soria Jean-Charles, Tan Daniel S. W., Chiari Rita, Wu Yi-Long, Paz-Ares Luis, Wolf Juergen, et al. First-line ceritinib versus platinum-based chemotherapy in advanced <em>ALK</em>-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. . 2017;389:917-929|https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)30123-X.pdf|2269
Lungenkarzinom|"2.1"|2022|Wolf, Jürgen|Hintergrund|||Standard|Soria Jean-Charles, Tan Daniel S. W., Chiari Rita, Wu Yi-Long, Paz-Ares Luis, Wolf Juergen, et al. First-line ceritinib versus platinum-based chemotherapy in advanced <em>ALK</em>-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. . 2017;389:917-929|https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)30123-X.pdf|2269
Lungenkarzinom|"2.1"|2022|Kollmeier, Jens|Hintergrund|||Standard|Tonnies M., Pfannschmidt J., Bauer T. T., Kollmeier J., Tonnies S., Kaiser D. Metastasectomy for synchronous solitary non-small cell lung cancer metastases. . 2014;98:249-56|https://www.ncbi.nlm.nih.gov/pubmed/24820385|2269
Lungenkarzinom|"2.1"|2022|Pfannschmidt, Joachim|Hintergrund|||Standard|Tonnies M., Pfannschmidt J., Bauer T. T., Kollmeier J., Tonnies S., Kaiser D. Metastasectomy for synchronous solitary non-small cell lung cancer metastases. . 2014;98:249-56|https://www.ncbi.nlm.nih.gov/pubmed/24820385|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Evidenzbasiertes Statement|A|False|Standard|Goldstraw P., Chansky K., Crowley J., Rami-Porta R., Asamura H., Eberhardt W. E., et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. . 2016;11:39-51|https://www.ncbi.nlm.nih.gov/pubmed/26762738|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Standard|Goldstraw P., Chansky K., Crowley J., Rami-Porta R., Asamura H., Eberhardt W. E., et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. . 2016;11:39-51|https://www.ncbi.nlm.nih.gov/pubmed/26762738|2269
Lungenkarzinom|"2.1"|2022|Eberhardt, Wilfried|Hintergrund|||Erstautor|Eberhardt W. E., Mitchell A., Crowley J., Kondo H., Kim Y. T., Turrisi A. 3rd, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. . 2015;10:1515-22|https://www.ncbi.nlm.nih.gov/pubmed/26536193|2269
Lungenkarzinom|"2.1"|2022|Kollmeier, Jens|Hintergrund|||Standard|Tonnies S., Tonnies M., Kollmeier J., Bauer T. T., Forster G. J., Kaiser D., et al. Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer. . 2016;93:28-34|https://www.ncbi.nlm.nih.gov/pubmed/26898611|2269
Lungenkarzinom|"2.1"|2022|Guckenberger, Matthias|Hintergrund|||Erstautor|Guckenberger M., Mantel F., Gerszten P. C., Flickinger J. C., Sahgal A., Letourneau D., et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. . 2014;9:226|https://www.ncbi.nlm.nih.gov/pubmed/25319530|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Evidenzbasiertes Statement|A|False|Erstautor|Wolf M., Holle R., Hans K., Drings P., Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. . 1991;63:986-992|https://www.ncbi.nlm.nih.gov/pubmed/1648949|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Hintergrund|||Erstautor|Wolf M., Holle R., Hans K., Drings P., Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. . 1991;63:986-992|https://www.ncbi.nlm.nih.gov/pubmed/1648949|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Evidenzbasierte Empfehlung|B|False|Standard|Havemann K., Wolf M., Holle R., Gropp C., Drings P., Manke H. G., et al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. . 1987;59:1072-1082|https://www.ncbi.nlm.nih.gov/pubmed/3028596|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Hintergrund|||Standard|Havemann K., Wolf M., Holle R., Gropp C., Drings P., Manke H. G., et al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. . 1987;59:1072-1082|https://www.ncbi.nlm.nih.gov/pubmed/3028596|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Evidenzbasierte Empfehlung|B|False|Erstautor|Wolf M., Pritsch M., Drings P., et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. . 1991;9:614-624|https://www.ncbi.nlm.nih.gov/pubmed/1648598|2269
Lungenkarzinom|"2.1"|2022|Wolf, Martin|Hintergrund|||Erstautor|Wolf M., Pritsch M., Drings P., et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. . 1991;9:614-624|https://www.ncbi.nlm.nih.gov/pubmed/1648598|2269
Lungenkarzinom|"2.1"|2022|Kraywinkel, Klaus|Hintergrund|||Erstautor|Kraywinkel Klaus, Schönfeld Ina. Epidemiologie des nichtkleinzelligen Lungenkarzinoms in Deutschland. None. 2018;24:946|https://doi.org/10.1007/s00761-018-0480-2|2269